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Escherichia coli is the leading cause of urinary tract (UTI) and bloodstream infections 
in humans and animals. Most infections like this are due to strains of pathotypes known 
as extraintestinal pathogenic E. coli (ExPEC) or uropathogenic E. coli (UPEC). 
Numerous virulence genes have been associated with strains causing extraintestinal 
infections, such as adhesins, toxins, siderophores and capsular antigens, that enable them 
to colonize host surfaces, capture available iron, injure host tissues and avoid host defence 
systems. The treatment of these infections has been seriously complicated by the 
appearance of multidrug-resistant (MDR) strains and especially by the rapid 
dissemination of extended-spectrum β-lactamase-producing E. coli (ESBLEC). 
 
The present doctoral thesis includes five publications (Flament-Simon SC et al. 2020 
Antibiotics 9 (4) 161 doi.org/10.3390/antibiotics9040161; Flament-Simon SC et al. 2020 
Front Cell Infect Microbiol 10:125 doi: 10.3389/fcimb.2020.00125; Flament-Simon SC 
et al. 2019 Front Microbiol 10:1183 doi: 10.3389/fmicb.2019.01183; Flament-Simon SC 
et al. 2020 Microorganims 8 (11):E1712 doi: 10.3390/microorganisms8111712; Flament-
Simon SC et al. 2020 Front Microbiol 2020 11:387 doi: 10.3389/fmicb.2020.00387) and 
unpublished data with the following aims: 
 
I. Evaluate the prevalence of sequence type 131 (ST131) and its subclones among E. 
coli  strains consecutively isolated from patients with extraintestinal infections in 
2016 and among ESBLEC isolated in 2015, in two hospitals (Lucus Augusti 
University hospital and AP-HP Beaujon hospital), paying special attention to the 
emergence of new highly virulent and/or MDR clones. 
II. Gain knowledge of phenotypic and genotypic characteristics of the ST131 strains 
and other high-risk clones isolated from humans and animals, determining 
phylogroups, clonotypes, sequence types (STs), O:H serotypes, Virulence Factor 
(VF)-encoding genes, antibiotic resistance including the whole genome sequencing 
(WGS) of a subset of strains to perform core genome (CG) and plasmidome 
analysis. 
III. Gain knowledge about early biofilm formation (EBF) in E. coli strains implicated 
in extraintestinal infections and contrast the biofilm-forming ability with genotypic 
characteristics of the strains.  
IV. Study production animals (pigs) and companion animals (dogs) as reservoirs for 
ST131 strains and other high-risk clones for humans and investigate potential clone 
transfer. 
 
Overall, we undertook a total of six studies of molecular epidemiology as well as a 
genomic analysis of E. coli strains. Within the four first studies, we analysed a total of 
394 strains which were producers of extraintestinal infections retrieved from two different 
hospitals (Lucus Augusti hospital in Lugo and the Beaujon hospital in Paris), whereas in 
the remaining two studies we analysed strains from canine and porcine origin. The 
phenotypical characterization includes: (I) serotyping, (II) antimicrobial susceptibility 
testing and (III) biofilm determination. The molecular characterisation includes: (I) the 
description of virulence profiles through the identification of VF-encoding genes by 
Polymerase Chain Reaction (PCR) followed by the definition of the virulence profile 




through PCR followed by amplicon sequencing, (III) the determination of the 
phylogenetic groups of E. coli  through PCR, (IV) the determination of clonotypes (fumC-
fimH) and sequence types (ST) through PCR followed by amplicon sequencing, (VI) the 
identification of the clades and subclades of ST131 E. coli by PCR and (VII) the 
identification of the fimB gene by PCR followed by amplicon sequencing in a subset of 
strains from the human origin collection of bacteria and finally, (VIII) we performed the 
whole genome sequencing (WGS) of a total of 109 E. coli  strains belonging to three 
different studies, allowing us to perform the core genome (CG) and plasmidome analysis. 
Statistical analysis include Shapiro-Wilk normality test, non-parametric Mann-Whitney-
Wilcoxon test, two-tailed Fisher’s exact test and analysis of variance (ANOVA) test. P-
values < 0.05 were considered statistically significant. Correlation between quantitative 
variables was assessed by Pearson correlation coefficient, and the assessment of 
repeatability was via the Bland and Altman, (1986) statistical method. 
In the first study, we undertake a molecular analysis of a total of 196 E. coli  strains 
derived from consecutive cases of extraintestinal infections throughout 2016 in Spain 
(100 from Lucus Augusti hospital in Lugo) and France (96 from Beaujon hospital in 
Clichy). We determined phylogroups, clonotypes, sequence types (STs), O:H serotypes, 
virulence factor (VF)-encoding genes and antibiotic resistance. We observed that 
approximately 10% of the infections were caused by ST131 strains in both hospitals and 
approximately 60% of these infections were caused by strains belonging to only 10 STs 
(ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, ST131 and ST141). ST88 strains 
were frequent, especially in Spain, while ST141 strains significantly predominated in 
France. The 23 ST131 strains displayed four clonotypes: CH40-30, CH40-41, CH40-22 
and CH40-298. Only 13 (6.6%) strains were carriers of extended-spectrum beta-
lactamase (ESBL) enzymes. However, 37.2% of the strains were multidrug-resistant 
(MDR). Approximately 40% of the MDR strains belonged to only four of the dominant 
clones (B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-39-ST88 and D-CH35-27-
ST69). Among the remaining MDR strains, two strains belonged to B2-CH14-64-
ST1193, i.e., the new global emergent MDR clone. Moreover, a hybrid ExPEC-
enteroaggregative strain belonging to the A-CH11-54-ST10 clone was identified. 
In the second study, we completed a molecular analysis of a total of 188 extended-
spectrum β-lactamase-producing Escherichia coli  (ESBLEC) collected throughout 2015 
in the Lucus Augusti University hospital and the AP-HP Beaujon hospital, with regard to 
other STs and to characterize the types of ESBL produced, serotypes, virulence factor 
(VF)-encoding genes and the ST131 clades and subclades. ST131 was detected in 33 
(39.1%) and 46 (47.9%) of the strains in Lucus Augusti and Beaujon, respectively. The 
109 remaining strains displayed 57 other STs, the following STs being displayed by at 
least three strains: ST10 (8 strains), ST23 (3), ST38 (4), ST58 (3), ST88 (5), ST95 (4), 
ST167 (3), ST354 (5), ST361 (3), ST410 (6), ST648 (4), ST744 (3), and ST1615 (6). 
ST354, ST410 and ST1615 were significantly (P< 0.05) more frequent in Lucus Augusti 
(5.4%, 6.5% and 6.5%) than in Beaujon (0% for the three STs). Furthermore, we 
described two strains belonging to the emergent clone B2-CH14-64-ST1193. CTX-M-15 
was the commonest ESBL detected in the two hospitals (44.6% in Lucus Augusti and 
50.0% in Beaujon). CTX-M-14 was significantly (P=0.0003) more frequent in Lucus 
Augusti (31.5%) than in Beaujon (10.4%), whereas CTX-M-1 (20.8% versus 7.6%; P = 
0.008) and CTX-M-27 (15.6% versus 6.5%; P=0.0389) were more frequent in Beaujon 
than in Lucus Augusti. The ST131 strains showed a higher virulence score (mean 13.367) 




strains, most of them (52; 65.8%) belonged to subclade C2 (also known as subclone 
H30Rx) followed by those belonging to subclade C1 (cluster C1-M27: 16 strains, 20.3%; 
cluster non-C1-M27: 6 strains, 7.6%) and clade A (4 strains; 5.1%). Besides, the C2 
subclade strains showed a higher VF-encoding gene score (mean 14.250) compared with 
the C1-M27 cluster strains (mean 10.875) (P<0.001).  
In the third study, we analyzed the biofilm formation of E. coli strains that produced 
extraintestinal infections in humans. E. coli biofilm formation has mostly been assessed 
in specific pathogenic E coli groups. Here, we assessed the early biofilm formation (EBF), 
i.e. adhesion stage, using the BioFilm Ring Test® on 394 E. coli  clinical isolates (EC) 
[196 consecutively isolated (CEC) in 2016 and 198 ESBL-producing E. coli  (ESBLEC) 
isolated in 2015]. Then, biofilm-forming ability was contrasted with phylogroups, 
clonotypes (CH) and sequence types (ST), all being used to define clones, virulence 
factors (VF) and FimB. According to both biofilm production levels at 2h, 3h and 5h, and 
EBF kinetics over 5h, CEC and ESBLEC strains segregated into three EBF groups: strong 
(G1), moderate (G2) and weak (G3) producers. At 2h, strong producers were more 
frequent among CEC (n=28; 14.3%) than among ESBLEC (n=8; 4%) (P=0.0004). As 
CEC and ESBLEC strains showed similar individual EBF kinetics in each group, 
comparison of strain features between each group was applied to gathered CEC and 
ESBLEC strains and after 2h incubation, 2h being the most representative point time of 
the CEC and ESBLEC strain segregation into the three groups. Phylogroup B2 displayed 
by 51.3% of the 394 strains was more frequent in G1 (77.8%) than G3 (47.6%) 
(P=0.0006). The 394 strains displayed 153 clones of which 31 included at least three 
strains. B2-CH14-2-ST127, B2-CH40-22-ST131, B2-CH52-5/14-ST141 and E-CH100-
96-ST362 clones were associated with G1 (P<0.03) and accounted for 41.7% of G1 
strains. B2-CH40-30-ST131 clone was associated with G3 (P<0.0001) and accounted for 
25.5% of G3 strains. VF mean was higher among G1 than among G3 strains (P<0.001). 
FimB-P2 variant was associated with G1 (P=0.0011) and FimB-P1 variant with G3 
(P=0.0023). Clone, some VF, and FimB were associated with EBF, clonal lineage being 
able to explain 72 % of the variability of EBF. Among our 394 strains, less than a 10% 
of the strains were able to quickly and persistently produce high levels over 5h. These 
strains belong to a few clones previously described in various studies as dominant gut 
colonisers in mammalians and birds and comprised B2-CH40-22-ST131clone i.e. the 
ancestor of the globally disseminated B2-CH40-30-ST131 clone that is the dominant 
clone among the weak biofilm producers (G3).  
In the fourth study, we investigate the insights of ST131 clonal complex ESBLEC 
(STC131 group constituted by 30 genomes) and other emerging ESBL lineages (non-
STC131 group constituted by 45 genomes) through the analysis of a total of 75 ESBLEC 
whole sequenced genomes (51 genomes from Lucus Augusti hospital and 24 genomes 
from Beaujon hospital). These genomes come from different clinical samples: 57 isolates 
from urine, 11 from blood and 7 from various other sources including one from bile, one 
from ascitic fluid, one from a bone, two from wounds and two from digestive infections. 
We carried out a phylogenetic research that includes the core genome (CG) and 
plasmidome analysis. Through the CG analysis, we observed correlation with the 
phylogenetic groups of the genomes and described two new clades among the ST131 
clonal complex represented by strains with the fimH5 and fimH35 alleles. We in silico 
investigated the presence of 164 VF-encoding genes and 13 point mutations (PMs) related 
to the expression of resistance to antibiotics in the chromosome of 75 ESBLEC genomes. 




than the non-STC131 group of genomes (62 versus 47) and a higher mean of PMs than 
the non-STC131 group (5 versus 3).  Besides, there was a clear association between 
ExPEC status, UPEC status and the STC131 group of genomes (P<0.0001). The 75 
ESBLEC genomes harbours 21 presumptive integrative conjugative elements (ICEs) and 
a total of 228 plasmids, of which 86 (32%) were found within the STC131 group and 142 
(62%) were found within the non-STC131 group. The 92% of the plasmid belonged to 
MOBF, MOBP and MOBQ families of relaxases. Besides, we described a wide variety of 
incompatibility groups (Inc.) and this diversity was higher within the non-STC131 than 
the STC131 group (12 Inc. including Col-like, F, Q, I, X, Y, P, 13, HI2, N, R and B/O/K/Z 
versus 6 Inc. including Col-like, F, X, 13, N, and B/O/K/Z, respectively). We noticed that 
Col-like and IncF plasmids were equally dominant within both groups of genomes. The 
IncF plasmids vary greatly in their composition and carried almost all the virulence and 
resistance genes found in the plasmidome of the 75 ESBLEC analysed genomes. 
Moreover, we localized the genes encoding for ESBL enzymes in 67 out of the 75 
genomes, of which 21 were integrated in the chromosome (31%) and 46 of them were 
carried by plasmids (69%). Furthermore, we observed a correlation between the presence 
of specific types of IncF and the different ST131 clades. We found two blaCTX-M-27 
codifying genes carried by [F1:A2:B20]-IncF plasmids and five blaCTX-M-15 codifying 
genes carried by [F2:A1:B-]-IncF plasmids associated with subclades C1 and C2, 
respectively. Thus, that argues for the existence of a plasmid-clade association. Regarding 
clade A, we describe the presence of [F29:A-:B10]-IncF plasmids and ICEs as distinctive 
features from genomes from clade C.  
In the fifth study, under a “one health” perspective and the worldwide antimicrobial 
resistance concern, we investigated ExPEC, UPEC, and MDR E. coli from 197 strains 
recovered from healthy dogs in Spain between 2013 and 2017. A total of 91 (46.2%) 
strains were molecularly classified as ExPEC and/or UPEC, including 50 clones, among 
which four clones were dominant (B2-CH14-180-ST127, B2-CH52-14-ST141, B2-
CH103-9-ST372 and F-CH4-58-ST648) and 15 had been identified among strains 
causing extraintestinal infections in Spanish and French humans in 2015 and 2016. A 
total of 28 (14.2%) strains were classified as MDR, associated with B1, D, and E 
phylogroups, and included 24 clones, of which eight had been identified among the 
human clinical isolates. We selected 23 ST372 strains, 21 from healthy dogs, and two 
from human clinical isolates for WGS and built an SNP-tree with these 23 genomes and 
174 genomes obtained from public databases (128 from canine origin strains and 46 from 
human origin strains). These 197 genomes were segregated into six clusters. Cluster 1 
comprised 74.6% of the strain genomes, mostly composed of canine origin strain 
genomes (P< 0.00001). Clusters 4 and 6 also included canine origin strain genomes, while 
clusters 2, 3, and 5 were significantly associated with human origin strain genomes. 
Finding several common clones and clone-related serotypes in dogs and humans suggests 
a potentially bidirectional clone transfer that argues for the one health perspective. 
In the sixth study, we analysed strains belonging to the clone ST131 from porcine 
origin, which are scarcely documented. We undertook the WGS, CG and plasmidome 
analysis of seven isolates collected from diarrhoeic piglets and four from pork meat. All 
of the 11 ST131 strains belonged to serotype O25b:H4 and clade B, and showed fimH22 
allele or mutational derivatives. The 11 porcine strains possessed virulence traits that 
classified the strains as avian pathogenic, uropathogenic and extraintestinal pathogenic E. 
coli like status (APEC, UPEC and ExPEC like) and constituted virotype D. The CG was 




origins. Within clade B the CG showed nine sub-clusters, allowing us to describe five 
new subclades (B6, B6-like, B7, B8, B9). There was an association between subclade B6, 
PST43, virotype D2 and food origin, while subclade B7 included PST9 strains with 
virotype D5 from diarrhoeic piglets (P=0.007). The distance between human and porcine 
origin strains from subclades B6 and B7 had an average of 20 SNP/Mb and 15 SNP/Mb, 
respectively. [F2:A-:B1]-IncF, ColE1-like and IncX plasmids were the most prevalent. 
Besides, IncF plasmids harboured a ColV region frequent among APEC strains. 
Antimicrobial resistance genes conferring resistance to penicillin, tetracycline, 
quinolones and colistin were the most common. The mcr-1.1 gene was detected in 5 of 
11 porcine origin strains, integrated into the chromosome of one strain and into plasmids 
in the remainder strains (two MOBH11/IncHI2-ST4, one MOBP3/IncX4 and one 
MOBF12/IncF [F2:A-:B1] supposedly cointegrated with an IncHI2). The surrounding 
environments of the mcr-1 cassette showed variability. However, there were conserved 
structures within the same plasmid family. In conclusion, CG analysis defined five new 
subclades. The ST131 porcine strains belonged to new subclades B6 and B7. Moreover, 
porcine and clinical human strains were strongly related. The 11 porcine ST131 strains 
harboured a wide variety of plasmids, virulence and resistance genes. Furthermore, 
epidemic plasmids IncX4 and IncHI2 are responsible for the acquisition of mcr-1.1 gene. 
We hypothesize that the APEC-IncF plasmid acquired the mcr-1.1 gene via cointegrating 
an IncHI2 plasmid, which is worrying due to combination of virulence and resistance 
attributes in a single mobile genetic element. 
 
Of the results obtained, we concluded: 
1. Approximately 10% of the extraintestinal E. coli infections that had occurred in 
2016 in the two studied hospitals were caused by ST131 strains, and 
approximately 60% of these infections were caused by strains belonging to only 
10 STs (ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, ST131 and ST141). 
2. The majority of ST12, ST73, ST95 and ST141 human extraintestinal strains were 
susceptible to most antibiotics, indicating that MDR was not the reason for their 
success. The results of the present study support the idea that their success is 
mainly due to the high number of VF-encoding genes that they possess. 
3. Among the MDR human extraintestinal strains, four clones are predominant, 
especially: B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-39-ST88 and D-
CH35-27-ST69. 
4. Despite the enormous genetic diversity observed in our ESBLEC collection (71 
clones amongst 188 ESBLEC), it can be concluded that the majority of the strains 
belong to only three clonal complexes (CC10, CC23, and CC131) and that ST131 
subclade C2 associated with the production of CTX-M-15 remains the most 
prevalent E. coli lineage among the ESBLEC strains identified in the studied 
Spanish and French hospitals. 
5. Among our 394 extraintestinal E. coli strains, <10% are able to quickly and 
persistently produce high biofilm levels over 5 h. These strains belong to a few 
clones previously described in various studies as dominant gut colonizers in 
mammalians and birds, and comprised the B2-CH40-22-ST131 clone, i.e., the 
ancestor of the globally disseminated B2-CH40-30-ST131 clone that is the 





6. The core genome analysis of ESBLEC highlights genomic diversity among ESBL 
E. coli population. That includes representatives from phylogroups A, B1, B2, C, 
E and F. We described two new clades in ST131 clonal complex represented by 
genomes harbouring the fimH5 and fimH35 alleles. Clade C is characterised by 
showing less SNPs distance in the core genome than its sister clades A and B. 
7. There is a correlation between VF-encoding gene profiles and STs.  
8. There is an impressive diversity of plasmids among ESBLEC. However, MOBF, 
MOBP and MOBQ families of relaxases represent 92% of the plasmidome and 
Col-like and IncF are the most frequent incompatibility groups. Besides, most of 
the virulence and resistance associated encoding genes are carried by plasmids 
belonging to the IncF family. 
9. In ST131 lineage, the plasmid incompatibility group diversity is higher among 
subclade C2 than among clade A and cluster C1-M27 subclade C1. Clade A is 
related with the presence of ICEs and [F29:A-:B10]-IncF plasmids. 
10. The intestinal tract of healthy dogs appears as an important reservoir of ExPEC 
and/or UPEC, and, in a lesser extent, of MDR E. coli strains. 
11. Among the canine strains displaying an ExPEC and/or UPEC status, clone B2-
CH103-9-ST372 was dominant. 
12. WGS analysis suggests that canine strains of clone B2-CH103-9-ST372, 
belonging to cluster 1 (serotypes O4:H31, O21:H31 and O83:H31) and cluster 6 
(serotype O6:H31) might cause extraintestinal infections in both humans and 
dogs, whereas those strains of this clone belonging to cluster 2 and serotypes 
O18:H31 and O45:H31 might cause only human infections. 
13. Clade B of ST131 showed a huge genetic diversity, and five new subclades were 
defined (B6, B6-like, B7, B8, and B9). The majority of ST131 porcine strains 
belong to new subclades B6 and B7. 
14. Most porcine ST131 strains are MDR (91%) and carry many antibiotic resistance 
genes. Colistin resistance was introduced through MGEs and had been able to 
stabilize chromosomally. IncX4 and IncHI2 epidemic mcr-1–harboring plasmids 
are responsible for acquired colistin resistance encoded by mcr-1.1 gene. The 
surrounding environment of the mcr-1 cassette is variable but within the same 
family of plasmids, insertion, and stabilization had common structures. 
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Escherichia coli es la principal causa de infecciones del tracto urinario (ITU) y del 
torrente sanguíneo en seres humanos y animales. La mayoría de estas infecciones se 
deben a cepas de patotipos conocidos como E. coli patógenos extraintestinales (ExPEC) 
o E. coli uropatógenos (UPEC). Se han asociado numerosos genes de virulencia con cepas 
que causan infecciones extraintestinales, como adhesinas, toxinas, sideróforos y 
antígenos capsulares, que les permiten colonizar las superficies del huésped, capturar el 
hierro disponible, dañar los tejidos del hospedador y evitar los sistemas de defensa del 
hospedador. El tratamiento de estas infecciones se ha complicado seriamente por la 
aparición de cepas multirresistentes (MDR) y especialmente por la rápida diseminación 
de cepas de E. coli productoras de β-lactamasas de espectro extendido (ECBLEE). 
 
La presente tesis doctoral incluye cinco publicaciones (Flament-Simon SC et al.2020 
Antibiotics 9 (4) 161 doi.org/10.3390/antibiotics9040161; Flament-Simon SC et al.2020 
Front Cell Infect Microbiol 10: 125 doi: 10.3389/fcimb .2020.00125; Flament-Simon SC 
et al.2019 Front Microbiol 10: 1183 doi: 10.3389/fmicb.2019.01183; Flament-Simon SC 
et al.2020 Microorganims 8 (11): E1712 doi: 10.3390/microorganisms8111712; Flament-
Simon SC et al.2020 Front Microbiol 2020 11: 387 doi: 10.3389/fmicb.2020.00387) y 
datos sin publicar con los siguientes objetivos: 
 
I. Evaluar la prevalencia de la secuencia tipo 131 (ST131) y sus subclones entre 
cepas de E. coli causantes de infecciones extraintestinales en seres humanos 
aisladas de casos consecutivos en 2016 y entre cepas ECBLEE aisladas en 2015, 
en dos hospitales (hospital universitario Lucus Augusti y hospital AP-HP 
Beaujon), prestando especial atención a la aparición de nuevos clones altamente 
virulentos y/o MDR. 
II. Adquirir conocimiento de las características fenotípicas y genotípicas de las cepas 
ST131 y otros clones de alto riesgo aislados de seres humanos y animales, 
determinando los filogrupos, clonotipos, secuencias tipo (ST), serotipos O:H, 
genes que codifican Factores de Virulencia (FV), resistencia a los antibióticos, 
además de la secuenciación del genoma completo (whole genome sequencing) 
(WGS) de un subconjunto de cepas para realizar el análisis de su genoma esencial 
(core genome) (CG) y de su plasmidoma. 
III. Adquirir conocimientos sobre la formación temprana de biopelículas (early 
biofilm formation) (EBF) en cepas de E. coli implicadas en infecciones 
extraintestinales y comparar la capacidad de formación de biopelículas con las 
características genotípicas de las cepas. 
IV. Estudiar animales de producción (cerdos) y animales de compañía (perros) como 
reservorios de cepas ST131 y otros clones de alto riesgo para seres humanos e 
investigar la posible transferencia de clones. 
 
En total realizamos seis estudios de epidemiología molecular, así como un análisis 
genómico de cepas de E. coli. En los cuatro primeros estudios analizamos un total de 394 
cepas productoras de infecciones extraintestinales extraídas de dos hospitales (hospital 
Lucus Augusti de Lugo y hospital Beaujon de París), mientras que en los dos estudios 
restantes analizamos cepas de origen canino y porcino. La caracterización fenotípica 




determinación de biopelículas. La caracterización molecular incluye: (I) la descripción de 
los perfiles de virulencia a través de la identificación de genes que codifican FV mediante 
la reacción en cadena de la polimerasa (PCR) seguida de la definición de los estatus de 
virulencia vinculados a patotipos, (II) la descripción de perfiles de resistencias a los 
antibióticos mediante PCR seguida de la secuenciación de amplicones, (III) la 
determinación de los grupos filogenéticos de E. coli  mediante PCR, (IV) la determinación 
de clonotipos (fumC-fimH) y secuencias tipo (ST) mediante PCR seguida de la 
secuenciación de amplicones, (VI) la identificación de los clados y subclados de E. coli 
ST131 por PCR, (VII) la identificación del gen fimB por PCR seguida de la secuenciación 
de amplicones en un subconjunto de cepas de la colección de bacterias de origen humano 
y finalmente, (VIII) realizamos la secuenciación del genoma completo (WGS) de un total 
de 109 cepas de E. coli pertenecientes a tres estudios diferentes, permitiéndonos realizar 
el análisis del CG y del plasmidoma. El análisis estadístico incluye la prueba de 
normalidad de Shapiro-Wilk, la prueba no paramétrica de Mann-Whitney-Wilcoxon, la 
prueba exacta de Fisher y la prueba de análisis de varianza (ANOVA). Los valores P<0,05 
se consideraron estadísticamente significativos. La correlación entre variables 
cuantitativas se evaluó mediante el coeficiente de correlación de Pearson, y la evaluación 
de la reproductibilidad se realizó mediante el método estadístico de Bland y Altman, 
(1986). 
En el primer estudio realizamos el análisis molecular de un total de 196 cepas de E. 
coli derivadas de casos consecutivos de infecciones extraintestinales aisladas a lo largo 
del año 2016 en España (100 cepas procedentes del hospital Lucus Augusti de Lugo) y 
Francia (96 cepas procedentes del hospital Beaujon de Clichy). Determinamos los 
filogrupos, clonotipos, secuencias tipo (ST), serotipos O:H, genes que codifican FV y 
genes que codifican resistencia a los antibióticos. Observamos que aproximadamente el 
10% de las infecciones fueron causadas por cepas del clon ST131 en ambos hospitales y 
que aproximadamente el 60% de estas infecciones fueron causadas por cepas 
pertenecientes a solo 10 STs (ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, 
ST131 y ST141). Las cepas ST88 fueron frecuentes, especialmente en España, mientras 
que las cepas ST141 fueron significativamente predominantes en Francia. Identificamos 
23 cepas ST131 que representaron cuatro clonotipos: CH40-30, CH40-41, CH40-22 y 
CH40-298. Sólo 13 (6,6%) cepas fueron portadoras de β-lactamasas de espectro 
extendido (BLEE). Sin embargo, el 37,2% de las cepas fueron MDR. Aproximadamente 
el 40% de las cepas MDR pertenecieron a tan sólo cuatro de los clones dominantes (B2-
CH40-30-ST131, B2-CH40-41-ST131, C-CH4-39-ST88 y D-CH35-27-ST69). Entre las 
cepas MDR restantes, dos pertenecieron al clon B2-CH14-64-ST1193, es decir, el nuevo 
clon MDR emergente a nivel mundial. Además, identificamos una cepa híbrida ExPEC-
enteroagregativa perteneciente al clon A-CH11-54-ST10. 
En el segundo estudio, completamos el análisis molecular de un total de 188 cepas de 
E. coli productoras BLEE recolectadas a lo largo del año 2015 en el hospital universitario 
Lucus Augusti y el hospital AP-HP Beaujon, con objeto de analizar los clados y subclados 
del clon ST131, otros STs y caracterizar los tipos de enzimas BLEE producidos, los 
serotipos y los genes que codifican FV. ST131 se detectó en 33 (39,1%) y 46 (47,9%) de 
los aislamientos procedentes del hospital Lucus Augusti y del hospital Beaujon, 
respectivamente. Las 109 cepas restantes constituyeron 57 STs diferentes, donde las 
siguientes STs incluyeron al menos tres representantes: ST10 (8 cepas), ST23 (3), ST38 
(4), ST58 (3), ST88 (5), ST95 (4), ST167 (3), ST354 (5), ST361 (3), ST410 (6), ST648 




más frecuentes en Lucus Augusti (5,4%, 6,5% y 6,5%) que en Beaujon (0% para las tres 
STs). Además, describimos dos cepas pertenecientes al clon emergente B2-CH14-64-
ST1193. CTX-M-15 fue la enzima BLEE detectada con mayor frecuencia en los dos 
hospitales (44,6% en Lucus Augusti y 50,0% en Beaujon). CTX-M-14 fue 
significativamente (P=0,0003) más frecuente en Lucus Augusti (31,5%) que en Beaujon 
(10,4%), mientras que CTX-M-1 (20,8% versus 7,6%; P=0,008) y CTX-M-27 (15,6% 
versus 6,5%; P=0,0389) fueron más frecuentes en Beaujon que en Lucus Augusti. Las 
cepas ST131 presentaron una media de genes que codifican FV superior (media 13,367) 
en comparación con las cepas no-ST131 (media 7,661) (P <0,001). De entre las 79 cepas 
ST131, la mayoría (52; 65,8%) pertenecieron al subclado C2 (también conocido como 
subclón H30Rx), seguidas por cepas pertenecientes al subclado C1 (grupo C1-M27: 16 
cepas, 20,3%; grupo no C1-M27: 6 cepas, 7,6%) y al clado A (4 cepas; 5,1%). Además, 
las cepas del subclado C2 mostraron una media de genes que codifican FV superior 
(media 14,250) que las cepas pertenecientes al grupo C1-M27 (media 10,875) (P <0,001). 
En el tercer estudio, analizamos la formación biopelículas en cepas de E. coli 
productoras de infecciones extraintestinales en seres humanos. La formación de 
biopelículas en E. coli ha sido evaluada principalmente en grupos específicos de E. coli 
patógenos. Aquí evaluamos la formación temprana de biopelículas (EBF), es decir, la 
etapa de adhesión, utilizando el BioFilm Ring Test® en 394 aislados de origen clínico de 
E. coli (EC) [196 casos consecutivos (ECC) en 2016 y 198 E. coli productores de BLEE 
(ECBLEE) aislados en 2015]. Tras lo cual, la capacidad de formación de biopelículas se 
contrastó con los filogrupos, clonotipos (CH) y secuencias tipo (STs) utilizados para 
definir los clones, los factores de virulencia (FV) y FimB. De acuerdo con los niveles de 
producción de biopelículas a las 2h, 3h y 5h, y la cinética de EBF durante 5h, las cepas 
pertenecientes a ECC y ECBLEE se segregaron en tres grupos de EBF: fuertes 
productores (G1), moderados productores (G2) y débiles productores (G3). A las 2h, los 
fuertes productores fueron más frecuentes entre ECC (n=28; 14,3%) que entre ECBLEE 
(n=8; 4%) (P=0,0004). Como las cepas de ECC y ECBLEE mostraron cinéticas 
individuales de EBF similares por grupo, la comparación de las características de las 
cepas pertenecientes a cada grupo en las colecciones ECC y ECBLEE se aplicaron de 
forma conjunta tras 2h de incubación, siendo las 2h el tiempo de lectura más 
representativo de la segregación de cepas de ECC y ECBLEE en tres grupos. El filogrupo 
B2 representado por el 51,3% de las 394 cepas fue más frecuente en G1 (77,8%) que en 
G3 (47,6%) (P=0,0006). Las 394 cepas constituyeron 153 clones de los cuales 31 
incluyeron al menos tres representantes. Los clones B2-CH14-2-ST127, B2-CH40-22-
ST131, B2-CH52-5/14-ST141 y E-CH100-96-ST362 se asociaron con G1 (P<0,03) 
representando el 41,7% de las cepas de G1. El clon B2-CH40-30-ST131 se asoció con 
G3 (P <0,0001) representando el 25,5% de las cepas de G3. La media de FV fue mayor 
entre G1 que entre G3 (P<0,001). La variante proteica FimB-P2 se asoció con G1 
(P=0,0011) y la variante proteica FimB-P1 con G3 (P=0,0023). Los clones, algunos FV 
y FimB se asociaron con EBF, siendo el grupo clonal explicativo del 72% de la 
variabilidad de EBF. De las 394 cepas analizadas, menos del 10% fueron capaces de 
producir niveles altos de biopelícula de forma rápida y persistente durante 5 h. Estas cepas 
pertenecieron a un número limitado de clones descritos en varios estudios anteriores como 
colonizadores intestinales dominantes en mamíferos y aves, incluyendo el clon B2-CH40-
22-ST131, es decir, el antepasado del globalmente extendido clon B2-CH40-30-ST131 




En el cuarto estudio, buscamos profundizar en los conocimientos sobre el complejo 
clonal ST131 productor de BLEE de E. coli (grupo STC131 constituido por 30 genomas) 
y otros linajes de E. coli productores de BLEE emergentes (grupo no-STC131 constituido 
por 45 genomas), a través del análisis de la secuenciación del genoma completo de un 
total de 75 cepas BLEE de E. coli (51 genomas del hospital Lucus Augusti y 24 genomas 
del hospital de Beaujon). Estos genomas provienen de diferentes muestras clínicas: 57 
aislados de orina, 11 de sangre y 7 de diversas fuentes distintas, incluyendo una de bilis, 
una de líquido ascítico, una de hueso, dos de heridas y dos de infecciones digestivas. 
Llevamos a cabo una investigación filogenética que incluyó el análisis del CG y del 
plasmidoma. A través del análisis del CG, observamos correlación con los grupos 
filogenéticos de los genomas y describimos dos nuevos clados pertenecientes al complejo 
clonal ST131 representados por cepas con los alelos fimH5 y fimH35. Investigamos in 
silico la presencia de 164 genes que codifican FV y 13 mutaciones puntuales (MP) 
relacionadas con la expresión de resistencias a los antibióticos en el cromosoma de los 75 
genomas E. coli BLEE. El grupo de genomas STC131 presentó un promedio mayor de 
genes que codifican FV que el grupo de genomas no-STC131 (62 versus 47) y un 
promedio mayor de MP que el grupo no-STC131 (5 versus 3). Además, observamos una 
clara asociación entre el estatus ExPEC, el estatus UPEC y el grupo de genomas STC131 
(P<0,0001). Los 75 genomas BLEE albergaron 21 presuntos elementos conjugativos 
integradores (integrative conjugative elements) (ICEs) y un total de 228 plásmidos, de los 
cuales 86 (32%) hallados en el grupo STC131 y 142 (62%) hallados en el grupo no-
STC131. El 92% de los plásmidos pertenecieron a las familias de relaxasas MOBF, MOBP 
y MOBQ. Además, describimos una amplia diversidad de grupos de incompatibilidad 
(Inc.) siendo esta diversidad mayor en el grupo no-STC131 frente al grupo STC131 (12 
Inc. incluyendo Col-like, F, Q, I, X, Y, P, 13, HI2, N, R y B/O/K/Z versus 6 Inc. 
incluyendo Col-like, F, X, 13, N y B/O/K/Z, respectivamente). Observamos que los 
plásmidos de tipo Col e IncF fueron dominantes en ambos grupos de genomas. Los 
plásmidos IncF presentaron una composición variable siendo portadores de casi todos los 
genes de virulencia y resistencia hallados en el plasmidoma de los 75 genomas BLEE 
analizados. Además, localizamos los genes que codifican las enzimas BLEE en 67 de los 
75 genomas, de los cuales 21 estaban integrados en el cromosoma (31%) y 46 estaban 
vehiculados por plásmidos (69%). También observamos una correlación entre la 
presencia de tipos específicos de IncF y los diferentes clados de ST131. Encontramos dos 
genes codificadores de blaCTX-M-27 vehiculados por plásmidos [F1:A2:B20]-IncF y cinco 
genes codificadores de blaCTX-M-15 vehiculados por plásmidos [F2:A1:B-]-IncF asociados 
con los subclados C1 y C2, respectivamente. Todo ello aboga la existencia de una 
asociación plásmido-clado. Con respecto al clado A, describimos la presencia de 
plásmidos [F29:A-:B10]-IncF y la presencia de ICEs como características distintivas de 
los genomas del clado C. 
En el quinto estudio, bajo la perspectiva de “una sola salud” y la preocupación 
mundial por el incremento de las resistencias a los antimicrobianos, investigamos 197 
cepas de E. coli aisladas de perros sanos en España entre 2013 y 2017 para establecer las 
que eran ExPEC, UPEC y MDR. Un total de 91 (46,2 %) cepas se clasificaron a nivel 
molecular como ExPEC y/o UPEC, incluyendo 50 clones, entre los cuales cuatro clones 
fueron dominantes (B2-CH14-180-ST127, B2-CH52-14-ST141, B2-CH103-9-ST372 y 
F-CH4-58-ST648) y 15 habían sido previamente identificados entre las cepas que 
causaron infecciones extraintestinales en seres humanos españoles y franceses en 2015 y 




B1, D y E, y representadas por 24 clones, de los cuales ocho habían sido identificados 
previamente entre los aislados clínicos humanos. Seleccionamos 23 cepas ST372, 21 
cepas procedentes de perros sanos y dos cepas procedentes de aislados clínicos humanos 
para WGS, tras lo cual construimos un árbol filogenético basado en (single nucleotide 
polymorphisms) SNPs con estos 23 genomas y otros 174 genomas obtenidos de bases de 
datos públicas (128 procedentes de cepas de origen canino y 46 procedentes de cepas de 
origen humano). Estos 197 genomas se segregaron en seis grupos. El grupo 1 comprendió 
el 74,6% de los genomas, constituido en su mayoría por genomas de cepas de origen 
canino (P<0,00001). Los grupos 4 y 6 también incluyeron genomas de cepas de origen 
canino, mientras que los grupos 2, 3 y 5 se asociaron significativamente con genomas de 
cepas de origen humano. Encontramos varios clones con serotipos comunes entre los 
presentes en perros y seres humanos, lo cual sugiere una potencial transferencia 
bidireccional de clones, que respalda la perspectiva de un mundo con “una sola salud”. 
En el sexto estudio analizamos cepas pertenecientes al clon ST131 de origen porcino, 
las cuales están escasamente documentadas. Realizamos WGS, analizamos el CG y el 
plasmidoma de siete cepas procedentes de lechones con diarrea y cuatro cepas 
procedentes de carne de cerdo. Las 11 cepas pertenecieron al serotipo O25b:H4 y al clado 
B de ST131 presentando el alelo fimH22 o mutaciones alélicas derivadas del mismo. Las 
11 cepas codificaron FV que las clasificaron como equivalentes a patógenos aviares, 
uropatógenos y patógenos extraintestinales de E. coli (equivalentes a APEC, UPEC y 
ExPEC) y constituyeron el virotipo D. El CG se realizó incluyendo los genomas de todas 
las cepas de origen porcino además de 73 cepas ST131 de referencia con distintos 
orígenes. Dentro del clado B, el CG se segregó dando lugar a nueve subgrupos, lo que 
nos permitió describir cinco nuevos subclados (B6, B6-like, B7, B8, B9). Observamos 
una asociación entre las cepas pertenecientes al subclado B6, PST43, virotipo D2 y con 
origen alimentario, y una asociación entre cepas pertenecientes al subclado B7, PST9, 
virotipo D5 y procedentes de lechones con diarrea (P=0,007). La distancia entre los 
genomas de origen humano y porcino de los subclados B6 y B7 tuvo un promedio de 20 
SNP/Mb y 15 SNP/Mb, respectivamente. Los plásmidos [F2:A-:B1]-IncF, tipo ColE1 e 
IncX fueron los más prevalentes. Además, los plásmidos IncF codificaron una región 
ColV frecuente entre cepas APEC. Los genes de resistencia antimicrobiana hallados con 
mayor frecuencia fueron aquellos que confieren resistencia a la penicilina, tetraciclina, 
quinolonas y colistina. El gen mcr-1.1 se detectó en 5 de las 11 cepas de origen porcino, 
integrado en el cromosoma de una cepa y vehiculado por plásmidos en el resto (dos 
MOBH11/IncHI2-ST4, un MOBP3/IncX4 y un MOBF12/IncF [F2:A-:B1] supuestamente 
cointegrado con un IncHI2). Los entornos del casete mcr-1 mostraron variabilidad. Sin 
embargo, observamos estructuras conservadas dentro de una misma familia de plásmidos. 
En conclusión, el análisis del CG definió cinco nuevos subclados. Las cepas ST131 de 
origen porcino pertenecen a los nuevos subclados B6 y B7. Además, las cepas de origen 
clínico humanas y las cepas de origen porcino están estrechamente relacionadas. Las 11 
cepas ST131 porcinas albergaron una amplia variedad de plásmidos, genes de virulencia 
y resistencia. Además, los plásmidos epidémicos IncX4 e IncHI2 son responsables de la 
adquisición del gen mcr-1.1. Establecemos la hipótesis de que el plásmido APEC-IncF 
adquirió el gen mcr-1.1 mediante la cointegración de un plásmido IncHI2, lo cual es 
preocupante debido a la combinación de atributos de virulencia y resistencia en un solo 





De los resultados obtenidos, concluimos: 
1. Aproximadamente el 10% de las infecciones extraintestinales causadas por E. coli 
acontecidas en 2016 en los dos hospitales estudiados fueron causadas por cepas 
del clon ST131, y aproximadamente el 60% de estas infecciones fueron causadas 
por cepas pertenecientes a solo 10 STs (ST10, ST12, ST58, ST69, ST73, ST88, 
ST95, ST127, ST131 y ST141). 
2. La mayoría de las cepas ST12, ST73, ST95 y ST141 causantes de infecciones 
extraintestinales en seres humanos fueron susceptibles a la mayoría de los 
antibióticos, lo que indica que la MDR no fue la razón de su éxito. Los resultados 
del presente estudio apoyan la idea de que su éxito se debe principalmente a que 
albergan una gran cantidad de genes que codifican FV. 
3. Entre las cepas MDR causantes de infecciones extraintestinales en seres humanos, 
predominan cuatro clones: B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-
39-ST88 y D-CH35-27-ST69. 
4. A pesar de la enorme diversidad genética observada en nuestra colección de cepas 
de E. coli productoras de BLEE (71 clones presentes en 188 cepas BLEE), se 
puede concluir que la mayoría de las cepas pertenecen a solo tres complejos 
clonales (CC10, CC23 y CC131) y que el subclado C2 de ST131 asociado a la 
producción de CTX-M-15 sigue siendo el linaje de E. coli más prevalente entre 
las cepas de E. coli productoras de BLEE identificadas en los hospitales español 
y francés estudiados. 
5. Entre nuestras 394 cepas de E. coli procedentes de infecciones extraintestinales, 
<10% son capaces de producir niveles altos de biopelícula de forma rápida y 
persistente durante 5 h. Estas cepas pertenecen a unos pocos clones descritos 
previamente en varios estudios como colonizadores intestinales dominantes en 
mamíferos y aves, e incluyen al clon B2-CH40-22-ST131, es decir, el antepasado 
del globalmente extendido clon B2-CH40-30-ST131, que es el clon dominante 
entre las cepas débiles productores de biopelículas. 
6. En el análisis del CG de cepas de E. coli productoras de BLEE destaca la 
diversidad genómica, incluyendo representantes de los filogrupos A, B1, B2, C, 
E y F. Describimos dos nuevos clados en el complejo clonal ST131 representados 
por genomas que albergan los alelos fimH5 y fimH35. El clado C se caracteriza 
por mostrar una menor distancia de SNP en su genoma esencial en comparación 
a sus clados hermanos A y B. 
7. Existe una correlación entre los perfiles de genes que codifican FV y las STs. 
8. Existe una impresionante diversidad de plásmidos entre los genomas de E. coli 
productores de BLEE. Sin embargo, las familias de relaxasas MOBF, MOBP y 
MOBQ representan el 92% del plasmidoma y Col-like e IncF son los grupos de 
incompatibilidad más frecuentes. Además, la mayoría de los genes que codifican 
factores asociados a la virulencia y a la resistencia son vehiculados por plásmidos 
pertenecientes a la familia IncF. 
9. En el linaje ST131 la diversidad de grupos de incompatibilidad de plásmidos es 
mayor en el subclado C2 que en el clado A y el subclado C1-M27. El clado A está 
relacionado con la presencia de ICEs y plásmidos [F29:A-:B10]-IncF. 
10. El tracto intestinal de los perros sanos constituye un importante reservorio de 





11. Entre las cepas de origen canino que presentaron el estatus ExPEC y/o UPEC, el 
clon B2-CH103-9-ST372 fue dominante. 
12. El análisis de WGS sugiere que las cepas de origen canino del clon B2-CH103-9-
ST372, pertenecientes al grupo 1 (serotipos O4:H31, O21:H31 y O83:H31) y al 
grupo 6 (serotipo O6:H31) podrían causar infecciones extraintestinales tanto en 
seres humanos como en perros, mientras que las cepas de este clon pertenecientes 
al grupo 2 y los serotipos O18:H31 y O45:H31 podrían causar solo infecciones en 
seres humanos. 
13. El clado B de ST131 mostró una enorme diversidad genética y definimos cinco 
nuevos subclados (B6, B6-like, B7, B8 y B9). La mayoría de las cepas ST131 de 
origen porcino pertenecen a los nuevos subclados B6 y B7. 
14. La mayoría de las cepas de ST131 de origen porcino son MDR (91%) y albergan 
muchos genes de resistencia a los antibióticos. La resistencia a la colistina se 
introdujo a través de elementos genéticos móviles y logra estabilizarse en el 
cromosoma. Los plásmidos epidémicos IncX4 e IncHI2 que albergan el gen mcr-
1 son responsables de la resistencia adquirida a la colistina codificada por el gen 
mcr-1.1. El entorno circundante del casete mcr-1 es variable, pero dentro de la 
misma familia de plásmidos, la inserción y la estabilización conserva estructuras 
comunes. 
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Escherichia coli é a principal causa de infeccións do tracto urinario (ITU) e do 
torrente sanguíneo en seres humanos e animais. A maioría destas infeccións débense a 
cepas de patotipos coñecidos como E. coli patóxeno extraintestinal (ExPEC) ou E. coli 
uropatóxeno (UPEC). Asociáronse numerosos xenes de virulencia con cepas que causan 
infeccións extraintestinales, como adhesinas, toxinas, sideróforos e antíxenos capsulares, 
que lles permiten colonizar as superficies do hóspede, capturar o ferro dispoñible, danar 
os tecidos do hospedador e evitar os sistemas de defensa do hospedador. O tratamento 
destas infeccións complicouse seriamente pola aparición de cepas multirresistentes 
(MDR) e especialmente pola rápida diseminación de cepas de E. coli produtoras de β- 
lactamasas de espectro estendido (ECBLEE). 
 
A presente tese doutoral inclúe cinco publicacións (Flament-Simon SC et al..2020 
Antibiotics 9 (4) 161 doi. org/10.3390/ antibiotics9040161; Flament- Simon SC et 
al.2020 Front Cell Infect Microbiol 10: 125 doi: 10.3389/ fcimb .2020.00125; Flament- 
Simon SC et al.2019 Front Microbiol 10: 1183 doi: 10.3389/ fmicb.2019.01183; Flament- 
Simon SC et al. 2020 Microorganims 8 (11): E1712 doi: 10.3390/ microorganisms 
8111712; Flament- Simon SC et al. 2020 Front Microbiol 2020 11: 387 doi: 10.3389/ 
fmicb.2020.00387) e datos sen publicar cos seguintes obxectivos: 
 
I. Avaliar a prevalencia da secuencia tipo 131 (ST131) e os seus subclones entre 
cepas de E. coli causantes de infeccións extraintestinales en seres humanos illadas 
de casos consecutivos en 2016 e entre cepas ECBLEE illadas en 2015, en dous 
hospitais (hospital universitario Lucus Augusti e hospital AP-HP Beaujon), 
prestando especial atención á aparición de novos clons altamente virulentos e/ou 
MDR.  
II. Adquirir coñecemento das características fenotípicas e xenotípicas das cepas 
ST131 e outros clons de alto risco illados de seres humanos e animais, 
determinando os filogrupos, clonotipos, secuencias tipo (STs), serotipos O:H, 
xenes que codifican Factores de Virulencia (FV), resistencia aos antibióticos, 
ademais da secuenciación do xenoma completo (whole genome sequencing) 
(WGS) dun subconxunto de cepas para realizar a análise do seu xenoma esencial 
(core genome) (CG) e do seu plasmidoma.  
III. Adquirir coñecementos sobre a formación temperá de biopelículas (early biofilm 
formation) (EBF) en cepas de E. coli implicadas en infeccións extraintestinales e 
comparar a capacidade de formación de biopelículas coas características 
xenotípicas das cepas.  
IV. Estudar animais de produción (porcos) e animais de compañía (cans) como 
reservorios de cepas ST131 e outros clons de alto risco para seres humanos e 
investigar a posible transferencia de clons.  
 
En total realizamos seis estudos de epidemioloxía molecular, así como unha análise 
xenómica de cepas de E. coli. Nos catro primeiros estudos analizamos un total de 394 
cepas produtoras de infeccións extraintestinales extraídas de dous hospitais (hospital 
Lucus Augusti de Lugo e hospital Beaujon de París), mentres que nos dous estudos 
restantes analizamos cepas de orixe canina e porcina. A caracterización fenotípica inclúe: 




determinación de biopelículas. A caracterización molecular inclúe: (I) a descrición dos 
perfís de virulencia a través da identificación de xenes que codifican FV mediante a 
reacción en cadea da polimerasa ( PCR) seguida da definición dos status de virulencia 
vinculados a patotipos, (II) a descrición de perfís de resistencias aos antibióticos mediante 
PCR seguida da secuenciación de amplicones, (III) a determinación dos grupos 
filoxenéticos de E. coli mediante PCR, (IV) a determinación de clonotipos (fumC-fimH) 
e secuencias tipo (STs) mediante PCR seguida da secuenciación de amplicones, (VI) a 
identificación dos clados e subclados de E. coli ST131 por PCR, (VII) a identificación do 
xene fimB por PCR seguida da secuenciación de amplicones nun subconxunto de cepas 
da colección de bacterias de orixe humana e finalmente, (VIII) realizamos a secuenciación 
do xenoma completo (WGS) dun total de 109 cepas de E. coli pertencentes a tres estudos 
diferentes, permitíndonos realizar a análise do CG e do plasmidoma. A análise estatística 
inclúe a proba de normalidade de Shapiro- Wilk, a proba non paramétrica de Mann- 
Whitney- Wilcoxon, a proba exacta de Fisher e a proba de análise de varianza (ANOVA). 
Os valores P<0,05 consideráronse estatisticamente significativos. A correlación entre 
variables cuantitativas avaliouse mediante o coeficiente de correlación de Pearson, e a 
avaliación da reproductibilidad realizouse mediante o método estatístico de Bland e 
Altman, (1986).  
No primeiro estudo realizamos a análise molecular dun total de 196 cepas de E. coli 
derivadas de casos consecutivos de infeccións extraintestinales illadas ao longo do ano 
2016 en España (100 cepas procedentes do hospital Lucus Augusti de Lugo) e Francia 
(96 cepas procedentes do hospital Beaujon de Clichy). Determinamos os filogrupos, 
clonotipos, secuencias tipo (STs), serotipos O:H, xenes que codifican FV e xenes que 
codifican resistencia aos antibióticos. Observamos que aproximadamente o 10% das 
infeccións foron causadas por cepas do clon ST131 en ambos os hospitais e que 
aproximadamente o 60% destas infeccións foron causadas por cepas pertencentes a só 10 
STs (ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, ST131 e ST141). As cepas 
ST88 foron frecuentes, especialmente en España, mentres que as cepas ST141 foron 
significativamente predominantes en Francia. Identificamos 23 cepas ST131 que 
representaron catro clonotipos: CH40-30, CH40-41, CH40-22 e CH40-298. Só 13 (6,6%) 
cepas foron portadoras de β-lactamasas de espectro estendido (BLEE). Con todo, o 37,2% 
das cepas foron MDR. Aproximadamente o 40% das cepas MDR pertenceron a tan só 
catro dos clons dominantes (B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-39- ST88 
e D- CH35-27- ST69). Entre as cepas MDR restantes, dúas pertenceron ao clon B2-CH14-
64-ST1193, é dicir, o novo clon MDR emerxente a nivel mundial. Ademais, identificamos 
unha cepa híbrida ExPEC-enteroagregativa pertencente ao clon A-CH11-54-ST10. 
No segundo estudo, completamos a análise molecular dun total de 188 cepas de E. 
coli produtoras BLEE colleitadas ao longo do ano 2015 no hospital universitario Lucus 
Augusti e o hospital AP- HP Beaujon, con obxecto de analizar os clados e subclados do 
clon ST131, outros STs e caracterizar os tipos de encimas BLEE producidos, os serotipos 
e os xenes que codifican FV. ST131 detectouse en 33 (39,1%) e 46 (47,9%) dos 
illamentos procedentes do hospital Lucus Augusti e do hospital Beaujon, 
respectivamente. As 109 cepas restantes constituíron 57 STs diferentes, onde as seguintes 
STs incluíron polo menos tres representantes: ST10 (8 cepas), ST23 (3), ST38 (4), ST58 
(3), ST88 (5), ST95 (4), ST167 (3), ST354 (5), ST361 (3), ST410 (6), ST648 (4), ST744 
(3) e ST1615 (6). ST354, ST410 e ST1615 foron significativamente (P <0,05) máis 
frecuentes en Lucus Augusti (5,4%, 6,5% e 6,5%) que en Beaujon (0% para as tres ST). 




CTX- M-15 foi a encima BLEE detectada con maior frecuencia nos dous hospitais (44,6% 
en Lucus Augusti e 50,0% en Beaujon). CTX-M-14 foi significativamente (P=0,0003) 
máis frecuente en Lucus Augusti (31,5%) que en Beaujon (10,4%), mentres que CTX- 
M-1 (20,8% versus 7,6%; P=0,008) e CTX-M-27 (15,6% versus 6,5%; P=0,0389) foron 
máis frecuentes en Beaujon que en Lucus Augusti. As cepas ST131 presentaron unha 
media de xenes que codifican FV superior (media 13,367) en comparación coas cepas 
non- ST131 (media 7,661) (P <0,001). De entre as 79 cepas ST131, a maioría (52; 65,8%) 
pertenceron ao subclade C2 (tamén coñecido como subclón H30Rx), seguidas por cepas 
pertencentes ao subclade C1 (grupo C1-M27: 16 cepas, 20,3%; grupo non-C1-M27: 6 
cepas, 7,6%) e ao clado A (4 cepas; 5,1%). Ademais, as cepas do subclade C2 mostraron 
unha media de xenes que codifican FV superior (media 14,250) que as cepas pertencentes 
ao grupo C1-M27 (media 10,875) (P <0,001).  
No terceiro estudo, analizamos a formación de biopelículas en cepas de E. coli 
produtoras de infeccións extraintestinales en seres humanos. A formación de biopelículas 
en E. coli foi avaliada principalmente en grupos específicos de E. coli patóxenos. Aquí 
avaliamos a formación temperá de biopelículas (EBF), é dicir, a etapa de adhesión, 
utilizando o BioFilm Ring Test® en 394 illados de orixe clínica de E. coli (EC) [196 
casos consecutivos (ECC) en 2016 e 198 E. coli produtores de BLEE (ECBLEE) illados 
en 2015]. Tras o cal, a capacidade de formación de biopelículas contrastouse cos 
filogrupos, clonotipos (CH) e secuencias tipo (ST) utilizados para definir os clons, os 
factores de virulencia (FV) e FimB. De acordo cos niveis de produción de biopelículas ás 
2h, 3h e 5h, e a cinética de EBF durante 5h, as cepas pertencentes a ECC e ECBLEE se 
segregaron en tres grupos de EBF: fortes produtores (G1), moderados produtores (G2) e 
débiles produtores (G3). Ás 2h, os fortes produtores foron máis frecuentes entre ECC 
(n=28; 14,3%) que entre ECBLEE (n=8; 4%) (P=0,0004). Como as cepas de ECC e 
ECBLEE mostraron cinéticas individuais de EBF similares por grupo, a comparación das 
características das cepas pertencentes a cada grupo nas coleccións ECC e ECBLEE 
aplicáronse de forma conxunta tras 2h de incubación, sendo as 2h o tempo de lectura máis 
representativo da segregación de cepas de ECC e ECBLEE en tres grupos. O filogrupo 
B2 representado polo 51,3% das 394 cepas foi máis frecuente en G1 (77,8%) que en G3 
(47,6%) (P=0,0006). As 394 cepas constituíron 153 clons dos cales 31 incluíron polo 
menos tres representantes. Os clons B2-CH14-2-ST127, B2-CH40-22-ST131, B2-CH52-
5/14-ST141 e E-CH100-96-ST362 asociáronse con G1 (P <0,03) representando o 41,7% 
das cepas de G1. O clon B2-CH40-30-ST131 asociouse con G3 (P<0,0001) representando 
o 25,5% das cepas de G3. A media de FV foi maior entre G1 que entre G3 (P <0,001). A 
variante proteica FimB-P2 asociouse con G1 (P = 0,0011) e a variante proteica FimB-P1 
con G3 (P=0,0023). Os clons, algúns FV e FimB asociáronse con EBF, sendo o grupo 
clonal explicativo do 72% da variabilidade de EBF. Das 394 cepas analizadas, menos do 
10% foron capaces de producir niveis altos de biopelícula de forma rápida e persistente 
durante 5h. Estas cepas pertenceron a un número limitado de clons descritos en varios 
estudos anteriores como colonizadores intestinais dominantes en mamíferos e aves, 
incluíndo o clon B2-CH40-22-ST131, é dicir, o antepasado do globalmente estendido 
clon B2-CH40-30-ST131 dominante no grupo de cepas débiles produtoras de biopelículas 
(G3).  
No cuarto estudo, buscamos profundar nos coñecementos sobre o complexo clonal 
ST131 produtor de BLEE de E. coli (grupo STC131 constituído por 30 xenomas) e outras 
liñaxes de E. coli produtores de BLEE emerxentes (grupo non-STC131 constituído por 




cepas BLEE de E. coli (51 xenomas do hospital Lucus Augusti e 24 xenomas do hospital 
de Beaujon). Estes xenomas proveñen de diferentes mostras clínicas: 57 illados de 
ouriños, 11 de sangue e 7 de diversas fontes, incluíndo unha de bilis, unha de líquido 
ascítico, unha de óso, dous de feridas e dúas de infeccións dixestivas. Levamos a cabo 
unha investigación filoxenética que incluíu a análise do CG e do plasmidoma. A través 
da análise do CG, observamos correlación cos grupos filoxenéticos dos xenomas e 
describimos dous novos clados pertencentes ao complexo clonal ST131 representados por 
cepas cos alelos fimH5 e fimH35. Investigamos in silico a presenza de 164 xenes que 
codifican FV e 13 mutacións puntuais (MP) relacionadas coa expresión de resistencias 
aos antibióticos no cromosoma dos 75 xenomas E. coli BLEE. O grupo de xenomas 
STC131 presentou unha media maior de xenes que codifican FV que o grupo de xenomas 
non-STC131 (62 versus 47) e unha media maior de MP que o grupo non-STC131 (5 
versus 3). Ademais, observamos unha clara asociación entre o status ExPEC, o status 
UPEC e o grupo de xenomas STC131 (P <0,0001). Os 75 xenomas BLEE albergaron 21 
presuntos elementos conxugativos integradores (integrative conjugative elements) (ICEs) 
e un total de 228 plásmidos, dos cales 86 (32%) achados no grupo STC131 e 142 (62%) 
achados no grupo non-STC131. O 92% dos plásmidos pertenceron ás familias de 
relaxasas MOBF, MOBP e MOBQ. Ademais, describimos unha ampla diversidade de 
grupos de incompatibilidade (Inc.) sendo esta diversidade maior no grupo non-STC131 
fronte ao grupo STC131 (12 Inc. incluíndo Col- like, F, Q, I, X, E, P, 13, HI2, N, R e 
B/O/K/Z versus 6 Inc. incluíndo Col- like, F, X, 13, N e B/ O/K/Z, respectivamente). 
Observamos que os plásmidos de tipo Col e IncF foron dominantes en ambos os grupos 
de xenomas. Os plásmidos IncF presentaron unha composición variable sendo portadores 
de case todos os xenes de virulencia e resistencia achados no plasmidoma dos 75 xenomas 
BLEE analizados. Ademais, localizamos os xenes que codifican as encimas BLEE en 67 
dos 75 xenomas, dos cales 21 estaban integrados no cromosoma (31%) e 46 estaban 
vehiculados por plásmidos (69%). Tamén observamos unha correlación entre a presenza 
de tipos específicos de IncF e os diferentes clados de ST131. Atopamos dous xenes 
codificadores de blaCTX- M-27 vehiculados por plásmidos [F1:A2:B20]-IncF e cinco xenes 
codificadores de blaCTX- M-15 vehiculados por plásmidos [F2:A1:B-]-IncF asociados cos 
subclados C1 e C2, respectivamente. Todo iso avoga a existencia dunha asociación 
plásmido- clado. Con respecto ao clado A, describimos a presenza de plásmidos [F29:A-
:B10]-IncF e a presenza de ICEs como características distintivas dos xenomas do clado 
C.  
No quinto estudo, baixo a perspectiva de “unha soa saúde” e a preocupación mundial 
polo incremento das resistencias aos antimicrobianos, investigamos 197 cepas de E. coli 
illadas de cans sans en España entre 2013 e 2017 para ExPEC, UPEC e MDR. Un total 
de 91 (46,2 %) cepas clasificáronse a nivel molecular como ExPEC e/ou UPEC, incluíndo 
50 clons, entre os cales catro clons foron dominantes (B2-CH14-180-ST127, B2-CH52-
14-ST141, B2-CH103-9-ST372 e F-CH4-58-ST648) e 15 foran previamente 
identificados entre as cepas que causaron infeccións extraintestinales en seres humanos 
españois e franceses en 2015 e 2016. Un total de 28 (14.2%) cepas clasificáronse como 
MDR, asociadas aos filogrupos B1, D e E, e representadas por 24 clons, dos cales oito 
foran identificados previamente entre os illados clínicos humanos. Seleccionamos 23 
cepas ST372, 21 cepas procedentes de cans sans e dúas cepas procedentes de illados 
clínicos humanos para WGS, tras o cal construímos unha árbore filoxenética baseado en 
(single nucleotide polymorphisms) SNPs con estes 23 xenomas e outros 174 xenomas 




procedentes de cepas de orixe humana). Estes 197 xenomas se segregaron en seis grupos. 
O grupo 1 comprendeu o 74,6% dos xenomas, constituído na súa maioría por xenomas 
de cepas de orixe canina (P<0,00001). Os grupos 4 e 6 tamén incluíron xenomas de cepas 
de orixe canina, mentres que os grupos 2, 3 e 5 asociáronse significativamente con 
xenomas de cepas de orixe humana. Atopamos varios clons con serotipos comúns entre 
os presentes en cans e seres humanos, o cal suxire unha potencial transferencia 
bidireccional de clons, que apoia a perspectiva dun mundo con “unha soa saúde”.  
No sexto estudo analizamos cepas pertencentes ao clon ST131 de orixe porcina, as 
cales están escasamente documentadas. Realizamos WGS, analizamos o CG e o 
plasmidoma de sete cepas procedentes de leitóns con diarrea e catro cepas procedentes de 
carne de porco. As 11 cepas pertenceron ao serotipo O25b:H4 e ao clado B de ST131 
presentando o alelo fimH22 ou mutacións alélicas derivadas do mesmo. As 11 cepas 
codificaron FV que as clasificaron como equivalentes a patóxenos aviarias, uropatóxenos 
e patóxenos extraintestinales de E. coli (equivalentes a APEC, UPEC e ExPEC) e 
constituíron o virotipo D. O CG realizouse incluíndo os xenomas de todas as cepas de 
orixe porcina ademais de 73 cepas ST131 de referencia con distintas orixes. Dentro do 
clado B, o CG se segregou dando lugar a nove subgrupos, o que nos permitiu describir 
cinco novos subclados (B6, B6- like, B7, B8, B9). Observamos unha asociación entre as 
cepas pertencentes ao subclade B6, PST43, virotipo D2 e con orixe alimentaria, e unha 
asociación entre cepas pertencentes ao subclade B7, PST9, virotipo D5 e procedentes de 
leitóns con diarrea (P=0,007). A distancia entre os xenomas de orixe humana e porcina 
dos subclados B6 e B7 tivo unha media de 20 SNP/Mb e 15 SNP/Mb, respectivamente. 
Os plásmidos [F2:A-:B1]-IncF, tipo COLE1 e IncX foron os máis prevalecentes. 
Ademais, os plásmidos IncF codificaron unha rexión ColV frecuente entre cepas APEC. 
Os xenes de resistencia antimicrobiana achados con maior frecuencia foron aqueles que 
confiren resistencia á penicilina, tetraciclina, quinolonas e colistina. O xene mcr-1.1 
detectouse en 5 das 11 cepas de orixe porcina, integrado no cromosoma dunha cepa e 
vehiculado por plásmidos no resto (dous MOBH11/IncHI2-ST4, un MOBP3/IncX4 e un 
MOBF12/IncF [F2:A-:B1] supostamente cointegrado cun IncHI2). As contornas do casete 
mcr-1 mostraron variabilidade. Con todo, observamos estruturas conservadas dentro de 
una mesma familia de plásmidos. En conclusión, a análise do CG definiu cinco novos 
subclados. As cepas ST131 de orixe porcina pertencen aos novos subclados B6 e B7. 
Ademais, as cepas de orixe clínica humanas e as cepas de orixe porcina están 
estreitamente relacionadas. As 11 cepas ST131 porcinas albergaron unha ampla variedade 
de plásmidos, xenes de virulencia e resistencia. Ademais, os plásmidos epidémicos IncX4 
e IncHI2 son responsables da adquisición do xene mcr-1.1. Establecemos a hipótese de 
que o plásmido APEC-IncF adquiriu o xene mcr-1.1 mediante a cointegración dun 
plásmido IncHI2, o cal é preocupante debido á combinación de atributos de virulencia e 
resistencia nun só elemento xenético móbil.  
 
Dos resultados obtidos, concluímos: 
1. Aproximadamente o 10% das infeccións extraintestinales causadas por E. coli 
acontecidas en 2016 nos dous hospitais estudados foron causadas por cepas 
do clon ST131, e aproximadamente o 60% destas infeccións foron causadas 
por cepas pertencentes a só 10 STs ( ST10, ST12, ST58, ST69, ST73, ST88, 





2. A maioría das cepas ST12, ST73, ST95 e ST141 causantes de infeccións 
extraintestinales en seres humanos foron susceptibles á maioría dos 
antibióticos, o que indica que a MDR non foi a razón do seu éxito. Os 
resultados do presente estudo apoian a idea de que o seu éxito débese 
principalmente a que albergan unha gran cantidade de xenes que codifican FV. 
3. Entre as cepas MDR causantes de infeccións extraintestinales en seres 
humanos, predominan catro clons: B2-CH40-30-ST131, B2-CH40-41-ST131, 
C-CH4-39-ST88 e D-CH35-27-ST69. 
4. A pesar da enorme diversidade xenética observada na nosa colección de cepas 
de E. coli produtoras de BLEE (71 clons presentes en 188 cepas BLEE), 
pódese concluír que a maioría das cepas pertencen a só tres complexos 
clonales (CC10, CC23 e CC131) e que ST131 subclade C2 asociado á 
produción de CTX- M-15 segue sendo a liñaxe de E. coli máis prevalecente 
entre as cepas de E. coli produtoras de BLEE identificadas nos hospitais 
español e francés estudados. 
5. Entre as nosas 394 cepas de E. coli procedentes de infeccións extraintestinales, 
<10% son capaces de producir niveis altos de biopelícula de forma rápida e 
persistente durante 5 h. Estas cepas pertencen a uns poucos clons descritos 
previamente en varios estudos como colonizadores intestinais dominantes en 
mamíferos e aves, e inclúen ao clon B2-CH40-22-ST131, é dicir, o antepasado 
do globalmente estendido clon B2-CH40-30-ST131, que é o clon dominante 
entre as cepas débiles produtores de biopelículas. 
6. Na análise do CG de cepas de E. coli produtoras de BLEE destaca a 
diversidade xenómica. Incluíndo representantes dos filogrupos A, B1, B2, C, 
E e F. Describimos dous novos clados no complexo clonal ST131 
representados por xenomas que albergan os alelos fimH5 e fimH35. O clado C 
caracterízase por mostrar unha menor distancia de SNP no seu xenoma 
esencial en comparación ás súas clados irmáns A e B. 
7. Existe unha correlación entre os perfís de xenes que codifican FV e as STs. 
8. Existe unha impresionante diversidade de plásmidos entre os xenomas de E. 
coli produtores de BLEE. Con todo, as familias de relaxasas MOBF, MOBP e 
MOBQ representan o 92% do plasmidoma e Col-like e IncF son os grupos de 
incompatibilidade máis frecuentes. Ademais, a maioría dos xenes que 
codifican factores asociados á virulencia e á resistencia son vehiculados por 
plásmidos pertencentes á familia IncF. 
9. Na liñaxe ST131 a diversidade de grupos de incompatibilidade de plásmidos 
é maior no subclado C2 que no clado A e o subclado  C1-M27. O clado A está 
relacionado coa presenza de ICEs e plásmidos [F29:A-:B10]-IncF. 
10. O tracto intestinal dos cans sans constitúe un importante reservorio de cepas 
ExPEC e/ou UPEC e, en menor medida, de cepas de E. coli MDR. 
11. Entre as cepas de orixe canina que presentaron o status ExPEC e/ou UPEC, o 
clon B2-CH103-9-ST372 foi dominante. 
12. A análise de WGS suxire que as cepas de orixe canina do clon B2-CH103-9- 
ST372, pertencentes ao grupo 1 (serotipos O4:H31, O21:H31 e O83:H31) e 
ao grupo 6 (serotipo O6:H31) poderían causar infeccións extraintestinales 
tanto en seres humanos como en cans, mentres que as cepas deste clon 
pertencentes ao grupo 2 e os serotipos O18:H31 e O45:H31 poderían causar 




13. O clado B de ST131 mostrou unha enorme diversidade xenética e definimos 
cinco novos subclados (B6, B6-like, B7, B8 e B9). A maioría das cepas ST131 
de orixe porcina pertencen aos novos subclados B6 e B7. 
14. A maioría das cepas de ST131 de orixe porcina son MDR (91%) e albergan 
moitos xenes de resistencia aos antibióticos. A resistencia á colistina 
introduciuse a través de elementos xenéticos móbiles e logra estabilizarse no 
cromosoma. Os plásmidos epidémicos IncX4 e IncHI2 que albergan o xene 
mcr-1 son responsables da resistencia adquirida á colistina codificada polo 
xene mcr-1.1. A contorna circundante do casete mcr-1 é variable, pero dentro 
da mesma familia de plásmidos, a inserción e a estabilización conserva 
estruturas comúns.  
 
Palabras chave: Escherichia coli, E. coli, estrutura clonal, formación de biofilm, 
xenes de virulencia, resistencia a antibióticos; β-lactamases, CTX-M, BLEE, ExPEC, 
UPEC, clons de alto risco, ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, ST131, 









Escherichia coli est la principale cause d'infections des voies urinaires (IVU) et de la 
circulation sanguine chez l'homme et l'animal. La plupart de ces infections sont dues à 
des souches d'agents pathogènes connus comme E. coli pathogène extraintestinales 
(ExPEC) ou E. coli uropathogènes (UPEC). Nombreux gènes de virulence ont été 
associés à des souches qui provoquent des infections extraintestinales, telles que les 
adhésines, les toxines, les sidérophores et les antigènes capsulaires, qui leur permettent 
de coloniser les surfaces de l'hôte, de capturer le fer disponible, d'endommager les tissus 
de l'hôte et de contourner les systèmes de défense de l'hôte. Le traitement de ces infections 
a été sérieusement compliqué par l'émergence de souches multirésistantes (MDR) et en 
particulier par la rapide propagation de souches d'E. coli productrices de β-lactamases à 
spectre étendu (ECBLSE). 
 
La présente thèse de doctorat comprend cinq publications (Flament-Simon SC et al. 
2020 Antibiotics 9 (4) 161 doi.org/10.3390/antibiotics9040161; Flament-Simon SC et al. 
2020 Front Cell Infect Microbiol 10: 125 doi: 10.3389/fcimb .2020.00125; Flament-
Simon SC et al. 2019 Front Microbiol 10: 1183 doi: 10.3389/fmicb.2019.01183; Flament-
Simon SC et al. 2020 Microorganims 8 (11): E1712 doi: 10.3390/microorganisms 
8111712; Flament-Simon SC et al. 2020 Front Microbiol 2020 11: 387 doi: 
10.3389/fmicb.2020.00387) et des données non publiées avec les objectifs suivants: 
 
I. Évaluer la prévalence de la séquence type 131 (ST131) et de ses sous-clones parmi 
les souches d'E. coli provoquant des infections extraintestinales chez l'homme 
isolées de cas consécutifs en 2016 et parmi des souches ECBLSE isolées en 2015, 
dans deux hôpitaux (Hôpital universitaire Lucus Augusti et AP-HP Beaujon), en 
accordant une attention particulière à l'apparition de nouveaux clones hautement 
virulents et/ou MDR. 
II. Acquérir des connaissances sur les caractéristiques phénotypiques et 
génotypiques des souches ST131 et d'autres clones à haut risque isolés chez 
l'homme et l'animal, déterminer les phylogroupes, les clonotypes, les séquences 
type (ST), les sérotypes O:H, les gènes codant pour les Facteurs de Virulence 
(FV), la résistance aux antibiotiques, en plus du séquençage total du génome 
(whole genome sequencing) (WGS) d'un sous-ensemble de souches pour effectuer 
l'analyse de leur génome essentiel (core genome) (CG) et de leur plasmidome. 
III. Acquérir des connaissances sur la formation précoce de biofilm (early biofilm 
formation) (EBF) sur les souches d'E. coli impliquées dans des infections extra-
intestinales et comparer la capacité de formation de biofilm avec les 
caractéristiques génotypiques des souches. 
IV. Étudier les animaux d'élevage (porcs) et les animaux de compagnie (chiens) 
comme réservoirs des souches ST131 et d'autres clones à haut risque pour les 
humains et rechercher l'éventuel transfert de clones. 
 
Au total, nous avons mené six études d'épidémiologie moléculaire, ainsi qu'une 
analyse génomique des souches d'E. coli. Au cours des quatre premières études, nous 
avons analysé un total de 394 souches productrices d'infections extraintestinales prélevées 
dans deux hôpitaux (hôpital universitaire Lucus Augusti à Lugo et hôpital Beaujon à 




canine et porcine. La caractérisation phénotypique comprend: (I) le sérotypage, (II) les 
tests de sensibilité aux antibiotiques et (III) la détermination de production de biofilm. La 
caractérisation moléculaire comprend: (I) la description des profils de virulence par 
l'identification des gènes codant pour les FV au moyen de la réaction en chaîne par 
polymérase (PCR) suivie de la définition des profil de virulence liés aux pathotypes, (II) 
la description des profils de résistance aux antibiotiques par PCR suivi d'un séquençage 
d'amplicon, (III) la détermination des groupes phylogénétiques d'E. coli par PCR, (IV) la 
détermination des clonotypes (fumC-fimH) et des séquences type (ST) par PCR suivie 
d'un séquençage d'amplicon, (VI) l'identification des clades et sous-clades d'E. coli ST131 
par PCR, (VII) l'identification du gène fimB par PCR suivie d'un séquençage d'amplicon 
pour un sous-ensemble des souches de la collection de bactéries d'origine humain et 
finalement, (VIII) nous avons réalisé le WGS d'un total de 109 souches d'E. coli 
appartenant à trois études différentes, permettant d'effectuer l'analyse de leur GC et de 
leur plasmidome. L'analyse statistique comprend le test de normalité de Shapiro-Wilk, le 
test non paramétrique de Mann-Whitney-Wilcoxon, le test exact de Fisher et le test 
d'analyse de variance (ANOVA). Les valeurs P<0,05 ont été considérées comme 
statistiquement significatives. La corrélation entre les variables quantitatives a été évaluée 
en utilisant le coefficient de corrélation de Pearson, et l'évaluation de la reproductibilité a 
été réalisée en utilisant la méthode statistique de Bland et Altman, (1986). 
Au cours de la première étude, nous avons réalisé l'analyse moléculaire d'un total de 
196 souches d'E. coli dérivées de cas consécutifs d'infections extraintestinales isolés tout 
au long de 2016 en Espagne (100 souches de l'hôpital universitaire Lucus Augusti de 
Lugo) et en France (96 souches de l'Hôpital Beaujon de Clichy). Nous avons déterminé 
les phylogroupes, les clonotypes, les séquences type (ST), les sérotypes O:H, les gènes 
codant pour des FV et les gènes codant pour la résistance aux antibiotiques. Nous avons 
observé qu'environ 10% des infections étaient causées par des souches du clone ST131 
dans les deux hôpitaux et qu'environ 60% de ces infections étaient causées par des 
souches appartenant à seulement 10 STs (ST10, ST12, ST58, ST69, ST73, ST88, ST95, 
ST127, ST131 et ST141). Les souches ST88 étaient fréquentes, notamment en Espagne, 
tandis que les souches ST141 étaient significativement prédominantes en France. Nous 
avons identifié 23 souches ST131 qui représentaient quatre clonotypes: CH40-30, CH40-
41, CH40-22 et CH40-298. Seules 13 souches (6,6%) étaient porteuses de β-lactamases 
à spectre étendu (BLSE). Cependant, 37,2% des souches étaient MDR. Environ 40% des 
souches MDR appartenaient à seulement quatre des clones dominants (B2-CH40-30-
ST131, B2-CH40-41-ST131, C-CH4-39-ST88 et D-CH35-27-ST69). Parmi les souches 
MDR restantes, deux appartenaient au clone B2-CH14-64-ST1193, c'est-à-dire le 
nouveau clone MDR émergeant dans le monde. De plus, nous avons identifié une souche 
hybride ExPEC-enteroaggregative appartenant au clone A-CH11-54-ST10. 
Lors de la deuxième étude, nous avons effectué l'analyse moléculaire d'un total de 
188 souches d'E. coli productrices de BLSE collectées tout au long de 2015 à l'hôpital 
universitaire Lucus Augusti et à l'hôpital AP-HP Beaujon, afin d'analyser les clades et 
sous-clades du clone ST131, d'autres STs et caractériser les types d'enzymes BLSE 
produites, les sérotypes et les gènes codant pour des FV. ST131 a été détecté dans 33 
(39,1%) et 46 (47,9%) des isolats de l'hôpital universitaire Lucus Augusti et de l'hôpital 
Beaujon, respectivement. Les 109 souches restantes constituaient 57 STs différentes, où 
les STs suivantes comprenaient au moins trois représentants: ST10 (8 souches), ST23 (3), 
ST38 (4), ST58 (3), ST88 (5), ST95 (4), ST167 (3), ST354 (5), ST361 (3), ST410 (6), 




(P <0,05) plus fréquents chez Lucus Augusti (5,4%, 6,5% et 6,5%) qu'à Beaujon (0% 
pour les trois STs). De plus, nous décrivons deux souches appartenant au clone émergent 
B2-CH14-64-ST1193. CTX-M-15 a été l'enzyme BLSE la plus fréquemment détectée 
dans les deux hôpitaux (44,6% à Lucus Augusti et 50,0% à Beaujon). CTX-M-14 a été 
significativement (P=0,0003) plus fréquente à Lucus Augusti (31,5%) que chez Beaujon 
(10,4%), tandis que CTX-M-1 (20,8% versus 7, 6%; P=0,008) et CTX-M-27 (15,6% 
versus 6,5%; P=0,0389) étaient plus fréquentes à Beaujon qu'à Lucus Augusti. Les 
souches ST131 présentaient une moyenne de gènes codant pour des FV plus élevé 
(moyenne 13,367) par rapport aux souches non-ST131 (moyenne 7,661) (P<0,001). 
Parmi les 79 souches ST131, la majorité (52; 65,8%) appartenait au sous-clade C2 
(également appelé sous-clone H30Rx), suivi des souches appartenant au sous-clade C1 
(groupe C1-M27: 16 souches, 20,3%; non-C1 -Groupe M27: 6 souches, 7,6%) et au clade 
A (4 souches; 5,1%). De plus, les souches du sous-clade C2 présentaient une moyenne de 
gènes codant pour des FV plus élevé (moyenne de 14 250) que les souches appartenant 
au groupe C1-M27 (moyenne de 10 875) (P <0,001). 
Durant la troisième étude, nous avons analysé la formation de biofilm pour les 
souches d'E. coli qui causent des infections extraintestinales chez l'homme. La formation 
de biofilm sur E. coli a été évaluée principalement pour des groupes spécifiques d'E. coli 
pathogènes. Nous évaluons ici la formation précoce de biofilm (EBF), c'est-à-dire le stade 
d'adhésion, à l'aide du BioFilm Ring Test® pour 394 isolats d'origine clinique d'E. coli 
(EC) [196 cas consécutifs (ECC) isolés en 2016 et 198 E coli producteur de BLSE 
(ECBLSE) isolés en 2015]. Après quoi, la capacité de formation du biofilm a été 
comparée aux phylogroupes, clonotypes (CH) et séquences types (ST) utilisés pour 
définir les clones, les facteurs de virulence (FV) et FimB. Selon les niveaux de production 
de biofilm à 2h, 3h et 5h, et la cinétique EBF pendant 5h, les souches appartenant à ECC 
et ECBLSE ont été séparées en trois groupes EBF: forts producteurs (G1), producteurs 
modérés (G2) et faibles producteurs (G3). A 2h, les forts producteurs étaient plus 
fréquents chez ECC (n=28; 14,3%) que chez ECBLSE (n=8; 4%) (P=0,0004). Les 
souches ECC et ECBLSE présentaient une cinétique individuelle de EBF similaire par 
groupe, par conséquent, la comparaison des caractéristiques des souches appartenant à 
chaque groupe des collections ECC et ECBLSE a été appliquée ensemble après 2h 
d'incubation, étant les 2h le temps de lecture le plus représentative de la ségrégation des 
souches ECC et ECBLSE en trois groupes. Le phylogroupe B2 représenté par 51,3% des 
394 souches était plus fréquent chez G1 (77,8%) que parmi G3 (47,6%) (P=0,0006). Les 
394 souches constituaient 153 clones dont 31 comprenaient au moins trois représentants. 
Les clones B2-CH14-2-ST127, B2-CH40-22-ST131, B2-CH52-5/14-ST141 et E-
CH100-96-ST362 étaient associés à G1 (P <0,03) représentant 41,7% des souches G1. Le 
clone B2-CH40-30-ST131 était associé à G3 (P <0,0001) représentant 25,5% des souches 
G3. La moyenne des FV était plus élevée chez G1 que chez G3 (P <0,001). La variante 
protéique FimB-P2 a été associée à G1 (P=0,0011) et la variante protéique FimB-P1 à G3 
(P=0,0023). Les clones, certains FV et FimB étaient associés à l'EBF, le groupe clonal 
étant l'explicatif de 72% de la variabilité de l'EBF. Sur les 394 souches analysées, moins 
de 10% ont pu produire des niveaux élevés de biofilm rapidement et de manière 
persistante pendant 5 h. Ces souches appartenaient à un nombre limité de clones, décrits 
dans plusieurs études antérieures comme colonisateurs intestinaux dominants chez les 
mammifères et les oiseaux, dont le clone B2-CH40-22-ST131, c'est-à-dire l'ancêtre du 
clone globalement étendu B2-CH40-30-ST131 et dominant dans le groupe des souches 




Au cours de la quatrième étude, nous cherchons à approfondir les connaissances 
sur le complexe clonal ST131 produisant des BLSE d'E. coli (groupe STC131 composé 
de 30 génomes) et d'autres lignées d'E. coli émergentes produisant des BLSE (groupe 
non-STC131 composé de 45 génomes), par l'analyse du séquençage complet du génome 
d'un total de 75 souches BLSE d'E. coli (51 génomes de l'hôpital universitaire Lucus 
Augusti et 24 génomes de l'hôpital de Beaujon). Ces génomes proviennent de différents 
échantillons cliniques: 57 isolats d'urine, 11 isolats de sang et 7 isolats de différentes 
sources, dont un de bile, un d'ascite, un d'os, deux de plaies et deux d'infections digestives. 
Nous avons effectué une recherche phylogénétique comprenant l'analyse du GC et du 
plasmidome. Grâce à l'analyse du GC, nous avons observé une corrélation avec les 
groupes phylogénétiques des génomes et décrit deux nouveaux clades appartenant au 
complexe clonal ST131 représenté par des souches avec les allèles fimH5 et fimH35. Nous 
avons étudié in silico la présence de 164 gènes codant pour des FV et 13 mutations 
ponctuelles (MP) liées à l'expression de la résistance aux antibiotiques sur le chromosome 
des 75 génomes BLSE d'E. coli. Le groupe des génomes STC131 présentaient une 
moyenne plus élevé de gènes codant pour des FV que le groupe des génomes non-STC131 
(62 versus 47) et une moyenne plus élevée de MP que le groupe non-STC131 (5 versus 
3). En outre, nous avons observé une association claire entre le statut ExPEC, le statut 
UPEC et le groupe génomique STC131 (P <0,0001). Les 75 génomes BLSE abritaient 21 
présumés éléments conjugatifs intégratifs (ICE) et un total de 228 plasmides, dont 86 
(32%) trouvés dans le groupe STC131 et 142 (62%) trouvés dans le groupe non-STC131. 
92% des plasmides appartenaient aux familles de relaxases MOBF, MOBP et MOBQ. De 
plus, nous décrivons une grande diversité de groupes d'incompatibilité (Inc.), cette 
diversité étant plus grande dans le groupe non-STC131 par rapport au groupe STC131 
(12 Inc. incluant Col-like, F, Q, I, X, Y, P , 13, HI2, N, R et B/O/K/Z versus 6 Inc. y 
compris Col-like, F, X, 13, N et B/O/K/Z, respectivement). Nous avons observé que les 
plasmides de type Col et IncF étaient dominants dans les deux groupes de génomes. Les 
plasmides IncF présentaient une composition variable, étant porteurs de presque tous les 
gènes de virulence et de résistance trouvés dans le plasmidome des 75 génomes BLSE 
analysés. De plus, nous avons localisé les gènes codant pour les enzymes BLSE dans 67 
des 75 génomes, dont 21 étaient intégrés dans le chromosome (31%) et 46 étaient portés 
par des plasmides (69%). Nous avons également observé une corrélation entre la présence 
de types spécifiques d'IncF et les différents clades de ST131. Nous avons trouvé deux 
gènes codant pour blaCTX-M-27 portés par des plasmides [F1:A2:B20]-IncF et cinq gènes 
codants pour blaCTX-M-15 portés par des plasmides [F2:A1:B-]-IncF associés au sous-
clades C1 et C2, respectivement. Tout cela prône l'existence d'une association plasmide-
clade. Concernant le clade A, nous décrivons la présence de plasmides [F29:A-:B10]-
IncF et la présence d'ICE comme caractéristiques distinctives des génomes du clade C. 
Lors de la cinquième étude, du point de vue «une seule santé» et de la préoccupation 
mondiale concernant l'augmentation de la résistance aux antimicrobiens, nous avons 
étudié 197 souches d'E. coli isolées chez des chiens en bonne santé en Espagne entre 2013 
et 2017 pour etablir les quelles étaient ExPEC, UPEC et MDR. Un total de 91 (46,2%) 
souches ont été classées au niveau moléculaire en ExPEC et/ou UPEC, constituaient 50 
clones, parmi lesquels quatre clones dominaient (B2-CH14-180-ST127, B2-CH52-14-
ST141, B2-CH103-9-ST372 et F-CH4-58-ST648) et 15 avaient déjà été identifiées parmi 
les souches ayant causé des infections extraintestinales chez les patients espagnol et 
français en 2015 et 2016. Un total de 28 (14,2%) souches ont été classées comme MDR, 




préalablement identifiés parmi des isolats cliniques humains. Nous avons sélectionné 23 
souches ST372, 21 souches de chiens sains et deux souches d'isolats cliniques humains 
pour WGS, après quoi nous avons construit un arbre phylogénétique basé sur (single 
nucleotide polymorphisms) SNPs avec ces 23 génomes et 174 autres génomes obtenus à 
partir de bases de données publiques (128 souches d'origine canine et 46 souches d'origine 
humain). Ces 197 génomes ont été séparés en six groupes. Le groupe 1 comprenait 74,6% 
des génomes, constitués principalement de génomes de souches d'origine canine 
(P<0,00001). Les groupes 4 et 6 comprenaient également des génomes de souches 
d'origine canine, tandis que les groupes 2, 3 et 5 étaient significativement associés aux 
génomes de souches d'origine humaine. Nous avons trouvé plusieurs clones avec des 
sérotypes communs parmi ceux trouvés chez les chiens et les humains, suggérant un 
potentiel transfert bidirectionnel de clones, soutenant la perspective d'un monde avec 
«une seule santé». 
Durant la sixième étude, nous avons analysé des souches appartenant au clone ST131 
d'origine porcine, qui sont rarement documentées. Nous avons réalisé le WGS, analysé le 
GC et le plasmidome de sept souches de porcelets souffrant de diarrhée et de quatre 
souches isolés de viande de porc. Les 11 souches appartenaient au sérotype O25b:H4 et 
au clade B de ST131, présentant l'allèle fimH22 ou des mutations alléliques dérivées de 
celui-ci. Les 11 souches codées des FV qui les classaient comme équivalentes aux 
pathogènes aviaires, uropathogènes et pathogènes extraintestinaux d'E. coli (équivalent à 
APEC, UPEC et ExPEC) et constituaient le virotype D. L'analyse du GC a été réalisée en 
incluant les génomes de toutes les souches d'origine porcins ainsi que 73 souches ST131 
de référence d'origines différentes. Au sein du clade B, le CG a été ségrégué donnant 
naissance à neuf sous-groupes, ce qui nous a permis de décrire cinq nouveaux sous-clades 
(B6, B6-like, B7, B8, B9). Nous avons observé une association entre les souches 
appartenant au sous-clade B6, PST43, virotype D2 et d'origine alimentaire, et une 
association entre les souches appartenant au sous-clade B7, PST9, virotype D5 et isolés 
de porcelets souffrant de diarrhée (P=0,007). La distance moyenne entre les génomes 
d'origine humaine et porcine des sous-clades B6 et B7 était de 20 SNP/Mb et 15 SNP/Mb, 
respectivement. Les plasmides [F2: A-:B1]-IncF, de type ColE1 et IncX étaient les plus 
fréquent. Par ailleur, les plasmides IncF codaient pour une région ColV commune parmi 
les souches APEC. Les gènes de résistance aux antibiotiques les plus fréquemment 
trouvés étaient ceux qui confèrent une résistance à la pénicilline, à la tétracycline, aux 
quinolones et à la colistine. Le gène mcr-1.1 a été détecté dans 5 des 11 souches d'origine 
porcine, intégré dans le chromosome d'une souche et porté par des plasmides pour le reste 
(deux MOBH11/IncHI2-ST4, un MOBP3/IncX4 et un MOBF12/IncF [F2:A-:B1] 
vraisemblablement co-intégré avec un IncHI2). Les environnements du gène mcr-1 ont 
montré une grande variabilité. Cependant, nous observons des structures conservées au 
sein d'une même famille de plasmides. En conclusion, l'analyse du GC a défini cinq 
nouveaux sous-clades. Les souches ST131 d'origine porcine appartiennent aux nouvelles 
sous-clades B6 et B7. De plus, les souches cliniques humaines et les souches porcines 
sont étroitement liées. Les 11 souches porcines ST131 abritaient une grande variété de 
plasmides, de gènes de virulence et de résistance. De plus, les plasmides épidémiques 
IncX4 et IncHI2 sont responsables de l'acquisition du gène mcr-1.1. Nous émettons 
l'hypothèse que le plasmide APEC-IncF a acquis le gène mcr-1.1 par co-intégration d'un 
plasmide IncHI2, ce qui est inquiétant en raison de la combinaison d'attributs de virulence 





A partir des résultats obtenus, nous concluons: 
1. Environ 10% des infections extraintestinales causées par E. coli survenues en 
2016 dans les deux hôpitaux étudiés étaient causées par des souches du clone 
ST131, et environ 60% de ces infections étaient causées par des souches 
appartenant à seulement 10 STs (ST10 , ST12, ST58, ST69, ST73, ST88, ST95, 
ST127, ST131 et ST141). 
2. La plupart des souches ST12, ST73, ST95 et ST141 causant des infections 
extraintestinales chez l'homme étaient sensibles à la plupart des antibiotiques, ce 
qui indique que la MDR n'était pas la raison de leur succès. Les résultats de la 
présente étude soutiennent l'idée que leur succès est principalement dû au fait 
qu'ils hébergent un grand nombre de gènes codant pour des FV. 
3. Parmi les souches MDR causant des infections extraintestinales chez l'homme, 
quatre clones prédominent: B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-
39-ST88 et D-CH35-27-ST69. 
4. Malgré l'énorme diversité génétique observée dans notre collection de souches 
d'E. coli productrices de BLSE (71 clones présents dans 188 souches de BLSE), 
on peut conclure que la plupart des souches appartiennent à seulement trois 
complexes clonaux (CC10, CC23 et CC131 ) et que le sous-clade C2 de ST131 
associée à la production de CTX-M-15 reste la lignée d'E. coli la plus répandue 
parmi les souches d'E. coli productrices de BLSE identifiées dans les hôpitaux 
espagnols et français étudiés. 
5. Parmi nos 394 souches d'E. coli provenant d'infections extraintestinales, <10% 
sont capables de produire rapidement et de manière persistante des niveaux élevés 
de biofilm pendant 5 h. Ces souches appartiennent à quelques clones 
précédemment décrits dans diverses études comme colonisateurs intestinaux 
dominants chez les mammifères et les oiseaux, et comprennent le clone B2-CH40-
22-ST131, c'est-à-dire l'ancêtre du clone globalement étendu B2-CH40-30-
ST131, qui est le clone dominant parmi les souches faibles productrices de 
biofilm. 
6. Dans l'analyse du GC des souches d'E. coli productrices de BLSE, la diversité 
génomique se démarque. Y compris des représentants des phylogroupes A, B1, 
B2, C, E et F. Nous décrivons deux nouveaux clades dans le complexe clonal 
ST131 représenté par des génomes abritant les allèles fimH5 et fimH35. Le clade 
C se caractérise par une distance mineur de SNPs au sein du génome essentiel par 
rapport à ses clades frères A et B. 
7. Il existe une corrélation entre les profils des gènes codant des FV et les STs. 
8. Il existe une diversité impressionnante de plasmides parmi les génomes d'E. coli 
producteurs de BLSE. Cependant, les familles de relaxases MOBF, MOBP et 
MOBQ représentent 92% du plasmidome et Col-like et IncF sont les groupes 
d'incompatibilité les plus fréquents. De plus, la plupart des gènes codant pour des 
facteurs associés à la virulence et à la résistance sont portés par des plasmides 
appartenant à la famille IncF. 
9. Dans la lignée ST131, la diversité des groupes d'incompatibilité plasmidique est 
plus grande pour le sous-clade C2 que pour le clade A et le groupe C1-M27 du 
sous-clade C1. Le clade A est lié à la présence d'ICEs et de plasmides [F29:A-
:B10]-IncF. 
10. Le tractus intestinal des chiens sains constitue un réservoir important de souches 




11. Parmi les souches d'origine canine présentant un statut ExPEC et/ou UPEC, le 
clone B2-CH103-9-ST372 était dominant. 
12. L'analyse du WGS suggère que les souches d'origine canine du clone B2-CH103-
9-ST372, appartenant au groupe 1 (sérotypes O4:H31, O21:H31 et O83:H31) et 
au groupe 6 (sérotype O6:H31) pourraient provoquer des infections 
extraintestinales tant chez l'homme que chez le chien, alors que les souches de ce 
clone appartenant au groupe 2 et les sérotypes O18:H31 et O45:H31 ne pourraient 
provoquer d'infections que chez l'homme. 
13. Le clade B de ST131 a montré une énorme diversité génétique et nous avons défini 
cinq nouveaux sous-clades (B6, B6-like, B7, B8 et B9). La plupart des souches 
ST131 d'origine porcine appartiennent aux nouvelles sous-clades B6 et B7. 
14. La plupart des souches ST131 d'origine porcine sont MDR (91%) et contiennent 
de nombreux gènes de résistance aux antibiotiques. La résistance à la colistine a 
été introduite par des éléments génétiques mobiles et parvient à se stabiliser sur le 
chromosome. Les plasmides épidémiques IncX4 et IncHI2 hébergeant le gène 
mcr-1 et sont responsables de la résistance acquise à la colistine codée par le gène 
mcr-1.1. L'environnement du gène mcr-1 est variable, mais au sein d'une même 
famille de plasmides, l'insertion et la stabilisation conservent des structures 
communes. 
 
Mots clés: Escherichia coli; E. coli,  structure clonale, formation de biofilm, gènes 
de virulence, résistance aux antibiotiques; β-lactamases, CTX-M, BLSE, ExPEC, UPEC, 
clones à haut risque, ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, ST131, 









AAC Aminoglycoside acyltransferase 
ACT Artemis comparison tool  
adk Adenylate Kinase gene 
aEPEC Atypical enteropathogenic E. coli  
AIEC Disease-associated adherent-invasive E. coli 
AM/AMP Ampicillin  
AMC Amoxicillin-clavulanic acid 
AME Aminoglycoside modifying enzyme 
AMP/SAM Ampicillin-sulbactam 
AN Amikacin  
ANT Aminoglycoside nucleotidyltransferase 
APEC Avian pathogenic E. coli 
APH Aminoglycoside phosphotransferase  
ARG Antibiotic resistance gene 
ARG-ANNOT Antibiotic resistance gene-annotation 
AST Antimicrobial susceptibility test  
ATM Aztreonam 
ATP Adenosine triphosphate  
BEAs Biofilm eradication agents  
BFI Biofilm formation index  
BHI Brain heart infusion agar 
BLAST Basic Local Alignment Search Tool 
bp Base pairs 
BRIG BLAST Ring Image Generator  
C Chloramphenicol 
CARD Comprehensive antibiotic research database  
CAZ Ceftazidime 
CC Clonal complexes  
CDS Coding Sequence 
CEC E. coli consecutively isolated  
CG Core genome  
CGE Center for Genomic Epidemiology 
cgMLST Core genome MLST  




CLSI Clinical and Laboratory Standards Institute  
COL/CL Colistin 
CTX Cefotaxime 




DAEC Diffusely adherent E. coli 
DEC Diarrheagenic E. coli 
DHPS Dihydropteorate synthetases 




DPMT PCR-based degenerate primer MOB typing  
EAEC Enteroaggregative E. coli  
EBF Early biofilm formation  
EHEC Enterohaemorrhagic E. coli 
EIEC Enteroinvasive E. coli  
EPEC Enteropathogenic E. coli 
ESBL Extended-spectrum betalactamase 
ESBLEC Extended-spectrum β-lactamase-producing Escherichia coli  
ETEC Enterotoxigenic E. coli  
EUCAST European Union Committee on Antimicrobial Susceptibility Testing  
ExPEC Extraintestinal pathogenic E. coli  
FAB FII, FIA and FIB IncF replicons 
FAO Food and Agriculture Organisation 
FBP Foodborne pathogen 
FD Nitrofurantoin 
FED Cefepime 
fimH Type 1 fimbrial adhesin gene 
FMT Fecal microbiota transplant  
FOS Fosfomycin  
FOX Cefoxitin 
fumC Fumarate hydratase gene 
GEN/GM Gentamicin  
GES Guyana extended-spectrum-lactamase  
GIM German imipenemase 
GI Genomic island 
gyrB DNA gyrase gene 
HGT Horizontal gene transfer 
HNM Non-motile strains  
HPI High pathogenicity island  
HUH His-hydrophobe-His endonuclease superfamily  
I Intermediate 
IBCs Intracellular bacterial communities  
icd Isocitrate/isopropylmalate dehydrogenase gene 
ICE Integrative conjugative element  
IM Inner membrane  
IMI Imipenemase 
IMP Imipenem  
IMP Imipenemase metallo-betalactamase 
In Integrons  
Inc. Incompatibility groups  
InPEC Intestinal pathogenic E. coli 
IR Inverted repeat  
IS Insertion sequence  
kb Kilobases 
KPC Klebsiella pneumoniae carbapenemase  
LPS Lipopolysaccharide 
LREC from Spanish “Laboratorio de Referencia de Escherichia coli” 





mcr Mobile colistin resistance gene 
mdh Malate dehydrogenase gene 
MDR Multidrug-resistant 
MDT Secondary multidrug transporter  
MFS Major facilitator superfamily  
MGE Mobile genetic element 
MI Minocycline 
MIC Minimum inhibitory concentration  
MLEE Multi-locus enzyme electrophoresis 
MLST Multi-locus sequence typing 
MOB Relaxase protein  
Mpf Mating pair formation proteins  
na Not-applicable 
NAL Nalidixic acid 
NCBI National Center for Biotechnology Information 
nd Not-detected 
NDM New Delhi metallo-betalactamase 
NGS Next-generation sequencing  
NIH National Library of Medicine  
NMEC Neonatal meningitis‐associated E. coli 
NN Tobramycin 
OIE World Organisation for Animal Health 
OM Outer membrane  
ONT Non-typeable O-antigen  
ORF Open reading frame  
OXA-48 Oxacillinase-48-types betalactamase 
p Plasmid 
PAI Pathogenicity island 
pAmpC Plasmidic aquired cephalosporinase  
PBRT PCR-based replicon typing  
PCR Polymerase chain reaction  
PDR Pan-drug-resistant  
PFGE Pulse-field gel electrophoresis 
PI/TZP Piperacillin-tazobactam 
PLACNET Plasmid constellation network 
PM Point mutations  
pMLST PCR-based replicon subtyping  
PMQR Plasmid-mediated quinolone resistance  
PST Sequence type according to the Pasteur scheme 
purA Adenylosuccinate dehydrogenase gene  
QIRs Quiascent intracellular reservoirs 
R Resistant  
rmtB Plasmid-mediated 16S rRNA methylases  
RND Resistance-nodulation-cell division family 
RST Replicon typing scheme  
rUTI Recurrent UTI infection  




SEPEC Sepsis‐causing E. coli 
SGS Second-generation sequencing or short-read sequencing technologies  
SIM Seoul imipenemase 
SME Serratia marcescens enzyme 
SMR Small multidrug resistance family 
SMRT Single-molecule real-time  
SNP Single nucleotide polymorphism  
SPM Sao Paulo metallo-betalactamase  
spp Specie  
SS Saline solution 
ST Sequence type according to Achtman scheme 
STc Sequence type complexes 
STEC Shiga toxin-producing E. coli  
ST Sequence type 
SXT Trimethoprim-Sulfamethoxazole  
tEPEC Typical and enteropathogenic E. coli 
TGS Third-generation sequencing or long-read sequencing appeared  
TI Ticarcillin 
TMP/SMX Trimethoprim-sulfamethoxazole 
Tn Transposons  
TOB Tobramycin 
tra Transfer region genes  
TSA Tryptone soya agar  
UPEC Uropathogenic E. coli 
USC Universidade de Santiago de Compostela  
UTI Urinary tract infections 
VF Virulence factor 
VFDB Virulence factor database  
VIM Verona integron-encoded metallo-betalactamase  
vs. Versus  
wgMLST Whole genome MLST 
WGS Whole-genome sequencing 
WHO World Health Organisation 








1.1. A BRIEF INTRODUCTION TO MICROBIOLOGY 
Microbiology is the study of microorganisms including bacteria (bacteriology). 
Bacteria are believed to be the oldest living organisms on Earth. Their traces date back 3 
billion years (Hacker and Carniel, 2001). The Eubacteria (Bacteria sensus stricto) and the 
Archaea (ancient bacteria) domains represent two of the three greatest branches of 
cellular life, both constituted by unicellular prokaryotes. The third branch includes plants, 
animals, and fungi kingdoms, pluricellular eukaryotes. The Eubacteria domain is divided 
into 40 kingdoms and the Archaea domain is divided in two kingdoms (Dykhuizen, 
2005). Therefore, bacteria are very diverse and include a wide spectrum of different shape 
and size species. The three most basic bacteria shapes are known as coccus (spherical), 
bacillus (rod-shaped) and spiral (twisted). However, there are also pleomorphic bacteria 
that can adopt several shapes. In regards to size, the smallest bacterium which has been 
discovered is named Nanobacterium and it has 100 nm in length, while the largest 
discovered bacterium named Thiomargarita namibiensis has a length of 0.75 mm. 
Besides, bacteria can be found everywhere, within animals, plants, soil, water and air 
(Dykhuizen, 2005). 
From a human point of view bacteria has two sides, as they can appear to be our 
“enemies” or “allies”. On one hand, many diseases have their origin in bacteria and they 
are responsible for some of the most devastating pandemics in human history, such as 
plague (Yersinia pestis) or cholera (Vibrio cholerae) (Morabia, 2020). On the other hand, 
many other types of bacteria are great contributors in environmental protection and/or in 
the human industry, for instance, food production. Besides, bacteria are part of animals’ 
microbiota, including humans, which include up to 500 species of bacteria. The 
microbiota performs a wide range of essential and beneficial functions, such as 
controlling mucosal immunity, breaking down nutrients and preventing pathogen 
colonization. Moreover, according to medical research, bacteria can reduce intestinal 
decay and slow down aging (Kundu et al., 2017; Levy et al., 2017). 
Biological evolution drives from the plasticity of the genomes, the rate of phenotype 
generation and the selective pressure exerted by the environment (Arber, 2000). In 
relation to the evolution of bacteria, human antimicrobial therapy is exercising an 
artificial selective pressure that is contributing to the selection of antimicrobial-resistant 
mutants (Dykhuizen, 2005). In eukaryotes, genetic variability results from sexual 
reproduction. Instead, prokaryotes reproduce asexually and have other mechanisms 
contributing to genetic variabilities, such as point mutations, recombinations and 
horizontal gene transfer (HGT). HGT allows bacteria to transfer, replace, or acquire 
pieces of DNA (or whole new genes) into their genomes. Furthermore, bacterial genetic 
exchange can be done between species or even genera. Therefore, bacteria evolve in 
impressively short periods of time (Ochman et al., 2000). 
Antoine van Leeuwenhoek (1632-1723), Louis Pasteur (1822-1895), and Robert 
Koch (1843-1910) are known as the first contributors to microbiology. Since then, the 
microbiology science has become vast and multidisciplinary, evolving in parallel with the 
development of new technologies. Nowadays the bacterial genome can be entirety 
sequenced and numerous whole-organism (or “omics”) methods can be applied for 
bacteriology research (van Dijk et al., 2014; Lo et al., 2017). 
Despite the continuous development of science, outbreaks are nearly constant and 
pandemics still occur, of which the current COVID-19 is proof. Research against 
constantly mutating microorganisms is far from over. 




1.2. ESCHERICHIA COLI AND GENOMICS 
The protagonist of this thesis, Escherichia coli, is a non-sporulating facultative 
anaerobe Gram-negative bacterium which belongs to the Enterobacteriaceae family. E. 
coli was discovered by Theodor Escherich in 1885 (Escherich, 1885) and it currently is 
one of the most studied bacteria worldwide. Interestingly, this bacterium has huge 
genome plasticity representing a versatile and diverse specie (Dobrindt et al., 2003; 
Beghain et al., 2018; Denamur et al., 2020). Whilst E. coli is part of the gastrointestinal 
microbiota of warm-blooded animals and reptiles (Gordon and Cowling, 2003) (non-
pathogenic/commensal strains), some E. coli strains can also be the etiological agent of a 
diverse range of clinical diseases that affect all age groups in humans and animals (Blanco 
et al., 2002), causing more than 2 millions deaths per year in humans (Kosek et al., 2003; 
Russo, 2003). Also, environmental strains have been estimated to represent half of E. coli 
population (Savageau, 1983). In addition, among resistant bacteria, E. coli is the most 
common Gram-negative bacterial pathogen (Poirel et al., 2018). In consequence, the 
ability to distinguish types beyond the species is essential and helpful in many 
circumstances in E. coli.  
Nowadays, it is known that the genus Escherichia is composed of E. albertii, E. 
fergusonii, five cryptic Escherichia linages (clades I to V) (Walk et al., 2009; Clermont 
et al., 2011; Luo et al., 2011) and E. coli sensu stricto (Beghain et al., 2018). E. coli 
cryptic lineages are highly divergent at the nucleotide level but phenotypically similar to 
E. coli sensu stricto and conventional phenotypic test such as API20 Enterobacteriaceae 
(BioMérieux) or MALDI-TOF mass spectrometry fail to distinguish them (Walk et al., 
2009). In this thesis we will refer to E. coli sensus stricto or classical E. coli.  
Due of the common rearrangements and recombinational events that occur in 
bacterial genomes, bacterial progeny (clones) may not be identical (Ochman et al., 2000; 
Spratt, 2004). In bacteriology, clonal lineages refer to closely related strains which have 
diverged from a common ancestor and are indistinguishable or highly similar to each 
other, using a particular molecular typing procedure (Mathers et al., 2015). 
Genomics is known to be the study of the structure and function of the genome of an 
organism. For its analysis, DNA sequencing methods, recombinant DNA and 
bioinformatics tools are employed (Johnson and Russo, 2018). The first E. coli genome 
which was completely sequenced was E. coli K-12 strain MG1655 in 1997 (Blattner, 
1997). To date, thousands of E. coli genomes at different levels of completion are 
available in public databases. As of August 2020, the National Center for Biotechnology 
Information (NCBI) database accounted for 20,587 genome assembly and annotation 
reports of E. coli belonging from a wide range of sources.  
The number of genes present in the E. coli genome varies from approximatively 4,000 
to 6,000 genes (which corresponds to 4.2-6.0 Mbp), whereas a set of around 2000 genes 
provides the genetic information required for essential cellular processes which are 
present in all members of a specie (core genome) (Bergthorsson and Ochman, 1998). 
There is also a flexible set of strain-specific genes which provide genetic information that 
enables the harboring strains to adapt to particular environmental conditions (accessory 
genome). The accessory genome includes all the genes encoding bacteriophage elements, 
virulence-associated determinants and acquired resistance to antimicrobials.  
The vast amount of sequence information generated in the era of “genomics” strongly 
supports horizontal gene transfer (HGT) as a cornerstone in the adaptive evolution of 
prokaryotes, including E. coli. As more E. coli strains are sequenced, the core genome 




Touchon et al., 2020). In a recent study, it was shown that the pan genome (the total 
number of genes) of 4,000 E. coli strains accounted for more than 26,000 genes (Decano 
and Downing, 2019). 
1.3. PATHOGENIC E. COLI AND PATHOGENOMIC  
The term “colibacillosis” broadly refers to a disease caused by E. coli (Poirel et al., 
2018). Historically, pathogenic E. coli strains were separated into disease-associated 
groups (pathotypes) (recently reviewed in Denamur et al., 2020).  
Pathogenic E. coli are classified into two categories: (I) intestinal pathogenic E. coli 
or InPEC when they are the causative agent of intestinal infections and (II) extraintestinal 
pathogenic E. coli or ExPEC when they are the causative agent of extraintestinal 
infections once outside the gastrointestinal tract (reservoir) of the host (Russo and 
Johnson, 2000). ExPEC within the intestine rarely causes any complications and exists in 
a beneficial symbiotic relationship with the intestinal microbiota (Wiles et al., 2008). 
There are seven well‐studied InPEC pathotypes classified by pathogenicity 
mechanisms attributed to their ability to cause gastrointestinal diseases like diarrhea 
(Nataro and Kaper, 1998; Kaper et al., 2004), including Shiga toxin‐producing E. coli 
(STEC), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), 
enteroaggregative E. coli (EAEC), diffusely adherent E. coli (DAEC), enteroinvasive E. 
coli (EIEC),  and the Crohn's disease-associated adherent-invasive E. coli (AIEC) 
(Darfeuille-Michaud et al., 1998). The Enterohaemorrhagic E. coli (EHEC) is a type of 
STEC that can cause severe enteric diseases, such as hemolytic uraemic syndrome or 
hemorrhagic colitis  leading to acute renal failure and often death (Kaper et al., 2004).  
ExPEC represents a distinctive group of E. coli strains that posseses an enhanced 
ability to overcome the host’s defenses and cause a wide spectrum of syndromes, ranging 
from urinary tract infections (UTI) to life-threatening bloodstream infections (e.g. skin 
and soft tissue infections, biliary infections, infective pyelonephritis, pelvic inflammatory 
disease, bone infections, neonatal meningitis and avian colisepticemia). There are four 
well‐studied ExPEC pathotypes, including avian pathogenic E. coli (APEC), 
uropathogenic E. coli (UPEC), neonatal meningitis‐associated E. coli (NMEC) and 
sepsis‐causing E. coli (SEPEC) (Dale and Woodford, 2015). However, the attribution to 
one specific pathotype does not exclude the strain to be able to cause infection at another 
anatomical site (Ron, 2006; Dale and Woodford, 2015). During recent years, complex 
hybrid pathotypes have also been described as, for example, a shiga toxin (STEC) EAEC 
carrier which caused illness in more than 3 thousand people as well as 54 deaths during a 
large outbreak in 2011 (Frank et al., 2011). 
Pathogenomics investigates processes involved in bacterial pathogenesis on the 
genome level. Distinctive genetic features can be linked to different lifestyles in E. coli 
(Dobrindt, 2005; Tenaillon et al., 2010). The differentiation of (pathogenic) variants 
facilitate risk assessment, diagnostics and the prevention of E. coli infections. To date, 
molecular studies have yielded numerous important insights on this matter (Dobrindt, 
2005; Johnson and Russo, 2018).  
A genomic comparison of the commensal strain MG1655 (E. coli K12), strain 
EDL933 (EHEC) and strain CFT073 (UPEC) (Table 1) revealed that less than 40% (2996 
genes) of their combined set of proteins were common to all three strains (Welch et al., 
2002). Furthermore, a comparison between MG1655 and EDL933 genomes showed 0.53 




CFT073 genome reveals 1.3 Mb without a counterpart in either of the other genomes 
(Dobrindt, 2005). 
Table 1. Characteristics of publicly available complete E. coli genome sequences 
Strain Pathotype Size (bp) G+C content (%) 




MG1655 K-12 4,639,221 50.8 4,294 U00096 (Blattner, 1997) 
CFT073 UPEC 5,231,428 50.5 5,533 AE014075 (Welch et al., 2002) 
EDL933 EHEC 5,528,445 50.5 5,361 AE005174 (Perna et al., 2001) 
Adapted from (Dobrindt, 2005)  
1.3.1. EPIDEMIOLOGY AND E. COLI ATTRIBUTES 
Epidemiology studies diseases within populations, whilst molecular epidemiology 
emphasises observations on a molecular level in order to identify bacterial traits and host 
characteristics that may help to predict the occurrence, severity and/or clinical 
manifestations of a particular disease. This field of research also makes a contribution to 
identifying relevant reservoirs and transmission pathways, which are helpful in 
developing preventive strategies. As a limitation, molecular epidemiological studies 
require complementary experimental assessment to be conclusive, because gene 
expression has to be taken under consideration to make phenotype-genotype associations 
(Honardoost et al., 2018; Johnson and Russo, 2018).  
Firstly, E. coli is a zoonotic pathogen, which means that it can be transmitted, in both 
directions, between animals and humans, and cause various diseases (Manges and 
Johnson, 2012). ExPEC strains are important pathogens to both humans and certain 
animals. In this thesis, we will focus on the study of ExPEC strains and their hosts (also 
referred to as reservoirs). 
1.3.1.1. ExPEC related to human diseases 
ExPEC strains are the leading causative agent of human extraintestinal infections 
globally (Manges et al., 2019). In numerous cases, they are opportunistic pathogens 
causing ExPEC-related illeness in patients with a compromised immune system (Russo 
and Johnson, 2000; Foxman, 2003; Nielubowicz and Mobley, 2010; Singer, 2015; 
Johnson et al., 2016a; Biran and Ron, 2018). 
In particular, UPEC strains are the infective agent of  urinary tract infections (UTIs) 
and pyelonephritis in up to 80% of cases (Dale and Woodford, 2015), while NMEC 
strains are one of the most common causes of neonatal bacterial meningitis accounting to 
30% of cases (Chu et al., 2014). In addition, NMEC infections are associated with rates 
of 10 to 40% mortality and up to 50% of neurological sequelae in survivors (Mulder and 
Zanen, 1984; Mulder et al., 1984; Klinger et al., 2000; Stoll et al., 2011). Furthermore, 
ExPEC are the leading cause of abscesses as well as a major cause of septicaemia.  
1.3.1.2.ExPEC related to animal diseases 
ExPEC strains are also the causative agent of diseases in food-producing animals and 
are associated with important economic losses in the food industry worldwide. In poultry, 
APEC strains cause infections by inhalation of fecal dust which spread, causing 
septicemia, pericarditis, and high rates of mortality (Antão et al., 2008). In dairy cattle, 
E. coli is responsible for more than 80% of cases of acute mastitis, a common 
inflammatory response of the mammary gland that significantly decrease milk production 
(Shpigel et al., 2008; Poirel et al., 2018). In pig farms, outbreak of acute sepsis, 




E. coli is also responsible for infections of the lower and upper urinary tract in companion 
animals (Pomba et al., 2016; Bouillon et al., 2018; Hutton et al., 2018). 
Secondly, E. coli as a common inhabitant of the gastrointestinal tract, it is subject to 
frequent encounters with antibiotics leading to developing resistance against the 
antibiotics that are frequently consumed by the host (Looft et al., 2012). Thus, this 
bacterial group can be regarded as a sentinel for resistance to antibiotics (SCENIHR, 
2010). Besides, E. coli is discharged to the environment through feces and wastewater 
treatment plants (Anastasi et al., 2012) and for this reason, it is  considered a major source 
of contamination and hazard for infection under a “one health” perspective (Pomba et al., 
2016; Poirel et al., 2018).  
Thirdly, host to host direct transmission through close contact also represents a  major 
route of dispersion of E. coli strains, including human close contact with companion 
animals (Pomba et al., 2016).  
Lastly, it is known that E. coli can also be transmited through food and for this reason 
some food-producing animals which are reservoirs of ExPEC strains are considered major 
hazards. The linkage between ExPEC strains in food products and human outbreaks has 
lead to the definition of foodborne ExPEC infection. 
1.4.TYPING METHODS IN E. COLI  
Apart from pathotype, individual strains of E. coli can be classified using a variety of 
molecular and non-molecular techniques. The implementation of molecular 
methodologies has allowed a more detailed analysis of E. coli lineages (Clermont et al., 
2011; Beghain et al., 2018). With the application of multi-locus enzyme electrophoresis 
(MLEE), a detailed phylogenetical study of E. coli variants started. Milkman associated 
intragenic recombination of certain segments of the genome with bacterial lineages and 
proposed to use it to decipher the species phylogeny (Milkman and Stoltzfus, 1988). 
Ultimately, techniques such as pulse-field gel electrophoresis (PFGE) and whole-genome 
sequencing (WGS) provide the greatest resolution for this purpose and are both valuable 
in the context of surveillance and outbreak analysis. However, PFGE is a labor-intensive 
technique with a complex interpretation which complicates data exchange amongst 
laboratories. For this reason, PFGE has rapidly become an out-dated method since DNA 
sequencing has become more economical and widely available (Johnson and Russo, 
2018).  
1.4.1. SEROTYPE DETERMINATION  
Serotypes are determined by the identification of three types of somatic (O), capsular 
(K) and flagellar (H) antigens of E. coli (serotyping). From which the K antigen is 
considerably more complicated to determine. Thus, the determination of O-groups 
(serogroup) and H-groups became a gold standard (Orskov and Orskov, 1992). There are 
182 different O-groups and 53 H-types in E. coli and thousands of different combinations 
(O:H) have been described (Nataro and Kaper, 1998). 
Serotyping was the first typing method available to delineate variants within E. coli 
(Kauffmann and Ørskov, 1956; Orskov et al., 1977) because these biomarkers are often 
associated with specific pathotypes (Kaper et al., 2004). 
The O-antigen refers to a unique polysaccharide of the outer membrane of E. coli. 
This antigen is chromosomally encoded in a cluster designated as the O-antigen gene 
cluster (O-AGC) which includes wzx, wzy, wzm, and wzt genes (Stenutz et al., 2006; 
Fratamico et al., 2016). The H-antigen refers to the flagellar protein that is codified by up 




(Machado et al., 2000; Wang et al., 2003; Fratamico et al., 2016). Currently, serotyping 
can be performed by conventional phenotypic methods as well as by molecular methods 
(see below).  
 Phenotypic technique: the conventional serotyping method uses antisera with 
specific antibodies to test the surface antigens of E. coli, which are detected 
by agglutination reactions (serology).  
 Genotypic techniques: PCR-based or in silico determination through WGS. 
Molecular methods for H-typing target fliC genes and other less frequent 
flagellin-associated genes (flkA, fllA, flmA or flnA) and for O-typing target 
wzx, wzy, wzm, and wzt genes (Joensen et al., 2015).  
The phenotypic determination of E. coli antigens has several drawbacks. In fact, 
many E. coli strains could remain non-typeable because their O- or H-antigens are not 
expressed in vitro or because they autoagglutinate during the procedure. Also, this method 
requires specific antiseras which are only available in specialized laboratories and might 
vary in quality showing cross-reactivity with different serogroups. Additionally, 
conventional serotyping is a relatively costly and labor-intensive technique. For these 
reasons, in silico serotyping is likely to replace traditional serotyping in the future 
(Fratamico et al., 2016). Nonetheless, for the identification of potential vaccine 
candidates it is necessary to identify the most unique genes from pathogenic 
microorganisms that are most effective in stimulating immunity to produce antibodies 
(Moriel et al., 2016). In this regard, the phenotypic determination of E. coli antigens 
provides relevant information that cannot be retrieved through genotypic methods. 
1.4.2. PHYLOGENETICAL TYPING  
In general, E. coli strains with common phylogenetical origins show similar traits, 
including serotype and pathotype (Picard et al., 1999; Gordon and Cowling, 2003; Méric 
et al., 2013; Clermont et al., 2019). Thus, the attribution of a given strain to a clonal or 
phylogenetic group is meaningful and it is usually performed in epidemiological studies.  
E. coli phylogroups and clonal groups include closely related strains classed under 
different criteria (see below). 
1.4.2.1 Phylogroup determination  
Phylogroups are defined as a large phylogenetic entity within the species (Denamur 
et al., 2020). Thanks to technological advances, eight phylogroups for E. coli (sensu 
stricto) have been recognised to date (A, B1, B2, C, D, E, F, and G). Besides, an additional 
group named H has also been described (Lu et al., 2016b).  
The phylogenetical studies performed by Beghain et al., (2018) and Clermont et al. 
(2019), show that phylogroups B2, F, D and G are the more ancient lineages conforming 
one cluster which had further diverge with the emergence of phylogroup E, followed by 
phylogroups C, B1 and A which constituted an other cluster. Interestingly, phylogroups 
B2, F and D encompass the majority of extraintestinal pathogenic strains, whereas 
commensal E. coli strains as well as strains associated with enteric diseases are generally 
derived from the most recently diverged phylogroups (Picard et al., 1999; Escobar-
Páramo et al., 2004).  
Clermont and colleagues have provided several PCR assays to easily perform 
phylotyping through the determination of “marker” genes (arpA-1, arpA-gE, trpA-gC, 
chuA, yjaA, TspE4.C2, ybgD and cfaB) (Clermont et al., 2000, 2013, 2019). This 




1.4.2.2 Clonal group determination 
Thanks to the conserved nature of the core genome in E. coli, it is possible to establish 
the taxonomic distances between strains based on the comparison of highly conserved 
chromosomal genes (housekeeping genes) (Chaudhuri and Henderson, 2012). The multi-
locus sequence typing (MLST), using either the Warwick University (Wirth et al., 2006) 
or the Pasteur Institue (Jaureguy et al., 2008) schemes in addition to the two-locus CH 
typing scheme (Weissman et al., 2012) are the most extended nucleotide sequence-based 
techniques used for this purpose in E. coli.  
In MLST schemes, an arbitrary number is assigned to each unique loci sequence 
(seven loci in the Warwick University scheme and eight loci in the Pasteur Institute 
scheme). MLST allows classifying strains into distinct sequence types (STs), which are 
defined as isolates with identical allelic profiles (Maiden et al., 1998) and into broader 
clonal complex (CC) (clonal population with strong association of alleles) (Maiden et al., 
2013).  
The CH scheme allows predicting the MLST-based profile with up to 95% accuracy 
(Weissman et al., 2012) by the determination of the fumC and fimH alleles (two locus). 
Although CH typing will not replace traditional MLST for more detailed phylogenetic 
studies, CH typing works as a rapid screening test. Besides, clonotypes split large STs 
into a smaller number of clonal subgroups (clonotypes) allowing to decipher more clonal 
diversity (Dale and Woodford, 2015). 
Moreover, WGS allows to perform a quantitative analysis of strain divergences by 
studying single nucleotide polymorphism (SNPs) in the core genome of bacterial 
population and enables in silico typing of strains for various genotyping schemes 
including MLST and CH. Besides, the MLST approach has recently been extended to 
core genome MLST (cgMLST) and whole genome MLST (wgMLST) with the purpose 
of obtaining a higher level of resolution in terms of taxonomic distances (Maiden et al., 
2013).  
1.5. VIRULENCE PROFILES IN E. COLI AND VIRULOME  
In 1988, Johnson and colleagues described “Virulence Factor (VF)” as any bacterial 
function that facilitates infection (Johnson et al., 1988).  
Molecular epidemiology studies have proved that some molecular markers exhibit a 
greater prevalence within E. coli isolates from diverse extraintestinal infection compared 
to those isolated from feces of healthy carriers (Johnson et al., 2003; Moreno et al., 2008; 
Kudinha et al., 2013; Nielsen et al., 2014). However, the epidemiological association 
with virulence dose not necessarily reflect causality (Schreiber et al., 2017; Johnson and 
Russo, 2018).  
Three hypotheses of disease causation have been proposed for ExPEC isolates. 
Firstly, it has been suggested that most urinary tract infections (UTI) are opportunistic 
infections caused by bacteria that predominate in the faecal flora (the prevalence 
hypothesis). Secondly, it has been proposed that E. coli requires some specific virulent 
traits to become pathogenic and represent a distinctive subset of the fecal E. coli 
population (special pathogenicity hypothesis) (Whittam et al., 1989; Johnson et al., 2003, 
2005b, 2005c; Moreno et al., 2008; Thompson et al., 2011; Nielsen et al., 2014). 
However, neither of those previous definitions are truly adequate, nor are the definitions 
mutually exclusive (Manges et al., 2019). In third place, there is now growing evidence 
that a commensal E. coli will develop into a pathogen through the selection of VF-roles 




to pathogenesis (the coincidental evolution hypothesis) (Grozdanov et al., 2004; 
Dobrindt, 2005; Tenaillon et al., 2010; Denamur et al., 2020). Paradoxically, certain data 
suggests that virulence may be a product of commensalism, as it has been shown that a 
considerable fraction of virulence-associated genes in ExPEC are also present in many 
commensal E. coli isolates, increasing their adaptability and competitiveness 
(Nowrouzian et al., 2001, 2003; Le Gall et al., 2007; Duprilot et al., 2019). Besides, 
colonising sites outside the gastrointestinal tract are unlikely to provide any selective 
advantage in terms of transmissibility (Johnson and Russo, 2018; Denamur et al., 2020).  
In ExPEC a wide set VFs have been described (virulome). It is apparent there is a 
considerable variability of VF profiles within phylogenetic groups, clonal groups, and 
even among subclones and that no single virulence factor is sufficient to cause disease 
(Lane et al., 2007; Hannan et al., 2012; Sarkar et al., 2014; Conover et al., 2016). 
Additionally, certain VFs commonly occur together among clinical isolates 
suggesting genetic linkage (Johnson and Stell, 2000; Kanamaru et al., 2003; Dahbi et al., 
2014). For example, in NMEC the invasion of brain endothelium protein (ibeA gene) and 
the cytotoxic necrotising factor 1 (cnf-1 gene). Thus, even if known VFs are not the actual 
determinants of virulence, they are useful markers and potential clinical predictors. 
VFs are usually grouped by functional categories, including those related to (I) 
adherence and colonisation, (II) nutritional and metabolism flexibility (III) evasion of the 
host immune system (IV) persistence and (V) toxin production. Additionally, it has been 
observed that clinical isolates often contain multiple VFs from a particular functional 
category and it has been hypothesised that a synergistic interaction among VFs may occur 
(Holden and Gally, 2004). Conversely, some virulent strains lack known representatives 
of one or more of these functional categories and it has been hypothesised that this 
apparent deficit may be compensated by other functional categories. It is also possible 
that these strains contain VFs from other unrecognised categories (Johnson et al., 2001, 
2002). It is hoped that genome comparison between closely related pathogenic and non-
pathogenic variants will reveal new potential targets for preventive interventions and 
development of vaccines. 
1.5.1. Adherence and colonisation  
The attachment of bacteria to mucosal surfaces is the initial event in the pathogenesis of 
most infectious diseases. Moreover, the adherence ability of pathogenic E. coli is 
frequently related to host and even tissue specificity (adhesins-receptor) promoting 
colonisation (Beachey, 1981; Kline et al., 2009). Different surface appendages have been 
associated with the initial stage of infection in ExPEC, including (I) fimbral adhesins (II) 
non-fimbral adhesins and (III) flagella.  
1.5.1.1. Fimbrial adhesins  
Fimbriae or fimbrias are long proteinaceous organelles that extend from the surface of 
many bacteria and mediate in diverse functions, including adherence and biofilm 
formation. Fimbrial adhesins are often located at the tip of the fimbrial organelle and 
recognise specific ligands of the host epithel (Kline et al., 2009). In Gram-negative 
bacteria, fimbrias are usually assembled via different protein translocation systems, such 
as the chaperone–usher (CU) pathway, type IV secretion pathway and the extracellular 
nucleation precipitation pathway. Among which the CU pathway is the most abundant 
and therefore constitute for example type 1 fimbriae, P fimbriae, Dr/Afa family fimbriae 




than one type of fimbriae, which may increase the probability of a successful survival 
under changing environmental conditions (Holden and Gally, 2004). 
 Type 1 fimbriae is encoded in the bacterial chromosome by the fim operon 
that codifies for several subunits named FimA, FimC, FimD, FimF, FimH and 
FimG (Thankavel et al., 1997), where FimH represent the actual adhesin 
(monoadhesin fimbriae) (Mulvey, 2002; Kline et al., 2009; Busch and 
Waksman, 2012). 
 P-fimbriae or pyelonephritis-associated pili is encoded by the pap operon that 
codifies for several subunits named PapA, PapC, PapE, PapF and PapK, 
where PapG represent the actual adhesin (monoadhesin fimbriae) (Mulvey, 
2002; Kline et al., 2009; Busch and Waksman, 2012). 
 Dr/Afa family fimbriae constitute polyadhesins fimbrias encode by the afa, 
dra, and daa operons which have a similar genetic organization (Servin, 2005, 
2014). Dr family fimbriae can bind red blood cells (RBCs) thanks to receptor 
specificity to the Dr blood group antigen (Nowicki et al., 1988, 2001).  
 S/F1C fimbriae. The S fimbriae is encoded by the sfa operon that codifies for 
several subunits named SfaA, SfaG, SfaH and SfaS, where the SfaS is actual 
adhesin. The F1C fimbriae is an analog of the S fimbriae, which is encoded 
by foc genes (Mulvey, 2002). 
 Curli fibrils are adhesive amyloids organelles assembled via a nucleation-
dependent process and which biosynthesis is encoded by the csg operon that 
codifies for the curli fibers proteins CsgA and CsgB (Kline et al., 2009).  
1.5.1.2. Non-fimbrial adhesins 
This group is constituted of a wide number of heterogeneous structures with adhesive 
properties such as autotransporter (AT) proteins, which contribute to the adherence and 
colonisation of ExPEC, like for example the type 1 secretion A protein (TosA), the factor 
adherence E. coli protein (FdeC), the IrgA homologue adhesin (Iha), the temperature-
sensitive hemagglutinin (Tsh), the outer membrane protein antigen 43 (Ag-43) and the 
surface-located trimeric AT proteins (UpaH, UpaC and UpaG) (Tarr et al., 2000; Johnson 
et al., 2005a; Ulett et al., 2007; Allsopp et al., 2010, 2012; Kobayashi et al., 2010; Wells 
et al., 2010; Vigil et al., 2011; Nesta et al., 2012; Xicohtencatl-Cortes et al., 2019). 
1.5.1.3.Flagella  
The flagella is an organelle made from protein monomers called flagellins (FliC proteins) 
and it is composed of a basal body, a hook, a motor, and a filament (Macnab, 1996; 
Machado et al., 2000; Wang et al., 2003). This structure confers adhesive and invasive 






1.5.2. NUTRIENTS AVAILABILITY AND METABOLIC PATHWAYS 
Within the intestine, most nutrients are in sufficient quantities and the carbon source 
is considered as the main nutritional limitation for E. coli (Conway and Cohen, 2015). In 
contrast, outside the intestine, there is a high range of nutritionally-divers environments 
to overcome (Mann et al., 2017). For this purpose, in ExPEC isolates VFs have been 
described and established into three categories: (I) the regulation of metabolic pathways 
(II), secretion systems machinery and (III) iron acquisition.  
1.5.2.1. Regulation of metabolic pathways  
The two-component signaling system (TCS) is the main signal transduction pathway 
to sense and respond to environmental stimuli in bacteria, including quorum sensing 
signals (Stock et al., 2000). The TCS is composed of a membrane-bound sensor histidine 
kinase (HK) and a cytoplasmatic response regulator of gene expression (RR). It has been 
proposed that the TCS has a role in mediating the effective regulation of some metabolic 
pathways in ExPEC. Some TCSs that have been associated with extraintestinal 
pathogenesis are the BarA/UvrY, EvgS/EvgA, KguS/KguR and PhoQ/phoP systems 
(Tomenius et al., 2006; Eguchi et al., 2011; Cai et al., 2013).  
1.5.2.2. Secretion systems machinery 
The secretion systems machinery contributes to pathogenesis by facilitating the 
transport of molecules across bacterial membranes (physical barriers), for example 
siderophores, exopolysaccharides and toxins (Fox et al., 2020).  
1.5.2.3. Iron acquisition systems 
Iron is a critical nutritional requirement for the survival and growth of bacteria. Thus, 
ExPEC isolates typically contain genes codifying for iron sequestration. It is therefore 
essential for septicemic pathogens to be able to acquire the iron that is bound to blood 
proteins (such as ferritin, hemosiderin) (Robinson et al., 2018).  
Siderophores are molecules synthesized to bind ferric ions (Fe3+) that belong to a 
high-affinity iron acquisition system energized by the Ton complex. The Ton complex is 
a cytoplasmatic membrane-localised complex that interacts with the bacterial outer 
membrane specific siderophores-receptors to facilitate iron uptake. The biosynthesis of 
siderophores in E. coli requires to be activated through an EntD transferase (PPTase) 
(Martin et al., 2013). In ExPEC, several types of siderophores have been described, with 
different chemical structures and affinity for iron, including (I) enterobactin, (II) 
salmochelins, (III) aerobactin and (IV) yersiniabactin (Robinson et al., 2018).  
 Enterobactin is encoded within the core genome of E. coli. The initial 
biosynthesis is codified by ent genes and utilisation is codified by fep and fes 
genes. 
 Salmochelin was originally identified in Salmonella species and it is coded 
by a non-conserved iro gene cluster. The initial biosynthesis is codified by 
iroB, iroC and iroE and utilisation is codified by iroN and iroD. 
 Aerobactin was originally identified in Aerobacter aerogenes and it is coded 
by a non-conserved set of genes. The initial biosynthesis is codified by the 
operon iucABCD and utilisation is codified by iutA (outer membrane 
receptor).  
 Yersiniabactin (Ybt) was originally identified in Yersinia pestis. The Ybt 
system is encoded in a multioperon pathogenicity island named as the 
Yersinia high pathogenicity island (HPI). The initial biosynthesis is codified 




Recent data suggests a complementary role for Ybt as a metallophore that 
could conform stable complexes with copper and other metals, such as cobalt 
and nickel (Koh et al., 2015).  
Other iron uptake systems are the Sit, Chu, Hma, Fec and Fhu systems (Nagy et al., 
2001; Rodriguez-Siek et al., 2005; Hagan and Mobley, 2009; Chu and Vogel, 2011). 
Besides, ExPEC may also produce toxins such as alfa-haemolysin, which causes cell lysis 
and the subsequent release of micronutrients, like heme, which is the most abundant iron 
complex in the host (Wiles and Mulvey, 2013). 
1.5.3. EVASION OF THE HOST IMMUNE SYSTEM 
Successful pathogens have developed a wide range of anti-immune strategies that 
play critical roles in their abilities to cause disease (Finlay and McFadden, 2006). In this 
regard, many VFs have been described in ExPEC isolates, such as protectins. For 
example, the increased serum survival (Iss), the production of conjugal transfer surface 
exclusion protein (TraT) and the presence of an outer membrane protein A (OmpA) 
(Johnson et al., 2000). Additionally, surface molecules such as capsules, 
lipopolysaccharides (LPS) and outer-membrane vesicles also play a significant role 
avoiding the host immune responses (Phan et al., 2013). 
1.5.3.1.Lipopolysaccharides (LPS) and capsules 
The external side of the outer-membrane in ExPEC is composed of various 
lipopolysaccharide (O antigen) and it can also be covered with a capsular layer (K 
antigen). These external structures can inhibit the complement-mediated killing and the 
phagocytic action of the host immune system (Johnson, 1991; Russo et al., 2009; Goller 
and Seed, 2010; Phan et al., 2013).  
1.5.3.2.Outer-membrane vesicles 
Outer-membrane vesicles contribute to vehiculate and protect (structural protection) 
many toxins, adhesins, enzymes and other non-protein antigens while they are released 
from the bacterial cell to the external environment (Ellis and Kuehn, 2010). 
1.5.4. PERSISTENCE 
In order to maintain the infection, ExPEC isolates have developed several strategies 
such as: (I) biofilm production (further explained in more detail, see biofilm formation), 
(II) the constitution of intracellular bacterial communities (IBCs) and (III) the constitution 
of quiascent intracellular reservoirs (QIRs).  
Both IBCs and QIRs contribute to the virulence of UPEC. Briefly, IBCs are clonal 
collections of bacterial cells encased within a biofilm-like matrix and/or the cytoplasm of 
superficial cells of the bladder. These IBCs have been observed in the murine model, 
human cell-culture model and shed into human urine (Anderson, 2003; Justice et al., 
2004; Rosen et al., 2007; Andersen et al., 2012). QIRs are small communities consisting 
of 4 to 10 bacterial cells that are nonreplicating and can be present in both superficial 
epithelial and transitional bladder cells. QIRs can persist for 12 weeks (Mysorekar and 
Hultgren, 2006). Beyond being protected from antibiotics (Blango et al., 2014), such 
reservoirs have been associated with recurrent infections (Wiles et al., 2008; Goller and 
Seed, 2010; Hannan et al., 2012).  
1.5.5. TOXIN PRODUCTION  
Toxins are molecules which may cause defects in the function or shape of the host 
cells, stop the cell cycle, or even originate cell lysis. In ExPEC, the production of several 




necrotizing factor 1 (CNF1), the cytolethal distending toxin (CDT), the vacuolating 
autotransporter cytotoxin (Vat) and the secreted autotransporter toxin (Sat) (Wiles et al., 
2008; Denamur et al., 2020).  
1.6. UROPATHOGENIC E. COLI (UPEC)  
Urinary tract infection (UTI) is diagnosed when a certain number of bacteria are 
retrieved from urine (generally >105/ml) (Smelov et al., 2016). UTIs have numerous 
outcomes, including asymptomatic bacteriuria, acute, chronic, and recurrent UTI 
infection (rUTI). Besides, UTIs can be clinically classified as uncomplicated or 
complicated. The majority of uncomplicated UTIs are manifested as infections of the 
lower urinary tract, which has two levels: the infection and inflammation of the urethra 
(urethritis) or the urinary bladder (cystitis). In complicated UTIs, the infection ascends 
thought ureters to the upper urinary tract resulting in kidney infection (pyelonephritis) 
and even potentially bloodstream infection (septicemia). Fortunately, UTIs rarely cause 
any serious damage and they can be naturally cleared by the host immune system. 
Nonetheless, some complicated cases required prolonged therapy and are associated with 
serious complications and treatment failure (Micali et al., 2014; Flores-Mireles et al., 
2015; Smelov et al., 2016; Zacchè and Giarenis, 2016; Terlizzi et al., 2017). 
In humans, a prevalence of about 150 million UTIs per year worldwide has been 
estimated (Harding and Ronald, 1994). Also, it has been stated that almost half of women 
and 12% of men will experience at least one UTI during their lifetime. Furthermore, it is 
estimated that one-third of women will be prescribed antibiotics to treat a UTI before the 
age of 24 and will experience a rUTI despite antibiotic treatments (Foxman et al., 2000; 
Foxman, 2003, 2014; Micali et al., 2014; Tamadonfar et al., 2019).  
There are different pathogens implicated in UTIs, including Gram-negative bacilli 
like Klebsiella or Gram-positive cocci such as Enterococcus or Staphylococcus. 
However, it has been estimated that uropathogenic E. coli (UPEC) accounts for up to 75% 
of all cases. Furthermore, UPEC infections have an associated risk of around 30% of 
recurrent infection within 6 months (Foxman et al., 2000; Ronald, 2003; Singer, 2015).  
It has been recognised that fecal microbiota is a primary source of E. coli causing 
UTIs via the fecal‐urethral pathway (Yamamoto et al., 1997; Johnson et al., 2016a). The 
fecal-urethral infection model derivates from the ascending infection model developed by 
Tomas Stamey in the late 1970s. This model suggests that UTIs are caused by strains 
which are present in the host’s own microbiota. Following a progressive ascending 
colonisation process through the urethra up to the bladder.  
UPEC pathogenesis cycle starts with the adhesion to the bladder and further progress 
with the colonisation of the bladder lumen. Some UPEC may reach interstitial spaces 
and/or even intracellular sites and constitute intracellular bacterial communities (IBCs). 
As a host response to infection, the urothelium typically exfoliates and exposes the 
underlying transitional epithelium that UPEC can further invade, conforming small 
quiescent intracellular reservoirs (QIRs) (Terlizzi et al., 2017).  
Favoring the prevalence hypothesis, a correlation with the host fecal predominant E. 
coli strains and the urine-infective E. coli strain has been observed (Yamamoto et al., 
1997). Concerning the special pathogenicity hypothesis, several studies have 
demonstrated that UPEC exhibits more VFs than the host concurrent fecal clones 
(Johnson et al., 2003, 2005c, 2005b; Moreno et al., 2008; Bahadori et al., 2019). In a 




infective E. coli strain was distinct from any fecal strain in the same patient (Bahadori et 
al., 2019).  
There is evidence corroborating host-to-host transmission (whether direct or indirect) 
and different ways of transmission have been addressed including sexual activities, 
vaginal microbiota, contaminated food, or even close animal contact (Singer, 2015). 
Regarding rUTI, studies reported recurrences caused by the same strain which were 
identified in the previous infection (Ulla-Maija Kärkkäinen, 2000; Jantunen et al., 2002; 
Johnson et al., 2016a). Those recurrences could suggest (I) an underlying host 
predisposition and/or (II) the existence of a persisting endogenous focus, and/or (III) the 
reintroduction of the strain from a persisting external reservoir. In either situation, broader 
knowledge and investigation of the route of transmission and spread of ExPEC strains 
may help to control and prevent further infections (Singer, 2015). 
1.7.RESISTANCE PROFILE IN E. COLI AND RESISTOME  
In the following section, we revisit the theoretical framework around antibiotic 
therapy and bacterial resistance.  
1.7.1. ANTIBIOTICS AND THEIR USE 
Antibiotics are a diverse group of antimicrobial substances which target specific 
bacterial structures or processes that interfere with bacterial growth and reproduction 
(bacteriostatic effect) and/or cause bacterial death (bactericidal effect) (Pal et al., 2017). 
The introduction of antibiotics, through the discovery of penicillin by Alexander 
Fleming in 1928, revolutionised the treatment of bacterial diseases and was a milestone 
for the development of modern medicine. Thanks to antibiotics, many lethal diseases such 
as scarlet fever, purulent pharyngitis, diphtheria, or gonorrhea were effectively inhibited 
and human life expectancy was substantially extended (Laxminarayan et al., 2016; 
Durand et al., 2019).  
Nowadays, antibiotics are extensively used for different proposes in human society 
(i.e. human medicine, veterinary medicine, aquaculture and agriculture) (Cabello, 2006; 
Van Boeckel et al., 2014; Meek et al., 2015). In fact, it has been estimated that the use of 
antimicrobials in food-production animals reached approximately 131,109 tons in 2013 
and will continue to increase (Van Boeckel et al., 2017). In medicine, antibiotics are used 
to treat and prevent infections (prophylaxis). For example, during medical procedures 
such as surgery or organ transplants, and they are crucial for patients with compromised 
immune function (Holmes et al., 2016; Laxminarayan et al., 2016). However, since the 
“golden age” of the development of antibiotics in 1960s, very few new antibiotics have 
been discovered. The main antibiotic classes and their mechanism of action are 
summarised in Table 2. 
The use of antibiotics by humans began less than 70 years ago, but bacteria have been 
evolving with natural antimicrobial compounds for billions of years (Martínez, 2012, 
2014). The human overuse and misuse of these compounds is exerting a selective pressure 
among bacteria which has favoured and accelerated the development of bacterial 
resistance mechanisms. Subsequently, once treatable bacteria are now either untreatable 
or require to use last line of antibiotics (Ventola, 2015). Therefore, Multidrug-resistant 
(MDR), extensively drug-resistant (XDR) and pan-drug-resistant (PDR) strains of E. coli, 
Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa are now 
reported worldwide (Boucher et al., 2009; Shlaes et al., 2013).  
The World Health Organization (WHO) has warned that a postantibiotic era could be 




introducing the “Access”, “watch” and “reserve” (AWaRe) classification of antibiotics 
(WHO, 2017). In 2019, there was an update on the AWaRe classification Database (see 
AWaRe web portal, in https://adoptaware.org/). The “access” category includes 
antibiotics with activity against a wide range of common susceptible pathogens, which 
can be used for empiric treatments (48 antibiotics). The “watch” category includes 
antibiotics with higher resistance potential that should be used with precaution (110 
antibiotics). Lastly, the “reserve” category includes antibiotics which should be used only 
if other options have failed (last-resort antibiotics) (22 antibiotics). Besides, in 2004 the 
world organisation for animal health (OIE) has also developed a list of critically important 





Table 2. Antibiotics classes, agents and mechanism of action. 
Antibiotic Class Representative antibiotic agents Antimicrobial action 
Beta-lactams 
Penicillins1, cephalosporins (1st, 2nd, 3rd and 4th 
generations), monobactams (aztreonam), carbapenems 
(imipenem, meropenem), cefamycin (cefoxitin) 
Inhibit bacteria cell wall biosynthesis 
(bactericidal) 
Aminoglycosides Streptomycin, neomycin, kanamycin, gentamicin and tobramycin 




Nalidixic acid, delafloxacin, norfloxacin, 
Flumequine, enrofloxacin, ciprofloxacin, 
levofloxacin and moxifloxacin 
Interfere with bacteria DNA replication 
and transcription (bactericidal) 
Glycopeptides Vancomycin, dalbavancin, oritavancin and teicoplanina 
Inhibit bacteria cell wall biosynthesis 
(bactericidal) 
Lipopeptides Daptomycin and surfactin 
Disrupt multiple cell membrane 
functions. Inhibit the synthesis of 
proteins, RNA and DNA by bacteria 
(bactericidal) 
Streptogramins Streptogramin A+B, virginiamycin A+B and Pristinamycin 
Inhibit the synthesis of proteins by 
bacteria (bactericidal). 
Polypeptide 
antibiotics Polymyxin B, polymyxin E (colistin) and bacitracin 




Inhibit bacteria cell wall biosynthesis 
(bactericidal) 
Nitrofurans Nitrofurantoin Inhibit enzymatic pathways (bactericidal) 
Nitroimidazoles Metronidazole and ornidazole Interfere with bacteria DNA replication and transcription (bactericidal) 
Ansamycins Geldanamycin, naphthomycin and Rifamycin Inhibit the synthesis of RNA by bacteria (bactericidal) 
Macrolides 
Erythromycin, josamycin, midecamycin, 
spiramycin, fidaxomicin, azithromycin and 
clarithromycin 
Inhibit the synthesis of proteins by 
bacteria (bacteriostatic agent, 
occasionally bactericidal at high dose 
levels) 
Lincosamides Lincomycin and clindamycin 
Inhibit the synthesis of proteins by 
bacteria (bacteriostatic agent, bactericidal 
agent at high dose levels) 
Tetracyclines 
Tetracycline, chlortetracycline, oxytetracycline, 
eravacycline, minocycline, doxycycline, 
limecycline and glycylcyclines (3rd generation 
tetracyclines: tigecycline ) 
Inhibit the synthesis of proteins by 
bacteria (bacteriostatic) 
Phenicols Chloramphenicol Inhibit the synthesis of proteins by bacteria (bacteriostatic) 
Aminocyclitols Spectinomycin 
Inhibit the synthesis of proteins by 
bacteria (bacteriostatic, occasionally 
bactericidal at high dose levels) 
Sulfonamides Prontosil, sulfanilamide, sulfadiazine, sulfamethoxazole 
Inhibit metabolic pathways of bacteria 
(bacteriostatic) 
Trimethoprim Trimethoprim Inhibit metabolic pathways of bacteria (bacteriostatic) 
Oxazolidinones Linezolid, posizolid, cycloserine, Tedizolid Inhibit the synthesis of proteins by bacteria (bacteriostatic) 





Inhibit the synthesis of proteins by 
bacteria (bacteriostatic, bactericidal agent 
at high dose levels) 
Steroid antibiotics Fusidic acid Inhibit the synthesis of proteins by bacteria (bacteriostatic) 
Ketolides  Telithromycin 
Inhibit the synthesis of proteins by 
bacteria (bacteriostatic, bactericidal agent 
at high dose levels) 
1Frequently used in combination with clavulanic acid, sulbactam or tazobactam (beta-lactamase inhibitors) (Blondeau, 




An important task for medical microbiology is to perform antimicrobial susceptibility 
tests (ASTs) to guide antibiotic therapy. ASTs provide the phenotypic resistance profile 
of bacteria and a broad variety of methods have been developed for this purpose 
(phenotypic testing has been reviewed in detail by Jorgensen and Ferraro, (2009). 
Fundamentally, AST assesses how well bacteria grow in presence of a tested antibiotic 
and the results can be expressed either as a concentration (minimum inhibitory 
concentration or MIC) or zone diameter (in millimeters). These results allow classifying 
the bacterial strain phenotype to a given antibiotic in one of three categories: susceptible, 
resistant and intermediate. 
According to the international standard, (ISO 20776-1) these terms are defined as 
follows: (I) “susceptible” when a bacterial strain is inhibited in vitro by a concentration 
of drug that is associated with a high likelihood of therapeutic success, (II) “resistant” 
when a bacterial strain is inhibited in vitro by a concentration of drug that is associated 
with a high likelihood of therapeutic failure (II) “intermediate” when a bacterial strain is 
inhibited in vitro by a concentration of drug that is associated with an uncertain 
therapeutic effect - this last category suggests that a  higher-than-normal drug dosage may 
be needed to ensure efficacy.  
As a whole, data of this type can be used to form a picture of the degree of resistance 
to each drug in the population at large and classify bacteria in one of the following three 
categories: (I) “usually sensible” when less than 10% of the bacteria population showed 
resistance (II) “not usually sensible” when 10 to 15 % of the bacteria population showed 
resistance and such antibiotic is not recommended for “empirical” treatments, and (III) 
“usually resistant” when more than 50% of the bacteria population was not sensible and 
such antibiotic is not recommended for treatment (Rodloff et al., 2008; Blondeau, 2009; 
Martínez, 2014; Fernández-Rodríguez and Prieto-Lago, 2017a).  
For the success of antimicrobial therapy, it is essential to correctly assign clinical 
isolates to the interpretive categories. Thus, standardizing testing techniques and 
establishing breakpoints (Hombach et al., 2013). In this regard, the international 
organisations Clinical and Laboratory Standards Institute (CLSI) and the European Union 
Committee on Antimicrobial Susceptibility Testing (EUCAST) provide standards with 
the aim of converting MIC and zones of inhibition measurements into categorical 
resistance determinations (CLSI, 2017; EUCAST, 2020).  
1.7.2. BACTERIAL RESISTANCE IN E. COLI 
Resistance can be defined as the ability of a microorganism to multiply in the presence 
of a toxic compound and is applicable to bacteriostatic and bactericidal antibiotics, 
whereas tolerance determines the absence of growth yet with the existence of bacterial 
survival in the presence of a bactericidal antibiotic (Lewis, 2007, 2008).  
Bacteria can display intrinsic resistance or develop acquired resistance against 
antibiotics (see below) and the resistome includes all existing resistance genes (known or 
unknown) of a given bacteria (Perry et al., 2014).  
Intrinsic resistances occur in all taxonomically related bacteria, when the 
physiological or biochemical makeup of that species naturally makes these groups of 
bacteria resistant to a specific drug. Intrinsic resistances are chromosomally encoded and 
can only be transmitted vertically (descendence). Acquired resistance is only present in a 
certain lineage of bacteria derived from a susceptible parent due to the presence of a 
resistance gene that is not natively present. Acquired resistances are frequently encoded 
outside the chromosome in mobile genetic elements (MGEs) and can be transferred 




Moreover, is not uncommon for a single bacterium to express resistance to different 
compounds simultaneously. The MDR, XDR and PDR denominations describe the most 
worrying patterns of resistance. MDR was defined as “acquired non-susceptibility to at 
least one agent in three or more antimicrobial categories”, XDR was noted as “non-
susceptibility to at least one agent in all but two or fewer antimicrobial categories” and 
PDR was defined as “non-susceptibility to all agents in all antimicrobial categories” 
(Magiorakos et al., 2012). These phenomenons are mainly caused by co- or cross-
resistance mechanisms.  
Co-resistance occurs when a bacterium due to the acquisition of two or more different 
resistance genes acquires resistance to more than one family of antibiotics. In contrast, 
cross-resistance means that the acquisition of one specific mechanism of resistance results 
in resistance to more than one family of antibiotics. These phenomenons can maintain 
and promote antibiotic resistance in bacterial populations even in the absence of one of 
the affected compounds (co-selection) (Pal et al., 2017). 
There are six main mechanisms of bacterial resistance: (I) enzymatic alteration of the 
antibiotic; (II) alteration or protection of the target site; (III) restriction of access to the 
target, (IV) overproduction of the target (V) reduced permeability and (VI) active efflux 
(Martínez, 2014; Munita and Arias, 2016).  
Over the past few decades, antimicrobial resistance among E. coli clinical isolates 
has increased significantly. In what follows we will outline the effluxome activity and 
acquired antibiotic resistance genes (ARGs) reported in E. coli.  
1.7.2.1. The E. coli effluxome 
The “effluxome” of E. coli includes a whole set of transporters which function in a 
coordinated mode in order to maintain appropriate homeostasis under changing 
environmental conditions (Schuldiner, 2018). Furthermore, it contributes to reducing the 
intracellular antibiotic concentration by decreasing passive uptake (bacterial porines) or 
increasing active efflux (bacterial efflux systems) through bacterial membranes in a 
process termed efflux (Figure 1).  
 
Figure 1. E. coli effluxome chematic representation. The influx of drugs (shown as pills) through 
the OM (outer membrane) and IM (inner membrane) occurs in one or more of the following three 
pathways: porin channels, specific protein channels and the LPS-containing asymmetric lipid 
bilayer region. Further, these drugs can by extruded out by single-component efflux transporters 
(e.g., Tet pumps) or multi-component efflux transporters (e.g., AcrAB-TolC tripartite efflux 
systems that typically contain a supplier, an OM channel protein [OMP], and an accessory 




What is more, recent studies have pointed out efflux as a first-line defense mechanism 
which allows bacteria to fix specific beneficial mutation favorising the development and 
spread of resistant mutants. Also, several studies support that efflux pump overproduction 
mechanism in E. coli isolates is becoming more widespread over time (Pagès et al., 2008; 
Fernandez and Hancock, 2012; Nikaido and Pagès, 2012; Schuldiner, 2018). 
1.7.2.1.1. Bacterial Porines  
Porin proteins are channels which allow the passive diffusion of hydrophilic small 
molecules through the outer membrane (OM) permeability barrier. Therefore, porins are 
one major route of entry for hydrophilic antibiotics within the bacterial cell. For this 
reason, mutations affecting the expression and/or function of porins have a direct impact 
on the susceptibility of bacteria to antibiotics.  
The loss of a particular porin has generally a minor to moderate effect on the overall 
resistance of the microorganism, leading to a low-level resistance (not phenotypically 
significant). However, the accumulation of mutational events affecting various resistance 
mechanisms can gradually confer a high-level resistance (phenotypically significant). 
Several types of porins have been described and can be broadly classified as general 
porins, such as OmpF and PhoE in E. coli and specific porins for those which enable the 
uptake of specific substrates (Pagès et al., 2008; Fernandez and Hancock, 2012). 
1.7.2.1.2. Bacterial efflux systems 
Bacterial efflux systems or pumps are energy-dependent systems which facilitate the 
transport of toxic compounds out of the bacterial cell.  
Efflux systems can be divided in two main classes: (I) the ATP-binding cassette 
(ABC) transporters and (II) the secondary multidrug transporters (MDTs). The major 
difference between those classes is the source of energy required for transport. ABC-type 
systems use the energy derived from ATP hydrolysis, whereas MDTs utilize proton 
motive force. MDTs comprise the majority of clinically relevant efflux systems and 
encompass (I) the major facilitator superfamily (MFS), (II) the small multidrug resistance 
(SMR) family, (III) the multidrug and toxic compound extrusion (MATE) family, and 
(IV) the resistance-nodulation-cell division (RND) family (Fernandez and Hancock, 
2012; Schuldiner, 2018).  
Some members of the ABC transporters (e.g., MacB), the RND family (e.g., AcrAB–
TolC complex), the MATE family (e.g., MdtK), and even the MFS (e.g., EmrB) are 
structured as tripartite complexes. The suppliers (first component) are located in the inner 
membrane (IM) (cytoplasmic membrane) and remove toxic compounds from the 
cytoplasm to the periplasmic space. Suppliers interact with the periplasmic adaptor 
protein (second component) and the outer membrane (OM) channel (third component) to 
finally excrete the desired substance to the external medium (Fernandez and Hancock, 
2012; Schuldiner, 2018).  
Most efflux systems are chromosomally encoded and can transport multiple different 
substrates despite certain examples of specific efflux pumps. In general, specific efflux 
pumps are encoded in mobile genetic elements (MGEs)(Butaye, 2003). 
1.7.2.2. Acquired resistance to β-lactams in E. coli  
The beta-lactam family includes a broadly used group of antibiotic agents due to their 
wide spectrum of action and low toxicity.  
Bacterial resistance to beta-lactams is mainly due to the production of enzymes 
(betalactamases). Some betalactamases are intrinsic to E. coli (i.e., penicillin binding 




enzymes generally express a low level of resistance and are not phenotypically 
significant. Most betalactamases are harbored in mobile genetic elements (MGEs) and 
can be transferred horizontally between bacteria, confering high levels of drug resistance 
(Munita and Arias, 2016).  
Currently, hundreds of betalactamases have been described and two classification 
schemes have been globally accepted based on either their structure or by their functional 
properties. Firstly, the Ambler or structural classification is based on the enzyme amino 
acid identities and active site. It separates betalactamases into 4 classes: A, C and D serine 
betalactamases and B metallo-betalactamases (Ambler, 1980). On another note, the Bush-
Jacoby or functional classification separates betalactamases into four categories (each 
with several subgroups) according to their biochemical function and correlated the 
properties of the enzyme with the expressed resistance (Bush and Jacoby, 2010; Bush, 
2013).  
1.7.2.2.1. Extended-spectrum β-lactamases (ESBLs) 
Extended-spectrum betalactamases (ESBLs) are a group of enzymes which cause 
resistance to the oxyiminocephalosporins (i.e., cefotaxime, ceftazidime, ceftriaxone, 
cefuroxime, cefepime) and the monobactams (i.e., aztreonam), but not the cephamycins 
(i.e., cefoxitin) or the carbapenems (i.e., imipenem, ertapenem). They are inhibited by 
betalactamase  inhibitors (i.e., clavulanic acid, sulbactam, and tazobactam) (Munita and 
Arias, 2016). Class A betalactamases are the most common sources of acquired ESBLs 
in E. coli, and include SHV, TEM and CTX-M families.  
The cefotaximase of Munich (CTX-M) is a family of enzymes which has become the 
most prevalent ESBL driver worldwide (CTX-M enzymes origin and diffusion has been 
recently reviewed in detail by Bevan et al. (2017). This group has been structurally 
classified into several subfamilies, among which subfamilies CTX-M-1 (e.g., CTX-M-15 
variant) and CTX-M-9 (e.g., CTX-M-14 and CTX-M-27 variants) are the most frequently 
reported worldwide.  
Extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) is an 
important cause of urinary tract and bloodstream infections, as well as other types of 
human extraintestinal infections (Arnaud et al., 2015; Mamani et al., 2019). The main 
sequence type (ST) responsible for the global increase in ESBLEC is, without a doubt, 
ST131 (Nicolas-Chanoine et al., 2007b, 2014). Subclade C2 (also known as subclone 
H30Rx) associated with the production of CTX-M-15 seems to be the most expanded and 
successful ST131 sublineage (Banerjee et al., 2013b; Price et al., 2013; Dahbi et al., 2014; 
Peirano et al., 2014b; Sauget et al., 2016). However, cluster C1-M27 that belongs to 
subclade C1 and produces CTX-M-27 has recently expanded, first in Japan (Matsumura 
et al., 2016, 2017b), then in other countries (Thailand, Australia, Canada, USA, France, 
Italy, Germany, The Netherlands and Spain) (Blanc et al., 2014; Birgy et al., 2016; Bevan 
et al., 2017; Merino et al., 2018; Peirano and Pitout, 2019). The other STs frequently 
found among ESBLEC are ST10, ST38, ST405, ST410, ST648 and ST1193 (Brisse et 
al., 2012; Naseer et al., 2012; Peirano et al., 2012; Izdebski et al., 2013; Peirano and 
Pitout, 2019). Besides there are notable differences with regard to the ESBLEC 
epidemiology according to the countries, including, sometimes, the emergence of new 
lineages. Thus, a new clade of ST131 associated with the production of the CTX-M-101 
enzyme and the fimH27 allele has recently been identified in E. coli responsible for 
bacteremia in Denmark (Roer et al., 2017). 
The horizontal gene transfer (HGT) of a wide variety of mobile genetic elements 




recurrent rearrangements in and around ESBL genes have made their surrounding genetic 
environments very diverse (Dhanji et al., 2011; Munita and Arias, 2016; Bevan et al., 
2017). 
1.7.2.2.2. Plasmidic aquired cephalosporinases (pAmpC) 
Plasmidic aquired cephalosporinases (pAmpC) are plasmid-borne enzymes that cause 
resistance to narrow-, broad-, and expanded-spectrum cephalosporins and cephamycins 
and which are not inhibited by betalactamase  inhibitors (Munita and Arias, 2016). This 
group belongs to class C betalactamases.  
During the last decade, a wide variety of plasmid-borne ampC genes have been 
reported (Jacoby, 2009), including CMY-, DHA-, and ACC-type betalactamases, 
amongst which the CMY-type is the most prevalent (Philippon et al., 2002).  
1.7.2.2.3. Carbapenemases 
Carbapenemases are a group of enzymes which have the ability to hydrolyze almost 
all beta-lactam antibiotics, including carbapenems (last line of beta-lactams). 
Carbapensemases include members belonging to classes A, B, and D betalactamases 
which confer a wide and versatile spectrum of resistance to beta-lactams.  
Class A includes Serratia marcescens enzymes (SME), imipenemases (IMI), New 
Delhi metallo-betalactamases (NDM), Guyana extended-spectrum-lactamases (GES) and 
the Klebsiella pneumoniae carbapenemases (KPC) families; class D includes 
oxacillinase-48-types betalactamases (OXA-48); and class B which are metallo-
betalactamases (MBLs) includes Imipenemase metallo-betalactamases (IMP), Verona 
integron-encoded metallo-betalactamases (VIM), Sao Paulo metallo-betalactamases 
(SPM), German imipenemases (GIM) and Seoul imipenemases (SIM) families (Munita 
and Arias, 2016).  
These enzymes were first discovered among nonpathogenic bacteria and were 
commonly chromosomally encoded. Nowadays, plasmid-encoding carbapenemases have 
been reported in several studies, involving KPC, NDM and OXA-58 enzymes that 
represent major threats for human medicine (Nordmann et al., 2011). Fortunately, 
carbapenemase-producers are not as widespread as ESBL-producers within E. coli yet, 
but they are increasing (Peirano et al., 2014a).  
1.7.2.3. Acquired resistance to polimyxins and other families of antibiotics in E. coli 
Due to the extensive use of antibiotics, the therapeutic options against enterobacteria 
have changed over the last years and resistance to almost all classes of antibiotics has 
been reported in E. coli. Worryingly, resistance to last-resort antibiotics such as 
carbapenems and polimyxins has already been reported in the pandemic E. coli clone 
ST131 (Trobos et al., 2009; Schink et al., 2013; Hasman et al., 2015; Sonnevend et al., 
2016; Ewers et al., 2016; Kuo et al., 2016; de Toro et al., 2017; Ortiz de la Tabla et al., 
2017; García-Meniño et al., 2018; Liu et al., 2018b; Ellaby et al., 2019; Hojabri et al., 
2019; Reid et al., 2019). Colistin (polymyxin E) is associated with nephro and 
neurotoxicity. However, it has been widely used in veterinary medicine. Livestock, and 
particularly porcine farming, has been singled out as reservoir for colistin resistance 
(García-Meniño et al., 2019) and foodborne pathogens (FBPs) that could have 
devastating health and economic consequences (Sekse et al., 2017).  
Intrinsic resistance to colistin has been related with two chromosomally encoded 
systems, the PhoPQ component and the pmrCAB operon (Olaitan et al., 2014; Poirel et 
al., 2018). However, the newly discovered plasmid-borne mobile colistin resistance (mcr) 




the description of the mcr-1 gene by Liu et al. (2016b) ⁠, several amino acid variants have 
been described, encoded in mcr-2 to mcr-9 genes (AbuOun et al., 2017; Borowiak et al., 
2017; Carattoli et al., 2017; Yin et al., 2017; Wang et al., 2018b; Yang et al., 2018; 
Carroll et al., 2019) ⁠. Besides, several sub-variants for some of them have been reported, 
i.e. thirteen nucleotide and protein variants in the mcr-1-family (designated mcr-1.1 to 
mcr-1.13) (Partridge et al., 2018a)⁠.  
Colistin plasmid-borne resistance has widely spread geographically (Kempf et al., 
2016). It has been described in numerous genera of Enterobacteriaceae including 
Escherichia, Moraxella, Klebsiella, Salmonella, Enterobacter, Cronobacter, Shigella, 
Kluyvera, Citrobacter and Raoultella (Campos et al., 2016; Zhao and Zong, 2016; Liu et 
al., 2016d, 2016a; Olaitan et al., 2016; Pham Thanh et al., 2016; Stoesser et al., 2016a; 
Zeng et al., 2016; AbuOun et al., 2017; Li et al., 2017c; Luo et al., 2017). Although mcr 
genes have been found in a large diversity of clones, Matamoros et al. (2017) and García-
Meniño et al. (2019) established the ST10 and ST155 E. coli clones as potential reservoirs 
of the mcr-1 gene.  
The mcr gene has been detected in many plasmid types, including IncI2, IncHI2, 
IncP, IncX4, IncY, IncF and ColE10-like ones (Madec and Haenni, 2018) ⁠ from different 
origins (Sun et al., 2018) ⁠. Nevertheless, Matamoros et al., (2017) ⁠ and García-Meniño et 
al. (2019) found that the majority of the mcr-carrier plasmids belonged mainly to four 
plasmid incompatibility groups: IncX4, IncI2, IncHI2 and ColE10-like⁠. In contrast, it 
remains rare to find colistin resistance genes chromosomally encoded, in accordance to 
Li et al. (2018) studies, where the prevalence of chromosomal mcr carrier isolates was 
estimated in 4% of the analysed isolates. 
Broadly, the mcr-1 cassette is described as an approximately 2,600 base pair fragment 
containing the mcr-1 gene followed by a phosphoesterase (Poirel et al., 2016). It has been 
proposed that the ISApl1 insertion sequence (IS) mediates the transmission of mcr-1 by 
forming circular intermediates, which can translocate (Tegetmeyer et al., 2008; Chandler 
and Siguier, 2013; Snesrud et al., 2016; Zurfluh et al., 2016a, 2016b; Li et al., 2017a)⁠. 
Table 3 summarises ARGs described in E. coli which confer resistance to families of 
antibiotics distinct from beta-lactams. Among them it can be noted the recently described 





Table 3. Resistant determinants described in E. coli (excluding b-lactam resitant determinants).  
Drug class  Efflux mechanisms Alterations in drug targets Other acquired mechanisms 
Quinolones and 
fluoroquinolones 
RND-type efflux pump 
(e.g., AcrAB-TolC ) and 
QepA and OqxAB active 
efflux pumps1 
Mutations in DNA 
gyrase (GyrA and GyrB 
subunits) and 
topoisomerase IV (ParC 
and ParE subunits)2 
Plasmid-mediated quinolone 
resistance (PMQR): Qnr-like 
proteins (QnrA, QnrB, 
QnrC,QnrD, and QnrS) and 
AAC(6′)-Ib-cr acetyltransferase3. 
Aminoglycosides 
RND-type efflux pump 
(e.g., AcrAD-TolC). 
 
Mutations on the 16S 
RNA and/or the S5 and 
S12 ribosomal proteins. 
Plasmid-mediated 16S rRNA 












Mutations in the glpT 
and uhpA/T genes 
encoding proteins 
related to the fosfomycin 
uptake system. 
Fosfomycin-modifying enzymes 
such as the metalloenzymes 
FosA, FosB, and FosX or the 
kinases FomA and FomB. 
Tetracyclines 
MF-type efflux pump (e.g., 
Tet efflux proteins [tet(A), 
tet(B), tet(C), tet(D), tet(E), 
tet(G), tet(J), tet(L)]). 
 
Tetracycline resistance genes 
encoding ribosome protective 
proteins [tet(M) and tet(W)], and 
an oxidoreductase that inactivates 
tetracyclines [tet(X)]. 
Phenicols 
MF-type efflux pump (e.g., 
active efflux of non-
fluorinated phenicols 
(cmlA genes) or fluorinated 
and non-fluorinated 
phenicols (floR genes)). 
Target site methylation 
by rRNA methylases 
(cfr gene6) 
Enzymatic inactivation of non-
fluorinated phenicols by 
chloramphenicol 
acetyltransferases (cat genes). 
Sulfonamides  




Acquisition of dihydropteorate 
synthetases (DHPS) (sul1, sul2, 
or sul3 genes). 
Trimethoprim  






Acquisition of dihydrofolate 
reductases  
(dfrA and dfrB genes). 
Macrolides 
MF-type efflux pump (e.g., 
macrolide specific efflux 
pump encoded by mef(A)) 
and RND-type efflux pump 
(e.g., AcrAB-TolC) 
Modification of the 
macrolide target (23S 




mph(B) genes) and esterases 






Modification of the 
outer membrane through 
mutations in PmrA 
and/or PmrB or in the 
PhoPQ two-component 
system or its regulator 
MgrB.  
Acquisition of MCR 
phosphoethanolamine 
transferases (mcr gene) 
1Plasmid-born; 2Single mutations in the gene gyrA may confer resistance to quinolones, but for resistance to 
fluoroquinolones, further mutations within gyrA and/or parC are needed; 3Also confer resistance to 
aminoglycosides; 4Affect the ability of aminoglycosides to bind to the ribosome via methylation of the 
aminoglycoside-binding site; 5For each enzyme, several variants have been reported; 6Confers resistance to 
five classes of antimicrobial agents, including fluorinated and nonfluorinated phenicols (Munita and Arias, 




1.8. BIOFILM FORMATION 
Since the first definition of biofilms provided by Costerton et al. (1978) 30 years ago, 
it is well established that the majority of bacteria found in nature exists attached to 
surfaces within the structured biofilm ecosystem (Costerton et al., 1978; Hall-Stoodley et 
al., 2004).  
Biofilms are complex three-dimensional communities of microorganisms which are 
adhered to a surface and housed in a protective extracellular polymeric substance. The 
production of biofilm follows three steps: (I) early development, (II) maturation and (III) 
dispersion. The early development step starts with the initial adhesion of planktonic 
bacteria (free-floating) to a surface and followed by the matrix formation. The maturation 
step occurs while the biofilm reaches its maximum cell density. Lastly, during the 
dispersion step microcolonies of bacteria are released to colonise new surfaces (for a 
comprehensive review, see Lebeaux et al., 2014).  
In biofilms bacteria communicate (quorum Sensing) to display unified responses that 
benefit the entire community (Dickschat, 2010). For example, by controlling the 
population density (access to nutrients) or by the expression of co-ordinated virulence 
phenotypes. Also, biofilms contribute to the bacteria evasion of the host immune response 
and induce a decrease of antibiotic susceptibility (tolerance) (Lewis, 2007, 2008). 
Bacterial biofilms are known for their resistance to antibiotics, disinfectants, and 
components of the innate and adaptative inflammatory defense system of the body (Høiby 
et al., 2011). Accordingly, biofilm-growing bacteria cause chronic infections, persisting 
inflammation, tissue damage, and foreign body infections (Høiby et al., 2011). Thus, it 
was shown that persistence of staphylococcal infections related to foreign bodies is due 
to biofilm formation (Sabaté Brescó et al., 2017). Likewise, chronic Pseudomonas 
aeruginosa lung infections in cystic fibrosis patients are caused by biofilm-growing 
mucoid isolates (Høiby et al., 2010). It has been estimated that in humans around 80% of 
all bacterial infections involve biofilms (Davies, 2003). Besides, biofilms have also been 
related with a great part of food-borne outbreaks due to its ability to growth and persist 
on food processing facilities (Piercey et al., 2016).  
Antibiotic tolerance within biofilms is multifactorial and reversible (it disappears 
when the biofilm is disrupted). It has been proved that the persister cells are not resistant 
mutants (Lebeaux et al., 2014). Nonetheless, biofilm communities can be exposed to 
subinhibitory concentrations of antibiotics. Factor which is known to increase the 
likelihood of selecting antibiotic-resistant mutants. Besides, biofilms provides a 
favourable environment for horizontal gene transfer (HGT) .Thus, contributing to the 
exchange of antibiotic resistance genes (Ghigo, 2001; Madsen et al., 2012). 
Concerning E. coli, which can exist as a harmless commensal in the mammalian 
digestive tract and as a pathogen causing significant morbidity and mortality worldwide, 
its ability to form biofilm has been extensively studied from non-pathogenic E. coli K12 
strains (Beloin et al., 2008). With regard to pathogenic E. coli, biofilm involvement in 
pathogenesis has been well defined in diarrheagenic E. coli, notably enteroaggregative E. 
coli (Sherlock et al., 2004; Sheikh et al., 2008; Schiebel et al., 2017) and in adherent-
invasive E. coli that have been implicated in the origin and perpetuation of Crohn’s 
disease (Martinez-Medina et al., 2009b). Production of biofilm by extraintestinal 
pathogenic E. coli (ExPEC) was mostly assessed in uropathogenic E. coli (Watts et al., 
2010; Ponnusamy et al., 2012; Agarwal et al., 2013; Tapiainen et al., 2014). All these 
studies highlighted various biofilm formation phenotypes among uropathogenic E. coli 




biofilm formation focusing on the pandemic extended-spectrum β-lactamase (ESBL)-
producing and multidrug-resistant ST131 E. coli clone (Nicolas-Chanoine et al., 2014) 
showed highly contrasting results: very low levels (Novais et al., 2012) and moderate 
levels (Hussain et al., 2014) of biofilm formation. Sarkar et al. (2016) studying ST131 
isolates expressing or non-expressing type 1 fimbriae showed that biofilm growth 
depended on type 1 fimbriae expression and assay conditions. In another recent study it 
is shown that ST131 isolates may express different phenotypes according to their fimH 
allele encoding adhesins of type 1 fimbriae, namely, significantly higher levels of early 
biofilm production by isolates of ST131 H22 subclone than those of ST131 H30 subclone 
(Nicolas-Chanoine et al., 2017). 
1.9. MOBILE GENETIC ELEMENTS (MGES) AND EVOLUTION OF PATHOGENIC E. 
COLI 
Mobile genetic elements (MGEs) are segments of DNA which encode enzymes and 
other proteins that mediate the movement of other DNA pieces and can be divided into 
two groups as follows: (I) MGEs with the ability to move DNA segments within the 
genome of a single bacterium (i.e., intracellular mobility) and (II) MGEs that allow 
movement of DNA between bacteria (i.e., intercellular mobility) (Partridge et al., 2018b; 
Peirano and Pitout, 2019).  
MGEs contribute to chromosome rearrangements and plasmid integration of genes. 
Thus, facilitating the exchange of genes between bacteria. All the capture, transposition 
and recombination of DNA through MGEs have a profound impact on the ongoing 
evolution of bacterial pathogens (Hacker and Kaper, 2000; Reid et al., 2000; Dobrindt et 
al., 2002, 2004). Notably, resistance and virulence-associated genes are frequently 
located on MGEs such as prophages, plasmids and genomic islands (GIs) (Dobrindt, 
2005).  
1.9.1. INTRACELLULAR MOBILITY 
MGEs contributing to intracellular mobility include (I) insertion sequences (IS), (II) 
transposons (Tn) and (III) integrons (In). These types of MGEs can be found in different 
locations as well as in multiple copies within the bacterial genome (Orlek et al., 2017). 
Insertion sequences (IS) and transposons (Tn) are DNA segments which are able to 
move almost randomly to new locations through a ‘cut and paste’ mechanism. On the 
other hand, integrons (In) are genetic elements that can capture and allow the expression 
of exogenous genes using a site-specific recombination mechanism (Partridge et al., 
2018b). 
 Insertion sequences (IS) elements are the simplest types of MGEs and they 
typically contain a single open reading frame (ORF) coding for its own 
transposition (tnp gene). The major part are flanked by identical short terminal 
inverted-repeat (IR) sequences in opposite orientation (its binding sites) 
(Siguier et al., 2014).  
 Transposons (Tn) are larger than IS elements and besides the function 
required for its transposition, they usually carry a resistance gene (or another 
marker). We refer to a composite transposon when a pair of closely related IS 
elements are present at each end of a transposon. Afterwards, the merged 
elements move together leading to the transposition of the composite region 




 Integrons’s (In) basic structure includes a site-specific integrase (intI), an 
integron-associated attachment site (attI), an integron-carried promoter (Pc) 
and a gene cassette with a downstream attachment site (attC). The integron 
promotor allows the expression of the cassette-associated genes (usually 
coding for resistance determinants). Integrons are divided into different 
classes (I–IV) according to the sequence of their integrase. The ones most 
frequently detected among clinical isolates belong to class I (Gillings, 2014).  
Figure 2. schematic representation of insertion sequence elements, composite 
transposons and unit transposons. Insertion sequences are flanked by inverted repeats 
(IRs) that are short identical sequences in opposite orientation. IR inverted repeat, res 
gene encoding for resolvase, tnp gene encoding for transposase, intl gene encoding for 
integrase, Pc integron-carried promoter, attI integron-associated attachment site, attC 
downstream attachment site. 
1.9.2. INTERCELLULAR MOBILITY  
The intercellular bacterial mechanisms of genetic exchange include (I) 
conjugation/mobilization (mediated by plasmids and integrative conjugative elements), 
(II) transduction (mediated by bacteriophages), and (III) transformation (uptake of 
extracellular DNA) (for a comprehensive review, see Thomas and Nielsen, 2005). 
1.9.2.1. Plasmids 
The bacterial genome is composed of a circular chromosome and plasmids. Plasmids 
are extrachromosomal elements that can self-replicate and harbor genetic information 
which is not essential for the survival of bacteria. This implies that although several 
plasmids can coexist in a single bacterium, they can also be naturally lost (Partridge et 
al., 2018b). 
The plasmid structure includes a backbone harbouring a set of housekeeping genes 
coding for essential plasmid functions that can be classified into three modules (see 
below), as well as a variable assortment of accessory genome (Orlek et al., 2017; 
Partridge et al., 2018b).  
The accessory genome represents a wide group of adaptive genes (usually resistance 
and virulence codifying genes) which might benefit bacteria in a particular environment. 
The accessory genome may also harbor other MGEs such as insertion sequences, 
transposons and/or integrons (Partridge et al., 2018b). 
1.9.2.1.1. Replication and copy number control module  
Plasmids encode the initiation of their own replication. Three strategies have been 
discerned in circular plasmids: (I) Theta-mode (II) Rolling circle and (III) strand 




machinery (helicases, polymerase, etc.) in order to replicate (del Solar et al., 1998; 
Partridge et al., 2018b). 
Plasmid replication usually initiates in the oriV (origin of vegetative replication) 
region that is recognised by replication proteins (rep genes). Furthermore, multireplicon 
plasmids (plasmids carrying multiple replication regions) are quite common, suggesting 
that the fusion between plasmids frequently occurs (cointegrated plasmids). In some 
cases, those extra-replicons decrease bacteria fitness and must be eliminated, although 
they can also be advantageous by increasing the plasmid host range (more flexible 
replicative machinery) (Orlek et al., 2017; Partridge et al., 2018b).  
Once replicated, plasmids must also regulate their number of copies per cell to ensure 
that they do not excessively burden the host (too high number of copies) or become lost 
during cell division (too low number of copies). For this purpose, two basic strategies 
have been discerned: (I) the antisense (countertranscript) RNA systems and (II) the 
blockage of ori sites. As a general rule, small plasmids usually show a high number of 
copies per cell (>15 plasmids/cell) whilst large plasmids show a low number of copies 
due to fitness cost (Sengupta and Austin, 2011; Orlek et al., 2017; Partridge et al., 2018b). 
It is impossible for plasmids with the same replication mechanism to coexist in the 
same cell, a phenomenon termed as incompatibility. This is usually due to cross-talk 
between the replication initiation systems of the two plasmids that “confuses” the copy 
number control (the two different plasmids are perceived as the same), leading to 
segregational instability (Couturier et al., 1988; Novick, 1989). This incompatibility trait 
has provided the basis for the initial classification of plasmids (see plasmid classification).  
1.9.2.1.2. Vertical inheritance module 
In order to guarantee their maintenance, plasmids must ensure to be distributed 
between daughter cells when the cell division takes place (segregational stability). In this 
regard, the vertical module includes multimer resolution (res genes), partitioning (par 
genes) and post-segregational killing toxin-antitoxin (TA) systems (Sengupta and Austin, 
2011; Orlek et al., 2017; Partridge et al., 2018b).  
Low-copy number plasmids require a sophisticated segregation system to ensure 
inheritance within a bacterial lineage, for example the ParRMC system in R plasmids and 
SopABC system in F plasmids. In contrast, high-copy number plasmids can be inherited 
through a random segregation process (Partridge et al., 2018b). 
Some plasmids can only be efficiently maintained in closely related bacterial taxa and 
they tend to be restricted to certain species or clones within species, (narrow-host-range 
plasmids) whilst others can replicate and maintain themselves within diverse genera of 
bacteria (broad-host-range plasmids). 
1.9.2.1.3. Horizontal transfer module 
Plasmids can be transferred between bacteria in a process termed as conjugation or 
mobilisation. The conjugative machinery sets up a specialised transfer pore and induces 
the transport of DNA from the donor to the recipient cell.  
This module varies within conjugative (self-transmissible) and non-conjugative 
plasmids (mobilizables). Self-transmissible plasmids encode the complete protein 
machinery for conjugal transfer, while mobilizable plasmids contain a minimal gene set 
and can only be transmitted in presence of another “helper plasmid”. Thus, this module 
is related with the plasmid size: conjugative plasmids tend to be large, (30 to 500 kb) 
whilst mobilizable plasmids (3 to 35 kb) and non-mobilizable infective plasmids (1 to 5 




The transfer region (tra genes) of conjugative plasmids includes DNA transfer 
replication (DTR) proteins (Mob; classified into 9 families) and mating pair formation 
proteins (Mpf; classified into 8 types)(Guglielmini et al., 2014). The Mob protein is a 
crucial relaxosome component for the initiation of DNA transfer in both conjugative and 
mobilizable plasmids. Additionally, this module encodes entry (surface) exclusion 
proteins which prevent the host from acting as recipient for the same or related plasmids 
(Garcillán-Barcia and de la Cruz, 2008).  
During conjugation, the Mob protein (relaxase) binds the origin of transfer (oriT) site 
and nicks DNA in a single-stranded substrate suitable for transfer (Hayes, 2001). Mob 
proteins belong to nine families included in four protein superfamilies (HUH 
endonucleases, tyrosine recombinases, Rep_trans RCR initiators, and PD-(D/E) XK 
restriction endonucleases). Six major families of relaxases can be found within 
Enterobacteria: MOBF, MOBH, MOBQ, MOBC, MOBP, and MOBV (Francia et al., 2004; 
Garcillán-Barcia et al., 2009, 2011; Alvarado et al., 2012) ⁠ which belong to the His-
hydrophobe-His (HUH) endonuclease superfamily (Chandler et al., 2013). These proteins 
provide the basis for the classification of self-transmissible and mobilizable plasmids (see 
plasmid classification). 
1.9.2.2. Prophages 
Prophages are a fragment of DNA incorporated into the bacterial genome through 
bacteriophages, which are viruses-like structures which infect and replicate into bacterial 
cells. They are extremely diverse in size, morphology and genomic organisation. The 
spread of genes (frequently virulence-associated) by phages has been proved to be very 
frequent within bacteria (Novick et al., 2010; Kasman and Porter, 2020). 
1.9.2.3. Genomic islands (GIs)  
A genomic island (GI) is a distinct region of the bacterial chromosome which varies 
in size (they may be composed of several hundred genes) and composition.  Generally, 
GIs encompass elements with mobility functions (referred to as integrative conjugative 
elements), resistance determinants (referred to as resistance islands) or virulence factors 
(referred to as pathogenicity islands) and in many cases are flanked by direct repeats. 
Although there is still limited knowledge about  the origin of GIs, it has been 
speculated that they derive from the integration of plasmids or phages into the 
chromosome (Dobrindt et al., 2004). 
1.9.2.3.1. Integrative Conjugative Elements (ICEs) 
An integrative Conjugative Element (ICE) is a self-transmissible fragment of DNA 
that is integrated into the bacterial chromosome and replicated as part of it, but it can also 
be excised from the chromosome and transferred horizontally in a plasmid-like way 
(Burrus et al., 2002; Carraro and Burrus, 2015). Structurally, ICE typically consists of a 
backbone (containing phage-like integration/excision functions, plasmid-like 
conjugation/ maintenance components and a regulation module) as well as accessory 
genes that confer beneficial traits for the host (for a comprehensive review please refer to 
Delavat et al., 2017). 
1.9.2.3.2. Pathogenicity islands (PAIs) 
Pathogenicity islands (PAIs) are fragments of DNA encoding various virulence-
associated genes (Dobrindt et al., 2004). Structurally, PAIs are generally large in size 
(>10 kb) and they have a G + C content which differs from the host bacterial core genome. 
These elements are frequently flanked by repeated sequences (attachment sites attL and 




bacteriophages, plasmids and insertion sequence. In contrast to the other MGEs, most 
PAIs lack an origin of replication and can neither replicate nor mobilise by themselves. 
It has been suggested that PAI mobility is manly mediated by PAI-encoded integrases 
through a site-specific recombination process and that horizontal transfer is mediated by 
other MGEs (Middendorf et al., 2004; Hochhut et al., 2006). Genomic research has 
shown that pathogenicity islands (PAIs) have played a major role in the transformation 
of avirulent into virulent bacteria. As a typical example through the adcquisition of the 
so-called “high pathogenicity island” (HPI), initially described in yersiniae (Schubert et 
al., 1998; Desvaux et al., 2020). 
PAIs are usually inserted close to a transfer-messenger RNA (tmRNA) locus and 
within E. coli 15 tDNA genes have been described as hotspots of integration, from which 
asnT, aspV, leuX, metV, pheV and thrW are the most frequently targed genes (PAI 
markers) (Desvaux et al., 2020).  
Almost identical PAIs have been reported within E. coli pathotypes. However, great 
variability exists with regard to their composition, structural organisation and 
chromosomal localisation (Hacker and Kaper, 2000; Hacker and Carniel, 2001; Dobrindt 
et al., 2002, 2004; Welch et al., 2002; Dobrindt, 2005). Samei A., et al. 2016 and Naderi 
G., et al. 2016 analysed the prevalence of PAI markers among pathogenic and commensal 
E. coli isolates and concluded that PAI markers were more prevalent among UPEC and 
DEC strains than commensal strains (98.7% and 94.8%, respectively vs. 88% in 
commensals). They also found that the average of PAIs per isolate was higher in UPEC 
and DEC isolates than in commensals (Naderi et al., 2016; Samei et al., 2016). Thus, 
PAIs can be regarded as a feature that distinguishes pathogens from commensal in E. coli. 
Besides, most VFs of ExPEC are encoded by PAIs (for a comprehensive review see 
Desvaux et al., 2020). 
1.10. PLASMID CLASSIFICATION AND TYPING 
Two central schemes for plasmid typing are widely used: (1) the replicon typing 
scheme which relies on the classical plasmid classification based on the 28 defined 
Incompatibility groups (Inc) defined in Enterobacteriaceae (Carattoli et al., 2005; 
Rozwandowicz et al., 2018) and (2) the relaxase (MOB) typing scheme based on 
differences in conjugation systems which relies on Mob proteins (Francia et al., 2004; 
Alvarado et al., 2012).  
In 1988, Couturier and colleagues cloned replicons representing Enterobacteriaceae 
Incompatibility groups, after which plasmids started to be classified according to 
Southern blot hybridizations (Couturier et al., 1988). However, this method is laborious 
and can be hardly performed on a large number of strains. Nowadays, the PCR-based 
replicon typing (PBRT) method allows a rapid determination of various genetic loci 
(including rep genes and replication regulatory sequences) for plasmid replicon typing. 
The PCR-based replicon subtyping (pMLST) method allows the assignment of a pMLST 
subtype for six common replicon types in Enterobacteriaceae (IncF, HI1, HI2, I1, N, 
A/C) by the determination of 2 to 6 core loci (depending on the broader replicon type).  
The PCR-based degenerate primer MOB typing (DPMT) method allows to classify 
γ-Proteobacterial plasmids into five of the main relaxase (MOB) types, based on the 
determination of the N-terminal relaxase sequences (Alvarado et al., 2012).  
Replicon and relaxase typing are complementary and when performed together they 
can improve plasmid analysis. Additionally, in both silico replicon and relaxase (MOB) 




The correspondence between typing schemes is summarised in Table 4. The replicon 
typing scheme uses traditional nomenclature, allows pMLST subtyping and classifies 
approximatively 75% of Enterobacteriaceae plasmids and 50% of plasmids of Gram-
positive bacteria. Nevertheless, as a drawback, some plasmids may contain more than one 
replication protein. Instead, there is only one relaxase per plasmid. Relaxases classifies 
approximatively 50% of Enterobacteriaceae plasmids and a less percentage of Gram-
positive bacteria. The main drawback is that it only allows the classification of 
transmissible (mobilizable) plasmids. In comparison, MOB typing has higher sensitivity 
and lower resolution than the replicon typing method (Orlek et al., 2017). 
The phylogenetic establishment of plasmids remains challenging due to the plastic 
nature of plasmid genomes (Boyd et al., 1996). Also, current typing schemes are not able 
to classify all plasmids (Orlek et al., 2017). Although it is still evolving, WGS has brought 
forth many new opportunities in this regard. Some common in silico whole genome 
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1IncF plasmids are usually multireplicons carriers with a highly mosaic structure. The replicon typing 
scheme (RST) is based on diversity in the replicon regions and applies a FAB numbers formula for IncF 
subtyping which is obtained by combinations of three replicons (FII:FIA:FIB, e.g., F1:A2:B2) (Carattoli et al., 




Table 5. Summary of common in silico whole genome sequence (WGS) based tools that can be 
used for plasmid analysis.  
Tool (s) Goals and comments 
SRST2 Mapping-based tool to detect loci of interest from reads by mapping to a reference database.  
KmerResistance Detect resistance genes by examining co-occurrence of k-mers between the query and a reference database.  
Artemis comparison tool (ACT), 
BLAST Ring Image Generator (BRIG) 
and Easyfig. 
Comparative genomics tools that allow to visualize homologies and gene 
content similarities between contigs and references using BLAST1. 
PlasmidFinder and plasmid MLST 
(pMLST) 
Detect replicon type/subtype from contigs based on their similarity with 
reference database.  
ResFinder Detect resistance genes from contigs based on their similarity with a reference database using BLAST1. 
Comprehensive antibiotic research 
database (CARD) 
Detect resistance genes from contigs based on their similarity with 
CARD database using BLAST1. 
Antibiotic resistance gene-annotation 
(ARG-ANNOT) 
Detect resistance genes from contigs based on their similarity with ARG-
ANNOT database using BLAST1. 
ISMapper Mapping-based tool to localize insertion sequences. Localize specific genes from a contig assembly. 
cBar Distinguish plasmid from chromosomal sequences based on pentamer frequencies.  
PLACNET 
Resolve plasmid structures from ambiguous assembly graphs according 
to the homology of contigs to reference sequences. The identification of 
plasmids is base on multiple traits (coverage, size, replication initiator 




Resolve plasmids or circular phages structures from ambiguous 
assembly graphs by assuming that different genetic units have distinct 
copy numbers. Fully automatic tool.  
plasmidSPAdes 
 
Resolve plasmid structures from ambiguous assembly graphs based on 
the estimated chromosomal coverage. Fully automatic tool.  
Bandage 
Assembly graph visualization and annotation tool that resolves plasmid 
structures from ambiguous assembly graphs. Facilitates interaction with 
de Bruijn graphs made by de novo assemblers such as Velvet (Zerbino 
and Birney, 2008), SPAdes (Bankevich et al., 2012) and Trinity 
(Grabherr et al., 2011). 
Mlplasmids 
Predict plasmids and chromosome sequences regardless of contig 
coverage and can be used as a basis for plasmid classification by other 
tools.  
MOB-suite Automated annotation of MOB Relaxases.  
MOBscan Automated annotation of MOB Relaxases.  
PlasFlow Identification of bacterial plasmid sequences based on genomic signatures. 
1Basic local alignment serch tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Carver et al., 2005; Zhou and Xu, 
2010; Alikhan et al., 2011; Sullivan et al., 2011a; Zankari et al., 2012b; McArthur et al., 2013; Lanza et al., 2014; 
Carattoli et al., 2014; Gupta et al., 2014; Inouye et al., 2014; Wick et al., 2015; Hawkey et al., 2015; Antipov et 
al., 2016; Rozov et al., 2016; Clausen et al., 2016; Arredondo-Alonso et al., 2017; Krawczyk et al., 2018; 




1.11. CLONES AND EVOLUTIONARY SUCCESS OF E. COLI 
The term clone refers to bacteria isolates which share similar traits, indicating that 
they belong to the same lineage and have a common ancestor, thus this knowledge allows 
to link isolates from different geographical areas and hosts.  
Notable differences in the prevalence of E. coli linages are observed among different 
hosts, regarding to the host specie (animals and human populations) and the host 
environment (Tenaillon et al., 2010). Besides, intra-host diversity has been reported in 
several studies and attributed to migration of strains. In this regard, strain sharing occurs 
more frequently amongst household members, including pets (Johnson et al., 2008c; 
Pomba et al., 2016). 
Phylogenetical groups prevalence differs between animals and humans. In a recent 
study through a compiled analysis of 1,117 human isolates and 1,154 animal isolates, it 
was observed that the B1 phylogenetical group occupated the third place of prevalence in 
humans, while in animals occupated the first place. After which, in both humans and 
animals the prevalence of phylogenetic groups varies from higher to lower in the 
following order: A, B2 and D (Tenaillon et al., 2010).  
Furthermore, it has become evident that certain ExPEC lineages or clonal groups are 
responsible for a large fraction of human and animal extraintestinal infections. 
Concerningly, these lineages are becoming increasingly multi-drug resistant (Smith et al., 
2007; Manges and Johnson, 2012; Denamur et al., 2020). This association has led to the 
definition of “high-risk clones”. 
Baquero et al. (2013) defined as “multi-drug-resistant (MDR) high-risk clone” those 
having the following characteristics: (I) international distribution, (II) possess various 
antimicrobial resistance determinants, (III) successful colonisation and persistance in 
hosts for long time intervals (>6 months), (IV) effective transmission among hosts, (V) 
extended pathogenicity and fitness and (VI) cause severe and/or recurrent infections. 
Examples of MDR high-risk clones among E. coli (termed under sequence types 
according to the Warwick University scheme) are ST10 clonal complex, ST38, ST69, 
ST88, ST131, ST155, ST167, ST315, ST393, ST405, ST410 and ST648 (Manges and 
Johnson, 2012; Riley, 2014; Wang et al., 2016; Bubpamala et al., 2018; van Hoek et al., 
2018; Denamur et al., 2020). Currently, some other clones are emerging among ESBL-
producing E. coli like ST1193 (Valenza et al., 2019). It has been suggested that the 
association with certain epidemic plasmids harboring numerous ARGs is an important 
contributor to the high-risk clones success (Mathers et al., 2015). Nonetheless, antibiotic 
susceptible lineages have also emerged globally among ExPEC infections, e.g. ST12, 
ST73, ST95, ST127 and ST141 (Gibreel et al., 2012; Denamur et al., 2020). Although 
the reason why these clones are prevailing over the others remains unclear, antimicrobial 
resistance and virulence factors are suspected contributors (Dobrindt, 2005; Stoesser et 
al., 2016b).  
Therefore, the fact of high-risk clones contributing to the spread of global multidrug 
resistance among Enterobacteria is undeniable. High-risk clones increase the prevalence 
of antibiotic resistance vertically due to co-evolution with certain ARG-carrier 
components (e.g. integrons, transposons and plasmids) (Mathers et al., 2015).  
Additionally, eminent clones favor the transmission of antibiotic resistance horizontally, 





1.11.1. THE EXPEC CLONES 
The majority of ExPEC isolates belong to B2 phylogenetic group. However, there is 
enormous diversity among E. coli isolates causing human and animal extraintestinal 
infections, but, epidemiological studies indicate that certain O:H serotypes, sequence 
types (STs) and clonotypes are more predominant and especially successful (Riley, 2014; 
Kallonen et al., 2017; LeCuyer et al., 2018; Zogg et al., 2018; Manges et al., 2019; 
Flament-Simon et al., 2020b; Valat et al., 2020).  
Twenty major STs (in order of highest to lowest prevalence: ST131, ST69, ST10, 
ST405, ST38, ST95, ST648, ST73, ST410, ST393, ST354, ST12, ST127, ST167, ST58, 
ST88, ST617, ST23, ST117 and ST1193) accounted for 85% of the E. coli isolates 
causing human extraintestinal infections from 217 meta-analyzed studies (1995 and 
2018), systematically reviewed by Manges et al. (Manges et al., 2019). However, most 
of the studies have been carried out on MDR and ESBL-producing isolates, but very few 
have been focused on any type of E. coli causing extraintestinal infections and, 
furthermore, on their clonal structure. Therefore, there is probably an overestimation of 
some STs and an underestimation of others.  
Seven clonal complexes (CC) or sequence type complexes (STc) harbour the most 
reported ExPEC clones isolated from humans in pathogenic conditions whitch are STc12, 
STc14, STc69 (also termed as clonal group A), STc73, STc95, STc127 and STc131 and 
(Denamur et al., 2020). Table 6 summarised the principal features of those eminent 
ExPEC STc.  
Table 6. Principal features of eminent ExPEC sequence type complexes (STc). 
Sequence type 
complex (STc) Phylogroup Serotypes Resistance profile 
STc12 B2 Mainly associated with O4:H1/H5 Emerging ESBL 
STc14 (including 
ST550, ST14 and 
ST1193) 
B2 Mainly associated with O75:H5 ESBL producers 
STc73 B2 Mainly associated with O6:H1 Mostly susceptible 
STc69 D Mainly associated with O11, O15, O17, O73, O77, O117 and H18 ESBL producers 
STc95 B2 Mainly associated with O1, O2, O18, O45 and H4/H7 Mostly susceptible 
STc127 B2 Mainly associated with O6:H31 Mostly susceptible 
STc131 B2 Mainly associated with O16:H5 and O25:H4 ESBL producers 
Sources: (Adams-Sapper et al., 2013; Danzeisen et al., 2013; Basmaci et al., 2015; Gordon et al., 2017a; Bourne 
et al., 2019; La Combe et al., 2019; Bogema et al., 2020; Denamur et al., 2020; Kidsley et al., 2020a). 
Three recent studies showed the dominance of some STs in dogs in Australia, the 
United States, and France, such as ST372, assessed to be specifically associated with 
dogs, and ST12, ST73, ST127 and ST141, assessed to be specifically associated with 
humans (LeCuyer et al., 2018; Kidsley et al., 2020b; Valat et al., 2020). On the other 
hand, within-household sharing of ExPEC ST73 and ST95 strains, those with same 
serotypes and VF-encoding genes have been documented in the United States among 
humans and dogs (Johnson et al., 2008a). Furthermore, in Australia and the United States, 
human and canine E. coli ST127, ST131 and ST1193 that exhibited identical virulence 
genotypes and highly similar PFGE profiles have been identified (Johnson et al., 2008b; 
Platell et al., 2011, 2012). These findings suggest that some E. coli infections may 




It seems that porcine ExPEC diseases are increasing frequency in China (Tan et al., 
2012; Zhu et al., 2017; Ma et al., 2020). In contrast to most humans and companion 
animal ExPEC clones, swines ExPEC isolates frequently belong to phylogroups A and 
B1 (Ding et al., 2012). In a recent study, nine main clonal complexes were described 
among the B2 and D ExPEC isolates from swine: CC12, CC648, CC354, CC141, CC405, 
CC457, CC1011, CC117 and CC95, witch based on their virulence profiles were 
classified into four clusters (named I to IV) (Ma et al., 2020). Cluster IV harboured strains 
belonging from B2 phylogroup and with the highest average of virulence-associated 
genes, and included three clonal complexes: CC12 (including ST12 and ST961 strains), 
CC95 (including ST95 strains) and CC141 (including ST141 strains) (Zhu et al., 2017). 
In poultry, STc88 belonging to phylogroups C (including ST410 strains) and STc95 are 
predominant among APEC strains (Moulin-Schouleur et al., 2007). 
1.11.2. THE HIGH-RISK CLONE SEQUENCE TYPE 131 (ST131) OF E. COLI  
E. coli ST131 is one of the most prevalent ExPEC clones. It is also responsible for 
the worldwide dissemination of MDR isolates within the E. coli group, mostly due to the 
acquisition of blaCTX-M-15 carriers IncF epidemic plasmids (Nicolas-Chanoine et al., 
2007b, 2014).  
Phylogenetical studies have revealed that E. coli ST131 belongs to four clades (A, B, 
C and I) and many different subclades, three within clade C (C1, C2, and C3) and six 
within clade B (from B1 to B5, plus intermediate B0). Recently, whole genome 
sequencing studies have shown that clade C has evolved from clade B. Clades are 
designated according to their fimH allele (type 1 fimbriae adhesin gene), while subclades 
are associated with antibiotic resistance patterns. In summary, clade B (fimH22) is a 
fluoroquinolone (FQ) and cephalosporin susceptible ancestor which evolved in clade C 
(fimH30) that was resistant to FQ and the predecessor of two sister subclades C1 (often 
carrier of the blaCTX–M–14 enzyme) and C2 (often carrier of the blaCTX–M–15 enzyme). 
Subsequently, two additional ST131 sublineages referred to C1-M27 (positive for the 
blaCTX–M–27 enzyme) and C1-nM27 have been described. Clade I constitutes a rare variant 
that had also emerged from clade B but presented the fimH54 allele. 
Even though ST131 clone is prevalent in human samples, it remains less frequent 
from animals and it is especially rare from porcine source (Reid et al., 2019). However, 
it has already been identified in many animal species including Antarctic pinnipeds (Mora 
et al., 2018). Indeed, in ST131 strains have been reported from companion animals as 
well as food products from animal origin like poultry meat (Ewers et al., 2010; Liu et al., 
2018a; Zogg et al., 2018). The majority of animal isolates belong to clade B, whereas 
those which cause extraintestinal infections in humans predominate those of clade C and 
particularly to subclades C1-nM27, C1-M27 and C2 (H30Rx). This could be one reason 
for the underrepresentation of ST131 clade B isolates in the literature and sequence 
databases (Reid et al., 2019). 
Some studies suggested a negative association between resistance genes and 
virulence-associated genes. This is not the case with ST131 clone. In a study performed 
by Colpan and colleagues, it was shown that fluoroquinolones resistant linages of ST131 
that acquired blaCTX-M-15 had also tended to further accumulate additional virulence-
associated factors (Colpan et al., 2013). In this regard, it has been postulated that the 
gyrA-parC mutations (i.e., gyrA1AB and parC1aAB) selected by fluoroquinolones could 
have reduced the fitness costs associated with the acquisitions of the IncF epidemic 
plasmids acting as compensatory mutations. It has also been noted that the inherent 




potential of ST131 clone has contributed to its fitness. Paradoxically, a recent study had 
proved that the most worldwide disseminated ST131 clade (clade C) in human infections 
displays a more attenuated virulence than its ancestor clade (clade B). Two explanations 
were proposed: (I) that the acquired FQ resistance came at a direct cost, but was 
compensated by allowing calde C to spread and (II) that a lower virulence may confer an 
evolutionary advantage by balancing transmission and host mortality. Further studies are 
needed to clarify these matters (Duprilot et al., 2019).  
The antimicrobial resistance of human ExPEC and UPEC isolates has increased 
dramatically due to the emergence of the pandemic clone ST131 and more especially to 
subclade C2 (also known as subclone H30Rx) (Nicolas-Chanoine et al., 2007a, 2014; 
Price et al., 2013; de Toro et al., 2017; Matsumura et al., 2017b; Jamborova et al., 2018; 
Flament-Simon et al., 2020a). This subclone has also been occasionally isolated from 
dogs in several countries (Kawamura et al., 2017; Belas et al., 2018; Maeyama et al., 
2018; Bortolami et al., 2019; Melo et al., 2019). The emergence of multidrug resistance 
(MDR) among E. coli causing infections in dogs is of great concern and increases the risk 
of treatment failure (Johnson et al., 2009; Harada et al., 2012; Wagner et al., 2014; 
Bogaerts et al., 2015; Falgenhauer et al., 2016; Liu et al., 2016b, 2016c; Zhang et al., 
2018; Marques et al., 2018; Chen et al., 2019b; Pepin-Puget et al., 2020). Additionally, 
exposure to dogs and/or dog faeces has been identified as a risk factor for the development 
of drug-resistant E. coli UTI in women (Ukah et al., 2018). 
1.12. ADVANCES IN MICROBIOLOGY RESEARCH: NEXT GENERATION 
SEQUENCING (NGS) TECHNOLOGIES 
In 1977, less than 50 years ago, the first DNA sequencing methods were developed 
(Maxam and Gilbert chemical chain termination method and Sanger sequencing) 
allowing to decipher complete genome sequences for the first time. Second-generation 
sequencing (SGS) or short-read sequencing technologies came after, including the 
methodologies developed by Roche Diagnostics, Illumina and Life Technologies 
companies. These were based on the polymerase chain reaction (PCR) and allowed to 
sequence the whole genome of bacteria. Afterwards, third-generation sequencing (TGS) 
or long-read sequencing appeared (no-PCR based technologies). In 2011, Pacific 
Biosciences (PacBio) developed the “single-molecule real-time” (SMRT) sequencing 
methodology A few years after, in 2014, Oxford Nanopore Technologies launched the 
“nanopore sequencing” methodology.  
The so-called next-generation sequencing (NGS) includes both SGS and TGS. This 
technology is now revolutionising the field of genomic research as it enables to explore 
genomes with an unprecedented resolution. For instance, contributing to distinguish 
pathogenic E. coli or tracing back outbreaks. Besides, WGS can be implemented for 
bacterial-resistance surveillance programs worldwide. However, NGS has still some 
challenges to overcome to be fully implemented worldwide (reviewed in Quainoo et al., 
2017):  
 To be cost-effective. 
 To be standardised to simplify interpretation and comparison of the data 
worldwide. 
 To overcome sequencing limitations related to read length, read depth, and 
error rate.  
 To improve bioinformatics analysis algorithms and develop friendly analysis 




In brief, there are two WGS analysis methods: (I) mapping the sequenced genome 
with another previously reconstructed genome (or loci) using alignment tools, and/or (II) 
without assuming a reference genome (de novo assembly). The use of coregenome 
sequences and references has proved to be adequate to infer phylogenies. Nonetheless, 
by definition coregenome phylogenies ignore the accessory genome (including plasmids, 
virulence genes, bacteriophages, and resistance genes). In fact, de novo assembly allows 
identifying structural variations and genomic rearrangements.  
1.12.1. THE READ LENGTHS LIMITATIONS 
Long repetitive elements in bacterial genome represent a particular obstacle 
(Arredondo-Alonso et al., 2017; Orlek et al., 2017). With SGS technology, the sequence 
length (35 to 700 bp) is shorter than with traditional Sanger sequencing platforms. Thus, 
genome assembly is complicated, and most assembly programs collapse and fail to 
assemble reads covering long repetitive elements. As a consequence, regions between 
repeats are usually found in separate contigs. TGS generates long-read sequences (10 kb 
to over 100 kb). However, this technology remains considerably more expensive and has 
higher error rates at its base level (Lu et al., 2016a; Orlek et al., 2017; Boolchandani et 
al., 2019).  
The read lengths limitations of SGS does not interfere with outbreak analysis; as 
phylogenetic trees are not reconstructed based on repetitive elements. In contrast, 
resistance regions in plasmids or genomic islands contain multiple copies of the same 
mobile element which constitute long repeats.  
In summary, genomic tools allow a compressive characterization of FBPs and the 
identification of clonal groups of bacteria that represent public health hazards (Kovac et 
al., 2017). However, epidemiological surveillance of epidemic plasmids related to 
antimicrobial resistances or/and virulence genes spreading in the bacterial population is 
still complicated due to the intrinsic plasticity of plasmids (Orlek et al., 2017). Future 
developments in real-time and long-read sequencing are predicted to overcome most of 
the technology limitations which we are facing today (Eid et al., 2009; Quainoo et al., 
2017). 
1.12.2. GAPS IN THIS GENOME COMPENDIUM 
The major clonal complexes and outbreaks-associated strains are largely represented 
in public genome databases. In contrast, there is a limited representation of commensal 
strains and other divergent lineages (Moriel et al., 2016). Besides, many strains lack 
information regarding their origin and clinical association as well as there is a surprisingly 
great proportion of unknown ORFs (Lo et al., 2017).  
1.12.3. PREDICTION OF PHENOTYPES 
The expression of certain genes is often context-dependent (Boolchandani et al., 
2019). Consequently, phenotypic traits predicted from resistance and virulence-
associated genes remain uncertain.  
Several studies showed up to 95% concordance between resistance phenotypic testing 
and genomic resistant profiles (Stoesser et al., 2013; Zankari et al., 2013; Tyson et al., 
2015; McDermott et al., 2016). Nevertheless, certain complex resistance mechanisms can 
remain undetected,  such as  carbapenem resistance arising from the combination of 
extended-spectrum betalactamases and efflux pumps or porin impermeability (Baroud et 
al., 2013), as well as novel antibiotic resistance genes or mutations (Ledeboer and 




To date, WGS cannot entirely replace phenotypic experiments, but they can greatly 
contribute to gain knowledge of bacterial pathogenesis.  
1.13. THERAPEUTIC APPROACH AND DEVELOPMENT OF ALTERNATIVE 
TREATMENTS 
Against bacterial infections, two approaches have been addressed: (I) direct strategies 
that target the bacteria viability (e.g. antibiotics) and (II) indirect strategies that enhance 
the host immune responses (e.g. vaccines).  
The research of anti-ExPEC targets can be particularly challenging for various 
reasons. To begin with, due to the heterogeneity of ExPEC strains. Secondly, as the 
expression of several genes is involved in ExPEC pathogenesis having overlapping 
activities. Thus, inhibiting one of them would probably be insufficient to prevent the 
infection (Cash, 2014). Lastly, because ExPEC strains are common inhabitants of the 
gastrointestinal tract in the host and therefore it is important to consider potential side 
effects on the balance of the intestinal microbiome (Brumbaugh and Mobley, 2012; 
O’Brien et al., 2016).  
Tigecycline (a semisynthetic tetracycline) is among the newest availables antibiotics 
against Gram-negative pathogens, as very few new antibiotics have been developed 
during the last decades. Fortunately, other alternatives are being investigated: (I) the use 
of nutritional supplementation therapies or probiotics and fecal microbiota transplant 
(FMT) to restore the microbiome (Saha et al., 2019; Saïdani et al., 2019), (II) the 
development of pilicides, curlicides and mannosides to prevent bacterial invasion, and 
biofilm eradication agents (BEAs) to inhibit biofilm formation (Han et al., 2010, 2012; 
Terlizzi et al., 2017) and (III) the development of anti-plasmid strategies to remove 
harmful plasmids, and phage therapy to kill bacteria (Schmidt, 2019; Ferry et al., 2020). 
Regarding vaccines, some new potential candidates have been identified using the 
reverse-vaccinology approach (Nesta et al., 2012; Moriel et al., 2016; Terlizzi et al., 
2017). 
1.14. POLICIES AGAINST THE EMERGENCE OF ANTIBIOTIC RESISTANCE  
Currently many pathogens have started to become resistant to the second- and third-
line drugs, including last-resort antibiotics (Gupta et al., 2011; Johnson and Woodford, 
2013; Ventola, 2015; Liu et al., 2016d). Therefore, antibiotics such as colistin and 
tigecycline are in some cases the last-resort against infections caused by MDR, XDR and 
PDR Gram-negative pathogens (Holmes et al., 2016; Laxminarayan et al., 2016; Yang et 
al., 2016; Yao et al., 2016). 
In particular, E. coli has become one of the most common MDR organisms, with 
ESBL-producing E. coli (ESBLEC) being dramatically extended world-wide (Nicolas-
Chanoine et al., 2007b; de Toro et al., 2017; Mamani et al., 2019). The hypothesis 
regarding the global circulation of antimicrobial-resistant bacteria and ARGs between 
animals, humans and the environment is now strongly supported by several studies which 
have found ESBLEC strains carried by hosts from natural ecosystems, including vultures 
(Neophron percnopterus var. majorensis), free-tailed bats (Tadarida teniotis) and many 
other wild animals (Radhouani et al., 2014; Cristóvão et al., 2017; Garcês et al., 2019; 
Carvalho et al., 2020).  
The description of MCR-producing E. coli strains appears to be concerning, as the 
co-occurrence of MCR, ESBL and carbapenemases production may result in untreatable 




producing E. coli isolates have been reported in several studies (Haenni et al., 2016; 
McGann et al., 2016; Hernández et al., 2017; Jin et al., 2018). Likewise, the co-
occurrence of MCR, ESBL and Carbapenemase genes in E. coli strains form animal origin 
has also been reported (e.g., one E. coli ST167 strain isolated from a chicken wing 
coproduced MCR-1, NDM-9, CTX-M-65 among other resistant determinants (Yao et al., 
2016); and one E. coli ST648 and one E. coli ST156 strains isolated from a single duck 
co-produced MCR-1, NDM-5 and CTX-M-55 among other resistant determinants (Yang 
et al., 2016)). 
In 2015, the incidence of infections with antibiotic-resistant bacteria in the European 
Union (EU) was estimated to be at 671,689 of which 33,110 were attributable deaths 
(Cassini et al., 2019). In Spain, it has been estimated that in the next 35 years the number 
of deaths caused by MDR bacterial infections could reach 40,000 infections per year 
(AEMPS, 2019). It has also been warned that if measures are not implemented, MDR 
bacterial infections will become the first cause of death in the developed world, 
outcompeting cancer (O’Neill, 2016). MDR bacterial infections also represent a high 
burden in terms of economical cost to society, in the EU alone it is estimated that MDR 
bacterial infections cost EUR 1.5 billion annually (ECDC/EMEA, 2009). Therefore, 
antimicrobial resistance affects sectors beyond human health, such as animal health, 
agriculture, food production and economic development. In veterinary medicine, 
resistance to frequently used antibiotics affect animal health and welfare (OIE, 2003).  
This problem is not isolated to Europe (Antibiotic resistance threats in the United 
States, 2019), as antibiotic resistance is now considered to be one of the most worrying 
global-health threats of our times (Mathers et al., 2015). In fact, antibiotic treatments are 
evolving into a time-dependent resource due to the emergence of resistances and it has 
become urgent to develop new therapeutic strategies, whislt also attempting to slow down 
the adaptive process of bacteria.  
Under the ‘One Health’ perspective and to ensure development and implementation 
of global strategies, the World Health Organisation (WHO), the World Organisation for 
Animal Health (OIE), the Food and Agriculture Organisation (FAO) and the Codex 
Alimentarius Commission presented overall goals that should be internationally followed 
(FAO-OIE-WHO, 2010, 2017). The proposed measures are summarised in the following 
points: 
 To promote rational use of antibiotics by implementing good practices in all 
sectors.  
 To reduce the spread of infections focusing on prevention.  
 To strengthen health systems and monitoring capabilities globally.  
 To strengthen regulation implementation and legislation globally.  
 To boost research and encourage the development of new treatments against 
bacterial infections (ECDC/EMEA, 2009).  
In consequence, the EU started the “European action plan” that aims to involve 
numerous sectors and actors, including human and veterinary medicine, agriculture, 
finance, environment, pharmaceutical industries and well-informed consumers. In the 
veterinary sector, the action plan against antimicrobial resistance emphasises the need to 
consider all other preventive and therapeutic options before using antibiotics. In food 
production, intervention strategies target each stage of the food chain from the perspective 
of “farm to table food safety”(FAO, 2011; WHO, 2011). In the research field, surveillance 
programs focus on the identification of antimicrobial emergence, reservoirs of pathogenic 




1.14.1. EUROPEAN POLICIES AGAINST THE EMERGENCE OF ANTIBIOTIC 
RESISTANCES 
In 2001, in order to ensure the availability and prolong the effectiveness of 
antimicrobial agents some guidelines were implemented on the prudent use of 
antimicrobial agents in human medicine (2002/77/EC) (European Commission, 2001) 
and the directive on the community code relating to veterinary medicinal products, 
(2001/82/EC) (European Parliament and Council, 2001) with special mention to oral 
antimicrobial treatments (medicated feed or water) in herds. In this regard, a veterinary 
prescription is mandatory and individual treatments of the affected animal(s) should be 
preferable over group or mass treatments. 
In 2011, a statement was published between the Commission to the European 
Parliament and the Council including a five-year action plan against the rising threats of 
Antimicrobial Resistance. The European plan supported and actively collaborated with 
the WHO (WHO, 2015), OIE (OIE, 2016), FAO (FAO, 2016) and the Codex 
Alimentarius Commission (Codex Alimentarius, 2011), as well as, the ECDC (European 
Centre for Diseases Control), EMA (European Medicines Agency) and EFSA (European 
food safety Authority) international organizations.  
In 2015, the Official Journal of the European Union published the European 
Parliament resolution on “safer healthcare in Europe: improving patient safety and 
fighting antimicrobial resistance (2016/C 353/02)” (European Parliament, 2015) and the 
commission notice on “guidelines for the prudent use of antibiotics in veterinary medicine 
(2015/C 299/04)” (European Commission, 2015).  
In 2017, an addional statement was published between  the Commission to the 
European Parliament and the Council detailing a second proposal on “a European one 
health action plan against antimicrobial resistance (AMR)(2017/2254-INI)” (European 
Commission, 2017). This report includes specific disposals to preserve some 
antimicrobials for human medicine and prohibits the preventive use of antimicrobials 
through medicated feed in animals (the use of antimicrobial agents as growth promoters 
is banned in Europe since 2006). 
1.14.2. NATIONAL POLICIES AGAINST THE EMERGENCE OF ANTIBIOTIC 
RESISTANCES 
In 2014, a national plan against antibiotic resistance was launched in Spain, named 
“Plan Nacional frente a la Resistencia a los Antibióticos (PRAN)”(AEMPS, 2014).  
In Spain, the implementation of PRAN has achieved a 7.2% reduction of antibiotic 
use in human medicine between 2015 and 2018 and 32.4% reduction of antibiotic sales 
for veterinary medicine between 2014 and 2017 (AEMPS, 2019).  
 






1. Evaluate the prevalence of sequence type 131 (ST131) and its subclones among 
E. coli strains consecutively isolated from patients with extraintestinal infections 
in 2016 and among extended spectrum β-lactamases ESBL-producing E. coli 
(ESBLEC) isolated in 2015, in two hospitals (Lucus Augusti University hospital 
and AP-HP Beaujon hospital), paying special attention to the emergence of new 
highly virulent and/or multidrug-resistant (MDR) clones. 
2. Gain knowledge of phenotypic and genotypic characteristics of the ST131 strains 
and other high-risk clones isolated from humans and animals, determining 
phylogroups, clonotypes, sequence types (STs), O:H serotypes, Virulence factor 
(VF)-encoding genes, antibiotic resistance including the whole genome 
sequencing of a subset of strains to perform core genome (CG) and plasmidome 
analysis. 
3. Gain knowledge about early biofilm formation (EBF) in E. coli strains implicated 
in extraintestinal infections and contrasted the biofilm-forming ability with 
genotypic characteristics of the strains.  
4. Study production animals (pigs) and companion animals (dogs) as reservoirs for 









3.1.EPIDEMIOLOGICAL BACKGROUND OF THE E. COLI COLLECTION 
3.1.1. HUMAN ORIGIN BACTERIAL COLLECTIONS 
Two collections of E. coli clinical isolates were studied. The first collection consisted 
of 196 non-duplicate (one isolate per patient) E. coli consecutively isolated (CEC) in 2016 
from two hospitals [Lucus Augusti hospital in Lugo (Spain), n = 100, and Beaujon 
hospital in Paris (France), n = 96]. This collection that comprised 13 ESBL-producing 
isolates came from different sources: 146 from urine, 22 from blood, 5 from bile, 3 from 
ascitic fluid, 6 from abscesses, and 14 from various other sources. As ESBL production 
is currently one of the most important worldwide threatening mechanisms of antibiotic 
resistance in E. coli clinical isolates, we studied a second collection consisting of 188 
non-duplicate ESBL-producing E. coli (ESBLEC) isolates obtained from the same two 
hospitals in 2015 (Lugo hospital, n = 92, and Beaujon hospital, n = 96). This collection 
comprised 139 isolates from urine, 25 from blood, seven from bile and 17 from various 
other sources. 
3.1.2. ANIMAL ORIGIN BACTERIAL COLLECTIONS 
3.1.2.1. Porcine bacterial collection 
We have performed the WGS of 11 resistant E. coli O25b:H4-B2-ST131 clade B 
isolates, seven from piglets with diarrhoea and four from pork meat. The isolates belong 
to extensive epidemiological studies accomplished in Spain. The seven isolates from 
diarrhoeic piglets were isolated during the period of 2006-2016 (García-Meniño et al., 
2018) and the four from pork meat during the years 2011 and 2012 (Herrera Estévez, 
2015). 
3.1.2.2. Canine bacterial collection  
We characterised a total of 197 non-duplicate E. coli isolated from faecal samples of 
104 healthy dogs collected in Spain between 2013 and 2017 in collaboration with the 
Society for the Protection of Animals and Plants in Lugo (Spain) (n=26) and the Rof 
Codina Veterinary Hospital in Lugo (Spain) (n= 78).  
3.1.3. REFERENCE BACTERIAL COLLECTION  
In all procedures, strains from LREC-USC were included as positive controls.  
3.2. BACTERIAL CONSERVATION  
All bacteria were conserved in the same conditions following the LREC-USC 
protocol: the isolated strains were cultured in nutrient agar with 0.75% (w / v) and were 
stored at room temperature in Vacutainer ™ tubes. Under these conditions, E. coli strains 
maintain their viability for at least 10 years. For the preparation of the conservation 
medium, a mixture of nutrient agar (11.5 g/l) (Applichem-Panreac) and nutrient broth (4 





3.3. PHENOTYPIC CHARACTERIZATION 
3.3.1. SEROTYPING 
The determination of O and H -antigens was carried out using the method previously 
described by Guinée et al. (1981) and modified by Blanco et al. (1996). This method 
determines E. coli O and H -antigens through positive agglutination with available O (O1 
to O181) and H (H1 to H56) antisera. The diagnostic antisera used in this thesis were 
produced and rendered monospecific in LREC-USC. The specificity was controlled by 
agglutination assays with known reference strains. The O-antigen types O31, O47, O67, 
O72, O93, O94 and O122 were excluded from this classification as it was proved they 
are not somatic antigens. For H-antigens, designations H13, H22, and H50 are no longer 
in use (Murray et al., 1999; Ratiner et al., 2010). Isolates that did not react with any 
antisera were classified as O non-typeable (ONT) or H non-typeable (HNT) and those 
that were non-motile were denoted as HNM.  
The LREC-USC serotyping procedure includes 176 specific O antisera and 51 
specific H antisera. To simplify the method, diagnostic antisera are grouped into 
polyvalent antisera constituted by a variable number of known monovalent antisera which 
are used in the first stage of antigen identification. 
3.3.1.1. Determination of O-antigens (serogrouping) 
Serogrouping includes two phases: (I) a presumptive determination of the O-antigen 
and (II) a serogroup confirmation by O-antigen titration.  
The first step is to prepare two O-antigen suspensions per tested strain. For this 
purpose, strains are cultured [on tryptone soya agar (TSA) and incubate 18-24h at 37ºC] 
and further suspended in 2 ml of 0.85% NaCl saline solution (SS). The bacterial 
concentration should be adjusted to number 6 of the McFarland Barium Sulfate Scale in 
order to reach approximatively 1,8 x109 bacteria per ml. The O-antigen is a thermostable 
polysaccharide (it remains viable after being heated at 100ºC for 2h) which is the major 
component of the outer membrane of Gram-negative bacteria. In many cases, E. coli 
strains are covered by another layer named capsule which is thermolatable and contain 
the K-antigen. Thus, one suspension is boiled for 1 hour (1h at 100ºC) and the second is 
autoclaved at 121°C for 2.5 h to guaranty K-antigen inactivation (uncovering O-antigen). 
After cooling, 2 ml of formalinized (0.5%, v/v) SS containing gentian violet (0.005%, 
w/v) are added in each suspension. Suspensions remain viable for months if they are kept 
tightly closed at 4°C.  
Presumptive determination of O-antigen: (I) dispense 50 µl of each polyvalent 
antiserum into the wells of a polystyrene microtiter plates and add 50 µl of the O-antigen 
suspension boiled at 100°C to each well, (II) cover and incubate the microtitre plates at 
37°C overnight, (III) examine for agglutination. When a positive reaction is obtained with 
one or more polyvalent antisera, O-antigen suspension must be assayed with all the 
monovalent antisera included in the corresponding polyvalent. If the reaction is negative 
with all polyvalent antisera, O-antigen suspensions autoclaved at 121°C for 2.5 h are 
tested with O antisera O8, O9, O20 and O101, and if there are still no positive reaction, 
the problem strain is considered non-typeable (ONT).  
The O-antigen determination is completed with the confirmation process of titration: 
(I) Dispense 50 µl of saline solution in wells 2 to 12 of a row of the microtitre plate, (II) 
Add 50 µl of a diluted O antiserum (1:40 or 1:80) to wells 1 and 2, (II) prepare a serial 
dilution (Transfer 50 µl from the second well to the next well, mix and continue until the 




12 as negative controls. Final dilution of the antiserum will be 1:80 (for antiserum 1:40) 
or 1:160 (for antiserum 1:80), (IV) add 50 µl of O-antigen suspension to each of the 
twelve wells of the corresponding row, from well 12 to well 1, (V) cover and incubate the 
microtitre plate at 37°C overnight, (VI) examine for agglutination. The titre represents 
the highest antiserum dilution that shows agglutination of the strain assayed. 
3.3.1.2. Determination of H-antigens 
H-antigens are found on the bacteria's flagellar filaments which are motile organelles 
of bacteria. In order to optimize the H-antigen–antiserum agglutination reactions, tested 
isolates require a previous flagellum growth induction. For this purpose, the isolates are 
inoculated and incubated overnight in 8 ml semi-solid medium contained in U-shaped 
tubes that allow bacterial mobility from one butt to the other (MIL medium) (Difco). This 
procedure is performed for each isolate at least three times until motility is fully expressed 
[strains that do not express motility after six repetitions are designated as non-motile 
strains (HNM) and cannot be phenotypically assign]. Once this stage is concluded, motile 
strains are inoculated into 7 ml of brain heart infusion (BHI) agar (Difco) and incubated 
at 37°C while shaking at 80 rpm for 6-8 h. Afterwards, 7 ml of formalinized (0.5%, v/v) 
SS are added. The final bacterial suspensions are left at room temperature overnight.  
For H-antigen determination, 500 µl of the bacterial suspension plus 500 µl of 
polyvalent antiserum are mixed into kahn tubes and leaved for incubation into water at 
45ºC for 2h. Subsequently, tubes are examined for agglutination. When a positive reaction 
is obtained with one or more polyvalent antisera, H-antigen suspension must be assayed 
with all the monovalent antisera included in the corresponding polyvalent.  
3.3.2. ANTIMICROBIAL SUSCEPTIBILITY TESTING AND ESBL TYPING 
Antimicrobial susceptibility was determined by the minimal inhibitory 
concentrations (MICs) and/or the disc diffusion method. Resistance was interpreted based 
on the recommended breakpoints of the CLSI. Fifteen classes of antimicrobial agents 
were analyzed: penicillins (ampicillin, ticarcillin), penicillins and β-lactamase inhibitors 
(amoxicillin-clavulanic acid, ampicillin-sulbactam and piperacillin-tazobactam), 1st and 
2nd generation of non-extended spectrum cephalosporins (cefazolin and cefuroxime), 
extended-spectrum cephalosporins (cefotaxime, ceftazidime and cefepime), cephamycins 
(cefoxitin), monobactams (aztreonam), carbapenems (imipenem, meropenem), 
aminoglycosides (gentamicin, tobramycin, amikacin), tetracyclines (doxycycline, 
minocycline and tigecycline), phenicols (chloramphenicol), nitrofurans (nitrofurantoin), 
quinolones (nalidixic acid, ciprofloxacin and levofloxacin), folate pathway inhibitors 
(trimethoprim-sulphamethoxazole), phosphonic acids (fosfomycin), and polymyxins 
(colistin).  
E. coli MDR was defined as resistance to one or more agents in three or more classes 
of tested drugs (Magiorakos et al., 2012).  
ESBL production detected by the double disk synergy test (Jarlier et al., 1988) was 
further confirmed by PCR. Genetic identification of ESBL and pAmpC types was carried 






3.3.3. DETERMINATION OF EARLY BIOFILM FORMATION (EBF) 
The kinetics of early biofilm formation (EBF) were assessed using the BioFilm Ring 
Test® (BioFilm Control, Saint-Beauzire, France) according to the manufacturer’s 
recommendations. Briefly, each isolate was sub-cultured twice on brain heart infusion 
(BHI) agar (Benton Dickinson, Le Pont-de-Claix, France) at 37°C for 24 h. Three 
colonies of the second subculture on BHI agar were suspended in BHI broth (Biofilm 
Control). Suspension was standardised to an optical density at 600 nm of 1.00 ± 0.05 
(Ultrospec10: Biochrom, Cambridge, United Kingdom) and then diluted at 1:250 in BHI 
broth to obtain a final concentration of approximately 106 UFC/ml. The bacterial 
suspension was supplemented (1% vol/vol) with magnetic microbeads (TONER 4, 
Biofilm Control) and 200 µ l of the mix was deposited in two wells of three polystyrene 
96-well microtiter plates that were incubated for 2, 3, and 5 h, respectively. At the end of 
each incubation time, 100 µ l of liquid contrast solution (LIC001, Biofilm Control) was 
added on the top of each well and the microplate was put on a magnetic block for 1 min. 
After magnet contact, free beads were attracted toward the centre of each well, forming a 
brown spot, while beads embedded in biofilms were blocked and remained undetectable. 
Each microplate was scanned using a BioFilm Control plate reader. The intensity of the 
spot was analysed using the BioFilm Ring Test®-software version 3.0.3 and expressed as 
a biofilm formation index (BFI) with values ranging from 20 (non-formation of biofilm) 
to 0 (high formation of biofilm) that is inversely proportional to attached bacteria that 
block the beads. BFI values ≤ 5 mean that the isolates are strong biofilm producers; BFI 
values between 6 and 14, moderate producers; BFI values between 15 and 19, weak 
producers; non-producers display a BFI value of 20. Each isolate was tested in three 
independent experiments and the average of the six measures was used as the final BFI 
value. For each experiment, isolates S250 and 39 previously described with the method 
carried out in the present study as strong and negative producers of biofilm, respectively, 
were used as controls (Nicolas-Chanoine et al., 2017). We also included BHI broth 
without bacteria as negative control. 
3.4. MOLECULAR CHARACTERISATION  
The molecular characterisation of the bacterial strains included: (I) the description of 
virulence profiles through the identification of Virulence factor (VF)-encoding genes by 
Polymerase Chain Reaction (PCR) followed by the definition of the virulence status, (II) 
the description of the antimicrobial resistances profile through PCR followed by amplicon 
sequencing, (III) the determination of the phylogenetic groups of E. coli through PCR, 
(IV) the determination of clonotypes (CH) and sequence types (ST) through PCR 
followed by amplicon sequencing, (VI) the identification of the clades and subclades of 
ST131 E. coli by PCR and (VII) the identification of the fimB gene by PCR followed by 
amplicon sequencing in a subset of strains from the human origin collection of bacteria.  
 
Polymerase Chain Reaction (PCR): LREC-USC protocol 
Approximately 10 µM (using 10 µ M sterile inoculating loops) of the cultured bacteria 
[on Tryptone Soy Agar (TSA) media] are suspended in 600 µl of sterile MiliQ water in 
an eppendorf tube and boiled at 100ºC for 5 min for DNA extraction. After centrifugation 
at 11.000 rpm for 2 min, 5 µl of supernatant are taken for PCR. All reactions are carried 
out in a 25 µl volume containing the extracted DNA plus 12.5 µl of buffer supplied with 
Taq polymerase, 2,5 mM MgCl2 and 200 µM of each nucleotide: dATP, dCTP, dGTP y 




allele-specific primers used) of the appropriate primers at 20 µM concentration. We 
adjusted the final volume of the reaction to 25 µl by adding MiliQ sterile water. PCR 
reactions are performed under the following conditions: denaturation 3 min at 94ºC, 35 
cycles of 1 min at 94ºC and 1 min at the specific primer-annealing temperature and a final 
extension step of 90 s at 72ºC. Plus, a final extension of 3 min at 72ºC. The lecture of the 
amplified DNA fragments is performed by conventional agarose gel electrophoresis 
under UV light [2% Seakem® LE agarose in 1X TAE buffer (1.6 M Tris, 0.8 M sodium 
acetate, 0.025 M EDTA) with 5 µl of Green Safe Premium marker (Nzytech) per 100 ml]. 
In all procedures negative and positive controls are systematically included.  
 
Sanger sequencing  
Amplicons were obtained by conventional PCR, carried out in a 50 µl volume containing 
1 µl extracted DNA plus 10 µl of the 5x My Taq™ Reaction Buffer (Bioline) that include 
5mM dNTPs, 15 mM MgCl2 plus 0.2 µl of MyTaqTM DNA polymerase (Bioline), and 
1 µl of the appropriate primers at 20 µM concentration. With the following conditions: 
denaturation 3 min at 94ºC, 35 cycles of 1 min at 94ºC and 1 min at the specific primer-
annealing temperature and 1 min at 72ºC. The final extension lasted for 3 min at 72ºC. In 
all procedures negative and positive controls were systematically included.  
Afterwards, forward and reverse complementary strands were sequenced at the 
Sequencing Facility of University of Santiago de Compostela (Lugo). They implemented 
the “BigDye™ Terminator v3.1 Cycle Sequencing” protocol.  
We further analysed the sequences using the BLAST sequence software and Genbank 
[registered trademark of the National Library of Medicine (NIH) and the National Center 
for Biotechnology Information (NCBI)]. 
 
3.4.1. SPECIES IDENTIFICATION AND PHYLOGENETIC GROUP ASSIGNMENT  
E. coli species was confirmed by detection of the beta-D-glucuronidase encoding 
gene uidA as performed in other studies (Martins et al., 1993). Assignment to the main 
phylogroups (A, B1, B2, C, D, E, F) was based on the protocol of Clermont et al., (2013). 
We completed species identification with the Escherichia genus discrimination PCR 
protocol describe by Lindsey et al. (2017) if the uidA gene was absent or the phylogroups 
assignment failed. Tables 7 and 8 include the PCR conditions and primers. Figure 3 





Table 7. Primers used for the determination of the phylogenetic groups A, B1, B2, C, D, E y F 
(Clermont et al., 2013). 













ChuA.2b TGCCGCCAGTACCAAAGACA Clermont et al. (2000) 






152 TspE4C2.2b AGTTTATCGCTGCGGGTCGC 
arpA AceK.f AACGCTATTCGCCAGCTTGC 400 ArpA1.r TCTCCCCATACCGTACGCTA 
TrpAgpC trpAgpC.1 AGTTTTATGCCCAGTGCGAG 219 56 ºC Lescat et al. (2013) trpAgpC.2 TCTGCGCCGGTCACGCCC 
arpA ArpAgpE.f GATTCCATCTTGTCAAAATATGCC 301 57 ºC Lescat et al. (2013) ArpAgpE.r GAAAAGAAAAAGAATTCCCAAGAG 
trpA trpBA.f CGGCGATAAAGACATCTTCAC 489 56 ºC Clermont et al. (2008) trpBA.r GCAACGCGGCCTGGCGGAAG 
 
Figure 3 Interpretation of PCR results for phylogroups designation Clermont et al. (2013). 
Distintion between A and C phylogroups depends on the results obtained with trpAgpC primers 
(The C phylogroups is assigned whit trpAgpC positivity). Distinction between D and E 
phylogroups depends on the results obtained with ArpAgpE primers (The E phylogroups is 
assigned whit ArpAgpE positivity). Distinction between phylogroup E and Clade I and between 
Clade I and Clade II requires complemented characterizsation with specific primers described in 
Clermont et al., (2011). 
Table 8. Primers used for the determination uidA gene and distinction of E. coli, E. albertii and E. 
fergusonii (Lindsey et al., 2017). 





























3.4.4. MLST, CH TYPING AND CLONE DETERMINATION  
The sequence types (STs) were established following the multilocus sequence 
typing (MLST) scheme of Achtman by gene amplification and sequencing of the seven 
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA), according to the 
protocol and primers specified at the E. coli MLST website 
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) (Wirth et al., 2006). Additionally, porcine 
isolates were also typed according to the MLST Pasteur Institute scheme. Clonotype 
identification was determined by fumC and fimH (CH) sequencing (Tchesnokova et al., 
2013; Roer et al., 2018). Clones were characterised by using the association of 
phylogroup, clonotype, and ST. 
Table 9. Primers used for clonotypes and Achtman sequence type designation.  
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3.4.5. IDENTIFICATION OF ST131 CLADES AND SUBCLADES  
The ST131 clades (A, B, C), subclades C2 (also known as subclone H30Rx) and C1, 
and cluster C1-M27 were established by PCR (Matsumura et al., 2017b). 
Table 10. Primers used for identification of ST131 clades and subclades (Matsumura et al., 2017b). 






























3.4.6. MOLECULAR CHARACTERISATION OF FIMB GENE 
We randomly selected 127 isolates from the human bacterial collection 
(approximately one-third of the isolates) by using the RAND function (Microsoft Excel) 
system for the fimB gene analysis. The fimB gene was amplified with specific primers 
(FimB F: 5′-AGCATGGCGTTTGTATGG-3′; FimB R: 5′-CCCTGGTATCTCAACTATCTCT-
3′) and sequenced as previously described (Nicolas-Chanoine et al., 2017). When the fimB 
gene was disrupted, the detection of the previously described IS3-like in H30 R isolates 
(Totsika et al., 2011; Nicolas-Chanoine et al., 2017) was performed by PCR using 
specific primers designed in this study (FimBw F: 5′-AGCATGGCGTTTGTATGG-3′; IS 
R: 5′-CTGAATGTGATGTGCCGATG-3′).  
Phylogenetic tree of FimB variants was constructed by the UPGMA method of 
MEGA 6. The 34 fimB gene sequences have been registered in the GenBank database 





3.4.2 VIRULENCE GENOTYPING  
Virulence factor (VF)-encoding genes of E. coli causing extraintestinal infections 
were screened by PCR (Clermont et al., 2013; Dahbi et al., 2014; Mamani et al., 2019). 
The used conditions and primers for PCR amplification of VF-encoding genes are 
indicated in Table 11.  
The isolates were presumptively designed as extraintestinal pathogenic E. coli 
(ExPEC) if positive for ≥2 of 5 markers, including papAH and/or papC, sfa/focDE, 
afa/draBC, kpsM II, and iutA (Johnson et al., 2015), and as uropathogenic E. coli (UPEC) 
if positive for ≥3 of 4 markers, including chuA, fyuA, vat, and yfcV (Spurbeck et al., 2012) 
and as avian pathogenic E. coli (APEC) if positive for ≥ 4 of 5 markers (hlyF, iutA, iroN, 
iss and ompT) (Johnson et al., 2008d). We established a virulence gene score with the 
number of extraintestinal virulence-associated genes, while the virotypes (A to F) of the 
ST131 isolates were established according to the scheme described in Table 12 according 
to Dahbi et al. (2014).  

















Virotype A + + − +/− − − − − − − − + − 
Virotype B − − + +/− − +/− − − − − − − +/− 
Virotype C1 − − − + − − − − − − − + − 
Virotype C2 − − − + − − − − − − − − + 
Virotype C3 − − − + − − − − − − − − − 
Virotype D1 − − +/− − + − − − − + − − + 
Virotype D2 − − +/− − + − + − − + − − + 
Virotype D3 +/− +/− +/− +/− + − − − − − − − + 
Virotype D4 − − +/− − + − − − − − + − − 
Virotype D5 − − +/− − + − + + + − − − + 
Virotype E − − − + − + − + + − − − + 





Table 11. Primers used for detection of Virulence factor (VF)-encoding genes of E. coli causing 
extraintestinal infections. 












(2000) FimH R GCAGTCACCTGCCCTCCGGTA 
fimAvMT78 
fimA215 ACTTTAGGATGAGTACTG 






papEF PapEF F GCAACAGCAACGCTGGTTGCATCAT 336 58-66 Yamamoto et al. (1995) PapEF R AGAGAGAGCCACTCTTATACGGACA 
papGII Pap-II f GGGCATTGCTACGGTAACCTG 545 54-60 ºC Mora et al. (2013) Pap-II r CGCTATTAATAGACAGATCACC 
papGIII Pap-III f CGGCAACTTTAAGCTATGTG 720 60-68 ºC Mora et al. (2013) Pap-III r TGTACCATCTCATCGTTGTCTC 
papC Forward GTGGCAGTATGAGTAATGACCGTTA 205 60 ºC Johnson et al. (2015) Reverse ATATCCTTTCTGCAGGGATGCAATA 
papAH 
papA-F ATGGCAGTGGTGTCTTTTGGTG 
720 70 ºC 
Johnson 
and Stell, 
(2000) papA-R CGTCCCACCATACGTGCTCTTC 
sfa/focDE 
sfa 1 CTCCGGAGAACTGGGTGCATCTTAC 
410 56-64 ºC 
Le 
Bouguenec 
et al. (1992) sfa 2 CGGAGGAGTAATTACAAACCTGGCA 








750 64 ºC 
Le 
Bouguenec 
et al. (1992) afa2 CATCAAGCTGTTTGTTCGTCCGCCG 
cnf 1 CNF1-F2 CAGGAGGTACTTAGCAGCGT 468 48-58 ºC Mora et al. (2013) CNF1-RC TAATTTTGGGTTTGTATC 
cdtB 
cdt-s1 GAAAGTAAATGGAATATAAATGTCCG 




hlyA hly f AACAAGGATAAGCACTGTTCTGGCT 1177 64 ºC Yamamoto et al. (1995) hly r ACCATATAAGCGGTCATTCCCGTCA 
hlyF Forward TCGTTTAGGGTGCTTACCTTCAAC 444 60 ºC Morales et al. (2004) Reverse TTTGGCGGTTTAGGCATTCC 
sat SatF GCAGCTACCGCAATAGGAGGT 937 60 ºC Johnson et al. (2013) SatR CATTCAGAGTACCGGGGCCTA 
vat vat-F TCAGGACACGTTCAGGCATTCAGT 1100 70 ºC Spurbeck et al. (2012) vat-R GGCCAGAACATTTGCTCCCTTGTT 
Siderophores 
iroN Ironec-f AAGTCAAAGCAGGGGTTGCCCG 665 62 ºC Johnson et al. (2000) Ironec-r GACGCCGACATTAAGACGCAG 
fyuA fyuA-F GTAAACAATCTTCCCGCTCGGCAT 850 63 ºC Spurbeck et al. (2012) fyuA-R TGACGATTAACGAACCGGAAGGGA 
iucD Aer f TACCGGATTGTCATATGCAGACCGT 602 54 ºC Yamamoto et al. (1995) Aer r AATATCTTCCTCCAGTCCGGAGAAG 
iutA aer-851f GGCTGGACATCATGGGAACTGG 301 66 ºC Johnson et al. (1997) aer-1152r CGTCGGGAACGGGTAGAATCG 
Capsule 
kpsM II 
KpsII f GCGCATTTGCTGATACTGTTG 
272 60 ºC 
Johnson 
and Stell, 






Table 11. Cont. 









kpsII f GCGCATTTGCTGATACTGTTG 
570 60 ºC 
Johnson and 
O’Bryan, 
(2004) KpsII-K2r AGGTAGTTCAGACTCACACCT 
kpsM II-
K5 
K5 f CAGTATCAGCAATCGTTCTGTA 
159 54 ºC Johnson and Stell, (2000) kpsII r CATCCAGACGATAAGCATGAGCA 
neuC-K1 
neu1 AGGTGAAAAGCCTGGTAGTGTG 
676 54 ºC 
Moulin-
Schouleur et 
al. (2006) neu2 GGTGGTACATCCCGGGATGTC 
kpsM III kps III f TCCTCTTGCTACTATTCCCCCT 392 54 ºC Johnson and Stell, (2000) kps III r AGGCGTATCCATCCCTCCTAAC 
Micellaneous 
cvaC CoIV-Cf CACACACAAACGGGAGCTGTT 680 68 ºC Johnson and Stell, (2000) CoIV-Cr CTTCCCGCAGCATAGTTCCAT 
ibeA Ibe10 f AGGCAGGTGTGCGCCGCGTAC 170 58 ºC Johnson and Stell, (2000) Ibe10 r TGGTGCTCCGGCAAACCATGC 
iss is-f CAGCAACCCGAACCACTTGATG 323 62 ºC Johnson et al. (2008e) is-r AGCATTGCCAGAGCGGCAGAA 
malX MALX-F GCATGAGCAGTGCGATACATCGC 828 68 ºC Mora et al. (2013) MALX-R AGGGCTGGGAAGTGGTTTAGCC 
ompT Forward ATCTAGCCGAAGAAGGAGGC 559 60 ºC Johnson et al. (2015) Reverse CCCGGGTCATAGTGTTCATC 
traT TraTf GGTGTGGTGCGATGAGCACAG 290 60 ºC Johnson and Stell, (2000) TraTr CACGGTTCAGCCATCCCTGAG 
tsh tsh03 GGTGGTGCACTGGAGTGG 640 54-56 ºC Dozois et al. (2000) tsh15 AGTCCAGCGTGATAGTGG 
usp usp-f ACATTCACGGCAAGCCTCAG 440 68 ºC Bauer et al. (2002) 
 
E. coli capsules are designated after interpretation of the PCR results following the 
scheme of Table 13.  
Table 13. Capsule designation based on PCR results. 
Capsule kpsM-II gene neuC-K1 gene kpsM-II-K2 gene kpsM-II-K5 gene 
type II-K1 + + + - 
type II-K2 + - + - 
type II-K5 + - + + 
 
In order to detect hybrid pathotypes, the 196 human clinical E. coli consecutively 
isolated (CEC) in 2016 were also examined for ten VF-encoding genes, specific for 
pathotypes of intestinal pathogenic E. coli (InPEC): typical and atypical enteropathogenic 
E. coli (tEPEC and aEPEC) (eae and bfpA genes), enteroinvasive E. coli (EIEC) (ipaH 
gene), enterotoxigenic E. coli (ETEC) (eltA and est genes), Shiga toxin-producing E. coli 
(STEC) (stx1 and stx2 genes) and enteroaggregative E. coli (EAEC) (aatA, aaiC and aggR 





Table 14. Primers used for detection of virulence factors encoding genes of intestinal pathogenic 
E. coli (InPEC) 








stx1 VT1‐F TCGCTGAATGTCATTCGCTCTGC 539 55 ºC 




358 55 ºC VT2‐F2 TGTCTTCAGCATCTTATGCAG 
VT2‐R CTGCTGTCCGTTGTCATGGAA 
EPEC 
eae EAE-V3F CATTGATCAGGATTTTTCTGGT 510 54 ºC Mora et al. (2011) EAE-MBR TCCAGAATAATATTGTTATTACG 
bfp BFP-NF1 ATGGTTTCTAAAATCATGAATAAG 262 55 ºC Bennett, (2003); García-Meniño et al. (2018) BFP-NR1 ATTATTCCGGAATTGCAGATGTGT 
ETEC 
estA STa-A ATTTTTATTTCTGTATTGTCTTT 176 50-52 ºC Penteado et al. (2002) STa-B GGATTACAACACAGTTCACAGCAGT 
estB Stb-F ATCGCATTTCTTCTTGCATC 175 54 ºC Blanco et al., (1997) Stb-R GGGCGCCAAAGCATGCTCC 
eltA LT-A-1 GGCGACAGATTATACCGTGC 696 54-56 ºC Schultsz et al. (1994) LT-A-2 CCGAATTCTGTTATATATGTC 
EIEC 
ipaH EI1 GCTGGAAAAACTCAGTGCCT 424 55 ºC Tornieporth et al. (1995) EI2 CCAGTCCGTAAATTCATTCT 
EAEC 
aatA pCVD432/start CTGGCGAAAGACTGTATCAT 630 60 ºC Schmidt et al. (1995) pCVD432/stop CAATGTATAGAAATCCGCTGTT 
 
3.4.3. ANTIMICROBIAL RESISTANCES GENOTYPING  
Genetic identification of blaESBL types (TEM, SHV and CTX-M enzymes), pAmpC 
types (LAT-1 to LAT-4, CMY-2 to CMY-7 and BIL-1) and the mcr genes (mcr-1, mcr-2, 
mcr-3, mcr-4 y mcr-5)  was carried out by PCR followed by amplicon sequencing (Perez-
Perez and Hanson, 2002; Leflon-Guibout et al., 2004a, 2004b; Blanco et al., 2009). The 
used primers are indicated in Table 15.  
The genetic environment of the mcr detected genes were manually revisited and 
compared to previously reported ones with CLC Sequence Viewer (Version 8.9, 





Table 15. Primers used for resistance gene detection. 











TG 542 55 ºC Mora et al. (2013) 
CTX‐C4 ACCGCGATATCGTTGGTGGTGCC 
blaCTX‐M-15 extremo 3´ 
CTX‐MF1 ATAAAACCGGCAGCGGTG 483 60 ºC Leflon-Guibout et al. (2004a) CTX‐MF2 GAATTTTGACGATCGGGG 
blaCTX‐M-grupo 1 
M13U GGTTAAAAAATCACTGCGTC 
863 60 ºC Saladin et al. (2002) M13L TTGGTGACGATTTTAGCCGC 




1123 52 ºC Mora et al. (2013) CTX-15-R GTATGCGCAAGCGCAGGTGG 
blaCTX‐M-grupo9 
CTX-M9-F GTGACAAAGAGAGTGCAACGG 
856 64 ºC Simarro et al. (2000) CTX-M9-R ATGATTCTCGCCGCTGAAGCC 
blaCTX‐M-grupo9 a 
CTX-M9-14-14B-
24F GAATACTGATGTAACACGGA 998 44 ºC García-Meniño et al. (2018) CTX-M9-RS AGCTGAAGATGTATATCAAG 
blaCTX‐M-grupo9a 
CTX-M9-14-14B-
24F GAATACTGATGTAACACGGA 989 52 ºC García-Meniño et al. (2018) CTX-M14-24-R CTGCGTTGTCGGGAAGATACG 
blaCTX‐M-grupo9 a 
CTX-M9-14B-F CCTATACCCGAGGCGCGACAG 
1059 44 ºC García-Meniño et al. (2018) CTX-M9-RS AGCTGAAGATGTATATCAAG 
blaCTX‐M-grupo9a 
CTX-M14-24-F CTAAATTCTTCGTGAAATAGTG 
1049 44 ºC García-Meniño et al. (2018) CTX-M14-24-R CTGCGTTGTCGGGAAGATACG 
blaSHV SHV-F2 TTGTCGCTTCTTTACTCGCC 879 64 ºC Mora et al. (2013) SHV-R2 CCCGGCGATTTGCTGATTTCGC 
blaSHVa 
SHV-1 GGGTTATTCTTATTTGTCGC 
930 48 ºC Rasheed et al. (1997) SHV-2 TTAGCGTTGCCAGTGCTC 
blaTEM 
TEM-1F ATGAGTATTCAACATTTCCG 
868 58 ºC Rasheed et al. (1997) TEM-1R CTGACAGTTACCAATGCT TA 
LAT-1 a LAT-4,  
CMY-2 a CMY-7, 
BIL-1 
CITMF TGGCCAGAACTGACAGGCAAA 
462 66 ºC Perez-Perez and Hanson, (2002) CITMR TTTCTCCTGAACGTGGCTGGC 
mcr-1 CLR5-F CGGTCAGTCCGTTTGTTC 309 57 ºC Liu et al., (2016d) CLR5-R CTTGGTCGGTCTGTAGGG 
mcr-1 mcr1_320bp_fw  AGTCCGTTTGTTCTTGTGGC  320 58 ºC Rebelo et al. (2018) mcr1_320bp_rev  AGATCCTTGGTCTCGGCTTG  
mcr-1a mcrS1-F GGGATTGCGCAATGATTGC 548 58 ºC García-Meniño et al. (2018) mcrS1-R CACCCAAACCAATGATACG 
mcr-1a mcrS1-F2 AAAGACGCGGTACAAGCAAC 1016 58 ºC García-Meniño et al. (2018) mcrS1-R2 CCCACCGCCCATAATACGAA 





3.5.WHOLE GENOME SEQUENCING (WGS), ASSEMBLY AND PRIMARY ANALYSIS 
We performed the WGS of a total of 109 E. coli strains belonging to three different 
studies: (I) 75 human ESBLEC (51 genomes from Lucus Augusti hospital and 24 
genomes from Beaujon hospital). These genomes come from different clinical samples: 
57 isolates from urine, 11 from blood and 7 from various other sources including one 
from bile, one from ascitic fluid, one from a bone, two from wounds and two from 
digestive infections; (II) 23 ST372 strains, 21 ST372 E. coli isolates from canine origin 
and two ST372 E. coli isolates human origin and (III) 11 resistant E. coli O25b:H4-B2-
ST131 clade B strains, seven from piglets with diarrhoea and four from pork meat. The 
whole genome sequencing and further analysis of the genomes were performed as 
follows. 
Total DNA was extracted with the QIAmp DNA Mini Kit (Qiagen). Libraries were 
prepared by using the TruSeq DNA PCR-Free protocol (Illumina) at the Genomics and 
Bioinformatics Core Facility (Centre for Biomedical Research of La Rioja, CIBIR). 
Paired-end 100 bp reads on fragments of 550 bp insert size were sequenced in an Illumina 
HiSeq 1500.  
Genomes were reconstructed by using PLACNET webserver (Vielva et al., 2017). 
Identification of Open Reading Frames (ORFs) and genome annotation of the assembled 
genetic elements was performed by using Prokka (Seemann, 2014).  
Genomes were in silico typed by the following databases: SerotypeFinder (Joensen 
et al., 2015)⁠, ClermontTyping Web (Beghain et al., 2018), MLSTtyper (Larsen et al., 
2012) ⁠, CHtyper (Camacho et al., 2009) ⁠. Three different databases were used for the 
identification of antibiotic resistance genes: ResFinder (Zankari et al., 2012a), CARD 
Resistance Gene Identifier (McArthur et al., 2013) ⁠and ARG-ANNOT (Antibiotic 
Resistance Gene-ANNOTation) (Gupta et al., 2014) ⁠. Besides, the PointFinder database 
(Zankari et al., 2017) was used to determine point mutations ⁠. The VirulenceFinder (Ren 
et al., 2017)⁠ and the VFDB (Chen et al., 2005)⁠ databases were used to explore virulence 
factors.  
The assembly information of draft genomes, database sources and input parameters 
can be found in annex 1: Tables S1 and S2. The datasets of the 11 LREC ST131 porcine 
origin genomes can be found in the NCBI sequence databases as part of BioProject 
SUB5714329, with accession codes SAMN11936814 to SAMN11937940. The 23 LREC 
ST372 canine and human origin genomes can be found in the NCBI sequence databases 
as part of BioProject PRJNA627579, with accession codes SAMN14677009 to 
SAMN14677031. 
3.5.1. CORE GENOME (CG) AND PHYLOGENETIC ANALYSIS  
In this thesis, four core genome (CG) analysis were performed: (I) a first CG (CG-1) 
including the 75 ESBLEC genomes from human strains sequenced in this thesis, (II) a 
second CG (CG-2) including 30 ST131 ESBLEC genomes from human strains sequenced 
in this thesis plus other 51 human ST131 E. coli full-genomes references, (III) a third CG 
(CG-3) including the 11 genomes from porcine ST131 strains sequenced in this thesis 
plus 73 ST131 E. coli full-genomes references and (IV) a fourth CG (CG-4) including the 
23 ST372 E. coli genomes sequenced in this study plus 174 ST372 E. coli full-genome 
references. Regarding CG-1, CG-2 and CG-3, the core genome was defined as the 
collection of genes present at least once in all the genomes analysed, with more than 90% 




single nucleotide position (SNP) tree analysis was done using the CSI Phylogeny 1.4 
server from the CGE with J22 strain as reference (ID: GCA_009497315). After analysing 
the SNP matrix, we took all the ST372 genomes from human strains plus some 
representatives from canine strains to made a tree visualization using EnteroBase (Zhou 
et al., 2020). References were retrieved from the Enterobase 
(http://enterobase.warwick.ac.uk/species/index/ecoli) and the NCBI Bioproject Database 
(https://www.ncbi.nlm.nih.gov/bioproject/). The accession number of the mentioned 
references can be found as Supplementary Tables 2 in Flament-Simon SC et al. 2020 
Microorganims 8 (11): E1712 doi: 10.3390/microorganisms8111712 and Flament-Simon 
SC et al. 2020 Front Microbiol 2020 11:387 doi: 10.3389/fmicb.2020.00387. 
3.5.2. MOBILE GENETIC ELEMENTS (MGES) ANALYSIS  
Plasmid reconstruction from WGS data was performed by PLACNETw method 
(Vielva et al., 2017). In PLACNETw representation, most plasmids and integrative 
conjugative elements (ICEs) can be recognised by their replication initiation proteins 
(RIP) and/or RELaxase proteins (REL), both of them considered as MGEs markers.  
Incompatibility groups (Inc) and pMLST subtypes were in silico determined with 
PlasmidFinder and pMLST (Carattoli et al., 2014), respectively⁠, via the CGE online 
services (http://genomicepidemiology.org/). Additionally, reconstructed plasmids were 
sub-typed according to the exact relaxase family subtype by phylogenetic comparison 
with previously defined relaxases subfamilies (Alvarado et al., 2012). Reconstructed 
plasmids and references belonging to the same Inc groups were compared by using BRIG 
(Alikhan et al., 2011) ⁠ and EasyFig tools, a comparative genomic tool that allows for 
visualizing homologies and similarities between contigs using BLAST (Sullivan et al., 
2011b) ⁠.  
All reference plasmids used in this study were recovered from NCBI database 
(https://www.ncbi.nlm.nih.gov/pubmed ) (annex 1, Table S3). Finally, ICEs typing from 
the ST372 genomes was complemented by in silico analysing the ICE-harbouring contigs 
with ICEberg (ICEfinder and VRprofile) (annex 1, Table S2). and comparing them with 
Easyfig (Sullivan et al., 2011a). 
3.6.STATISTICAL ANALYSIS 
Analysis of variance (ANOVA) test was performed to compare the mean number of 
virulence genes and the association of variables with biofilm formation phenotypes. 
Normality test was performed (Shapiro-Wilk test). Dichotomous variables were described 
using enumeration and percentages, and compared using two-tailed Fisher’s exact test. P-
values < 0.05 were considered statistically significant. Correlation between quantitative 
variables was assessed by Pearson correlation coefficient, and the assessment of 
repeatability was via the Bland and Altman, (1986) statistical method. Additionally, non-
parametric Mann-Whitney-Wilcoxon test on paired data was conducted. All analyses 








4.1. STUDY 1. CLONAL STRUCTURE, VIRULENCE FACTOR-ENCODING GENES AND 
ANTIBIOTIC RESISTANCE OF ESCHERICHIA COLI, CAUSING URINARY TRACT 
INFECTIONS AND OTHER EXTRAINTESTINAL INFECTIONS IN HUMANS IN SPAIN 
AND FRANCE DURING 2016 
This study was presented in part at the 28th European Congress of Clinical 
Microbiology and Infectious Diseases, Madrid, 21-24 April 2018 and published in 
Antibiotics the 4th of April of 2020 https://doi.org/10.3390/antibiotics9040161. 
4.1.1.  PHYLOGENETIC GROUPS 
The most frequent phylogenetic group in both hospitals was B2 (48%-Spain vs. 
58.3%-France) followed by the other six phylogenetic groups: A (14% vs. 15.6%), B1 
(10% vs. 8.3%), C (11% vs. 4.2%), D (9% vs. 5.2%), E (5% vs. 5.2%) and F (3% vs. 
3.1%). Although we observed a higher prevalence of B2 isolates in the French hospital 
and C isolates in the Spanish hospital, the differences were not statistically significant 
(annex 2, Table S4 and Figure 4). 
Figure 4. Comparison of the distribution of phylogenetic groups in the two hospitals. 
4.1.2.  SEROTYPES AND SEQUENCE TYPES 
Forty O serogroups were found, but 118 (60.2%) of the 196 isolates belonged to one 
of the following eight serogroups: O1 (3.6%), O2 (11.2%), O4 (6.6%), O6 (10.2%), O8 
(7.1%), O9 (5.1%), O18 (5.1%) and O25 (11.2%) (Figure 5). The isolates expressed 21 
different H antigens, but 119 (60.7%) isolates showed only seven types of flagellar 
antigens: H1 (11.2%), H4 (23.5%), H5 (4.1%), H6 (7.7%), H7 (6.1%), H18 (5.1%) and 








































Figure 5. Comparison of the distribution of O serogroups in the two hospitals. 
Seventy-one STs were found among the 196 studied isolates, but 61% and 63.5% of 
Spanish and French isolates, respectively, belonged to one of the ten following STs: ST10 
(3% vs. 6.3%), ST12 (4% vs. 4.2%), ST69 (8% vs. 5.2%), ST58 (4% vs. 1%), ST73 (9% 
vs. 12.5%), ST88 (9% vs. 3.1%), ST95 (6% vs. 4.2%), ST127 (3% vs. 4.2%), ST131 
(12% vs. 11.5%) and ST141 (3% vs. 11.5%). Statistically significant differences between 
the two hospitals were observed only with respect to ST141 (P = 0.026) (annex 2, Table 
S4 and Figure 6). 
Figure 6. Comparison of the distribution of sequence types in the two hospitals. 
A strong association between certain serotypes and STs was observed. Thus, the 11 
isolates of serotype O2:H6 were ST141, the 12 O6:H1 isolates were ST73, 5 of the 6 
O6:HNM isolates were ST127, 5 of the 6 O8:H4 isolates were ST88, 3 of the 4 O9:H4 
















































































Table 16. Clones, serotypes, and extraintestinal pathogenic E. coli (ExPEC), uropathogenic E. coli 
(UPEC), and multidrug resistant (MDR) status of the 196 isolates. 
Clone (number of isolates from 







A-CH11-54-ST10 (1/2) O48:HNM (1), O133:H40 (1), O153:HNT (1) 1 0 0 
B1-CH4-27-ST58 (2/1) O8:HNM (1), O9:H4 (1), O9:H25 (1) 0 0 1 
B2-CH13-27-ST12 (1/1) O4:H5 (1), O4:HNM (1) 2 2 0 
B2-CH13-106-ST12 (2/2) O4:H1 (3), O4:HNM (1) 4 4 0 
B2-CH24-10-ST73 (2/4) O2:H1 (1), O2:HNM (1), O6:H1 (3), O6:HNM (1) 6 6 1 
B2-CH24-12-ST73 (2/1) O6:H1 (1), O25:H1 (1), O25:H4 (1) 3 3 0 
B2-CH24-30-ST73 (0/3) O6:H1 (3) 3 3 1 
B2-CH24-103-ST73 (4/2) O6:H1 (4), O22:H1 (1), O22:HNM (1) 6 6 1 
B2-CH38-15-ST95 (2/2) O2:H5 (1), O2:H7 (1), O18:H7 (2) 4 4 0 
B2-CH38-27-ST95 (1/1) O2:H4 (1), O25:H4 (1) 2 2 1 
B2-CH38-41-ST95 (1/1) O1:H7 (2) 2 2 0 
B2-CH14-2-ST127 (1/2) O6:H31 (1), O6:HNM (2) 3 3 1 
B2-CH14-136-ST127 (1/1) O6:H31 (1), O6:HNM (1) 2 2 0 
B2-CH40-22-ST131 (1/2) O25:H4 (3) 3 3 2 
B2-CH40-30-ST131 (5/8) O25:H4 (13) 8 13 12 
B2-CH40-41-ST131 (5/1) O4:H5 (2), O4:HNM (1) O12:HNM (1), ONT:H5 (2) 3 3 4 
B2-CH52-5-ST141 (3/8) O2:H6 (8), O14:HNM (1), ONT:H4 (1), ONT:H6 (1) 11 11 0 
B2-CH52-14-ST141 (0/2) O2:H6 (2) 2 2 0 
B2-CH103-9-ST372 (1/1) O18:H31 (2) 0 2 0 
B2-CH14-64-ST1193 (1/1) O75:HNM (1), ONT:HNM (1) 1 2 2 
C-CH4-39-ST88 (9/1)  O8:H4 (5), O9:H4 (3), O9:HNM (1), ONT:H4 (1) 5 0 9 
D-CH35-27-ST69 (8/5) 
O15:H18 (2), O15:HNM (1), O18:HNM (1), 
O44:H18 (2), O77:HNM (1),  
O106:H4 (2), O175:HNM (1), ONT:H18 (3) 
9 0 6 
E-CH100-96-ST362 (2/1) O7:H6 (2), O21:HNT (1) 1 0 3 
E-CH37-27-ST405 (1/1) O18:H6 (1), O102:H4 (1) 1 0 1 
F-CH32-41-ST59 (3/0) O1:H7 (3) 3 3 0 
F-CH4-58-ST648 (0/2) O25:H4 (1), ONT:H42 (1) 2 1 1 
a Clones represented by a single isolate: A-CH11-23-ST10 (ONT:HNM) (F), A-CH11-27-ST10 (O14:HNM) (F), 
A-CH11-30-ST10 (O101:H4) (S), A-CH11-43-ST10 (O8:H4) (S), A-CH11-137-ST10 (O65:H10) (F), A-CH11-
168-ST10 (O10:HNM) (F), A-CH11-54-ST34 (O9:H1) (S), A-CH11-54-ST44 (ONT:H49) (S), A-CH11-41-ST93 
(O14:HNM) (F), A-CH11-NT-ST93 (O25:H4) (S), A-CH11-NEG-ST93 (O51:H52) (S), A-CH11-54-ST167 
(O101:H21) (S), A-CH99-54-ST361 (O9:HNM) (S), A-CH4-34-ST399 (O126:H27) (F), A-CH107-233-ST401 
(O21:H25) (S), A-CH7-53-ST540 (O14:HNM) (F), A-CH11-54-ST744 (ONT:H9) (S) , A-CH7-86-ST746 
(O171:HNT) (S), A-CH7-0-ST1139 (O9:HNM) (F), A-CH11-25-ST1141 (O73:H4) (S), A-CH4-NEG-ST1284 
(O101:HNM) (F), A-CH4-0-ST2795 (O21:HNT) (F) , A-CH11-43-ST3596 (O8:HNM) (F), A-CH11-27-ST3877 
(O38:HNM) (F), A-CH7-54-ST new 1-540 Like (O9:HNM) (F), A-CH27-23-ST new 2-437 like (O98:HNM) (S), 
B1-CH4-25-ST17 (O4:H2) (S), B1-CH4-24-ST58 (ONT:H21) (S), B1-CH4-25-ST58 (O75:H20) (S), B1-CH41-86-
ST101 (O103:H21) (S), B1-CH4-NEG-ST155 (ONT:HNM) (F), B1-CH8-31-ST210 (O155:H19) (S), B1-CH6-31-
ST448 (O148:H8) (F), B1-CH6-34-ST448 (ONT:H8) (S), B1-CH6-35-ST448 (O11:H10) (S), B1-CH6-31-ST453 
(O18:HNM) (F) , B1-CH4-32-ST767 (ONT:H9) (S), B1-CH6-32-ST847 (ONT:H2) (F), B1-CH4-30-ST2025 
(O8:HNM) (F), B1-CH4-NT-ST2077 (ONT:H2) (F), B1-CH4-NT-ST new 3-1071 like (O8:H8) (F), B2-CH13-6-
ST12 (O4:H5) (S), B2-CH13-223-ST12 (O4:H5) (F), B2-CH14-27-ST14 (O18:HNM) (S), B2-CH14-NT-ST14 
(O18:HNM) (F), B2-CH24-13-ST73 (O2:H1,12) (F), B2-CH24-27-ST73 (O6:H1) (F), B2-CH24-32-ST73 (O2:H1) 
(S), B2-CH24-NT-ST80 (O75:HNM) (F), B2-CH38-30-ST95 (ONT:H4) (S), B2-CH38-54-ST95 (O45:H7) (S), B2-
CH24-2-ST104 (O22:H1) (S), B2-CH14-180-ST127 (O6:HNM) (F), B2-CH14-224-ST127 (O6:HNM) (S), B2-
CH40-298-ST131 (O25:H4) (S), B2-CH52-76-ST141 (O2:H6) (F), B2-CH43-27-ST144 (O135:H4) (F), B2-CH14-
27-ST404 (O75:HNM) (S), B2-CH38-92-ST421 (O1:H7) (F), B2-CH40-22-ST428 (O106:H4) (F), B2-CH40-21-




ST636 (O83:H7) (S), B2-CH38-18-ST1231 (O18:H7) (S), B2-CH319-197-ST2015 (O2:H14) (F), B2-CH40-22-
ST2556 (ONT:H4) (F), B2-CH43-197-ST2558 (O2:H14) (S), B2-CH13-5-ST3352 (O4:HNM) (S), C-CH4-32-ST23 
(O5:H31) (F), C-CH4-27-ST88 (O8:H19) (F), C-CH4-NT-ST88 (O8:HNM) (F), C-CH4-27-ST new 4-88-like 
(O8:H40) (S), C-CH4-24-ST410 (O8:H9) (S), D-CH35-47-ST106 (O77:H18) (S), E-CH26-65-ST38 (O1:H15) (F), 
E-CH31-54-ST57 (O114:H10) (S),  E-CH26-270-ST115 (O2:H9) (S), E-CH26-27-ST963 (O2:H18) (F), E-CH26-5-
ST new 5 (ONT:H18) (F), F-CH45-97-ST117 (ONT:H4) (F). b Bold highlights those clones that presented at 
least one MDR isolate. S = Spain. F = France. 
4.1.3. CLONES 
A total of 107 clones (defined by the association of phylogroup, clonotype and ST) 
were identified among the 196 isolates, with 26 of them including at least two isolates 
and only nine at least four isolates: B2-CH13-106-ST12 (4 isolates), B2-CH24-10-ST73 
(6), B2-CH24-103-ST73 (6), B2-CH38-15-ST95 (4), B2-CH40-30-ST131 (13), B2-
CH40-41-ST131 (6), B2-CH52-5-ST141 (11), C-CH4-39-ST88 (10) and D-CH35-27-
ST69 (13) (Table 16). Only statistically significant differences were observed with 
respect to clone B2-CH52-5-ST141, which was more prevalent in the French hospital (P 
= 0.018).  
4.1.4. VIRULENCE FACTOR (VF)-ENCODING GENES 
Of the 31 VF-encoding genes analyzed, four (fimH, fyuA, chuA, ompT) were detected 
in more than 60% of the 196 isolates and 11 (papAH, papC, papEF, yfcV, vat, iucD, iutA, 
iroN, traT, malX, usp) in at least 40%. In contrast, five VF-encoding genes (afa/draBC, 
cdtB, tsh, kpsM II-K2, kpsM III) were found in less than 10% of the isolates (Table 17).  
There was a strong correlation between VF-encoding gene profiles and STs. A higher 
mean of VF-encoding gene score was observed in the isolates belonging to the following 
dominant B2- phylogenetic group STs (ST12, 17.1; ST73, 17.4; ST95, 18.2; ST127, 15.4; 
ST131, 12.3 and ST141, 16.2), compared with the dominant STs belonging to 
phylogroups A (ST10, 6.3), B1 (ST58, 8.4), C (ST88, 9.8) and D (ST69, 9.4) (Table 17 
and Figure 7). 
































Of the 196 isolates, 61.7% were presumptively classified as ExPEC and 54.1% as 
UPEC. All ST12, ST73, ST95, ST127 and ST141 isolates and the majority of ST131 
isolates were classified as UPEC. In contrast, none of the ST10, ST58, ST69 and ST88 
isolates presented the virulence markers necessary to be classified as UPEC (Table 17). 
4.1.5. CLONOTYPES, CLADES, SUBCLADES, CLUSTERS AND VIROTYPES OF ST131 
ISOLATES 
The 23 isolates of the dominant ST in both countries, i.e. ST131, were distributed in 
four clonotypes: CH40-30 (5 Spanish isolates vs. 8 French isolates), CH40-41 (5 vs. 1), 
CH40-22 (1 vs. 2) and CH40-298 (1 vs. 0) (annex 2, Table S4). 
Isolates of clade A and non-C1-M27 subclade C1 were the most commonly detected 
(6 isolates for each), followed by those of subclade C2 (also known as subclone H30Rx) 
(5 isolates), clade B (4 isolates) and cluster C1-M27 (1 isolate) (annex 2, Table S4 and 
Figure 8).  
Figure 8. Comparison of the distribution of sequence type (ST131) clades and clusters in the two 
hospitals. 
The previously determined ST131 virotypes were identified in 17 of the 23 ST131 
isolates (annex 2, Table S4), among which virotypes A (3 isolates), C2 (3 isolates) and 
C3 (3 isolates) were most prevalent. The virotypes of six strains could not be determined, 
since they showed new combinations of virulence genes not included in the classification 







































Table 17. Virulence factor (VF)-encoding genes observed from the 196 isolates and the isolates included in the 10 most frequent sequence types. 
Number (%) of isolates 


































fimH 193 (98.5) 23 9 8 5 13 21 12 10 7 14 
fimAvMT78 27 (13.8) 0 4 0 0 0 0 0 4 0 0 
papAH 84 (42.9) 6 1 8 0 6 18 10 7 6 7 
papC 87 (44.4) 6 1 8 0 7 18 10 7 6 7 
papEF 92 (46.9) 6 1 8 0 11 18 10 7 6 7 
sfa/focDE 58 (29.6) 1 0 8 0 0 20 0 2 5 13 
afa/draBC 11(5.6) 7 2 0 0 0 0 0 0 0 0 
yfcV 106 (54.1) 20 0 8 0 0 21 0 10 7 14 
Toxins 
sat 47 (24.0) 13 3 0 0 9 12 0 0 0 0 
cnf1 49 (25.0) 4 0 8 0 0 17 0 0 7 7 
hlyA 55 (28.1) 3 1 8 0 0 20 0 0 7 7 
hlyF 44 (22.4) 2 2 0 4 0 0 8 7 0 3 
cdtB 12 (6.1) 3 0 0 0 0 6 0 2 0 0 
tsh 7 (3.6) 0 0 0 0 0 0 0 2 0 1 
vat 80 (40.8) 0 0 7 0 0 20 0 10 7 14 
Iron uptake 
iucD 99 (50.5) 16 6 2 4 11 12 8 7 0 3 
iutA 99 (50.5) 16 6 2 4 11 12 8 7 0 3 
iroN 93 (47.4) 3 2 8 4 0 20 8 6 4 14 
fyuA 162 (82.7) 23 7 8 4 12 21 10 10 7 14 
chuA 135 (68.9) 23 0 8 0 12 21 0 10 7 14 
Capsule 
kpsM II 119 (60.7) 17 2 4 0 10 20 0 10 7 14 
neuC-K1 35 (17.9) 0 0 0 0 0 0 0 10 1 12 
kpsM II-K2 17 (8.7) 7 0 0 0 3 0 0 0 0 0 
kpsM II-K5 67 (34.2) 10 2 4 0 7 20 0 0 6 2 
kpsM III 6 (3.1) 0 0 3 0 1 0 0 0 0 0 
Miscellaneous 
cvaC 35 (17.9) 2 2 0 4 0 0 7 7 0 3 




Table 17. Cont. 
Number (%) of isolates 


































traT 111 (56.6) 17 4 6 5 7 4 9 8 3 6 
ibeA 23 (11.7) 4 0 0 0 0 0 0 4 0 3 
malX  109 (55.6) 21 0 8 0 0 21 0 10 7 14 
usp 107 (54.6) 23 0 8 0 0 21 0 10 7 14 
ompT 151 (77.0) 23 2 8 4 12 21 10 10 7 14 
ExPEC 
status 
121 (61.7) 15 2 8 0 9 21 6 10 7 14 
UPEC 
status 
106 (54.1) 20 0 8 0 0 21 0 10 7 14 
Range of 
VFs 
1 to 23 8-20 1-14 16-19 2-10 5-12 13-20 6-13 13-22 13-17 12-23 
Mean of 
VFs 
11.6 12.3 6.3 17.1 8.4 9.4 17.4 9.8 18.2 15.4 16.2 





4.1.6. ANTIMICROBIAL RESISTANCE 
The prevalence of resistance to ampicillin, doxycycline, nalidixic acid, ciprofloxacin 
and trimethoprim-sulfamethoxazole was >20%. In contrast, no isolates resistant to 
amikacin, colistin, fosfomycin or imipenem were detected (Table 18).  
Only 13 (6.6%) isolates produced an ESBL enzyme: CTX-M-1 (4 isolates), CTX-M-
14 (3), CTX-M-15 (3), CTX-M-27 (1), CTX-M-55 (1) and CTX-M-32 (1) (annex 2, Table 
S5). However, 73 (37.2%) of the 196 analyzed isolates were classified as MDR. MDR 
was especially associated with ST88 (83.3%) and ST131 (78.3%) isolates, but an 
important percentage of ST58 (40%) and ST69 (42.6%) isolates were also classified as 
MDR (Figure 9). The MDR differences between ST88 and ST131 with respect to ST10 
(33.3%), ST12 (12.5%), ST73 (14.3%), ST95 (10%), ST127 (28.6%) and ST141 (0%) 
were statistically significant. The new global emergent MDR clonal group, i.e. ST1193 
(Johnson et al., 2019; Tchesnokova et al., 2019), was displayed by two isolates, one from 
Spain and the other one from France (Table 16). Among the 73 MDR isolates, 31 (42.5%) 
belonged to only four clones: B2-CH40-30-ST131 (12 isolates), B2-CH40-41-ST131 (4), 
C-CH4-39-ST88 (9) and D-CH35-27-ST69 (6) (Table 16). Clone B2-CH40-30-ST131 
was also the most prevalent among the ESBL-producing isolates (4 of 13 isolates) (annex 
2, Table S5). 
Fourteen (papAH, papC, sfa/focDE, yfcV, cnf1, hlyA, vat, iroN, chuA, neuC-K1, ibeA, 
malX, usp and ompT) of the 31 analyzed VF-encoding genes were found to be associated 
with isolates that did not show multidrug resistance, while only the traT gene was found 
to be associated with MDR isolates (annex 2, Table S6).  



































4.1.7. HYBRID PATHOTYPES  
In one of the 196 isolates that displayed serotype O153:HNT, the three (aatA, aaiC 
and aggR) genes specific for  EAEC were detected. This hybrid ExPEC/EAEC isolate, 
which belonged to the A-CH11-54-ST10 clone, harbored 14 additional VF-encoding 
genes specific for ExPEC (fimH, fimAvMT78, papAH, papC, papEF, afa/draBC, sat, hlyA, 
iucD, iutA, fyuA, kpsM II-K5, traT, ompT), and was resistant to ampicillin and 
doxycycline. None of the genes specific for the different diarrheagenic E. coli pathovars 
was detected in the remaining 195 isolates.   
Table 18. Antimicrobial resistance observed from the 196 isolates and the isolates included in the 
10 most frequent sequence types. 
















































































(56.5) 0 0 
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(20) 0 0 
3 










(20) 0 0 
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(26.1) 0 0 
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(8.7) 0 0 
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ESBL 13 (6.6) 
5 




0 0 0 0 0 0 
aNone of the 196 isolates were resistant to the following antimicrobials: Imipenem (IMP10), amikacin 







4.2 STUDY 2. HIGH PREVALENCE OF ST131 SUBCLADES C2-H30RX AND C1-M27 
AMONG EXTENDED-SPECTRUM Β-LACTAMASE-PRODUCING ESCHERICHIA COLI 
CAUSING HUMAN EXTRAINTESTINAL INFECTIONS IN PATIENTS FROM TWO 
HOSPITALS OF SPAIN AND FRANCE DURING 2015 
This study was presented in part at the 28th European Congress of Clinical 
Microbiology and Infectious Diseases, Madrid, 21-24 April 2018, at the 29th European 
Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, 13-16 April 
2019 and published in Frontiers in Cellular and Infection Microbiology the 24th of March 
of 2020 https://doi.org/10.3389/fcimb.2020.00125. 
4.2.1. TYPES OF ESBL ENZYMES 
A total of 89 (47.3%) isolates were positive for CTX-M-15, 39 (20.7%) for CTX-M-
14, 27 (14.4%) for CTX-M-1, 21 (11.2%) for CTX-M-27, 11 (5.9%) for SHV-12, two 
(1.1%) for CTX-M-32 and one (0.5%) for CTX-M-55.  CTX-M-15 was the commonest 
ESBL detected in the two hospitals (44.6% in Lucus Augusti and 50.0% in Beaujon). 
CTX-M-14 was significantly ( P = 0.0003) more frequent in Lucus Augusti (31.5%) than 
in Beaujon (10.4%), whereas CTX-M-1 (20.8% versus 7.6%;  P = 0.008) and CTX-M-
27 (15.6% versus 6.5%;  P = 0.0389) were more frequent in Beaujon than in Lucus 
Augusti (Table 19).  
4.2.2. PHYLOGENETIC GROUPS 
The most frequent phylogenetic group was B2 (50.5%), followed by A (14.4%), C 
(11.7%), B1 (9.6%), F (6.9%), E (5.3%) and D (1.6%). Phylogenetic groups A, C and F 
were found more frequently among Lucus Augusti isolates, while phylogenetic group B2 
was more frequent among Beaujon isolates ( P < 0.05) (Table 19). 
Among CTX-M-15 and CTX-M-27-producing isolates, the most frequent 
phylogenetic group was B2, while among those producing CTX-M-1, CTX-M-14 and 
SHV-12, the most frequent phylogenetic groups were B1, C and F respectively (Table 
20). 
4.2.3. SEQUENCE TYPES 
ST131 was detected in 33 (39.1%) and 46 (47.9%) of isolates in Lucus Augusti and 
Beaujon, respectively. The 109 remaining isolates displayed 57 different STs and the 
following STs displayed at least three isolates: ST10 (8 isolates), ST23 (3), ST38 (4), 
ST58 (3), ST88 (5), ST95 (4), ST167 (3), ST354 (5), ST361 (3), ST410 (6), ST648 (4), 
ST744 (3), and ST1615 (6). ST354, ST410 and ST1615 were significantly (P< 0.05) more 
frequent in Lucus Augusti (5.4%, 6.5% and 6.5%) than in Beaujon (0% for the three STs) 
(Table 19 and Table 20). The new emerging global clone ST1193 was identified in one 
isolate from France and one from Spain. The majority (121 of 188; 64.4%) of ESBLEC 
isolates belonged to only three clonal complexes: CC10 (19 isolates), CC23 (22 isolates) 
and CC131 (80 isolates) (Table S1 in Flament-Simon SC et al. 2020 Front Cell Infect 
Microbiol 10:125 doi: 10.3389/fcimb.2020.00125). 
4.2.4. CLONOTYPES, CLADES AND SUBCLADES OF ST131 ISOLATES 
The 79 ST131 isolates were distributed in three clonotypes: CH40-30 (73 isolates), 
CH40-35 (2), CH40-41 (4) (Table 19).  Subclade C2 (also known as subclone H30Rx) 
was the commonest subclade detected among the 79 ST131 isolates (52 isolates; 65.8%), 
followed by cluster C1-M27 (16 isolates; 20.3%), cluster non-C1-M27 (6 isolates; 7.6%) 
and clade A (4 isolates; 5.1%). The 52 C2 subclade isolates were positive for CTX-M-




isolates of C1 subclade were positive for CTX-M-15 and one for CTX-M-14.  The four 
isolates belonging to clade A were positive for CTX-M-1 (2), CTX-M-15 (1) and CTX-
M-27 (1). 
Table 19. Characteristics of 188 ESBLEC isolated from extraintestinal infections.  
No. (%) of isolates 
Characteristic Lucus Augusti Hospital, Spain (n= 92) 
Beaujon Hospital,   
France (n= 96) P-Value 
ESBL enzyme 
CTX-M-1 7 (7.6) 20 (20.8) 0.008 
CTX-M-14 29 (31.5) 10 (10.4) 0.0003 
CTX-M-15 41 (44.6) 48 (50.0)  
CTX-M-27 6 (6.5) 15 (15.6) 0.0389 
CTX-M-32 2 (2.2) 0  
CTX-M-55 0 1 (1.0)  
SHV-12 8 (8.7) 3 (3.1)  
Phylogenetic group 
A 18 (19.6) 9 (9.4) 0.0367 
B1 7 (7.6) 11 (11.5)  
B2 38 (41.3) 57 (59.4) 0.0097 
C 16 (17.4) 6 (6.3) 0.0151 
D 1 (1.1) 2 (2.1)  
E 2 (2.2) 8 (8.3)  
F 10 (10.9) 3 (3.1) 0.0341 
ST131 
Total 33 (39.1) 46 (47.9)  
Clade A 1 (1.1) 3 (3.1)  
Subclade C1 
Cluster C1-M27 5 (5.4) 11 (11.5)  
Subclade C1 
Cluster non-C1-M27 0 6 (6.3) 0.0164 
Subclade C2 27 (29.3) 25 (26.0)  
Clade-Not typeable 0 1 (1.0)  
Clonotype CH40-30 30 (32.6) 43 (44.8)  
Clonotype CH40-35 2 (2.2) 0  
Clonotype CH40-41 1 (1.1) 3 (3.1)  
Virotype A 7 (7.6) 1 (1.0) 0.0280 
Virotype C1 1 (1.1) 1 (1.0)  
Virotype C2 10 (10.9) 15 (15.6)  
Virotype C3 0 2 (2.1)  
Virotype E 10 (10.9) 8 (8.3)  
Virotype F 3 (3.3) 11 (11.5) 0.0293 
Virotype A-like 1 (1.1) 6 (6.3)  
Virotype E-like 1 (1.1) 0  
Virotype-Not typeable 1 (1.1) 2 (2.1)  
Other STa 
ST10 6 (6.5) 2 (2.1)  
ST23 1 (1.1) 2 (2.1)  
ST38 0 4 (4.2)  
ST58 2 (2.2) 1 (1.0)  
ST88 1 (1.1) 4 (4.2)  
ST95 0 4 (4.2)  
ST167 2 (2.2) 1 (1.0)  
ST354 5 (5.4) 0 0.0265 
ST361 2 (2.2) 1 (1.0)  
ST410 6 (6.5) 0 0.0126 
ST648 3 (3.3) 1 (1.0)  
ST744 1 (1.1) 2 (2.1)  
ST1615 6 (6.5) 0 0.0126 




Table 20. Phylogenetic groups and sequence types according to ESBL enzymes. 
ESBL enzyme (no. 
of isolates) 
Phylogenetic 
groups Sequence types  
CTX-M-1 (27) 
A (3)  




E (2)  
F (1) 
ST10 (1), ST23 (2), ST34 (1), ST58 (1), ST69 (1), ST88 (3), ST90 (1), 
ST131 (2), ST155 (1), ST162 (1), ST205 (1), ST224 (1), ST453 (2), 
ST1266 (1), ST1431 (1), ST2067 (1), ST2558 (1), ST2766 (1), 
ST3778 (1), ST8152 (1), ST new 2-6057like (1), ST new 3-1268like 
(1)  
CTX-M-14 (39) 
A (8)  
B1 (4)   
B2 (10)   
C (11)  
E (2)  
F (4) 
ST10 (4), ST12 (1), ST59 (1), ST73 (1), ST88 (2), ST93 (1), ST95 (2), 
ST131 (1),  ST167 (3), ST354 (3), ST357 (1), ST362 (1), ST404 (2),  
ST405 (1), ST410 (3), ST448 (1), ST602 (1), ST1154 (1), ST1193 (1), 
ST1615 (6), ST5528 (1), ST10328 (1) 
CTX-M-15 (89) 
A (11)   
B2 (64)  
C (4)  
D (2)  
E (4)  
F (4) 
ST4 (1), ST34 (1), ST38 (2), ST44 (1), ST69 (1), ST90 (1), ST95 (2), 
ST127 (1),  ST131 (59), ST141 (1), ST358 (1), ST361 (3), ST405 (1), 
ST410 (3),  ST540 (1), ST648 (4), ST744 (2), ST1284 (1), ST2279 
(1), ST3075 (1), ST5214 (1) 
CTX-M-27 (21) 
B2 (18)  
C (1)  
E (2) 
ST131 (17), ST38 (2), ST90 (1), ST1193 (1) 
CTX-M-32 (2) B1 (2) ST58 (2) 
CTX-M-55 (1) A (1) ST744 (1) 
SHV-12 (11) 
A (4)   
B1 (1)  
C (1)  
F (5) 
ST10 (2), ST23 (1), ST117 (1), ST156 (1), ST354 (2), ST1485 (1), 
ST3778 (1), ST new 1-10 like (2) 
The most frequent STs are indicated in bold. 
4.2.5. CLONES 
A total of 71 clones (defined by the association of phylogroup, clonotype and ST) 
were identified among the 188 ESBLEC with 23 of them including at least two isolates 
and only five at least five isolates: A-CH11-54-ST10 (6 isolates), B2-CH40-30-ST131 
(73), C-CH4-24-ST410 (6), C-CH263-32-ST1615 (6) and F-CH88-58-ST354 (5) (Table 
21). 
4.2.6. SEROTYPES 
The 188 ESBLEC isolates belonged to 30 O serogroups and expressed 17 different 
H antigens, but 71 of the 79 ST131 isolates belonged to serotype O25:H4. The other 
prevalent serotypes were: O9:HNM (three ST361 isolates), O11:H9 (three ST1615 
isolates), O16:H5 (three ST131 isolates), O18:H7 (four ST95 isolates), O20:H9 (three 
ST410 isolates), O75:HNM (two ST404 and two ST1193 isolates of clonal complex 14), 
and O86:H18 (three ST38 isolates). The H4 and H5 flagellar antigens were associated 
with ST131, the H7 with ST95, the H9 with ST10, ST744 and four STs of the clonal 
complex 23 (ST23, ST90, ST410, ST1615), the H18 with ST38 and ST69, and the H6 
and the H45 antigens with ST648 (Table 21 and Table S1 in Flament-Simon SC et al. 





Table 21. ESBL enzymes, serotypes and ExPEC and UPEC status according to the clones 
including at least two isolates. 
Clones (no. of isolates from 
Spain and France) ESBL enzymes Serotypes ExPEC UPEC APEC 




0 0 2 
A-CH11-negative-ST167 




1 0 0 
A-CH11-54-ST744 (1/2) CTX-M-15 (2), CTX-M-55 (1) ONT:H9 (1), ONT:HNM (2) 0 0 0 
A-CH99-54-ST361 (2/1) CTX-M-15 (3) O9:HNM (3) 0 0 0 
B1-CH4-32-ST58 (1/1) CTX-M-1 (1), CTX-M-32 (1) O9:H25 (1), ONT:HNM (1) 1 0 2 
B1-CH6-31-ST453 (0/2) CTX-M-1 (2) O23:HNM (1), ONT:HNM (1) 0 0 1 
B2-CH38-15-ST95 (0/2) CTX-M-14 (2) O18:H7 (2) 2 2 2 
B2-CH38-294-ST95 (0/2) CTX-M-15 (2) O18:H7 (2) 2 2 2 




68 73 0 
B2-CH40-35-ST131 (2/0) CTX-M-15 (2) O25:H4 (2) 2 2 0 
B2-CH40-41-ST131 (1/3) CTX-M-1 (2), CTX-M-15 (1), CTX-M-27 (1) 
O16:H5 (3), 
O153:H5 (1) 3 2 0 
B2-CH14-27-ST404 (1/1) CTX-M-14 (2) O75:HNM (2) 2 2 0 
B2-CH14-64-ST1193 (1/1) CTX-M-14 (1), CTX-M-27 (1) O75:HNM (2) 2 2 0 
C-CH4-35-ST23 (1/2) CTX-M-1 (2), SHV-12 (1) O55:H9 (1), O78:HNM (2) 1 0 2 
C-CH4-41-ST88 (0/2) CTX-M-1 (1), CTX-M-14 (1) O8:HNM (1), O86:HNT (1) 2 0 0 
C-CH4-303-ST88 (0/2) CTX-M-1 (2) O9:H17 (2) 2 0 2 
C-CH4-142-ST90 (2/0) CTX-M-1 (1) CTX-M-15 and CTX-M-27 (1) O8:H9 (2) 0 0 0 




0 0 0 




0 0 0 
E-CH26-negative-ST38 (0/3) CTX-M-15 (1), CTX-M-27 (2) O86:H18 (3) 3 0 0 
E-CH37-27-ST405 (1/1) CTX-M-14 (1), CTX-M-15 (1) O102:H4 (1), O102:HNM (1) 0 0 0 
F-CH88-58-ST354 (5/0) CTX-M-14 (3), SHV-12 (2) 
O1:H34 (1),  
O1:HNM (1),  
O11:H4 (2), 
O153:HNT (1)  
1 2 0 





4.2.7. VIRULENCE FACTOR (VF)-ENCODING GENES 
Of the 188 ESBLEC isolates, 57.4% were classified as ExPEC, 52.7% as UPEC and 
12.8% as APEC. The prevalence of ExPEC (92.4% vs. 32.1%) (P<0.001) and UPEC 
(97.5% vs. 20.2%) (P<0.001) status were higher within ST131 isolates than within non-
ST131 isolates. In contrast, the prevalence of APEC (0% vs. 22%) status was higher 
among non-ST131 isolates (P<0.001) (Table 22).  
The ST131 isolates showed a higher VF-encoding gene score (mean 13.367) 
compared with the non-ST131 isolates (mean 7.661) (P<0.001). However, four isolates 
belonging to clones B2-CH38-15-ST95 and B2-CH38-294-ST95 were those with the 
highest number of virulence genes (mean 21.000).  
Nineteen VF-encoding genes (papAH, papC, papEF, afa/draBC, yfcV, sat, cnf1, 
hlyA, iucD, iutA, fyuA, chuA, kpsM II, kpsM II-K2, kpsM II-K5, traT, malX, usp and ompT) 
were significantly associated with ST131 isolates, whereas that ten (fimAvMT78, 
sfa/focDE, hlyF, tsh, vat, iroN, kpsM II-K1, cvaC, iss and ibeA) were significantly 
associated with non-ST131 isolates.  
The C2 subclade isolates showed a higher virulence score (mean 14.250) compared 
with C1-M27 isolates (mean 10.875) (P<0.001). The genes papAH, papC, papEF, cnf1 
and hlyA were associated with the C2 subclade isolates. 
The most prevalent virotypes identified in ST131 isolates were A (8 isolates), C2 
(25), E (18) and F (14) and a new virotype similar to A (virotype A-like) displayed by 
seven isolates. Further, a second new virotype similar to E (virotype E-like) was found in 
one isolate (Table S1 in Flament-Simon SC et al. 2020 Front Cell Infect Microbiol 10:125 
doi: 10.3389/fcimb.2020.00125). The virotype A was found more frequently among 
Lucus Augusti isolates (P = 0.0280), while virotype F was more frequent among Beaujon 





Table 22. Virulence factor-encoding genes in the studied 188 isolates and according to ST131 
lineage.  
Genes 
No. (%) of isolates P-Valuea P-Valuea 
Total 








(n = 52) 
ST131 
 (n = 79) 
Non-
ST131 








fimH 180 (95.7) 16 (100) 52 (100) 79 (100) 101 (92.7)   
fimAvMT78 27 (14.4) 0 0 0 27 (24.8)  < 0.00001 
papAH 50 (26.6) 0 30 (57.7) 31 (39.2) 19 (17.4) < 0.00001 0.0008 
papC 51 (27.1) 0 30 (57.7) 31 (39.2) 20 (18.3) < 0.00001 0.0013 
papEF 52 (27.7) 0 31 (59.6) 32 (40.5) 20 (18.3) < 0.00001 0.0007 
sfa/focDE 10 (5.3) 0 0 0 10 (9.2)  0.0036 
afa/draBC 20 (10.6) 0 10 (19.2) 15 (19.0) 5 (4.6)  0.0018 
yfcV 104 (55.3) 16 (100) 52 (100) 77 (97.5) 27 (24.8)  < 0.00001 
Toxin 
sat 82 (43.6) 15 (93.8) 50 (96.2) 74 (93.7) 8 (7.3)  < 0.00001 
cnf1 25 (13.3) 0 17 (32.7) 18 (22.8) 7 (6.4) 0.0049 < 0.00001 
hlyA 25 (13.3) 0 17 (32.7) 18 (22.8) 7 (6.4) 0.0049 < 0.00001 
hlyF 31 (16.5) 0 0 0 31 (28.4)  < 0.00001 
cdtB 5 (2.7) 0 1 (1.9) 1 (1.3) 4 (3.7)   
tsh 12 (6.4) 0 0 0 12 (11)  0.0011 
vat 17 (9) 0 0 0 17 (15.6)  0.00005 
Iron uptake 
iucD 132 (70.2 15 (93.8) 50 (96.2) 74 (93.7) 58 (53.2)  < 0.00001 
iutA 134 (71.3) 15 (93.8) 50 (96.2) 74 (93.7) 60 (55)  < 0.00001 
iroN 32 (17) 0 0 0 32 (29.4)  < 0.00001 
fyuA 128 (68.1) 16 (100) 52 (100) 79 (100) 49 (45)  < 0.00001 
chuA 121 (64.4) 16 (100) 52 (100) 79 (100) 42 (38.5)  < 0.00001 
Capsule 
kpsM II 106 (56.4) 15 (93.8) 49 (94.2) 73 (92.4) 33 (30.3)  < 0.00001 
kpsM II-K2 13 (6.9) 0 7 (13.5) 11 (13.9) 2 (1.8)  0.0015 
kpsM II-K5 83 (44.1) 15 (93.8) 42 (80.8) 62 (78.5) 21 (19.3)  < 0.00001 
neuC-K1 10 (5.3) 0 0 0 10 (9.2)  0.0036 
kpsM III 2 (1.1) 0 0 0 2 (1.8)   
Miscellaneous 
cvaC 21 (11.2) 0 0 0 21 (19.3)  < 0.00001 
iss 23 (12.2) 0 0 0 23 (21.1)  < 0.00001 
traT 139 (73.9) 13 (81.3) 42 (80.8) 64 (81) 75 (68.8)  0.0422 
ibeA 12 (6.4) 0 0 0 12 (11)  0.0011 
malX  113 (60.1) 16 (100) 52 (100) 79 (100) 34 (31.2)  < 0.00001 
usp 101 (53.7) 16 (100) 52 (100) 79 (100) 22 (20.2)  < 0.00001 
ompT 126 (67) 16 (100) 52 (100) 79 (100) 47 (43.1)  < 0.00001 
ExPEC status 108 (57.4) 15 (93.8) 50 (96.2) 73 (92.4) 35 (32.1)  < 0.00001 
UPEC status 99 (52.7) 16 (100) 52 (100) 77 (97.5) 22 (20.2)  < 0.00001 
APEC status 24 (12.8) 0 0 0 24 (22)  < 0.00001 





4.3. STUDY 3. ASSOCIATION BETWEEN KINETICS OF EARLY BIOFILM FORMATION 
AND CLONAL LINEAGE IN ESCHERICHIA COLI 
This study was presented in part at the 8ème Colloque du Réseau National Biofilms, 
Clermont-Ferrand, 5-6 December 2017 and published in Frontiers in Microbiology the 
31th of May of 2019 https://doi.org/10.3389/fmicb.2019.01183. 
4.3.1. KINETICS OF EARLY BIOFILM FORMATION 
Here we study the early biofilm formation (EBF) of the two human origin bacterial 
collection of E. coli clinical isolates. 
To assess the repeatability of the duplicate determination of biofilm formation 
performed on each of the 394 isolates at each time, we calculated Pearson’s correlation 
coefficient and Bland and Altman, (1986) analysis between the Biofilm formation index 
(BFI) obtained for each determination. Pearson’s correlation coefficient was high and 
constant over time: 0.96 at 2 h, 0.96 at 3 h, and 0.95 at 5 h (annex 2, Figure S1A), and the 
Bland and Altman, (1986) analysis showed that only 3.4% of values at 2 h, 5.5% at 3 h, 
and 6.8% at 5 h exceed the established standard deviation (annex 2, Figure S1B). 
Biofilm formation index values obtained at each time point (2, 3, and 5 h) showed a 
distribution of both CEC and ESBLEC isolates in the three levels of biofilm production 
(strong, moderate, and weak production) defined according to the BFI value ranges. After 
2 h of incubation, strong producers (BFI: 0–5) and moderate producers (BFI: 6–14) were 
more frequent among CEC isolates than ESBLEC isolates (P = 0.004 and P = 0.0189, 
respectively), whereas weak and non-producers (BFI: 15–20) were more frequent among 
ESBLEC isolates than among CEC isolates (P < 0.0001) (Table 23). After 3 h of 
incubation, such significant differences were still observed between CEC and ESBLEC 
isolates for the strong and weak producers but not for the moderate producers. After 5 h 
of incubation, no significant difference was observed between CEC and ESBLEC for the 
three types of producers. 
Table 23. Distribution of CEC and ESLEC isolates according to the biofilm index (BFI) values 
after 2, 3 and 5h of incubation. 
Number ( %) of isolates 
BFI 
range 
At 2h At 3h At 5h 
CEC 
n = 196 
ESBLEC 




n = 196 
ESBLEC 




n = 196 
ESBLEC 






(14.3) 8 (4.0) 0.0004 
36 
(18.4) 11 (5.6) <0.0001 
71 




(10.2) 8 (4.0) 0.0189 
39 
(19.9) 27 (13.6) 0.1064 
41 
(20.9) 45 (22.7) 0.7150 








(42.9) 83 (41.9) 0.9188 
 a Two-tailed P-Values by Fisher´s exact test. 
The study of individual BFI trajectories of the isolates of the three 2-h groups over 
time showed that both CEC and ESBLEC isolates displayed three distinct EBF kinetics. 
As indicated in Figures 10A, A’, most of the 28 CEC (27 non-ESBL producers) and the 
8 ESBLEC strong biofilm producers at 2 h (average BFI: 1 for the two collections) 
remained strong producers after 3 h (average BFI: 1 and 2, respectively) and 5 h (average 
BFI: 4 and 3, respectively) of incubation. Accordingly, these isolates were classified into 
group 1 (G1) corresponding to quickly and persistently strong biofilm producers. As 
indicated in Figures 10B, B’, the 20 CEC and 8 ESBLEC moderate producers at 2 h, with 




at 3 and 5 h than the strong producers. However, their average BFI at 3 h (7 and 11, 
respectively) and at 5 h (10 and 6, respectively) led us to classify them as mostly moderate 
producers over the study period [group 2 (G2)]. As indicated in Figures 10C, C’, the 148 
CEC and 182 ESBLEC weak producers at 2 h (average BFI: 18 for CEC and ESBLEC) 
also displayed a wide variability of BFI values at 3 and 5 h with a notable part of isolates 
becoming strong producers at 5 h. However, the average BFI values were 17 for CEC and 
18 for ESBLSE isolates at 3 h, and 12 for CEC and ESBLEC isolates at 5 h. Accordingly, 
we classified these isolates into group G3 corresponding to weak biofilm producers. We 
compared the individual BFI trajectories of all CEC isolates and CEC isolates over time 
without the 13 ESBL-producing isolates identified in this collection and found no 
significant difference (data not shown). 
Figure 10 shows that time point 2 h was the most representative time point of the 
division of our E. coli population into three groups. Accordingly, the comparisons 
between G1, G2, and G3 isolates will be made at time point 2 h in the rest of the study. 
Furthermore, the similarity of the individual biofilm formation kinetics of the CEC and 
ESBLEC isolates within each group led us to characterize altogether the CEC and 
ESBLEC isolates of each group in the rest of the study. 
Figure 10. Individual biofilm formation trajectories over time for the 394 isolates. Individual 
biofilm formation index (BFI) and average BFI values at each time point (2, 3, and 5 h) are 
represented as blue lines and a red connected line, respectively, for CEC isolates (A–C) and as 
green lines and a red connected line, respectively, for ESBLEC isolates (A’–C’). (A,A’) present the 
biofilm kinetics of the strong biofilm producers at 2 h (BFI≤5), (B,B’), the biofilm kinetics of the 
moderate producers at 2 h (BFI>5–≤14), and (C,C’), the biofilm kinetics of the weak (BFI>14 and 





4.3.2. CHARACTERIZATION OF PHYLOGROUPS, SEQUENCE TYPES, AND CLONES 
4.3.2.1 Phylogroups 
Most of the 394 isolates (51.3%) were assigned to phylogroup B2. The remaining 
isolates were distributed into phylogroups A (15.0%), B1 (9.6%), C (9.6%), E (5.1%), F 
(5.1%), and D (4.3%). Isolates belonging to phylogroup B2 were predominant among G1, 
G2, and G3 isolates (Figure 11). The seven phylogroups (A, B1, B2, C, D, E, and F) were 
detected among G3 isolates, four (A, B1, B2, and D) among G2 isolates, and four (B1, 
B2, E, and F) among G1 isolates (Figure 11). Isolates belonging to phylogroup B2 were 
more frequent among G1 isolates (77.8%) than among G3 isolates (47.6%) (P = 0.0006) 
(annex 2, Table S7). By contrast, isolates belonging to phylogroups A and C were 
significantly more frequent among G3 isolates than among G1 isolates (A: 16.1% vs. 0%, 
P = 0.0098; C: 11.5% vs. 0%,  P = 0.0419) (annex 2: Table S7). 
Figure 11. Distribution of phylogroups A, B1, B2, C, D, E, and F among G1, G2, and G3 isolates. 
G1: strong producers, G2: moderate producers, and G3: weak producers. Isolates belonging to 
phylogroup B2 were more frequent among G1 isolates (77.8%) than among G3 isolates (47.6%) (P 
= 0.0006). By contrast, isolates belonging to phylogroups A and C were significantly more 






4.3.2.2. Sequence Types 
The 394 E. coli isolates displayed 99 STs. The most frequent STs accounting for more 
than half (52.0%) of the isolates were ST131 (26.4%), ST73 (5.6%), ST10 (4.3%), ST88 
(4.3%), ST141 (4.1%), ST69 (3.8%), and ST95 (3.6%). The distribution of the seven most 
frequent STs among G1, G2, and G3 isolates is presented in Figure 12. These seven STs 
were displayed by G3 isolates whereas five were displayed by G2 isolates (absence of 
ST88 and ST95) and only three (ST131, ST141, and ST73) were displayed by G1 isolates. 
Among the three STs shared by the three groups, ST131 was significantly more frequent 
among G3 isolates than among G1 isolates (29.4% vs. 11.1%, P = 0.0289). By contrast, 
ST141 was more frequent among G1 isolates than among G3 (25.0% vs. 1.5%, P < 
0.0001) (annex 2, Table S8). 
 
Figure 12. Distribution of the most frequent sequence types (STs) among G1, G2, and G3 isolates. 
G1: strong producers, G2: moderate producers, and G3: weak producers. ST141 was more 
frequent among G1 isolates than among G3 (25.0 vs. 1.5%, P < 0.0001). By contrast, ST131 was 






A total of 153 clones were identified among the 394 isolates, with 31 of them 
including at least 3 isolates (Figure 13 and annex 2, Table S9) and 6 including at least 10 
isolates: B2-CH40-30-ST131 (87 isolates), D-CH35-27-ST69 (14 isolates), B2-CH52-5-
ST141 (13 isolates), C-CH4-39-ST88 (11 isolates), A-CH11-54-ST10 (10 isolates), and 
B2-CH40-41 ST131 (10 isolates). The 36 G1 isolates belonged to 26 clones (annex 2, 
Table S10). These 26 clones were also found in 25% of the G2 isolates (P < 0.0001) and 
in only 5.2% of the G3 isolates (P < 0.0001) (annex 2, Table S10). 
Five clones (B2-CH14-2-ST127, B2-CH40-22-ST131, B2-CH52-5-ST14, B2-CH52-
14-ST141, and E-CH100-96-ST362) were associated with G1 and accounted for 41.7% 
of G1 isolates, 10.7% of G2 isolates (P = 0.0105), and 2.4% of G3 isolates (P < 0.0001) 
(annex 2, Table S9). Only the B2-CH40-30-ST131 clone was associated with G3, 
accounting for 25.5% of G3 isolates, 10.7% of G2 isolates (P = 0.1068), and 0% of G1 
isolates (P < 0.0001) (annex 2, Table S9). 
 
Figure 13. Distribution of the 31 clones including at least three isolates among G1, G2, and G3. 
G1: strong producers, G2: moderate producers, and G3: weak producers. Five clones (B2-CH14-
2-ST127, B2-CH40-22-ST131, B2-CH52-5-ST14, B2-CH52-14-ST141, and E-CH100-96-ST362) were 
associated with G1 and accounted for 41.7% of G1 isolates, 10.7% of G2 isolates (P = 0.0105), and 
2.4% of G3 isolates (P < 0.0001). Only the B2-CH40-30-ST131 clone was associated with G3, 
accounting for 25.5% of G3 isolates, 10.7% of G2 isolates (P = 0.1068), and 0% of G1 isolates (P < 
0.0001). 
4.3.3. COMPARISON OF THE VIRULENCE FACTOR (VF)-ENCODING GENES AMONG G1, 
G2, AND G3 ISOLATES 
As indicated in Table 24, some VF-encoding genes were mostly observed among G1. 
These genes consisted of genes encoding adhesins (papAH, papC, papEF, sfa/focDE, 
and yfcV), genes encoding toxins (cnf1, hlyA, and vat), genes encoding two variants of 
group II capsule (kpsM II-K5 and neuC-K1), and miscellaneous genes (ibeA, malX, 
and ups). Inversely, the sat and traT genes were mostly observed among G3 isolates. 
Concerning the genes encoding proteins involved in iron uptake, those encoding ferric 
aerobactin receptors (iucD and iutA) were significantly more frequent among G3 isolates 




of VF-encoding genes was significantly higher among G1 isolates than among G3 isolates 
(13.8 vs. 10.4, P < 0.001) 
Table 24. Virulence factor-encoding genes displayed by G1, G2 and G3 isolates. 
Gene/Status 








n=330 G1 vs. G2 G1 vs. G3 
Adhesine       
fimH 383 (97.2) 36 (100) 27 (96.4) 320 (97)   
fimAVMT78 56 (14.2) 4 (11.1) 4 (14.3) 48 (14.5)   
papAH 135 (34.3) 19 (52.8) 12 (42.9) 104 (31.5)  0.0149b 
papC 140 (35.5) 20 (55.6) 12 (42.9) 108 (32.7)  0.0093b 
papEF 146 (37.1) 20 (55.6) 13 (46.4) 113 (34.2)  0.0168b 
sfa/focDE 69 (17.5) 22 (61.1) 9 (32.1) 38 (11.5) 0.0259a <0.0001b 
afa/dra BC 31 (7.9) 0 (0.0) 1 (3.6) 30 (9.1)   
yfcV 213 (54.1) 31 (86.1) 17 (60.7) 165 (50) 0.0396a <0.0001b 
Toxin       
sat 130 (33) 3 (8.3) 7 (25) 120 (36.4)  0.0006b 
cnf1 74 (18.8) 17 (47.2) 12 (42.9) 45 (13.6)  <0.0001b 
hlyA 80 (20.3) 17 (47.2) 13 (46.4) 50 (15.2)  <0.0001b 
hlyF 77 (19.5) 6 (16.7) 4 (14.3) 67 (20.3)   
cdtB 17 (4.3) 4 (11.1) 0 (0.0) 13 (3.9)   
tsh 21 (5.3) 2 (5.6) 2 (7.1) 17 (5.2)   
vat 99 (25.1) 23 (63.9) 15 (53.6) 61 (18.5)  <0.0001b 
Iron uptake       
iucD 237 (60.2) 8 (22.2) 13 (46.4) 216 (65.5)  <0.0001b 
IutA 239 (60.7) 8 (22.2) 13 (46.4) 218 (66.1)  <0.0001b 
iroN 129 (32.7) 25 (69.4) 14 (50) 90 (27.3)  <0.0001b 
fyuA 295 (74.9) 29 (80.6) 21 (75) 245 (74.2)   
chuA 260 (66) 33 (91.7) 21 (75) 206 (62.4)  0.0008b 
Capsule       
KpsM II 229 (58.1) 30 (83.3) 18 (64.3) 181 (54.8)  0.0011b 
KpsM II-K2 31 (7.9) 0 (0.0) 1 (3.6) 30 (9.1)   
KpsM II-K5 151 (38.3) 21 (58.3) 13 (46.4) 117 (35.5)  0.0105b 
neuC-K1 47 (11.9) 9 (25) 4 (14.3) 34 (10.3)  0.0153b 
KpsM III 8 (2.0) 0 (0.0) 1 (3.6) 7 (2.1)   
Miscellaneous       
cvaC 58 (14.7) 6 (16.7) 3 (10.7) 49 (14.8)   
iss 72 (18.3) 8 (22.2) 3 (10.7) 61 (18.5)   
traT 256 (65) 15 (41.7) 13 (46.4) 228 (69.1)  0.0014b 
ibeA 36 (9.1) 12 (33.3) 1 (3.6) 23 (7.0) 0.004b <0.0001b 
malX 226 (57.4) 31 (86.1) 17 (60.7) 178 (53.9) 0.0396a 0.0003b 
usp 211 (53.6) 28 (77.8) 17 (60.7) 166 (50.3)  0.0024b 
ompT 282 (71.6) 30 (83.3) 22 (78.6) 230 (69.7)   
Range 1-23 1-23 1-20 1-22   
Mean 10.8 13.8 11.8 10.4 0.001c 0.001c 
 a Two-tailed P values by Fisher´s exact test are shown where P< 0.05. b Significant differences after applying 
the Bonferroni correction because of the P < 0.025. c Analysis of variance (ANOVA test) was performed to 
compare the mean of virulence genes between the three groups. 
4.3.4. FIMB ALLELES 
Given that the ST131 clone with a fimH30 allele was the dominant clone among our 
E. coli population and that previous results had shown (I) an IS3-like-linked defective 
fimB gene encoding a co-factor of the regulation of the type 1 fimbriae synthesis in this 
clone (Totsika et al., 2011) and (II) the key role played by type 1 fimbriae in promoting 
biofilm formation in this clone (Sarkar et al., 2016), we analyzed the fimB gene in 127 
isolates randomly selected among the 394 isolates. PCR experiments showed no fimB 




A-CH11-0-ST93 (n = 2), A-CH11-0-ST167 (n = 1), A-CH99-54-ST361 (n= 1), A-CH7-
53-ST540 (n= 1), A-CH7-54-ST540 (n= 1), A-CH4-0-ST1284 (n= 1), B1-CH4-0-ST155 
(n= 1), B2-CH38-92-ST421 (n= 1), and E-CH26-0-ST38 (n= 1). An expected amplicon 
was detected in 89 (70.1%) isolates and an amplicon with a higher size was detected in 
28 (22.0%) isolates (annex 2, Table S11). Sequencing experiments showed the insertion 
of IS3-like in the fimB gene in these 28 (22%) isolates comprising 25 of the 26 selected 
CH40-30 ST131 isolates and the three selected CH24-30 ST73 isolates. Overall, an intact 
fimB gene was significantly more frequent among G1 isolates than among G3 isolates 
(P=0.03) (annex 2, Table S11). 
Through fimB gene sequencing of the 89 isolates with an expected fimB amplicon, 
34 fimB alleles were detected (annex 2, Table S12), of which 11 new variants compared 
with those currently registered in the GenBank database. These 34 alleles encoded 10 
FimB proteins (P1 to P10) (annex 2, Table S12). Phylogenetic tree built with these 10 
proteins (annex 2, Figure S2) revealed two large clusters. One of these clusters included 
the 14 alleles encoding FimB P1 and the other one included the eight alleles encoding 
FimB P2. FimB P2 and the closely related FimB P3 (annex 2, Figure S2) were associated 
with G1 and accounted for 69.2% of G1 isolates vs. 10.6% of G3 isolates (P< 0.0001). 
Inversely, FimB P1 was associated with G3, accounting for 69.7% of G3 isolates vs. 
23.1% of G1 isolates (P = 0.0023) (Figure 14 and in annex 2, Table S13). 
Figure 14. Distribution of the FimB protein (P) variants among G1, G2, and G3 isolates. G1: strong 
producers, G2: moderate producers, and G3: weak producers. FimB P2 and the closely related 
FimB P3 were associated with G1 and accounted for 69.2% of G1 isolates vs. 10.6% of G3 isolates 
(P < 0.0001). Inversely, FimB P1 was associated with G3 accounting for 69.7% of G3 isolates vs. 
23.1% of G1 isolates (P = 0.0023). 
4.3.5. CORRELATION BETWEEN BIOFILM PRODUCTION AND BACTERIAL 
CHARACTERISTICS 
The one-way ANOVA test using the individual BFI of 394 isolates showed that clonal 
lineage explained 72% of the EBF variability and FimB, 28%. Among the VF-encoding 
genes significantly associated with biofilm production, the sfa/focDE, cnf1, hlyA, vat, 
and iroN genes were those explaining from 8 to 16% of the variability of early biofilm 





4.4. STUDY 4. WHOLE GENOME ANALYSIS OF 75 ESBLEC FROM HUMAN ORIGIN 
The WGS-ESBLEC collection includes 30 genomes from sequence type complex 
131 (STC131) and 45 that are not from STC131, grouped in the categories STC131 and 
non-STC131 respectively. Clones were defined by the combination of phylogroup, 
clonotype (fumC and fimH alleles) and sequence type (ST).  
The STC131 group includes 21 genomes from subclade C2 distributed into 3 clones 
(n=19, B2-CH40-30-ST131; n=1, B2-CH40-35-ST131 and n=1, B2-CH40-5-ST2279), 
five genomes from clade A (B2-CH40-41-ST131) and four genomes from cluster C1M27 
subclade C1 (B2-CH40-30-ST131). Besides, the non-STC131 group includes three ST10 
(A-CH11-54-ST10), two ST23 (C-CH4-35-ST23), four ST38 (n=3, E-CH26-fimH 
negative-ST38 and n=1, E-CH26-65-ST38), four ST58 (n=2, B1-CH4-27-ST58 and n=2, 
B1-CH4-32-ST58), five ST88 (n=2, C-CH4-41-ST88; n=2, C-CH4-303-ST88 and n=1, 
C-CH4-39-ST88), four ST95 (n=2, B2-CH38-15-ST95 and n=2, B2-CH38-294-ST95), 
two ST167 (A-CH11-fimH negative-ST167), three ST354 (F-CH88-58-ST354), three 
ST361 (A-CH99-54-ST361), three ST410 (C-CH4-24-ST410), three ST648 (n=2, F-
CH4-171-ST648 and n=1, F-CH4- fimH negative-ST648), three ST744 (A-CH11-54-
ST744), three ST1193 (B2-CH14-64-ST1193) and three ST1615 (C-CH263-32-ST1615) 
genomes.  
The serotype composition of the STC131 group includes 25 O25:H4 genomes, four 
O16:H5 and one ONT:H5. The serotype composition of the non-STC131 group is diverse.  
4.4.2. COREGENOME (CG) AND PHYLOGENETIC ANALYSIS  
The 75 genomes were taken to calculate the CG and infer the phylogeny of the 
STC131 and non-STC131 ESBLEC genomes (Figure 15). The CG length was 
1551735+/-88 pb and comprised 1659 total of CDS (CG-1). The SNP (single nucleotide 
polymorphism) analysis revealed six clusters related to phylogroups. There are over 
29000 SNPs distance between the different phylogroup-clusters with a maximum of 
38854 SNPs. The ST38 genomes belong to phylogroup E (cluster 1) and were clustered 
in the first branch of the phylogenetic tree (starting from the top). Cluster 1 genomes have 
0 to 4331 SNPs distance between them with a mean of 2796 SNPs. The second branch 
was constituted by 11 genomes from phylogroup A (cluster 2) including ST10, ST167, 
ST361 and ST744. Cluster 2 genomes have 2 to 12452 SNPs distance between them with 
a mean of 6357 SNPs.The third branch was constituted by 17 genomes, which includes 
four from phylogroups B1 (cluster 3) and 13 from phylogroup C (cluster 4). Cluster 3 
includes the ST58 genomes and has 91 to 1066 SNPs distance between them with a mean 
of 625 SNPs. Cluster 4 includes ST23, ST88, ST410 and ST1615. They have 1 to 6154 
SNPs distance between them with a mean of 2806 SNPs. The fourth branch clustered 
genomes from phylogroup F (cluster 5) including ST354 and ST648. Cluster 5 has 0 to 
20601 SNPs distance between genomes with a mean of 12547 SNPs. Finally, the last 
branch was constituted by 37 genomes from phylogroup B2 (cluster 6) including ST95, 
ST1193, ST131 and ST2279 (clonal complex ST131). Cluster 6 has 0 to 16965 SNPs 
distance between genomes with a mean of 6037 SNPs. There are more than 12000 SNPs 
distance between ST95 and ST1193 with a mean of 7039 SNPs. The STC131 group of 
genomes was clustered together attending to ST131 clades and has 1 to 3535 SNPs 
distance between them with a mean of 1065 SNPs. Clade A has 1 to 37 SNPs distance 
between genomes. Clade C1-M27 has 8 to 20 SNPs distance between genomes and were 




distance between genomes. The distance between cluster C1-M27 and subclade C2 is 21 
to 83 SNPs while between clades C1-M27 and A, the distance is 3439 to 3463 SNPs.  
Subsequently, we performed a second CG (CG-2) that includes 81 STC131 genomes 
(Figure 16). The 30 STC131 ESBLEC group of genomes from this study plus other 51 
ST131 genomes from human origin (the accession number of the mentioned 51 references 
are in Supplementary Table 2 in Flament-Simon SC et al. 2020 Front Microbiol 2020 
11:387 doi: 10.3389/fmicb.2020.00387). The CG length was 1994444 +/- 283 pb and 
comprised 2147 total of CDS. The SNP analysis revealed six clusters related to the ST131 
clades with a maximum distance of 5794 SNPs between genomes. The first cluster 
includes 49 genomes from clade C (fimH30) and they have 1 to 124 SNPs distance 
between them with a mean of 44 SNPs. The second cluster constitutes a new clade that 
includes one genome from ST2279 (LREC293) with fimH5 allele that belongs to clonal 
complex 131 and has 320 to 390 SNPs distance with a mean of 336 SNPs to clade C. The 
third cluster includes 17 genomes from clade B (fimH22) and has 7 to 888 SNPs distance 
between them with a mean of 440 SNPs. Clade B is wide, including here seven 
subclusters: (I) five genomes from subcluster B0 that have 7 to 47 SNPs distance between 
them with a mean of 31 SNPs (the distance to the remaining genomes from cluster B is 
404 to 888 with a mean of 605 SNPs), (II) two genomes from subcluster B1 that have 48 
SNPs distance (the distance to the remaining genomes from cluster B is 84 to 688 with a 
mean of 356 SNPs), (III) two genomes from subcluster B3 that have 60 SNPs distance 
(the distance to the remaining genomes from cluster B is 396 to 822 with a mean of 574 
SNPs), (IV) two genomes frome subcluster B4 that have 45 SNPs distance ( the distance 
to the remaining genomes from cluster B is 670 to 888 with a mean of 771 SNPs), (V) 
one genome from subcluster B5 ( the distance to the remaining genomes from cluster B 
is 264 to 828 with a mean of 472 SNPs), (VI) three genomes frome subcluster B6 that 
have 21 to 35 SNPs distance between them with a mean of 29 SNPs ( the distance to the 
remaining genomes from cluster B is 164 to 687 with a mean of 421 SNPs) and (VII) two 
genomes frome subcluster B7 that have 23 SNPs distance ( the distance to the remaining 
genomes from cluster B is 164 to 688 with a mean of 391 SNPs). The fourth cluster 
includes one genome from clade I1 (fimH54) and the distance to genomes from cluster B 
is 1153 to 1991 with a mean of 1520 SNPs. The fifth cluster constitutes a second new 
clade that includes one genome (LREC287) with fimH35 allele and has 1038 to 2464 
SNPs distance with a mean of 1329 SNPs to genomes from clade C and clade B. The last 
cluster is constituted by 12 genomes from clade A (fimH41) that includes three 
subclusters: (I) subcluster A1 represented by one genome (SE15) that has 363 to 652 
SNPs distance with a mean of 397 SNPs to the remaining genomes form cluster A, (II) a 
subcluster represented by one genome (LREC288) that has 317 to 652 SNPs distance with 
a mean of 355 SNPs to the remaining genomes form cluster A and (III) 10 genomes from 














4.4.3. VIRULENCE PROFILE 
We in silico investigated the presence of 164 Virulence factor (VF)-encoding genes 
in the chromosome of 75 ESBLEC genomes.  
Comparatively, STC131 group of genomes has a higher average of virulence genes 
(VGs) than the non-STC131 group of genomes (62 vs. 47) (Table 25). However, the non-
STC131 group is constituted by 14 different STs. We observed that the mean of VGs is 
79 in ST95; 68 in ST38 and ST1193; 59 in ST648; 58 in ST354; 50 in ST88; 44 in 
ST1615; 40 in ST23; 38 in ST58; 34 in ST167; 30 in ST410; 26 in ST10 and ST361 and 
18 in ST744. There was a strong correlation between VF-encoding gene profiles and STs 
(Table 26). 
Table 25. Distribution of Virulence factor (VF)-encoding genes within the total of ESBLEC and 
within the STC131 and non-STC131 groups.  
Virulence factor (VF)-encoding genesa 
Number (%) of isolates P-valuea 
Total  
(n = 75) 
STC131  
(n = 30) 
non-
STC131 




Pilus, fimbrias and regulators of adhesion 
afaA fimbrial major subunit AfaA [Afimbrial adhesin AFA-I mannose-resistant adhesin (AI010)] 
16 
(21%) 7 (23%) 9 (20%)   
afaB-I chaperone AfaB [Afimbrial adhesin AFA-I mannose-resistant adhesin (AI010)] 
10 
(13%) 9 (30%) 1 (2%)  0.001 
afaC-I usher AfaC [Afimbrial adhesin AFA-I mannose-resistant adhesin (AI010)] 
9 
(12%) 9 (30%) 0 (0%)  0.001 
afaD  AfaD [Afimbrial adhesin AFA-I mannose-resistant adhesin (AI010)] 
18 
(24%) 7 (23%) 11 (24%)   
afaE-I AFA-I adhesin [Afa/Dr family (VF0212)] 10 (13%) 1 (3%) 9 (20%)   
afaE-II fimbrial adhesin AfaE-II [AFA-II chloramphenicol-resistant adhesin (AI011)]  1 (1%) 0 (0%) 1 (2%)   
afaA-VIII AfaA-VIII [Afimbrial adhesin AfaE-VIII (AI015)] 8 (11%) 0 (0%) 8 (18%)  0.019 
afaB-VIII chaperone protein AfaB-VIII [Afimbrial adhesin AfaE-VIII (AI015)] 
8 
(11%) 0 (0%) 8 (18%)  0.019 
afaC-VIII AfaC-VIII usher protein [Afimbrial adhesin AFA-I mannose-resistant adhesin (AI010)] 7 (9%) 0 (0%) 7 (16%)  0.037 
afaD-VIII AfaD-VIII [Afimbrial adhesin AfaE-VIII (AI015)] 8 (11%) 0 (0%) 8 (18%)  0.019 
afaE-VIII AfaE-VIII adhesin [Afimbrial adhesin AfaE-VIII (AI015)] 
8 
(11%) 0 (0%) 8 (18%)  0.019 
daaD DaaD precursor [F1845 fimbrial adhesin (AI016)] 2 (3%) 2 (7%) 0 (0%)   
daaE F1845 fimbrial adhesin [Afa/Dr family (VF0212)] 2 (3%) 2 (7%) 0 (0%)   
draA cytoplamic protein DraA [Dr adhesins (VF0223)] 4 (5%) 2 (7%) 2 (4%)   
draB chaperone protein DraB [Dr adhesins (VF0223)] 2 (3%) 0 (0%) 2 (4%)   
draC usher protein DraC [Dr adhesins (VF0223)] 3 (4%) 0 (0%) 3 (7%)   
draP DraP [Dr adhesins (VF0223)] 12 (16%) 9 (30%) 3 (7%)  0.010 
afaCD/draP Dr antigen-specific adhesin operons (ID: JN688153) 12 (16%) 9 (30%) 3 (7%) 0.010 
air inverse autotransporter adhesin EaeX/Air 3 (4%) 0 (0%) 3 (7%)   
f17d-C F17 fimbrial uscher [F17 pili (AI037)] 3 (4%) 0 (0%) 3 (7%)   
f17d-D F17 fimbrial chaperone [F17 pili (AI037)] 3 (4%) 0 (0%) 3 (7%)   





Table 25. Cont. 
Virulence factor (VF)-encoding genesa 
Number (%) of isolates P-valuea 
Total  
(n = 75) 
STC131  
(n = 30) 
non-
STC131 




Pilus, fimbrias and regulators of adhesion     
faeE fimbrial chaperone FaeE [K88 pili/F4 fimbriae (AI040)] 1 (1%) 0 (0%) 1 (2%)   
faeJ fimbrial protein FaeJ [K88 pili/F4 fimbriae (AI040)] 1 (1%) 0 (0%) 1 (2%)   
fimA Type-1 fimbrial protein A chain precursor [Type 1 fimbriae (VF0221)] 
11 
(15%) 1 (3%) 10 (22%)  0.042 
fimB Type 1 fimbriae Regulatory protein fimB [Type 1 fimbriae (VF0221)] 
44 
(59%) 7 (23%) 37 (82%)  <0.0001 




(100%) 39 (87%)   




(100%) 39 (87%)   




(100%) 39 (87%)   
fimF FimF protein precursor [Type 1 fimbriae (VF0221)] 69 (92%) 
30 
(100%) 39 (87%)   
fimG FimG protein precursor [Type 1 fimbriae (VF0221)] 69 (92%) 
30 
(100%) 39 (87%)   
fimH FimH protein precursor [Type 1 fimbriae (VF0221)] 69 (92%) 
30 
(100%) 39 (87%)   




(100%) 35 (78%) 0.012  
iha bifunctional enterobactin receptor/adhesin protein 31 (41%) 
22 
(73%) 9 (20%)  <0.0001 
nfaE Diffuse adherence fibrillar adhesin gene 12 (16%) 9 (30%) 3 (7%)  0.010 
papB regulatory protein PapB [P fimbriae (VF0220)] 17 (23%) 
10 
(33%) 7 (16%)   
papC usher protein PapC [P fimbriae (VF0220)] 17 (23%) 
10 
(33%) 7 (16%)   
papD chaperone protein PapD [P fimbriae (VF0220)] 17 (23%) 
10 
(33%) 7 (16%)   
papE P pilus minor subunit PapE [P fimbriae (VF0220)] 2 (3%) 2 (7%) 0 (0%)   
papF P pilus minor subunit PapF  [P fimbriae (VF0220)] 11 (15%) 
10 
(33%) 1 (2%)  0.0002 
papEFc  P pilus minor subunit (ID:X61239) 17 (23%) 
10 
(33%) 7 (16%)   
papG P pilus tip adhesin PapG [P fimbriae (VF0220)] 11 (15%) 
10 
(33%) 1 (2%)  0.0002 
papH P pilus termination subunit PapH [P fimbriae (VF0220)] 17 (23%) 
10 
(33%) 7 (16%)   
papI regulatory protein PapI [P fimbriae (VF0220)] 7 (9%) 0 (0%) 7 (16%)  0.037 
papJ P pilus assembly protein PapJ [P fimbriae (VF0220)] 17 (23%) 
10 
(33%) 7 (16%)   
papK P pilus minor subunit PapK [P fimbriae (VF0220)] 17 (23%) 
10 
(33%) 7 (16%)   




(93%) 5 (11%)  <0.0001 
sfaA S-fimbrial major subunit SfaA [S fimbriae (VF0222)] 4 (5%) 0 (0%) 4 (9%)   
sfaB S fimbrial switch regulatory protein SfaB [S fimbriae (VF0222)] 4 (5%) 0 (0%) 4 (9%)   
sfaE S fimbriae periplasmic chaperone SfaE [S fimbriae (VF0222)] 4 (5%) 0 (0%) 4 (9%)   




Table 25. Cont. 
Virulence factor (VF)-encoding genesa 
Number (%) of isolates P-valuea 
Total  
(n = 75) 
STC131  
(n = 30) 
non-
STC131 




Pilus, fimbrias and regulators of adhesion     
sfaG S fimbriae minor subunit SfaG [S fimbriae (VF0222)] 4 (5%) 0 (0%) 4 (9%)   
sfaH S fimbriae adhesin SfaH [S fimbriae (VF0222)] 4 (5%) 0 (0%) 4 (9%)   
sfaS S fimbriae minor subunit SfaS [S fimbriae (VF0222)] 4 (5%) 0 (0%) 4 (9%)   
sfaX regulatory protein SfaX [S fimbriae (VF0222)] 10 (13%) 0 (0%) 10 (22%)  0.012 
sfaY regulatory protein SfaY [S fimbriae (VF0222)] 3 (4%) 0 (0%) 3 (7%)   
sfaDE Sfa (S fimbriae) (ID: MN022635) 4 (5%) 0 (0%) 4 (9%)   
yfcV Putative chaperone-usher fimbria (ID: CP054236.1) 40 (53%) 
27 
(90%) 13 (29%) <0.0001 
yagV/ecpE E. coli common pilus chaperone EcpE [ECP (VF0404)] 73 (97%) 
29 
(97%) 44 (98%)   
yagW/ecpD polymerized tip adhesin of ECP fibers [ECP (VF0404)] 71 (95%) 
29 
(97%) 42 (93%)   




(100%)   




(100%)   




(100%)   
ykgK/ecpR regulator protein EcpR [ECP (VF0404)] 72 (96%) 
29 
(97%) 43 (96%)   
Transport and secretion systems  
espL1 Type III secretion system effector espL1 [LEE encoded T3SS (SS020)] 
23 
(31%) 0 (0%) 23 (51%)  <0.0001 
espL4 Type III secretion system effector EspL4 [LEE encoded T3SS (SS020)] 
11 
(15%) 0 (0%) 11 (24%)  0.005 
espP autotransporter serine protease [EspP (VF0208)] 1 (1%) 0 (0%) 1 (2%)   
espR1 Type III secretion system effector espR1 [LEE encoded T3SS (SS020)] 
10 
(13%) 0 (0%) 10 (22%)  0.012 
espR3 Type III secretion system effector espR3 [LEE encoded T3SS (SS020)] 1 (1%) 0 (0%) 1 (2%)   
espX1 Type III secretion system effector EspX1 [LEE encoded T3SS (SS020)] 
16 
(21%) 0 (0%) 16 (36%)  <0.0001 
espX4 Type III secretion system effector EspX4 [LEE encoded T3SS (SS020)] 
9 
(12%) 0 (0%) 9 (20%)  0.009 
espX5 Type III secretion system effector EspX5 [LEE encoded T3SS (SS020)] 
27 
(36%) 0 (0%) 27 (60%)  <0.0001 
espY1 Type III secretion system effector EspY1 [LEE encoded T3SS (SS020)] 7 (9%) 0 (0%) 7 (16%)  0.037 
espY2 Type III secretion system effector EspY2 [LEE encoded T3SS (SS020)] 
9 
(12%) 0 (0%) 9 (20%)  0.009 
espY3 Type III secretion system effector EspY3 [LEE encoded T3SS (SS020)] 4 (5%) 0 (0%) 4 (9%)   
espY4 Type III secretion system effector EspY4 [LEE encoded T3SS (SS020)] 4 (5%) 0 (0%) 4 (9%)   
gspC general secretion pathway protein C [T2SS (VF0333)] 55 (73%) 
18 
(60%) 37 (82%)  
gspD general secretion pathway protein D [T2SS (VF0333)] 54 (72%) 
17 
(57%) 37 (82%)  0.020 
gspE general secretion pathway protein E [T2SS (VF0333)] 53 (71%) 
17 





Table 25. Cont. 
Virulence factor (VF)-encoding genesa 
Number (%) of isolates P-valuea 
Total  
(n = 75) 
STC131  
(n = 30) 
non-
STC131 




Transport and secretion systems     
gspF general secretion pathway protein F [T2SS (VF0333)] 55 (73%) 
18 
(60%) 37 (82%)  
gspG general secretion pathway protein G [T2SS (VF0333)] 57 (76%) 
18 
(60%) 39 (87%)  0.012 
gspH general secretion pathway protein H [T2SS (VF0333)] 55 (73%) 
18 
(60%) 37 (82%)  
gspI general secretion pathway protein I [T2SS (VF0333)] 57 (76%) 
18 
(60%) 39 (87%)  0.012 
gspJ general secretion pathway protein J [T2SS (VF0333)] 57 (76%) 
18 
(60%) 39 (87%)  0.012 
gspK general secretion pathway protein K [T2SS (VF0333)] 60 (80%) 
18 
(60%) 42 (93%)  0.0007 
gspL  general secretion pathway protein L [T2SS (VF0333)] 60 (80%) 
18 
(60%) 42 (93%)  0.0007 
gspM general secretion pathway protein M [T2SS (VF0333)] 66 (88%) 
25 
(83%) 41 (91%)   
mchF ABC transporter protein MchF 11 (15%) 0 (0%) 11 (24%)  0.005 
mchC MchC protein 5 (7%) 0 (0%) 5 (11%)   
Toxins 
astA heat-stable enterotoxin 1 [EAST1 (VF0216)] 7 (9%) 0 (0%) 7 (16%)  0.037 
cba colicin B activity protein 1 (1%) 0 (0%) 1 (2%)   
cma colicin M activity protein Cma 1 (1%) 0 (0%) 1 (2%)   
cnf1 cytotoxic necrotizing factor 1 [CNF-1 (VF0240)] 7 (9%) 7 (23%) 0 (0%)  0.001 
hlyA Hemolysin A [Hemolysin (VF0225)] 7 (9%) 7 (23%) 0 (0%)  0.001 
hlyB Hemolysin B [Hemolysin (VF0225)] 6 (8%) 6 (20%) 0 (0%)  0.003 
hlyD Hemolysin D [Hemolysin (VF0225)] 7 (9%) 7 (23%) 0 (0%)  0.001 
sat secreted autotranspoter toxin (ID: AF289092) 28 (37%) 
23 
(77%) 5 (11%)  <0.0001 
senB enterotoxin [ShET2 (VF0258)] 1 (1%) 0 (0%) 1 (2%)   
tsh Temperature-sensitive hemagglutinin Tsh autotransporter-Serine protease 1 (1%) 0 (0%) 1 (2%)   
vat Vacuolating autotransporter toxin. Serine protease (ID: KR094957.1) 5 (7%) 0 (0%) 5 (11%)   
Capsuleb,c  
kpsM KpsM subunit [group II  capsule (VF0239)] 40 (53%) 
25 
(83%) 15 (33%)  <0.0001 
kpsM-K1 K1 type of groupe II capsules  7 (9%) 0 (0%) 7 (16%) 0.037 
kpsM-K2 K2 type of groupe II capsules 17 (23%) 
16 
(53%) 1 (2%) <0.0001 






Table 25. Cont. 
Virulence factor (VF)-encoding genesa 
Number (%) of isolates P-valuea 
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(n = 75) 
STC131  
(n = 30) 
non-
STC131 




Iron uptake     
ireA TonB-dependent siderophore receptor IreA 7 (9%) 0 (0%) 7 (16%)   0.037 
iroB glucosyltransferase IroB [Salmochelin (IA013)] 7 (9%) 0 (0%) 7 (16%)   0.037 
iroC ATP binding cassette transporter [Salmochelin (IA013)] 4 (5%) 0 (0%) 4 (9%)   
iroD esterase [Salmochelin (IA013)] 6 (8%) 0 (0%) 6 (13%)   
iroE esterase [Salmochelin (IA013)] 7 (9%) 0 (0%) 7 (16%)   0.037 
iroN salmochelin receptor IroN [IroN (VF0230)] 3 (4%) 0 (0%) 3 (7%)   
iucA aerobactin synthesis protein IucA [Aerobactin (VF0123)] 32 (43%) 
23 
(77%) 9 (20%)  <0.0001 
iucB aerobactin synthesis protein IucB [Aerobactin (VF0123)] 34 (45%) 
24 
(80%) 10 (22%)  <0.0001 




(77%) 10 (22%)  <0.0001 
iucD L-lysine 6-monooxygenase IucD [Aerobactin (VF0229)] 28 (37%) 
18 
(60%) 10 (22%)  0.001 
iutAc* ferric aerobactin receptor precusor IutA (ID: CP033091) 30 (40%) 
21 
(70%) 9 (20%)  <0.0001 




(100%) 17 (38%)  <0.0001 
chuS heme oxygenase ChuS [Chu (VF0227)] 47 (63%) 
30 
(100%) 17 (38%)  <0.0001 
chuT periplasmic heme-binding protein ChuT [Chu (VF0227)] 43 (57%) 
30 
(100%) 13 (29%)  <0.0001 
chuU heme permease protein ChuU [Chu (VF0227)] 47 (63%) 
30 
(100%) 17 (38%)  <0.0001 
chuV ATP-binding hydrophilic protein ChuV [Chu (VF0227)] 50 (67%) 
30 
(100%) 20 (44%)  <0.0001 




(100%) 17 (38%)  <0.0001 
chuX putative heme-binding protein ChuX [Chu (VF0227)] 37 (49%) 
30 
(100%) 7 (16%)  <0.0001 
chuY ChuY [Chu (VF0227)] 47 (63%) 
30 
(100%) 17 (38%)  <0.0001 
shuA outer membrane heme/hemoglobin receptor ShuA [Shu (VF0256)] 
10 
(13%) 0 (0%) 10 (22%)  0.012 
shuT periplasmic binding protein ShuT [Shu (VF0256)] 4 (5%) 0 (0%) 4 (9%)   
shuV ATP-binding component of hemin transport system [Shu (VF0256)] 7 (9%) 0 (0%) 7 (16%)  0.037 
shuX shu locus protein ShuX [Shu (VF0256)] 10 (13%) 0 (0%) 10 (22%)  0.012 




(97%) 23 (51%)  <0.0001 




(100%) 23 (51%)  <0.0001 




(93%) 20 (44%)  <0.0001 
ybtA transcriptional regulator YbtA [Yersiniabactin (VF0136)] 50 (67%) 
27 
(90%) 23 (51%)  0.001 




(97%) 23 (51%)  <0.0001 
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Number (%) of isolates P-valuea 
Total  
(n = 75) 
STC131  
(n = 30) 
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Iron uptake     
ybtQ inner membrane ABC-transporter YbtQ [Yersiniabactin (VF0136)] 52 (69%) 
29 
(97%) 23 (51%)  <0.0001 
ybtS salicylate synthase Irp9 [Yersiniabactin (VF0136)] 52 (69%) 
29 
(97%) 23 (51%)  <0.0001 
ybtT yersiniabactin biosynthetic protein YbtT [Yersiniabactin (VF0136)] 52 (69%) 
29 
(97%) 23 (51%)  <0.0001 
ybtU yersiniabactin biosynthetic protein YbtU [Yersiniabactin (VF0136)] 52 (69%) 
29 
(97%) 23 (51%)  <0.0001 
ybtX putative signal transducer [Yersiniabactin (VF0136)] 52 (69%) 
29 
(97%) 23 (51%)  <0.0001 
Miscellaneous 
aslA putative arylsulfatase [AslA (VF0238)] 55 (73%) 
30 
(100%) 25 (56%)  <0.0001 
capU putative hexosyltransferase CapU 7 (9%) 1 (3%) 6 (13%)   
gad Glutamate decarboxylase 32 (43%) 
16 
(53%) 16 (36%)   
eilA HilA/EilA family virulence transcriptional regulator 10 (13%) 0 (0%) 10 (22%)  0.012 
ibeA invasion protein IbeA [Ibes (VF0237)] 7 (9%) 0 (0%) 7 (16%)  0.037 
malX Pathogenicity-associated island marker (PAI) (CP054236.1) 43 (57%) 
30 
(100%) 13 (29%) <0.0001 
usp Uropathogenic-specific protein (bacteriocin) (NC_017651) 40 (53%) 
30 
(100%) 10 (22%) <0.0001 
ompT Outer membrane protein (protease) T (CP054227.1) 51 (68%) 
29 
(97%) 22 (49%) <0.0001 
Status clasification 




(87%) 18 (40%) <0.0001 
UPEC If positive for ≥3 of 4 markers, including chuA, fyuA, vat and yfcV. 36 (48%) 
26 
(87%) 10 (22%) <0.0001 
aWe in silico investigated the presence of 164 Virulence factor (VF)-encoding genes in the chromosome of 75 
ESBLEC genomes with a minimum of 90% identity and 80% of coverage. bGroup II capsules of E. coli have 
been determined by the detection of 21 genes, including the ksl genes that have been associated with KpsM-
II-K1 (7 genes from the UTI89 sequence, ID: CP000243), with KpsM-II-K2 (6 genes from Escherichia coli 
CFT073, ID: AE014075) and with KpsM-II-K5 (1 gene from the Nissle 1917 isolate, ID: AJ58688) plus seven 
common genes from group II capsules (KpsC, KpsD, KpsE, KpsF, KpsS, KpsT and KpsU). C85% identity and 
60% of minimum coverage. *Detection of iutA by PCR cover more variants (n=58; 77% positives). dTwo-tailed 






Table 26. Distribution of some Virulence Factor (VF)-encoding genes within the total of ESBLEC, the STC131 group and the non-STC131 group which includes ST10, ST23, ST38, ST58, 
ST88, ST95, ST167, ST354, ST361, ST410, ST648, ST744, ST1193 and ST1615. 
Genes Total  (n = 75) 
STC131 
(n = 30) 
non-
STC131 




(n = 2) 
ST38  
(n = 4) 
ST58  
(n = 4) 
ST88  
(n = 5) 
ST95  
(n = 4) 
ST167 




(n = 3) 
ST410 
 (n = 3) 
ST648  
(n = 3) 
ST744  
(n = 3) 
ST1193 
(n = 3) 
ST1615 














VIII 7 (9%) 0 7 (16%) 0 1 (50%) 0 0 3 (60%) 0 1 (50%) 0 0 0 0 0 0 2 (67%) 0.037 
afaD-




VIII 8 (11%) 0 8 (18%) 0 1 (50%) 0 0 3 (60%) 0 1 (50%) 0 0 0 0 0 0 
3 
(100%) 0.019 
astA 7 (9%) 0 7 (16%) 0 0 1 (25%) 0 2 (40%) 0 0 2 (67%) 0 0 0 0 0 2 (67%) 0.037 
eilA 10 (13%) 0 
10 
(22%) 0 0 
4 
(100%) 0 0 0 0 
3 
(100%) 0 0 
3 
(100%) 0 0 0 0.012 
ibeA 7 (9%) 0 7 (16%) 0 0 0 0 0 4 (100%) 0 
3 
(100%) 0 0 0 0 0 0 0.037 
sat 28 (37%) 
23 
(77%) 5 (11%) 0 0 1 (25%) 0 0 0 0 0 0 0 1 (33%) 0 
3 
(100%) 0 <0.0001 
malX 43 (57%) 
30 








(100%) 0 <0.0001 
afa/draP  12 (16%) 
9 
(30%) 3 (7%) 0 0 3 (75%) 0 0 0 0 0 0 0 0 0 0 0 0.010 
iutA 30 (40%) 
21 
(70%) 9 (20%) 0 0 2 (50%) 0 0 1 (25%) 0 0 0 0 1 (33%) 0 
3 
(100%) 2 (67%) <0.0001 
papC 17 (23%) 
10 
(33%) 7 (16%) 0 0 0 1 (25%) 4 (80%) 0 1 (50%) 0 0 0 1 (33%) 0 0 0   
papH 17 (23%) 
10 
(33%) 7 (16%) 0 0 0 1 (25%) 4 (80%) 0 1 (50%) 0 0 0 1 (33%) 0 0 0   
sfaDE  4 (5%) 0 4 (9%) 0 0 0 0 0 4 (100%) 0 0 0 0 0 0 0 0   
Group II 
capsules                                     
K1 7 (9%) 0 7 (16%) 0 0 0 0 0 4 (100%) 0 0 0 0 0 0 
3 
(100%) 0 0.037 
K2 17 (23%) 
16 
(53%) 1 (2%) 0 0 0 0 0 0 0 1 (33%) 0 0 0 0 0 0 <0.0001 
K5 16 (21%) 
9 
(30%) 7 (16%) 0 0 
4 
(100%) 0 0 0 0 0 0 0 
3 




Table 26. Cont. 
Genesa Total  (n = 75) 
STC131 
(n = 30) 
non-
STC131 




(n = 2) 
ST38  
(n = 4) 
ST58  
(n = 4) 
ST88  
(n = 5) 
ST95  
(n = 4) 
ST167 




(n = 3) 
ST410 
 (n = 3) 
ST648  
(n = 3) 
ST744  
(n = 3) 
ST1193 
(n = 3) 
ST1615 





chuA 47 (63%) 
30 
(100%) 17 (38%) 0 0 
4 








(100%) 0 <0.0001 
fyuA 52 (69%) 
29 
(97%) 23 (51%) 0 1 (50%) 3 (75%) 2 (50%) 4 (80%) 
4 
(100%) 0 2 (67%) 0 
3 
(100%) 1 (33%) 0 
3 
(100%) 0 <0.0001 
vat 5 (7%) 0 5 (11%) 0 0 0 0 0 2 (50%) 0 0 0 0 0 0 3 (100%) 0   
yfcV 40 (53%) 
27 








(100%) 0 <0.0001 
ExPEC  44 (59%) 
26 
(87%) 18 (40%) 0 0 
4 
(100%) 1 (25%) 4 (80%) 
4 
(100%) 0 1 (33%) 0 0 1 (33%) 0 
3 
(100%) 0 <0.0001 
UPEC  36 (48%) 
26 
(87%) 10 (22%) 0 0 0 0 0 
4 
(100%) 0 2 (67%) 0 0 1 (33%) 0 
3 
(100%) 0 <0.0001 
Mean of 
VGs 53 62 47 26 40 68 38 50 79 34 58 26 30 59 18 68 44  





4.4.4. RESISTANCE ASSOCIATED POINT MUTATIONS (PMS) 
Thirteen point mutations (PMs) related to the expression of resistance to antibiotics 
were investigated. The STC131 group showed a higher mean of PMs than the non-
STC131 group (5 vs. 3). In regards to the non-STC131 group, the higher mean of PM was 
observed in ST354 (mean=5). Followed by ST10, ST167, ST361, ST410, ST648, ST744 
and ST1193 (mean=4), ST1615 (mean=3), ST58 and ST88 (mean=1). ST38 and ST95 
did not have any of the investigated PMs (Table 27). 
Table 27. Chromosomal point mutations screened in 75 ESBLEC genomes, STC131 and non-
ST131 groups. 
Point Mutationsa Amino acid change 
Number (%) of isolates 
P-valueb 
STC131 vs. NON-STC131 Total  
(n = 75) 
STC131  
(n = 30) 
non-STC131  
(n = 45) 
gyrA p.S83L S -> L 59 (79%) 29 (97%) 30 (67%) 0.003 
gyrA p.D87N D -> N 53 (71%) 25 (83%) 28 (62%)  
parC p.S80I S -> I 56 (75%) 25 (83%) 31 (69%)  
parC p.E84V E -> V 30 (40%) 25 (83%) 5 (11%) <.0001 
parC p.A56T A -> T 3 (4%) 0 (0%) 3 (7%)  
parC p.G78C G -> C 1 (1%) 0 (0%) 1 (2%)  
parE p.S458A S -> A 12 (16%) 0 (0%) 12 (27%) 0.002 
parE p.I355T I -> T 3 (4%) 0 (0%) 3 (7%)  
parE p.L416F L -> F 6 (8%) 0 (0%) 6 (13%)  
parE p.I529L I -> L 29 (39%) 29 (97%) 0 (0%) <.0001 
16S (rrsH) r.1192C>T  1 (1%) 1 (3%) 0 (0%)  
16S (rrsB) r.1192C>T  2 (3%) 2 (7%) 0 (0%)  
16S (rrsC) r.1519A>T  1 (1%) 0 (0%) 1 (2%)  
Mean 3 5 3  
aScreened with a minimum of 90% identity and 80% of coverage. bTwo-tailed P-Values by Fisher´s exact 
probability test are shown where P < 0.05. Significant differences are indicated in bold. 
We observe that S83L and D87N gyrA PMs and S80I and E84V parC PMs are the 
most common. These PMs can be found in some genomes of the STC131 group and also 
in some genomes from the non-STC131 group such as ST10, ST167, ST354, ST361, 
ST410, ST648, ST744, ST1193 and ST1615. In contrast, the I529L parE PM is 
exclusively related to STC131 (P=<0.0001) while A56T and G78C parC PMs and 
S458A, I355T, L416F parE PMs are only present in the non-STC131 group. The 
remaining PMs were very rare among the genomes analysed (Table 27). 
4.4.5. MOBILE GENETIC ELEMENTS (MGES)  
The chromosome of the 75 ESBLEC genomes harbours 21 presumptive integrative 
conjugative elements (ICEs). We found four genomes which presented a MOBP codifying 
protein (one in clone A-CH11-54- ST10, one in clone B1-CH4-32-ST58, one in clone D-
CH26-65-ST38 and one in clone D-CH26-negative-ST38), four genomes that presented 
a MOBH codifying protein (in clone B2-CH40-41-ST131), eight genomes that presented 
a MOBQ codifying protein (three in clone B2-CH14-64-ST1193, two in clone C-CH4-24-
ST410, two in clone F-CH4-171-ST648 and one in clone B2-CH40-41-ST131), two that 
presented a MOBH and a MOBQ codifying protein (in clone D-CH26-fimH negative-






4.4.5.1. Plasmidome Analysis of 75 ESBLEC genomes 
Reconstruction by PLACNET allowed us to describe a presumptive plasmidome for 
each genome. The 75 ESBLEC genomes harbour a total of 228 plasmids. Allowing to 
describe a presumptive plasmidome which includes 97 large (>19 kb; mean of 164 kb) 
conjugative plasmids (Mpf proteins detected), 90 mobilizable plasmids (MOB proteins 
detected) and 41 presumptively no mobilizable infective plasmids (in which any relaxase 
and/or Mpf protein was detected). We identified 182 plasmids that harbour a relaxase 
protein and 46 in which no relaxase was detected (annex 2). Briefly, 86 of 228 plasmids 
were found within the 30 genomes that constituted the STC131 group. There were 34 
conjugatives, 33 mobilizables and 19 presumptively no mobilizable plasmids. The 
remaining 142 plasmids were found within the 45 genomes that constituted the non-
STC131 group. There were 63 conjugatives, 57 mobilizables and 22 presumptively no 
mobilizable plasmids (unpublished results).  
We explore the whole plasmidome of the 75 ESBLEC genomes and found the 
following relaxase (MOB) families: 74 MOBP type (41%) including 20 MOBP51 (11%), 
19 MOBP12 (10%); 10 MOBP3 (5%), one MOBP11 (1%) and 24 not subtype MOBP (13%); 
68 MOBF type (37%) including 40 MOBF12 (22%), 4 MOBF11 (2%) and 24 not subtype 
MOBF (13%); 26 MOBQ type (14%) including 12 MOBQ12 (7%), 9 MOBQu (5%) and 5 
not subtype MOBQ (3%); 6 MOBV2 (3%); 2 MOBH11 (1%) and 6 other minority MOB 
types (4%) (Table 28). 
In addition, by incompatibility (Inc.) group typing the plasmidome of the 75 ESBLEC 
genomes include: 98 Col-like, 78 IncF (75 multireplicon plasmids with many different 
FAB combinations, where [F2:A1:B-] (n=7), [F36:A4:B1] (n=5), [F18:A-:B1] (n=4) and 
[F29:A-:B10] (n=4) were the most frequent), 17 IncQ (14 IncQ1 and 3 IncQ not 
subtyped), 15 IncI (2 IncI1-ST3-CC3, 1 IncI1-ST26-CC2, 1 IncI1-ST275-CC2, 1 IncI1-
ST16, 1 IncI1-ST95-CC9, 1 IncI1-ST80-CC31, 1 IncI1-ST37-CC3, 5 IncI1-STnd and 2 
IncI2), 13 IncX (7 IncX1, 5 IncX4 and 1 IncX not subtyped), 12 IncB/O/K/Z (3 IncK, 2 
IncBO, and 7 IncB/O/K/Z not subtyped), 7 Inc13, 6 IncY, 5 IncP, 5 IncN (1 IncN-ST1, 1 
IncN-ST9, 3 IncN not subtyped), 2 IncHI2-ST1 and 1 IncR. Of which, 48 Col-like, 30 
IncF, 6 IncX, 4 Inc13, 4 IncN and 2 IncB/O/K/Z were found among the STC131 group 
of genomes and 50 Col-like, 48 IncF, 17 IncQ, 15 IncI, 10 IncB/O/K/Z, 7 IncX, 6 IncY, 
5 IncP, 3 Inc13, 2 IncHI2-ST1, 1 IncN, and 1 IncR were found among the non-STC131 
group of genomes. It should be considered that some plasmids harbour more than one Inc. 
group (this could be due to the existence of cointegrated plasmids or due to an impossible 





Table 28. Distribution of relaxase proteins (MOB) within 75 ESBLEC genomes, the STC131 and 
non-STC131 groups. 
MOB typing Total  (182 MOB/75 genomes) 
STC131  
(63 MOB/30 genomes) 
non-STC131  
(119 MOB/45 genomes) P-value
a 
MOBH11 2 (1%) 0 (0%) 2 (2%)  
MOBF 68 (37%) 28 (44%) 40 (34%)  
MOBF11 4 (2%) 2 (3%) 2 (2%)  
MOBF12 40 (22%) 12 (19%) 28 (24%)  
Not subtyped MOBF 24 (13%) 14 (22%) 10 (8%)  
MOBP 74 (41%) 15 (24%) 59 (50%) 0.001 
MOBP11 1 (1%) 0 (0%) 1 (1%)  
MOBP12 19 (10%) 1 (2%) 18 (15%)  
MOBP3 10 (5%) 6 (10%) 4 (3%)  
MOBP51 20 (11%) 5 (8%) 15 (13%)  
Not subtyped MOBP 24 (13%) 3 (5%) 11 (9%)  
MOBQ 26 (14%) 17 (27%) 9 (8%) 0.001 
MOBQ12 12 (7%) 7 (11%) 5 (4%)  
MOBQu 9 (5%) 5 (8%) 4 (3%)  
Not subtyped MOBQ 5 (3%) 5 (8%) 0 (0%)  
MOBV2 6 (3%) 3 (5%) 3 (3%)  
Other MOB 6 (3%) 0 (0%) 6 (3%)  
aTwo-tailed P-Values by Fisher´s exact probability test are shown where P < 0.05. Significant differences are 
indicated in bold. 
We also investigated the presence of virulence and resistance associated genes carried 
by plasmids. Therefore, we found the toxins codifying genes astA (n=1), cba (n=4), cma 
(n=6), senB (n=9), sat (n=1) and tsh (n=2); the salmochelin receptor iroN(n=8); the 
increased serum survival protein iss (n=11); the bifunctional adhesin protein iha (n=4) 
and the transporter proteins codifying genes mchF (n=7) and espP(n=3). Additionally, we 
found the beta-lactamases codifying genes blaCTX-M-27 (n=4), blaCTX-M-32 (n=1), blaCTX-M-
55 (n=2), blaCTX-M-15 (n=24), blaCTX-M-14 (n=11), blaSHV-12 (n=2), blaCTX-M-1 (n=4), blaOXA-1 
(n=16), blaTEM-1A (n=1), blaTEM-1B (n=29), blaTEM-190 (n=1), blaTEM-78 (n=1), blaTEM-141 
(n=1), blaTEM-206 (n=1), blaTEM-214 (n=1) and blaTEM-30 (n=1); the aminoglycoside-resistant 
codifying genes aadA1 (n=15), aadA2 (n=5), aadA5 (n=24), aadA9 (n=1), aadA13 
(n=1), aadA17 (n=1), ant(2'')-Ia (n=2), aac(3)-IIa (n=1), aac(3)-IId (n=11), aac(3)-IV 
(n=3), aph(3')-Ia (n=14), aph(3'')-Ib (n=29), aph(6)-Id (n=32), aph(4)-Ia (n=3) and 
aac(6')-Ib-cr (n=16); the trimethoprim-resistant codifying genes dfrA1 (n=6), dfrA5 
(n=5), dfrA7(n=1), dfrA12(n=2), dfrA8(n=1), dfrA14 (n=7) and dfrA17(n=27); the 
sulfonamide-resistant codifying genes sul1 (n=32), sul2 (n=34) and sul3 (n=6); the 
macrolide-resistant codifying genes erm(B) (n=1), lnu(F) (n=1), mdf(A) (n=1), mph(A) 
(n=25) and mph(B) (n=3); the phenicol-resistant codifiying genes cmlA1 (n=4), floR 
(n=3), catA1(n=7) and catB3 (n=16); the tetracycline-resistant codifying genes tet(A) 
(n=32), tet(B) (n=11)  and tet(M) (n=2) and the fosfomycin-resistant codifying gene 
fosA3 (n=1).  
The IncF plasmids vary greatly in their composition and carried almost all the 
virulence and resistance genes found in the plasmidome of the 75 ESBLEC genomes 
analysed (annex 2). The ESBL resistant phenotype was a common feature in the 75 
genomes that were selected for WGS and the location of the genes that confer this 




genomes sequenced. We found five blaCTX-M-1, nine blaCTX-M-14, 23 blaCTX-M-15, four 
blaCTX-M-27, one blaCTX-M-32, two blaCTX-M-55 and two blaSHV-12 carried by plasmids and 
three blaCTX-M-1, six blaCTX-M-14, ten blaCTX-M-15, one blaCTX-M-27 and one blaCTX-M-32 
located in the chromosome. The contigs that harboured the ESBL enzyme codifying 
genes were manually revised to confirm the plasmid location.  
4.4.5.2. E. coli ST131 clonal complex plasmidome 
The plasmidome of the 30 genomes from STC131 group showed some common 
features related with the ST131 clades that are summarised in Table 29. The major part 
of the genomes (n=24, 80%) harboured Col-like and IncF plasmids either alone or with 
other plasmids families (annex 2). 
The plasmidome harboured 16 ESBL enzymes encoding bla genes. Clade A 
harboured one blaCTX-M-1 carried by an IncF [F29:A-:B10] plasmid, cluster C1M27 
harboured two blaCTX-M-27 carried by IncF [F1:A2:B20] plasmids and subclade C2 
harboured 13 blaCTX-M-15 of witch 5 carried by IncF [F2:A1:B-] and 8 by other FAB type 
IncF plasmids.  
Table 29. Correlation between clades, ICEs, plasmid types and CTX-M genes in the STC131 group 
of genomes.  
Features ST131 Clade  A (n=5) C1M27 (n=4) C2 (n=21) STC131 
MOB types 
MOBF 6 4 18 28 
MOBP 0 5 9 14 
MOBQ 1 5 11 17 
MOBV2 0 0 3 3 
Incompatiblity groups (Inc.) [FAB formula] 
Col-like 5 16 27 48 
Inc13 0 1 3 4 
IncX 0 2 4 6 
IncK (IncB/O/K/Z) 0 0 2 2 
IncN 0 0 4 4 
IncF [F-:A-:B10] 1 0 0 1 
IncF [F1:A6:B66] 0 1 0 1 
IncF [F1:A2:B20] 0 2b 0 2 
IncF [F2:A-:B-] 0 0 0 0 
IncF [F2:A1:B-] 0 0 7c 7 
IncF [F4:A2:B20] 0 1 0 1 
IncF [F29:A-:B10] 4a 0 0 4 
IncF [F36:A4:B1] 0 0 2 2 
Other IncFd 0 0 11 11 
IncFIB (H89-PhagePlasmid) 1 0 0 1 
ICEs 5 0 0 5 




4.5. STUDY 5. MOLECULAR CHARACTERISTICS OF EXTRAINTESTINAL PATHOGENIC 
E. COLI (EXPEC), UROPATHOGENIC E. COLI (UPEC), AND MULTIDRUG RESISTANT E. 
COLI ISOLATED FROM HEALTHY DOGS IN SPAIN. WHOLE GENOME SEQUENCING OF 
CANINE ST372 ISOLATES AND COMPARISON WITH HUMAN ISOLATES CAUSING 
EXTRAINTESTINAL INFECTIONS 
This study was presented in part at the 29th European Congress of Clinical 
Microbiology and Infectious Diseases, Amsterdam, 13-16 April 2019 and published in 
Microorganisms the 31th of October of 2020 https://doi.org/10.3390/microorganisms8111712. 
4.5.1.  PHYLOGENETIC GROUPS OF THE 197 CANINE ISOLATES 
The most common phylogenetic group displayed by the 197 canine faecal E. coli 
isolates was B2 (42.6%), followed by A (16.2%), B1 (13.2%), F (9.1%), E (7.1%), C 
(5.1%), and D (3.0%) (annex 2, Table S14).  
4.5.2.  VIRULENCE FACTOR (VF)-ENCODING GENES IN THE 197 CANINE ISOLATES 
Of the 28 VF-encoding genes analysed, eight (fimH, yfcV, vat, iroN, fyuA, chuA, 
malX, and usp) were detected in more than 40% of the 197 canine isolates and nine 
(papAH, papC, sfa/focDE, cnf1, hlyA, kpsM II, kpsM II-K5, traT, ibeA) in at least 20%. 
In contrast, six VF-encoding genes (afa/draBC, sat, cdtB, neuC-K1, kpsM II-K2, kpsM 
III) were found in less than 10% of these isolates (Table 30).  
A higher mean of VF-encoding gene score was observed in the 84 canine isolates 
belonging to the dominant B2-phylogenetic group (mean of 12.79) (P < 0.05) compared 
with the isolates belonging to phylogroups A (2.31), B1 (2.96), C (6.60), D (5.67), E 
(4.14), and F (7.94) (Table 30). 
Of the 197 canine isolates, 74 (37.6%) were presumptively classified as ExPEC and 
82 (41.6%) as UPEC (Table 30) resulting in 91 ExPEC and/or UPEC isolates. The 
majority (85.7%; 78 of 91) of ExPEC and/or UPEC isolates belonged to phylogenetic 
group B2. In contrast, only 5.7% (6 of 106) of non-ExPEC and non-UPEC isolates were 
assigned to this phylogenetic group (P < 0.00001). The A, B1, C, and E phylogenetic 
groups were significantly associated with non-ExPEC and non-UPEC isolates (annex 2, 
Table S15). 
4.5.3.  ANTIMICROBIAL RESISTANCE IN THE 197 CANINE ISOLATES 
In total, 28 (14.2%) of the 197 analysed canine faecal E. coli isolates were classified 
as MDR. Multidrug resistance was significantly associated with isolates belonging to B1, 
D and E phylogenetic groups (annex 2, Table S16). Furthermore, only eight (28.6%) of 
MDR isolates showed the ExPEC and/or the UPEC status (annex 2, Table S17). 
In total, 10 of the 28 MDR isolates produced an ESBL enzyme: CTX-M-1 (four 
isolates), CTX-M-14 (four isolates), CTX-M-55 (one isolate) and SHV12 (one isolate). 





Table 30. Virulence factor (VF)-encoding genes detected in the 197 canine E. coli isolates. 
Relationship with phylogenetic groups. 
VF-Encoding 
Gene  
Number of Isolates (%) 
Total 
(n = 197) 
A 
(n = 32) 
B1 
(n = 26) 
B2 
(n = 84) 
C 
(n = 10) 
D 
(n = 6) 
E 
(n = 14) 
F 
(n = 18) 
Clade V 
(n = 1) 
NT 1 
(n = 6) 
Adhesins           
fimH 192 (97.5) 29 24 84 10 6 14 18 1 6 
fimAvMT78 20 (10.2) 12 1 1 0 0 2 3 0 1 
papAH 62 (31.5) 2 3 54 0 1 1 1 0 0 
papC 62 (31.5) 2 3 54 0 1 1 1 0 0 
sfa/focDE 66 (33.5) 0 2 63 0 0 0 1 0 0 
afa/draBC 1 (0.5) 0 0 0 0 1 0 0 0 0 
yfcV 96 (48.7) 4 0 80 0 0 0 11 0 1 
Toxins           
sat 3 (1.5) 0 0 2 0 0 0 1 0 0 
cnf1 54 (27.4) 0 0 53 0 0 0 1 0 0 
hlyA 56 (28.4) 0 2 54 0 0 0 0 0 0 
cdtB 8 (4.1) 0 0 6 0 0 0 2 0 0 
tsh 21 (10.7) 2 2 0 8 0 2 6 0 1 
vat 79 (40.1) 1 0 76 0 0 0 2 0 0 
Iron uptake           
iutA 33 (16.8) 3 3 7 8 1 2 9 0 0 
iroN 93 (47.2) 3 6 66 8 0 2 8 0 0 
fyuA 106 (53.8) 7 2 77 8 5 1 5 0 1 
chuA 122 (61.9) 0 0 84 0 6 14 18 0 0 
Capsule           
kpsM II 64 (32.5) 1 0 41 0 4 4 10 1 3 
neuC-K1 12 (6.1) 0 0 10 0 0 0 2 0 0 
kpsM II-K2 7 (3.6) 0 0 2 0 3 0 1 0 1 
kpsM II-K5 45 (22.8) 1 0 29 0 1 4 7 1 2 
kpsM III 6 (3.0) 1 0 2 0 2 1 0 0 0 
Miscellaneous           
cvaC 21 (10.7) 1 4 2 8 0 0 6 0 0 
iss 31 (15.7) 2 5 6 8 0 2 8 0 0 
traT 59 (29.9) 2 12 17 8 2 7 10 0 1 
ibeA 54 (27.4) 0 0 49 0 0 0 3 0 2 
malX  93 (47.2) 0 5 79 0 0 0 7 0 2 
usp 86 (43.7) 1 3 77 0 1 1 2 0 1 
ExPEC status 74 (37.6) 2 2 61 0 1 1 7 0 0 
UPEC status 82 (41.6) 1 0 77 0 0 0 4 0 0 
Range of VFs 0 to 18 0 to 10 1 to 10 2 to 17 1 to 8 5 to 7 2 to 7 3 to 18 3 1 to 9 
Mean of VFs 7.87 2.31 2.96 12.79 6.60 5.67 4.14 7.94 3.00 3.67 
1Using the revised protocol developed by Clermont et al. (2013) six isolates were not typeable (NT). These 
six isolates belonged to phylogroup A using the first protocol developed by Clermont et al. (2013) that 
classifies isolates into only four phylogenetic groups (A, B1, B2, D). 
4.5.4.  SEQUENCE TYPES, CLONES AND SEROTYPES DISPLAYED BY THE 91 CANINE 
EXPEC AND/OR UPEC ISOLATES AND 28 MDR ISOLATES 
Sequences types (STs), clones (defined by the association of phylogroup, clonotype 
and ST) and O:H serotypes were established only for the 91 canine isolates classified as 
ExPEC and/or UPEC and the 28 canine MDR isolates  
A total of 34 STs were identified in the canine ExPEC and/or UPEC isolates and 22 
in the MDR isolates. Among these STs, 18 were previously undescribed (annex 2, Table 
S18). Each of these 18 new STs were displayed by one isolate. Seven dominant STs 




canine ExPEC and/or UPEC and the 28 canine MDR isolates. There was a strong 
correlation between VF-encoding gene profiles and the dominant STs (Table 31). 
Table 31. Virulence factor (VF)-encoding genes detected in the 65 canine E. coli isolates included 
in the 7 most frequent sequence types identified in ExPEC, UPEC and MDR isolates. 
VF-Encoding Gene 
Number of Isolates 
B2-ST12 
(n = 9) 
D-ST38 
(n = 4) 
B2-ST73 
(n = 4) 
B2-ST127 
(n = 8) 
B2-ST141 
(n = 5) 
B2-ST372 
(n = 29) 
F-ST648 
(n = 6) 
Adhesins        
fimH 9 4 4 8 5 29 6 
fimAvMT78 0 0 0 0 0 0 0 
papAH 9 0 4 7 1 21 0 
papC 9 0 4 7 1 21 0 
sfa/focDE 9 0 3 8 4 26 1 
afa/draBC 0 0 0 0 0 0 0 
yfcV 9 0 4 8 5 29 6 
Toxins        
sat 0 0 0 0 0 0 0 
cnf1 8 0 4 7 0 23 0 
hlyA 9 0 4 7 1 23 0 
cdtB 0 0 2 0 0 0 1 
tsh 0 0 0 0 0 0 5 
vat 8 0 4 8 5 29 2 
Iron uptake        
iutA 1 0 0 1 0 0 6 
iroN 9 0 2 7 4 26 5 
fyuA 8 4 4 8 5 29 3 
chuA 9 4 4 8 5 29 6 
Capsule        
kpsM II 6 4 4 7 5 2 6 
neuC-K1 0 0 0 0 5 0 1 
kpsM II-K2 0 3 0 0 0 0 1 
kpsM II-K5 6 1 4 7 0 2 4 
kpsM III 2 0 0 0 0 0 0 
Miscellaneous        
cvaC 0 0 0 0 0 0 5 
iss 0 0 0 1 0 0 5 
traT 1 1 2 1 0 4 6 
ibeA 0 0 0 0 4 29 1 
malX  9 0 4 8 5 29 2 
usp 9 1 4 7 5 29 1 
ExPEC status 9 0 3 8 4 20 6 
UPEC status 8 0 3 8 5 29 3 
Range of VFs 12 to 16 5 to 7 14 to 16 12 to 17 10 to 14 8 to 16 9 to 18 
Mean of VFs 14.40 5.50 15.30 14.40 12.00 13.10 12.17 
 
A total of 50 clones were identified among the 91 canine isolates classified as ExPEC 
and/or UPEC, with 11 of them including at least two isolates and only four, at least four 
isolates i.e. B2-CH14-180-ST127 (four isolates), B2-CH52-14-ST141 (four isolates), B2-
CH103-9-ST372 (25 isolates) and F-CH4-58-ST648 (five isolates) (Table 32). In recent 
studies conducted by our research group (Flament-Simon et al., 2019, 2020b, 2020a), we 
had identified, as indicated in Table 32, 15 of the 50 canine ExPEC/UPEC clones 
comprising 49 isolates among the 261 human ExPEC and/or UPEC isolates included in a 
collection of 394 E. coli isolates causing extraintestinal infections. However, only 31 of 
the 49 human ExPEC and/or UPEC isolates presented the same clone-related O:H 
serotypes as the canine isolates (Table 32). Among these 31 human isolates, 28 belonged 
to B2 phylogroup clones and three to F phylogroup clones identified among canine 
isolates. These B2 clones were distributed into five ST lineages including four lineages 




currently established as the dominant lineage in dogs, namely lineage ST372. In dogs, we 
found three clones in the lineage ST73 with the same serotype (O6:H1). The eight human 
isolates sharing this lineage with dogs were distributed into the same three clones and 
displayed serotype O6:H1. In dogs, we found two clones in the lineage ST127 displaying 
two serotypes with one (O6:HNM) of them present in the two clones. The four human 
isolates sharing this lineage with dogs were distributed into the same two clones but 
displayed the common serotype (O6:HNM). In dogs, we found two clones in the lineage 
ST141 with the same serotype (O2:H6). The 11 human isolates that shared this lineage 
with dogs were distributed into the same two clones and displayed the same serotype as 
human isolates. In dogs, we found one clone in lineage ST1193 with one serotype 
(O75:HNM). Three human isolates shared this clone and serotype with dogs. Concerning 
the lineage ST372, we found five clones in dogs with one of them including isolates 
displaying six serotypes. The two human isolates sharing the lineage ST372 with dogs 
belonged to this multiple-serotype clone and both displayed one of the six serotypes 
(O83:H31). Concerning the three F group human isolates, they belonged to one of the 
three F group clones (F-CH32-41-ST59) identified in dogs and showed the same serotype 
(O1:H7).  
Among the 28 canine MDR isolates, we observed 24 different clones, of which nine 
had also been identified among the above cited 394 isolates causing infections in humans 
(Table 33) (Flament-Simon et al., 2019, 2020b, 2020a) 
4.5.5.  WHOLE GENOME SEQUENCING (WGS) AND MOLECULAR CHARACTERISATION 
OF ST372 ISOLATES 
For WGS, we selected 23 of the above studied ST372 isolates. They comprised 21 of 
the 29 Spanish canine faecal ST372 strains that were isolated in 2013 (n=9) and 2017 
(n=12) and two  previously published human ST372 strains isolated in 2016 (Flament-
Simon et al., 2019): strains LREC_341 isolated in Spain from an abscess and LREC_342 
isolated in France from a bone infection. Both human strains showed serotype O18:H31 
and clonotype CH103-9 whereas the 21 canine strains showed six different serotypes 
[O4:H31 (seven isolates), O83:H31 (four isolates), O25:H31 (four isolates), O15:H31 
(three isolates), O21:H31 (two isolates) and O117:H28 (one isolate)] and four clonotypes 
[CH103-9 (18 isolates), CH103-10, CH103-17, and CH103-240].  
The main objectives were to get more insights into the E. coli ST372 lineage that 
appears as one of the most prevalent E coli lineages among the canine faeces E. coli 
populations and to elucidate if there is any relation between canine and human ST372 
strains.  
To infer the phylogeny, we performed an SNP-tree with 197 genomes of ST372 
strains [23 from this study (labelled LREC strains) and 174 obtained from public 
databases] corresponding to 151 genomes from canine strains and 46 genomes from 
human strains (CG-4). A total of 70% of these genomes corresponded to strains collected 
between 2017 and 2019 while the remaining 30% corresponded to strains isolated 
between 1995 and 2016. Regarding geographical distribution, 46 genomes (23.4%) were 
from strains collected in Europe and 143 (72.6%) from strains collected in North America.  
The SNP analysis of the E. coli ST372 lineage revealed a wide and heterogeneous 
population allowing us to describe six clusters. Figure 17 only includes 97 representative 
genomes (including the 23 LREC genomes sequenced in this study and the 46 genomes 






Table 32. Clones and clonal-related serotypes of 91 canine ExPEC and/or UPEC isolates. 
Prevalence of the canine clones and clonal-related serotypes among ExPEC and/or UPEC isolates 
causing extraintestinal infections in humans (Flament-Simon et al., 2019, 2020b, 2020a).  
Clone of Canine ExPEC  
and/or UPEC Isolates  
Clone-Related Serotype 
of Canine ExPEC and/or 
UPEC Isolates 
(Number of Isolates) 
Number of Human 
ExPEC and/or UPEC 
Isolates with Same 
Clone of Canine 
Isolates (49 of 261) 
Number of Human ExPEC 
and/or UPEC Isolates with 
Same Clone and Serotype of 
Canine Isolates (31 of 261) 
A-CH11-NEG-ST93 O5:H4 (1) 3 0 
A-CH11-27-ST new 1 O4:H27 (1) 0 0 
B1-CH4-27-ST58 O8:H25 (1), O9:H25 (1) 0 0 
B2-CH13-5-ST12 O4:HNM (1), O18:H5 (1) 0 0 
B2-CH13-7-ST12 O4:H1 (1), O4:HNM (1) 0 0 
B2-CH13-130-ST12 O18:H5 (1) 0 0 
B2-CH13-223-ST12 O18:H5 (2) 1 0 
B2-CH13-430-ST12 O4:H5 (1) 0 0 
B2-CH13-431-ST12 O4:H5 (1) 0 0 
B2-CH24-9-ST73 O120:H31 (1) 0 0 
B2-CH24-27-ST73 O6:H1 (1) 1 1 
B2-CH24-30-ST73 O6:H1 (1) 4 3 
B2-CH24-103-ST73 O6:H1 (1) 6 4 
B2-CH24-1-ST80 O75:H7 (1) 0 0 
B2-CH38-30-ST95 O1:H7 (1) 1 0 
B2-CH14-2-ST127 O6:HNM (2) 4 3 
B2-CH14-180-ST127 O6:HNM (3), O6:H11 (1) 1 1 
B2-CH14-fimHTRnew 1-ST127 O6:H31 (1), O6:HNM (1) 0 0 
B2-CH40-NEG-ST131 O25:H4 (1) 0 0 
B2-CH52-5-ST141 O2:H6 (1) 13 9 
B2-CH52-14-ST141 O2:H6 (4) 2 2 
B2-CH103-9-ST372 
O4:H31 (9), O15:H31 (1), 
O21:H31 (3), O25:H31 
(4), O83:H31 (7), 
O117:H28 (1) 
2 2 
B2-CH103-10-ST372 O15:H31 (1) 0 0 
B2-CH103-17-ST372 O15:H31 (1) 0 0 
B2-CH103-240-ST372 O83:H31 (1) 0 0 
B2-CH103-706-ST372 O83:H31 (1) 0 0 
B2-CH96-433-ST646 O22:HNM (1) 0 0 
B2-CH43-fimHTRnew 2-ST929 O138:H14 (1) 0 0 
B2-CH13-175-ST961 O4:HNM (1) 0 0 
B2-CH52-428-ST998 O2:H6 (1) 0 0 
B2-CH14-64-ST1193 O75:HNM (2) 4 3 
B2-CH363-75-ST2622 O83:H6 (1) 0 0 
B2-CH195-2-ST5644 O175:H5 (1) 0 0 
B2-CH13-fimHTRnew 3-ST new 2 O18:HNM (1) 0 0 
B2-CH13-429-ST new 3 O4:H5 (1) 0 0 
B2-CH103-9-ST new 4 O4:H31 (1) 0 0 
B2-CH103-12-ST new 5 O6:HNM (1) 0 0 
B2-CH11-34-ST new 6  O5:H11 (1) 0 0 
B2-CH40-20-ST new 7 O1:H4 (1) 0 0 
B2-CH363-75-ST new 8 O83:H4 (1) 0 0 
B2-CH24-2-ST new 9 ONT:H1 (1) 0 0 
B2-CH24-1473-ST new 10 O120:H5 (1) 0 0 
B2-CH23-31-ST new 11 O103:H4 (1) 0 0 
B2-CH40-20-ST new 12 O1:H4 (1) 0 0 
B2-CH40-21-ST new 13 O13:H4 (1) 0 0 
D-CH35-27-ST new 14 O77:H18 (1) 0 0 
E-CH132-65-ST501 ONT:H1 (1) 0 0 
F-CH32-41-ST59 O1:H7 (1) 4 3 
F-CH4-27-ST648 O4:H6 (1) 1 0 
F-CH4-58-ST648 O153:H42 (5) 2 0 
Bold highlights those canine clones and clone-related serotypes also detected among ExPEC and/or UPEC 




Table 33. Clones and clonal-related serotypes of 28 canine multidrug resistant (MDR) E. coli isolates. Prevalence of the canine clones and clone-related serotypes among 
E. coli isolates causing extraintestinal infections in humans (Flament-Simon et al., 2019, 2020b, 2020a).  
Clone of Canine MDR 
Isolates  
Clone-Related Serotype of 
Canine MDR Isolates 
(Number of Isolates) 
Type of ESBL and pAmpC Enzymes 
Produced by Canine MDR Isolates 
Number of Human E. coli Isolates with Same 
Clone of Canine MDR Isolates (Number and 
Type ESBL Produced by Human Isolates)  
(35 of 394) 
Number of Human E. 
coli Isolates with 
Same Clone and 
Serotype of Canine 
MDR Isolates  
(1 of 394) 
A-CH11-54-ST10 O128:HNM (1) SHV12 10 (3 SHV12) 0 
A-CH11-NEG-ST93 O5:H4 (1) none 4 (1 CTX-M-14) 0 
A-CH11-54-ST8953 O101:HNM (1) CMY-2 0 0 
A-CH11-27-ST new 1 O4:H27 (1) none 0 0 
B1-CH4-27-ST58 O8:H25 (1), O9:H25 (1) none 4 (1 CTX-M-14 and 1 CTX-M-32) 1 
B1-CH4-121-ST155 O5:H11 (1) none 0 0 
B1-CH4-366-ST155 O9:H10 (1) CMY-2 1 (1 CTX-M-1) 0 
B1-CH4-425-ST new 15 O123:H11 (1) CTX-M-1 0 0 
B1-CH4-31-ST new 16 O8:H7 (1) CTX-M-1 0 0 
B1-CH29-38-ST new 17 O8:H49 (1) CTX-M-1 0 0 
B1-CH30-38-ST new 18 O12:H8 (1) CMY-2 0 0 
B2-CH13-223-ST12 O18:H5 (1) CMY-2 1 0 
B2-CH13-429-ST new 3 O4:H5 (1) CMY-2 0 0 
C-CH4-39-ST88 O45:HNM (1) CTX-M-1 11 (1 CTX-M-14) 0 
D-CH26-5-ST38 O86:H18 (3) CTX-M-14 0 0 
D-CH26-65-ST38 O1:H34 (1) CMY-2 2 (1 CTX-M-15) 0 
D-CH35-27-ST new 14 O77:H18 (1) none 0 0 
E-CH31-54-ST57 O27:H40 (1) CMY-2 1 0 
E-CH11-167-ST695 O99:H38 (1) none 0 0 
E-CH4-31-ST1011 O166:H45 (1) CTX-M-55 0 0 
E-CH23-221-ST1140 O44:H39 (1) none 0 0 
E-CH485-426-ST3774 O9:H31 (1) CMY-2 0 0 
F-CH88-145-ST457 O11:H25 (2) CMY-2 0 0 
F-CH4-27-ST648 O4:H6 (1) CTX-M-14 1 (1 CTX-M-15) 0 





Figure 17. SNP-tree of 79 representative ST372 E. coli genomes from 46 human strains and 33 canine 
strains.Tree visualization by EnteroBase (Zhou et al., 2020). The 33 genomes from canine strains 
are representatives of the different clusters identified in the SNP matrix of a previous SNP-tree 
performed with the 197 genomes analysed in this study. The identified serotypes are listed beside 





The criterion established to define a cluster was that it should include genomes with 
less than 200 SNPs distance between them. An exception to this rule was the inclusion of 
the genome ECOL-19-VL-SD-MI-0018, with a maximum of 391 SNP distance, in cluster 
4. Five genomes did not reach this criterion having more than 400 SNP distance between 
them and could form five other clusters. However, we have included those genomes in 
only one category (undefined) to simplify the following analysis.  
According to the phylogenetic tree built from the genome of the 197 strains, cluster 
1 comprised 147 (74.6%) of the 197 analysed genomes. This cluster was mostly 
composed of genomes of canine strains (138 genomes; 93.9%). Genomes of canine strains 
were also included in clusters 4 (9 genomes) and 6 (2 genomes) while only human strain 
genomes were included in clusters 2 (28 genomes), 3 (3 genomes) and 5 (3 genomes) 
(Table 34). Thus, cluster 1 comprised significantly more canine strain genomes (P < 
0.00001) while clusters 2 (P < 0.00001), 3 (P = 0.01209) and 5 (P = 0.01209) comprised 
significantly more human strain genomes. Twenty of the 21 genomes of the Spanish 
canine strains belonged to cluster 1 whereas, the genome of the remaining Spanish canine 
strain (LREC_356) belonged to cluster 4. The genomes of the Spanish and French human 
strains (LREC_341 and LREC_342) belonged to cluster 2.  
Table 34. Distribution into the phylogenetic clusters of the 197 canine and human ST372 strains. 
Cluster Number of Strains (%) p-Value 1 Canine (n = 151) Human (n = 46) 
1 138 (91.4) 9 (19.6) <0.00001 
2 0 28 (60.9) <0.00001 
3 0 3 (6.5) 0.01209 
4 9 (6.0) 0  
5 0 3 (6.5) 0.01209 
6 2 (1.3) 1 (2.2)  
Undefined 2 (1.3) 2 (4.3)  
1Two-tailed P-Values by Fisher´s exact probability test are shown where P < 0.05. 
Both clusters 1 and 2 were the most frequent clusters observed among the studied E. 
coli ST372 strains (canine and human) isolated in Europe and North America. However, 
cluster 1 was significantly associated with North America strains (P = 0.02476), while 
cluster 2 was especially associated with Europe strains (P = 0.01233) (Table 35). 
Table 35. Cluster distribution of the 197 studied ST372 strains according to countries. 
Cluster (Number 
of Strains) 




Countries (Number of Strains) Europe 
(n = 46) 
North 
America 
(n = 143) 
1 (n = 147) 30 (65.2) 117 (81.8) 0.02476 
USA (109), Spain (20), Canada (6), UK (4), 
Sweden (3), France (2), Germany (1), North 
America (2) 
2 (n = 28) 11 (23.9) 13 (9.1) 0.01233 USA (13), UK (8), Spain (1), France (1), The Netherlands (1), Australia (2), unknown (2) 
3 (n = 3) 0 0  Japan (1), Kenya (1), unknown (1) 
4 (n = 8) 1 (2.2) 7 (4.9)  USA (7), Spain (1), unknown (1) 
5 (n = 3) 3 (6.5) 0 0.01371 Denmark (2), France (1) 
6 (n = 3) 1 (2.2) 2 (1.4)  USA (2), UK (1) 
Undefined (n = 5) 0 4 (2.8)  USA (4), Australia (1) 





To compare the virulence profile of the 197 canine and human ST372 strains, we in 
silico investigated the presence of 32 VF-encoding genes in the 197 strains and defined 
their ExPEC and UPEC status. We also investigated the distribution of those VF-
encoding genes according to the classification of the strains into the six defined clusters. 
Table 36 summarized the results obtained from the mentioned analysis. Microbiological, 
geographical and genomic data of each of the 197 studied strains are available in 
Supplementary Table S2 in Flament-Simon SC et al. 2020 Microorganims 8 (11): E1712 
doi: 10.3390/microorganisms8111712. 
The canine ST372 strains showed a higher VF-encoding gene score (mean 16.79) 
compared with the human ST372 strains (mean 13.76). However, three human stains 
belonging to cluster 5 were those with the highest number of VF-encoding genes (mean 
21.67). Eight VF-encoding genes (papAH, papC, papEF, focCD, focG, cnf1, hlyA, and 
iroN) were significantly associated with canine ST372 isolates, whereas that five (hlyF, 
iutA, kpsM II, kpsM II-K5, and iss1) were significantly associated with human ST372 
isolates.  Interestingly, the ExPEC status was found more frequently among canine ST372 
strains (74.8%) than human strains (21.7%) (P < 0.00001) (Table 36). 
The more prevalent serotype was O83:H31 which represents 36.0 % of the 197 ST372 
strains followed by O4:H31 (17.8%), O15:H31 (15.2%), O18:H31 (10.2%), O45:H31 
(3.0%), O117:H28 (3.0%), O21:H14 (2.5%), O21:H31 (2.5%), O75:H31 (2.5%), O-
unknown:H31 (2.5%), O25:H31 (2.0%), O2:H6 (0.5%) and O-unknown:H28 (0.5%). The 
serotypes O4:H31 (P = 0.02631) and O15:H31 (P = 0.00062) were significantly 
associated with canine ST372 strains, whereas the serotypes O18:H31 (P < 0.00001) and 
O45:H31 (P = 0.00012) were significantly more frequent among human ST372 strains. 
The 65 canine strains of serotypes O4:H31 and O15:H31 belonged to cluster 1 and the 26 
human strains of serotypes O18:H31 and O45:H31 belonged to cluster 2 (Table 37). In 
contrast, the dominant serotype O83:H31 was frequently identified among canine 
(38.4%) and human (28.3%) strains, and, although the majority of the strains with this 
serotype belonged to cluster 1, O83:H31 strains were also found in clusters 3, 4 and 5.  
Table 37. Distribution of serotypes among the 197 ST372 strains according to origins (canine and 
human) and cluster types. 
Serotype 
In Silico 





Number of Isolates Belonging to Cluster Canine 
(n = 151) 
Human 
(n = 46) 
    1 2 3 4 5 6 Undefined 
O2:H6 1 (0.7) 0        1 
O4:H31 32 (21.2) 3 (6.5) 0.02631 35       
O6:H31 2 (1.3) 1 (2.2)       3  
O15:H31 30 (19.9) 0 0.00062 30       
O18:H31 0 20 (43.5) <0.00001  20      
O21:H14 5 (3.3) 0  5       
O21:H31 4 (2.6) 1 (2.2)  5       
O25:H31 4 (2.6) 0  4       
O45:H31 0 6 (13.0) 0.00012  6      
O75:H31 5 (3.3) 0  5       
O83:H31 58 (38.4) 13 (28.3)  53  3 9 3  3 
O117:H28 6 (4.0) 0  6       
O-unknown:H31 3 (2.0) 2 (4.3)  3 2      
O-unknown:H28 1 (0.7) 0  1       





Table 36. Distribution of the VF-encoding genes detected among the 197 ST372 E. coli genomes 
according to strain origins (canine/human) and cluster types.  
VF-Encoding  
Gene 






(n = 46) 
Cluster 1 
(n = 147) 
Cluster 2 
(n = 28) 
Cluster 3 
(n = 3) 
Cluster 4 
(n = 9) 
Cluster 5 
(n = 3) 
Cluster 6 
(n = 3) 
Undefined 
(n = 4) 
Adhesins           
fimH 151 (100) 46 (100) 147  28  3  9  3  3  4   
papAH 88 (58) 5 (11) 89  0  0  0  0  3  1  <0.00001 
papC 113 (75) 9 (20) 113  0 0  0  3  3 3  <0.00001 
papEF 112 (74) 9 (20) 113 0 0 0  3  2  3  <0.00001 
sfaDE 3 (2) 0 (0) 1  0  0  0  0  2  0   
sfaS 6 (4) 0 (0) 6  0  0  0 0  0  0  
focCD 136 (90) 12 (26) 144 0 0 0 1 1 2 <0.00001 
focG 138 (91) 12 (26) 144 0 0 0 1 3 2 <0.00001 
afaBCD/draP 0 0 (0) 0 0 0 0 0 0 0  
yfcV 150 (99) 46 (100) 146 28 3 9 3 3 4  
Toxins           
sat 0 0 (0) 0 0 0 0 0 0 0  
cnf1 117 (77) 11 (24) 120  0  0 0 3 3 2 <0.00001 
hlyA 117 (77) 11 (24) 119 0 0 0 3  3 3 <0.00001 
hlyF 1 (1) 3 (7) 1 0 0 0 3 0 0 0.04034 
cdtB 0 0 (0) 0 0 0 0 0 0 0   
vat 148 (98) 45 (98) 144 27 3 9 3 3 4  
Iron uptake               
iutA 1 (1) 3 (7) 1 0 0 0 3 0 0 0.04034 
iroN 139 (92) 14 (30) 144 0 0 0  3 3 3 <0.00001 
fyuA 151 (100) 46 (100) 147  28 3 9 3 3 4  
chuA 151 (100) 46 (100) 147 28 3 9 3 3 4  
ireA 5 (3) 1 (2) 5 0 0 0 0 0 1  
Capsule               
kpsM II 16 (11) 36 (78) 5 28 3 9 3 0 4 <0.00001 
kpsM II-K1 0 (0) 0 (0) 0 0 0 0 0 0 0  
kpsM II-K2 0 (0) 0 (0) 0 0 0 0 0 0 0  
kpsM II-K5 16 (11) 36 (78) 5  28 3 9 3 0 4 <0.00001 
Miscellaneou           
iss1 1 (1) 3 (7) 1 0 0 0 3 0 0 0.04034 
iss2 140 (93) 45 (98) 136 27 3 9 3 3 4  
traT 34 (23) 10 (22) 25 5 0 9 3 1 1  
ibeA 149 (99) 46 (100) 146 28 3 9 3 3 3  
malX-PAI 150 (99) 46 (100) 146 28 3 9 3 3 4  
usp 151 (100) 46 (100) 147 28 3 9 3 3 4  
ompT 151 (100) 46 (100) 147 28 3 9 3 3 4  
ExPEC status 113 (75) 10 (22) 113  0 1 0  3 3  3 <0.00001 
UPEC status 151 (100) 46 (100) 147  28  3  9 3  3 4   
Mean of VFs 16.79 13.76 16.93 12.11 12.00 13.00 21.67 18.00 17.00  





The three most prevalent serotypes in Europe were O4:H31 (23.9%), O83:H31 
(21.7%) and O18:H31 (19.6%), while in North America, they were O83:H31 (39.9%), 
O15:H31 (18.2%) and O4:H31 (16.8%). The serotypes O18:H31 (P = 0.02203) and 
O25:H31 (P = 0.00317) were more frequently observed in Europe, whereas the serotype 
O83:H31 (P = 0.03291) was more prevalent in North America (Table 38). 
Table 38. Serotypes of the 197 ST372 strains according to countries. 
Serotype  
In Silico 






Countries (Number of Strains) Europe 
(n = 46) 
North 
America 
(n = 143) 
O2:H6 0 1 (0.7)  USA (1) 
O4:H31 11 (23.9) 24 (16.8)  USA (23), Spain (7), UK (2), France (1), Sweden (1), Canada (1) 
O6:H31 1 (2.2) 2 (1.4)  USA (2), UK (1) 
O15:H31 4 (8.7) 26 (18.2)  USA (25), Spain (3), Canada (1), France (1) 
O18:H31 9 (19.6) 10 (7.0) 0.02203 USA (10), UK (7), Spain (1), France (1) 
O21:H14 1 (2.2) 4 (2.8)  USA (4), Sweden (1) 
O21:H31 3 (6.5) 2 (1.4)  Spain (2), UK (1), USA (1), Canada (1) 
O25:H31 4 (8.7) 0 0.00317 Spain (4) 
O45:H31 1 (2.2) 2 (1.4)  USA (2), Australia (2), Netherlands (1) 
O75:H31 0 5 (3.5)  USA (5) 
O83:H31 10 (21.7) 57 (39.9) 0.03291 USA (52), Spain (4), Canada (2), Denmark (2), UK (1), France (1), Sweden (1), Germany (1) 
O117:H28 1 (2.2) 5 (3.5)  USA (5), Spain (1) 
O-unknown:H31 1 (2.2) 4 (2.8)  USA (3), Canada (1), UK (1) 
O-unknown:H28 0 1 (0.7)  USA (1) 
1Two-tailed P-Values by Fisher´s exact probability test are shown where P < 0.05. 
The 23 LRCE genomes sequenced in this study were investigated in greater depth. 
These genomes were reconstructed to analyse the chromosome and plasmidome 
separately. The size of the chromosomes had an average of 5,043,308 pb and were 
encompassed in 55 to 178 contigs. We found an integrative conjugative element (ICE) 
with relaxase type MOBQ in all the genomes except for LREC_347 genome. These ICEs 
belong to the ICEKp1 family, a yersiniabactin synthesis-associated ICE type (similar to 
ICEEcoUMN026-1). The contigs that harboured the ICE region were revised allowing us 
to detect the presence of a pathogenic island (PAI) and some VF-encoding genes. The 
ICE contig retrieved from LREC_356 genome was the longest (2,540,863 pb) and showed 
a high percentage of homology with the contigs of the other genomes harbouring the ICE 
region (annex 2, Figure S3). Interestingly, the contig from LREC_356 harboured the 
ompT, iss, vat, fyvA, and yfcV virulence- encoding genes, the last three mentioned genes 
being those used (in addition to chuA) to define UPEC status. We also identified the 
secretion system effector homolog type T6SS and the PAI_AET37190. In second place, 
in terms of ICE contig length, was LREC_357 (1,677,509 pb) genome that harboured the 
iroN, iss, fyvA and yfcV virulence-encoding genes. The ICE contigs had not the same 
length [varying from 2,540,863 pb to 307,789 pb (short read sequencing limitations)] and 
all the genes mentioned as found in the ICE contig from LREC_356 were not retrieved 
in the other 20 genomes harbouring ICE contigs: three harboured the fyvA and yfcV genes 
(LREC_359, LREC_361 and LREC_344) and the remaining 17 genomes harboured the 
fyvA gene. We concluded that the presence of this type of ICE was a common feature in 
the ST372 genomes from the 22 of 23 studied Spanish strains and may be involved in the 
acquisition of their UPEC status. 
We also described 11 plasmids (four conjugative plasmids, six mobilizable plasmids 




to the following relaxase families (MOB) and incompatibility groups (Inc.): 
MOBP3/IncX1 (n=3); MOBP1/nd (n=2); MOBF12/IncFII-pCD1 (n=2); MOBF12/IncFII-
IncFIB (n=1); MOBH11/IncHI2 (n=1); MOBQu/ColRNAI (n=1); nd/p0111 (n=1). To 
predict plasmid transferability, we investigated the presence of mating pair formation 
(Mpf) system proteins. These proteins were present in all the previously described 
MOBF12 and MOBH11 conjugative plasmids. Furthermore, in silico analysis showed that 
these plasmids did not carry resistance or virulence encoding genes except for the cba 
and cma genes that were found in plasmid pLREC354_1 and a blaTEM gene found in 
pLREC346_1. Table 39 summarizes the MGE content of the 23 ST372 genomes. 
We in silico investigated the presence of 189 VF-encoding genes, 87 antibiotic-
resistance encoding genes (ARGs) and 18 types of point mutations (Supplementary Table 
S8 in Flament-Simon SC et al. 2020 Microorganims 8 (11): E1712 doi: 
10.3390/microorganisms8111712.). Through this analysis, the 23 ST372 strains were 
shown with an UPEC status and harbouring a wide variety of VF-encoding genes, 
reaching an average number of 80. In contrast, these 23 ST372 strains were shown as 
carrying very few ARGs. However, genes encoding drug efflux were detected but only in 
the two human strain genomes (LREC_341 and LREC_342) that also harboured 
antibiotic-resistance encoding genes: blaTEM-1A, sul1, aadA1, dfrA1 and mdf(A). These 





Table 39. Description of mobile genetic elements (MGE)s found in the 23 ST372 strain genomes sequenced in this study. 
Genome of Strain Serotype of Strain Origin Cluster 
MGEs MOB/Inc Typing; Size (kb) 
ICEs (kb of Contig) Number  of Plasmids Plasmid_1 Plasmid_2 
LREC_341 O18:H31 Human 2 MOBQ (308) 2 MOBP1/nd1; (164) nd/p0111; (92) 
LREC_342 O18:H31 Human 2 MOBQ (90) 2 MOBP1/nd; (720) MOBQu/ColRNAI; (4) 
LREC_343 O4:H31 Canine 1 MOBQ (474) 1 MOBF12/IncFII [F-:A-:B-], pCD1; (66)   
LREC_344 O4:H31 Canine 1 MOBQ (1208) 0     
LREC_345 O4:H31 Canine 1 MOBQ (158) 1 MOBF12/IncFII [F2:A-:B-], pCD1; (75)   
LREC_346 O4:H31 Canine 1 MOBQ (653) 1 MOBP3/IncX1; (47)   
LREC_347 O117:H28 Canine 1  1 MOBP3/IncX1; (38)   
LREC_348 O4:H31 Canine 1 MOBQ (472) 0     
LREC_349 O83:H31 Canine 1 MOBQ (707) 0     
LREC_350 O83:H31 Canine 1 MOBQ (707) 0     
LREC_351 O4:H31 Canine 1 MOBQ (653) 0     
LREC_352 O25:H31 Canine 1 MOBQ (658) 0     
LREC_353 O25:H31 Canine 1 MOBQ (658) 0     
LREC_354 O25:H31 Canine 1 MOBQ (658) 0     
LREC_355 O4:H31 Canine 1 MOBQ (157) 0     
LREC_356 O83:H31 Canine 4 MOBQ (2541) 2 MOBF12/IncFIB, IncFII [F-:A-:B52]; (162) MOBP3/IncX1; (36) 
LREC_357 O83:H31 Canine 1 MOBQ (1678) 0     
LREC_358 O25:H31 Canine 1 MOBQ (660) 0     
LREC_359 O21:H31 Canine 1 MOBQ (1317) 0     
LREC_360 O15:H31 Canine 1 MOBQ (86) 0     
LREC_361 O21:H31 Canine 1 MOBQ (1317) 0     
LREC_362 O15:H31 Canine 1 MOBQ (641) 0     
LREC_363 O15:H31 Canine 1 MOBQ (172) 1 MOBH11/IncHI2; (204)   





4.6 STUDY 6. PRODUCTION ANIMAL: WHOLE GENOME SEQUENCING AND 
CHARACTERISTICS OF MCR-1-HARBORING PLASMIDS OF PORCINE ESCHERICHIA COLI 
ISOLATES BELONGING TO THE HIGH-RISK CLONE O25B:H4-ST131 CLADE B 
This study was presented in part at the 29th European Congress of Clinical 
Microbiology and Infectious Diseases, Amsterdam, 13-16 April 2019 and published in 
Frontiers in Microbiology the 24th of March of 2020 
https://doi.org/10.3389/fmicb.2020.00387. 
 
4.6.1. CHARACTERIZATION OF THE ISOLATES BY CONVENTIONAL METHODS 
4.6.1.1. Pasteur Sequence Types (PST) and fimH alleles 
All of the 11 ST131 isolates belonged to serotype O25b:H4 and the phylogenetic 
group B2. The seven isolates from piglets with diarrhoea showed the PST9 whereas the 
four isolates from pork meat showed the PST43 (Table 40).  
Also all of the 11 ST131 isolates belonged to clade B and showed the fimH22 allele 
or mutational derivatives of the fimH22 allele (fimH161, fimH298, fimH326, fimH332, 
fimH336, fimH338, fimH374).  Resulting in clonotypes CH40-22 (3 isolates), CH40-161 
(1), CH40-298 (2), CH40-326 (1), CH40-332 (1), CH40-336 (1), CH40-338 (1) and 
CH40-374 (1).  
4.6.1.2  Virotypes 
The 11 ST131 isolates harboured between 17 and 20 virulence gene markers screened 
by PCR. All isolates harboured the following genes: iroN, iss, hlyF, ompT, papEF, papG 
III, kpsM-II-K5, iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, malX, ibeA, and usp. However, 
some genes were variables: papC and papAH (10 isolates), cnf1 (six isolates), hlyA (five 
isolates) and cdtB (four isolates). All isolates belonged to virotype D (Table 40). Six of 
seven isolates recovered from piglets with diarrhoea with PST9 showed the virotype D5 
(ibeA, papG III, cnf1, hlyA, kpsM-II-K5), while the four PST43 isolates from meat 
showed the virotype D2 (ibeA, papG III, cdtB, kpsM-II-K5). All the 11 porcine ST131 
isolates exhibited a virulence profile that satisfied the APEC, UPEC and ExPEC status 
and due to their origin were classified as APEC, UPEC and ExPEC like isolates (Table 
40 and Supplementary Table S1 in Flament-Simon SC et al. 2020 Front Microbiol 2020 
11:387 doi: 10.3389/fmicb.2020.00387). 
4.6.1.3  Resistance Phenotype 
The resistance profile of the 11 ST131 porcine isolates was determined, showing that 
all but one exhibited a MDR phenotype. Amoxicillin/clavulanic acid resistance was 
present in 10 isolates, quinolone resistance in seven, colistin resistance in five isolates 
(with mcr-1 gene), cotrimoxazole resistance in four isolates, chloramphenicol resistance 
in two isolates, aminoglycoside resistance in two isolates and tetracycline resistance in 
one isolate (Table 40). 
4.6.2. Whole Genome Sequencing (WGS) 
The draft genomes of the 11 ST131 porcine isolates yielded 32 to 78 contigs larger 
than 1 Kb, with assembly sizes ranging from 4.940 Mb to 5.451Mb (annex 1, Table S1). 
The WGS data were in complete agreement with our previous characterization performed 
with conventional methods.  
4.6.2.1. Core-genome (CG) and Phylogenetic Analysis  
A total of 84 E. coli genomes were taken from different clades and subclades of 
ST131 in order to calculate the ST131 core-genome (CG). The main objectives were in 




origins, with special attention to clade B of ST131 lineage. Due of that the CG analysis 
was dominated by clade B (n=49, 58%), and the remainder isolates belonged to clade C 
(n=26, 31%), clade A (n=8, 10%) and clade I (n=1, 1%). The final collection represented 
sequences from human (n=51, 61%), porcine (n=19, 23%), avian (n=8, 10%) and wild 
animals (Antarctic pinnipeds) (n=6, 7%) sources.  
The CG encompasses 2.98 Mb (length=2,983,333 +/- 7,338 pb), comprised by 3,100 
total CDS (CG-3). The SNPs analysis of the CG performed within ST131 lineage revealed 
a well-defined clade structure, similar to those previously described, including the three 
defined clades: A, B and C. In total, 14,838 SNPs were present in the alignment. 
Furthermore, there was a distance of 7,742 to 8,565 SNPs between isolates from clade A 
and clade C; 6,508 to 8,675 between isolates from clade A and clade B; and 2,214 to 
4,280 between isolates from clade B and clade C. The distance within clades varies 
greatly: being 36 to 1,782 SNPs in clade A, 8 to 2,051 SNPs in clade B and 1 to 723 SNPs 
in clade C (Figure 18 and supplementary Table S2 in Flament-Simon SC et al. 2020 Front 
Microbiol 2020 11:387 doi: 10.3389/fmicb.2020.00387).  
All isolates of porcine origin analysed in this study were grouped in clade B. As 
shown in Figure 18, clade B was characterized by the presence of a mixture of human, 
livestock and food origin genomes and showed the greatest intra-group diversity. We 
identified 11 clusters or subclades (B0, B1, B2, B3, B4, B5, B6, B6-like, B7, B8, B9), 
including three subclades (B3, B6, B7) with isolates of both human and animal origin. In 
this study, we described five new subclades, named B6, B6-like, B7, B8, and B9. There 
was a distance of 167 to 232 SNPs between isolates from B6 and B6-like and 172 to 304 
SNPs between isolates from B6 and B7. Further, B7 showed 119 to 145 SNPs distance 
with B1. Those subclades appeared as the closer within each other in clade B 
(Supplementary Table S2 in Flament-Simon SC et al. 2020 Front Microbiol 2020 11:387 
doi: 10.3389/fmicb.2020.00387). The 11 ST131 porcine isolates from this study were 
grouped in the new subclades B6 (LREC_160/PST43, LREC_161/PST43, 
LREC_168/PST43, LREC_176/PST43 from pork meat and virotype D2) and B7 
(LREC_153/PST9, LREC_154/PST9, LREC_155/PST9, LREC_157/PST9, 
LREC_158/PST9, LREC_159/PST9, LREC_162/PST9 from piglets with diarrhoea and 
virotype D5). The new subclade B6-like includes two isolates from porcine origin. 
Otherwise, new subclades B8 and B9 only include ST131 isolates from Antarctic 
pinnipeds.  
Notably, there were three (H1410, 19BA, H1698) isolates from human origin in 
subclade B6 and two (EcHUCA4, E61BA) in subclade B7. The distance between human 
isolates and porcine isolates from subclades B6 and B7 had an average of 60 SNPs and 
of 46 SNPs (i.e 20 SNP/Mb and 15 SNP/Mb), respectively.  
4.6.2.2. Plasmidome Analysis 
The 11 ST131 porcine isolates showed high heterogeneity in their plasmid content, 
harbouring between two to seven different plasmids (Table 41 and in annex 2, Figure S4). 
We find members of eight of the 17 main MOB plasmid groups found in γ‐proteobacteria. 
Ordered by prevalence: MOBF12 (n=13), MOBP51 (n=8), MOBP3 (n=3), MOBV2 (n=2), 
MOBH11 (n=2), MOBP12 (n=2), MOBP131 (n=1) and MOBQ12 (n=1). Finally, we described 
six plasmids (16%) in which any MOB protein was found (non-mobilizable-infective 
plasmids). Twenty-two plasmids were considered large (> 33 kb) and presumptively 
conjugative, and sixteen were small multicopy plasmids (< 7 kb).  
In summary, 38 plasmids were described in the 11 genomes analysed. The plasmids 
belonged to the following relaxase families (MOB) and incompatibility groups (Inc): 
MOBP51/ColE1-like (n=8), MOBF12/IncF [F2:A-:B1] (n=8), MOBF12/IncF [F2:A-:B1] 




MOBF12/IncF [F10:A-:B1] (n=2), MOBP12/IncI1-ST27/ST171 (n=2), MOBP3/IncX4 
(n=2), MOBV2/nd (not detectable) (n=2), MOBH11/IncHI2-ST4 (n=1), MOBH11/IncHI2-
ST4 plus and presumptively cointegrated IncQ1 (n=1), MOBP131/IncL/M plus and 
presumptively cointegrated IncQ1 (n=1), MOBP3/IncX1 (n=1), MOBQ12/nd (n=1). We 
also localized six plasmids that could not be affiliated with any categories.  
All 13 MOBF12/IncF plasmids were carriers of virulence genes. The genes 
iroBCDEN, iss, mchF, iutA, iucABCD were constant (Table 41). All the MOBF12/IncF 
plasmids found in our study were structurally compared by BRIG software, using the 
pJIE186_2 (NC_020271) plasmid as reference (annex 2, Figure S5). The plasmids 
analysed showed extensive sequence similarity over at least 100 kb, which includes not 
only backbone genes. The comparison emphasizes that all of them share an 80 kb 
conserved region comprising the virulence genes described previously as well as cvaABC, 
sitABC, ompT and hlyF. 
The eight MOBP51/ColE1-like plasmids identified in this study exhibited a wide size 
range (1,7-6,8 kb) and were analysed using the ColE1 plasmid (J01566.1) as reference 
(annex 2, Figure S6). The plasmids pLREC153_3, pLREC157_3, pLREC158_2 and 
pLREC161_3 (all of them greater than 6.8 Kb) showed the highest homology to the 
reference plasmid. All of them carried the colicin E1 cea and immunity (imm) genes, and 
the entry exclusion (exc1-exc2) system genes. On the other hand, plasmids from isolate 
LREC_160 were different among them and with the others, exhibiting a wide size range 
(1.8 to 5.6 Kb), and only pLREC160_4 carried the colicin E1 gene. 
Three MOBP3/IncX plasmids were present among our isolates. We found 
pLREC157_2 that belong to the IncX1 subcluster and had a similar backbone than 
p2ESCUM (NC_011739.1) but codes for a completely different replication initiation 
protein (annex 2, Figure S7). While pLREC154_2 and pLREC160_2 belong to the IncX4 
subcluster and were analysed using pSH696_34 (JX258654.1) as a reference (annex 2, 
Figure S8). Since pLREC160_2 carried the mcr.1-1 gene, some previous reported IncX4 
reference plasmids harboring the mcr gene were added. Compared to pSH696_34 plasmid 
pLREC160_2 and the other mcr carrier plasmids (pESTMCR and pICBEC7Pmcr) lacked 
of two important backbone genes: the conjugative coupling protein gene (traG) and the 
replication protein encoding region (rep). 
Structural comparison of the two MOBP12/IncI1-ST171 plasmids and the single 
MOBP131/IncL/M plasmid found within our isolates was also performed using pEK204 
(EU935740) and pEC743-OXA48 (CP015071.1) as references, respectively. Both 
showed a high coverage of homology with the reference (annex 2, Figure S9 and S10).  
We also described five small (1.5 kb) multicopy plasmid in which any relaxase 
protein was found, categorized as cryptic. Those cryptic no-MOB plasmids were analysed 
by using pEC10D (NC_017650.1) as reference (annex 2, Figure S11). BRIG comparison 
showed that four plasmids were highly similar to pEC10D and codes for the same 
replication protein (cryptic 1, from the HTH36 superfamily replication proteins). While 
pLREC159_6 codes for a different replication protein and was called cryptic 2 (Table 
41).  
Finally, we analysed the MOBV2 plasmids found in the isolates LREC_153 and 
LREC_157. A BLAST research was performed to identify a reference plasmid, being 
pEC0674 (MF684783.1) as the closest match. Two MOBV2-like related plasmids were 
also included for structural comparison (annex 2, Figure S12). Although no significant 
similarity was found between these latter two references and the pEC0674, the 
pLREC153_4 showed similarity with the replication protein, an hypothetical one and the 
Rec protein from the reference plasmid; whereas the pLREC157_4 only showed 




4.6.2.3. Antimicrobial Resistance Genes (ARGs) 
Many ARGs were found in the 11 ST131 porcine isolates (Table 41), including 
acquired resistance genes, point mutations and efflux/transporter genes.  
Besides constitutive genes (PBP and AmpH, that were present in all isolates), ARGs 
conferring resistance to penicillin (variants of blaTEM gene, accounting: blaTEM-1C, n=10; 
blaTEM-40, n=10; blaTEM-135, n=10; blaTEM-150, n=2; blaTEM-1A, n=2; blaTEM-54, n=1), 
tetracycline (variants of tet gene, accounting: tetA, n=9; tetC, n=9; tetR, n=8; tetM, n=1), 
quinolones (gyrA_S83L, n=7) and colistin (mcr-1.1, n=5) were the most common. In 
addition, we described genes conferring resistance to sulphonamides (variants of sul gene, 
accounting: sul2, n=4; sul3, n=4; sul1, n=3), trimetoprim (variants of drf gene, 
accounting: dfrA1, n=3; dfrA15, n=3; dfrA12, n=1), aminoglycosides (different ACCs, 
APHs and ANTs genes, accounting: APH-3''-Ib, n=3; APH-6'-Id, n=3; aadA1, n=3; 
ANT-3''-Ia, n=3; strA, n=3; strB, n=3; APH-3'-Ia, n=2; aadA2, n=2; AAC-3'-IIa, n=2; 
AAC-3'-IIc, n=2; aadA17, n=1), phenicols (variants of cmlA gene, catA1 and mdfA gene, 
accounting: mdfA, n=11; cmlA1, n=1; cmlA6, n=1; catA1, n=1) and to amonium 
quaternary biocide (qacEdelta1, n=3; qacHR, n=1) (Table 41).  
The phenotypic resistance profile in the studied genomes was due to genes carried by 
plasmids, except for quinolone resistance, which in our study is mediated by a Ser83Leu 
point mutation found in the chromosomal gyrA gene. In the case of LREC_158 isolate it 
exhibited the blaTEM genes (-1c, -40 and -135) variants set into a chromosomal assembled 
contig. However, these genes were located into IncL/M, IncX4, IncI1, IncF and IncHI2 
in the other analysed isolates (Table 41).  
As shown in Table 40, all but one isolate exhibited a MDR profile. Large conjugative 
MDR plasmids were identified in four of the ten isolates. These were typed as 
MOBH11/IncHI2-ST4 (pLREC159_1 and pLREC176_1), MOBF12/IncF (pLREC159_2, 
pLREC161_1) and MOBP131/IncL/M (pLREC153_2), and a non-typeable one 
(pLREC161_2). Most common antibiotic resistance profiles encode by these plasmids 
are ampicillin/penicillin, aminoglycosides, tetracyclines, sulphonamides, cotrimoxazole 
and polymyxins. Finally, we described some drug efflux genes in pLREC159_4 and 
pLREC161_2 (Table 41).  
Class 1 integrons were present in pLREC153_2 (IntI-attI [-sul2+aph-(3'')-Ib+aph-
(6)-Id+dfrA1+aadA1]-qacE1-sul1), pLREC159_2 (IntI-attI [dfrA1+aadA1]-qacE1-
sul1) and pLREC176_1 (IntI-attI [dfrA1+aadA1]-qacE1-sul1). No class 2 or 3 integrons 
were detected in our genomes.  
4.6.2.4. Colistin Resistance Vehicles and Genetic Environment  
Colistin resistance by mcr gene was found in five of the analysed isolates. Therefore, 
the mcr-carrying plasmids were investigated in greater depth. The mcr-1.1 gene was 
located in two MOBH11/IncHI2-ST4, a MOBP3/IncX4 and a MOBF12/IncF [F2:A-:B1], 
that was theoretically cointegrated with an IncHI2-ST-nt plasmid. Besides, the 
LREC_154 isolate showed the mcr-1.1 in a chromosomal location (Table 41). In this 
study, any point mutation in the chromosomally encoded genes pmrA or pmrB was found.  
The complete sequence of pLREC160_2 (MOBP3/IncX4) was 40,221 bp in size and 
contains 69 predicted ORFs. A structural comparison against other reference IncX4 
plasmids is shown in Figure 19, where pICBEC7Pmcr (34,992 pb, NZ_CP017246.1) was 
used as the internal reference. The structure of the mcr-1 carriers IncX4 plasmid remains 
stable if we exclude one ORF encoding for an IS91 family transposase present in 
pLREC160_2 and pICBEC7Pmcr. The BRIG comparison showed that the mcr-1 negative 
plasmid pJIE143 differs from pICBEC7Pmcr in a region of approximately 6 kb (encoding 




backbone, including the replication initiation protein gene (pir), conjugal transfer protein 
genes (tra) plus taxABC and pilX operons (annex 2, Figure S13 to S16).  
 
 
Figure 19. Structural comparison between mcr-1 plasmids and IncX4 references. The alignment 
includes five references and the one IncX4 mcr-1-bearing plasmid found in our study. The 
plasmid pICBEC7mcr (IncX4) was used as a reference to match with the other plasmids with 
[pMCR_WCHEC1618, pECGD-8-33, pESTMCR and pmcr1_IncX4] and without the mcr-1 gene 
[pIJE143]. The outer circle with black arrows denotes the annotation of reference sequence 
pICBEC7mcr. The image was generated using BRIG (default parameters with 90/70 as 
upper/lower threshold). 
Plasmid pLREC161_1 was 330,357 bp in size and contain 616 predicted ORFs. This 
MOBF12 plasmid belongs to the IncF [F2:A-:B1] incompatibility group and was 
theoretically cointegrated with an IncHI2 plasmid. A structural comparison with plasmid 
pMR0516mcr [F18:A-:B1] (KX276657.1) as an internal reference (225,069 bp) showed 
100% identity in more than 70 % of query coverage from BRIG (Figure 20). Genes 
involved in the conjugative transfer (tra, trb and pili operons), in the toxin-antitoxin 
system (vagC) and the inhibition of SOS response (psiAB) were present. Most of the 
differences were observed in the resistance module. It is worthy of note that pLREC161_1 
and pMR0516mcr plasmids contained APEC virulence genes and that the surrounding 
region of the mcr gene includes heavy metal resistance genes to tellurium (ter genes). 
Moreover, in annex 2, Figure S17, where pKP81_BE [F2:A-:B] (KU994859.1) was used 
as the reference, we observed 100% of identity in more than 78% of query coverage from 
BRIG with pLREC161_1. Interestingly plasmid R478 (IncHI2 reference plasmid, 
U62007.2) also shared with pKP81_BE some backbone genes and the tellurium resistance 
module like pMR0516mcr (annex 2, Figure S17). A wide part of the backbone in 




E. coli-K12, used as non-mcr plasmid reference (from coord. 55 kb to 99 kb). The 
ancestral IncF plasmid of ST131 (pECSF1) was also included in BRIG comparisons 
(annex 2, Figure S18).  
 
 
Figure 20. Structural comparison between mcr-1 plasmids, IncF and IncHI2 references. The 
alignment includes four references and the one IncF mcr-1-bearing plasmid found in our study. 
pMR0516mcr (IncF) was used as a reference to match with the other plasmids with [pKP81_BE 
(IncF)] and without mcr-1 gene [IncF plasmid from E. coli K12, pECSF1 (IncF) and R478 (IncHI2)]. 
The outer circle with black arrows denotes the annotation of pMR0516mcr. The image was 
generated using BRIG (default parameters with 90/70 as upper/lower threshold). 
There were two MOBH11/IncHI2-ST4 mcr-1 bearing plasmids: (I) pLREC159_1 
which was 248,461 bp in size and contain 420 predicted ORFs and, (II) pLREC176_1 
which was 278,079 bp in size and contain 523 predicted ORFs. Both showed 100% of 
identity over more than 75% of query coverage in BRIG comparison with pHNSHP45-2 
(KU341381.1) (Figure 21). The backbone was almost identical; nevertheless, the 
resistance module was distinct between them. The result of this comparative analysis 
showed that a wide range of resistance genes could be found in the MDR module of 
IncHI2 plasmids. Moreover, all the IncHI2 plasmids analysed presented a tellurium 
resistance module close to the mcr-1 cassette. The similarities between IncHI2 plasmids 





Figure 21. Structural comparison between mcr-1 plasmids and IncHI2 references. The alignment 
includes four references and the mcr-1-bearing plasmids from our study pLREC176_1 and 
pLREC159_1 which are IncHI2 and pLREC161_1 which is an IncF plasmid with a presumptively 
IncHI2 cointegrated. The plasmid pHNSHP45-2 (IncHI2) was used as a reference to match with 
the other plasmids with [p2474-MCR1 (IncHI2), pECJS-59-244 (IncHI2) and 
pMCR_WCHEC050613 (IncHI2)] and without the mcr-1 gene [R478 (IncHI2)]. The outer circle 
with black arrows denotes the annotation of reference sequence pHNSHP45-2. The image was 
generated using BRIG (default parameters with 90/70 as upper/lower threshold). 
Afterward, a comparison between all our mcr-1 bearing plasmid was performed with 
pHNSHP45-2 (MOBH11/IncHI2) as a reference, and as expected, almost none 
homologous region was found between plasmids from different families (annex 2, Figure 
S19). Nevertheless, pLREC161_1 (MOBF12/IncF [F2:A-:B1] plus IncHI2-ST-nt) 
plasmid shared a part of his backbone with the reference one, including the module 
encoding for tellurium resistance and the mcr gene. Suggesting that the mcr-1 cassette 
was introduced into pLREC161_1 through the cointegrated IncHI2 plasmid. 
We had also made a sequence alignment to analyze the surrounding region of our mcr 
bearing contigs and compare their structure against plasmids references (Figure 22). 
Regarding plasmid families, all the IncX4 plasmids were identical in terms of the genetic 




IncHI2 plasmid was variable. Interestingly, the mcr region in plasmids 
pMCR_WCHEC050613 (IncHI2) and plasmid pMR0516mcr (IncF) shared 100% of 
identity. It is also worth to note that the IncF mcr harboring plasmid pKP81_BE carried 
the tellurite resistance module surrounding the mcr gene like the IncHI2 plasmids. 
Finally, the genetic arrangement of the mcr-1 cassette was investigated (annex 2, 
Figure S20). All sequences share a 2,542 bp DNA segment, containing mcr-1.1 and a 
putative ORF, encoding a Pap2 superfamily protein. However, some variability in the last 
3’ end of the pap2 gene was observed.  
The genome reconstruction of LREC_154 showed that mcr gene was inserted into 
the chromosome. However, the mcr harboring contig only included mcr and pap2 genes. 
It was flanked at both ends by a partial ISApl1 sequence of 99 bp upstream and 405 pb 
downstream the mcr-1 cassette. In pLREC159_1 the mcr harboring contig was disrupted 
after a segment of 87 bp of DNA homologous to ISApl1 upstream the mcr gene. Probably 
the presence of the IS (repeated element) has interfered with the de novo reconstruction 
of the sequenced genome by the assembly of Illumina short reads. In addition, we 
identified the IS26 and an IS1294 surrounding the mcr-1 cassette in pLREC160_2. 
Plasmids pLREC159_1 and pLREC176_1 identified as IncHI2-ST4, had identical 
genetic environments downstream the mcr-1 cassette. 
4.6.3  STATISTICAL ANALYSIS 
The variables (cdtB, cnf1, hlyA, virotypes, PST and subclades) did not follow a 
Normal distribution (Shapiro-Wilk test: P-Value < 0.0001). We performed the Mann-
Whitney-Wilcoxon test to assessed significative differences in the distribution of features 
(virotype D5|subclade B7|PST9|cnf1|hlyA vs. virotype D2|subclade B6|PST43|cdtB 







Figure 22. Comparison of homologous region of the composite transposon Tn6330 (CP029493.1) 
containing mcr-1 gene with our sequences and other frequently used reference sequences 
analysed in this manuscript. Open arrows represent coding sequences (green for tellurium 
resistance; yellow for ISApl1; red for mcr-1 and blue for pap2) and indicate direction of 
transcription. The arrow size is proportional to the gene length. The shadow parallelograms 
denote genetic regions that exhibit sequence homology among different segments. Light shadow 
denotes regions with a lower level of sequence identity (99%) by BLAST. The image was 









Table 40. Features, molecular typing, virulence and resistance profiles of ST131 E. coli isolates from porcine origin. 


















(2008) O25:H4 B2 CH40-332 ST131/PST9 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cnf1, hlyA. 






(2006) O25:H4 B2 CH40-22 ST131/PST9 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, D-nt
i
 
AMC, AMP, AMP/SAM, CHL, 






(2010) O25:H4 B2 CH40-374 ST131/PST9 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cnf1, hlyA. 




(2010) O25:H4 B2 CH40-161 ST131/PST9 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cnf1, hlyA. 






(2010) O25:H4 B2 CH40-326 ST131/PST9 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cnf1, hlyA. 






(2009) O25:H4 B2 CH40-338 ST131/PST9 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cnf1 hlyA. 
D5 
AMC, AMP, AMP/SAM, COL, 







(2012) O25:H4 B2 CH40-298 ST131/PST43 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cdtB. 






(2012) O25:H4 B2 CH40-22 ST131/PST43 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cdtB. 






(2010) O25:H4 B2 CH40-336 ST131/PST9 
iroN, iss, hlyF, ompT, papEF (GIII), kpsM-II (K5), iucD, 
iutA, chuA, fyuA, yfcV, cvaC, traT, malX, ibeA, usp, cnf1. D5 







(2011) O25:H4 B2 CH40-298 ST131/PST43 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cdtB, tsh. 






(2011) O25:H4 B2 CH40-22 ST131/PST43 
iroN, iss, hlyF, ompT, papC, papAH, papEF (GIII), 
kpsM-II (K5), iucD, iutA, chuA, fyuA, yfcV, cvaC, traT, 
malX, ibeA, usp, cdtB. 
D2 AMP/SAM, COL, TI, TMP/SMX +  
(a) Phylogroups by Clermont et al. (2013); (b) CH, clonotype (fumC-fimH alleles); (c) ST, sequence type according to Achtman scheme; PST, sequence type according to the Pasteur scheme; (d) 
Extraintestinal virulence genes found by PCR; (e) All isolates exhibited the ExPEC, UPEC and APEC status; (f) The virotype was determined by PCR, based on the presence or absence of 13 
virulence genes (Dahbi et al. 2014); (g) AMP, ampicillin; AMC , amoxicillin-clavulanic acid; AMP/SAM, ampicillin-sulbactam; CZ, ceftazidime; CHL, chloramphenicol; COL, colistin; GEN, 
gentamicin, MI, minocycline; NAL, nalidixic acid; TI, ticarcillin; TMP/SMX, trimethoprim-sulfamethoxazole; TOB, tobramycin; PI/TZP, Piperacillin-tazobactam; (h) Multidrug drug resistance 




Table 41. Plasmid content of the ST131 E. coli isolates from porcine origin and location of resistance and virulence genes. 






proteinc Inc group (pMLST)
d Virulence genes e Resistence genes
f, point mutations (blue) and 
efflux/transporter  genes (green) 
LREC_153 
 
chr_LREC153 40 4,904,938 1 ndh nd nag papACDEFHJKX, hlyABD, cnf1, chuA PBP , AmpH, gyrA_S83L, mdfA 
pLREC153_1 8 330,910 1 MOBF12, MOBH11 RptA1 
IncF [F2:A-
:B1][IncHI2-ST4]i 
iroBCDEN, iss, mchF, iutA, 
iucABCD  
pLREC153_2 16 102,056 1 MOBP131 RptZ, RptC IncL/M [IncQ1]i  
blaTEM-1A/blaTEM-54/blaTEM-150, AAC(3')-IIa, AAC(3')-IIc, 
APH(3')-Ia, APH(3'')-Ib, APH(6')-Id, aadA1, strA, strB, 
sul1, sul2, sul3, dfrA1, dfrA15, tet(A), tet(C), qacEdelta1 
pLREC153_3 1 6,851 5 MOBP51 nd ColE1-like   
pLREC153_4 1* 2,461 4 MOBV2 RepL nd     
LREC_154 
 
chr_LREC154 111 4,946,997 1 nd nd na papBCDEFHIJKX, iss, iroBCDEN, iucABCD, iutA PBP, AmpH, gyrA_S83L, mdfA , mcr-1.1 
pLREC154_1 2 124,513 1 MOBF12 RptA1 IncF [F2:A-:B1] iroBCDEN, iss, mchF, iutA, iucABCD  
pLREC154_2 27 56,729 3 MOBP3 RptF IncX4   blaTEM-1C/blaTEM-40/blaTEM-135, tet(A), tet(C), tet(M), tet(R) 
LREC_155 
 
chr_LREC155 60 4,947,621 1 nd nd na 
papACDEFHJKX, hlyABD, 
cnf1, chuA, mchC, iha, 
iroBCDEN, iucABCD, iutA 
PBP, AmpH, mdfA 
pLREC155_1 25 316,521 1 MOBF12 RptA1 IncF [F2:A-:B1][IncHI2-ST-nt]i 
iroBCDEN, iss,cma, cba, 
mchF, iutA, iucABCD  
pLREC155_2 23 208,964 1 MOBP12 RptZ IncI1-ST27   blaTEM-1C/blaTEM-40/blaTEM-135, tet(A), tet(C), tet(R) 
LREC_157 
 
chr_LREC157 79 4,896,484 1 nd nd na 
papACDEFHJKX, hlyABD, 
cnf1, chuA, iroBCDEN, 
iucABCD, iutA 
PBP, AmpH, gyrA_S83L, mdfA 
pLREC157_1 12 137,775 1 MOBF12 RptA1 IncF [F2:A-:B1] iroBCDEN, iss, mchF, iutA, iucABCD blaTEM-1C/blaTEM-40/blaTEM-135 
pLREC157_2 1 46,172 1 MOBP3 RptF IncX1   
pLREC157_3 1 6,851 3-4 MOBP51 nd ColE1-like   
pLREC157_4 1* 2,047 5 MOBV2 nd (RepA partial hit) nd     
LREC_158 
 
chr_LREC158 58 4,853,444 1 nd nd na 
papACDEFHJKX, hlyABD, 
cnf1, chuA, iroBCDEN, 
iucABCD, iutA 
PBP, AmpH, blaTEM-1C/blaTEM-40/blaTEM-135, gyrA_S83L, 
mdfA 
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pLREC158_2 1* 6,648 4 MOBP51 nd ColE1-like   
pLREC158_3 1* 1,554 5 nd RptL2 nd (Cryptic_1)     
LREC_159 
 
chr_LREC159 97 4,869,944 1 nd nd na 
papACDEFHJKX, hlyABD, 
cnf1, chuA, iroBCDEN, 
iucABCD, iutA 
PBP, AmpH, gyrA_S83L, mdfA 
pLREC159_1 10 248,461 1 MOBH11 RptC IncHI2-ST4 [IncQ1] i  APH(3')-Ia, APH(3'')-Ib, APH(6)-Id, strA, strB, sul2, sul3, mcr-1.1 
pLREC159_2 9 177,070 1 MOBF12 RptA1 IncF[F2:A-:B1] iroBCDEN, iss, mchF, iutA, iucABCD 
blaTEM-1C/blaTEM-40/blaTEM-135, aadA1, AAC(3)-IIa, AAC(3)-
IIc, sul1, sul2, dfrA1, drfA15,tet(A), tet(C), tet(R), 
qacEdelta1 
pLREC159_3 1 68,523 1 MOBP12 RptZ Incl1-ST171   
pLREC159_4 1 2,014 2 MOBQ12 nd nd  aadA2, ANT(3'')-Ia, linG, lnu(F) 




nd (Cryptic_1)   
pLREC159_6 1* 1,507 3 nd nd (RepA partial hit) nd (Cryptic_2)     
LREC_160 
 
chr_LREC160 107 5,049,024 1 nd nd na 
papCDEFJK, sfaX, mchCF, 
iha, iss, chuA, iroBCDEN, 
iucABCD, iutA 
PBP, AmpH, mdfA 
pLREC160_1 18 145,187 1 MOBF12 RptA1 IncF [F2:A-:B1] iroBCDEN, iss, mchF, iutA, iucABCD blaTEM-1C/blaTEM-40/blaTEM-135, tet(A), tet(C), tet(R) 
pLREC160_2 5 40,221 2 MOBP3 RptF IncX4  blaTEM-1C/blaTEM-40/blaTEM-135, mcr-1.1 
pLREC160_3 1 5,630 3 MOBP51 nd ColE1-like   
pLREC160_4 1 5,006 4-5 MOBP51 nd ColE1-like   
pLREC160_5 1 4,515 3-4 MOBP51 nd ColE1-like   
pLREC160_6 1 1,765 3-4 MOBP51 nd ColE1-like   





Table 41. Cont. 






proteinc Inc group (pMLST)
d Virulence genes e Resistence genes
f, point mutations (blue) and 
efflux/transporter  genes (green) 
LREC_161 
 chr_LREC161 64 5,072,645 1 nd nd na 
papCDEFJK, sfaX, iss, chuA, 
iroBCDEN, iucABCD, iutA PBP, AmpH, mdfA 
 pLREC161_1 8 330,357 1 MOBF12 RptA1 
IncF [F2:A-
:B1][IncHI2-ST-nt]i 
iroBCDEN, iss, mchF, iutA, 
iucABCD blaTEM-1C/blaTEM-40/blaTEM-135, mcr-1.1, tet(A), tet(C), tet(R) 
 
pLREC161_2 15 33,473 2 nd RptF nd  blaTEM-1C, aadA2, aadA17, ANT(3'')-Ia, sul3, drfA12, linG, lnu(F), mef(B) 
pLREC161_3 1 6,826 3 MOBP51 nd ColE1-like   




nd (Cryptic_1)   
LREC_162 
 
chr_LREC162 46 4,720,511 1 nd nd na chuA, iroBCDEN, iucABCD, iutA PBP, AmpH, gyrA_S83L, mdfA 
pLREC162_1+2J 29 216,025 1 MOBF12 (2) J RptA1 IncF [F10:A-:B1] 
iroBCDEN, iss, mchF, iutA, 
iucABCD blaTEM-1C/blaTEM-40/blaTEM-135 
LREC_168 
chr_LREC168 113 5,117,208 1 nd nd na papCDEFJK, sfaX, iss, chuA, iroBCDEN, iucABCD, iutA PBP, AmpH, gyrA_S83L, mdfA 
pLREC168_1+2J  13 144,861 1 MOBF12 (2) J RptA1 IncF [F2:A-:B1] 
iroBCDEN, iss, mchF, iutA, 
iucABCD blaTEM-1C/blaTEM-40/blaTEM-135, tet(A), tet(C), tet(R) 
LREC_176 
 
chr_LREC176 145 5,039,239 1 nd nd na papDFJKX, sfaX, iss, chuA, iroBCDEN, iucABCD, iutA PBP, AmpH, mdfA 
pLREC176_1 15 278,079 1 MOBH11 RepFIB_RepA (x2) IncHI2-ST4  
blaTEM-1A/blaTEM-150, aadA1, aadA2, APH(6)-Id, APH(3'')-
Ib, strA, strB, sul1, sul2, sul3, drfA1, drfA15, mcr-1.1, 
tet(A), tet(C), tet(R), cmlA1, cmlA6, catA1, qacEdelta1, 
qacHR 
pLREC176_2 9 132,494 1 MOBF12 RptA1 IncF [F2:A-:B1] iroBCDEN, iss, mchF, iutA, iucABCD  
aChr, chromosome; p, plasmid. bApproximative number of plasmid copies based on sequencing coverage identified by PLACNET. cRelaxase and replication proteins were identified by the use of 
PLACNET databases. dIncompatibility groups were determined according to the PBRT scheme and pMLST subtypes according to the allele scheme in http://pubmlst.org/plasmid/. eVirulence 
genes were detected through VirulenceFinder and VFDB databases (minimum coverage of 90%, minimum identity of 75%); All genomes presented in their chromosome the following genes: aslA, 
cheBWY, chuSTUVWXY, csgBDEFG, entABCEFS, fdeC, fepABCDG, fes, fimABCDEFGHI, flgG, flhAC, fliGIMP, fyuA, gad, gspCDEFGHIJKLM, ibeA, irp1, irp2, kpsDM, OmpA, yagVWXYZ/ecpEDCBA, 
ybtAEPQSTUX, ykgK/ecpR. fAntimicrobial resistance genes were detected by using ARG-ANNOT, CARD and ResFinder databases (minimum coverage of 93%, minimum identity of 75%); All 
genomes presented in their chromosome the following genes (efflux pumps and transport modulators): acrAEFS, bacRS, cpxA, CRP, emrABEKRY, eptA, evgAS, gadWX, H-NS, kdpE, marA, 








5.1.STRAINS OF HUMAN ORIGIN 
5.1.1 CLONAL STRUCTURE OF E. COLI CAUSING EXTRAINTESTINAL INFECTIONS IN 
HUMANS 
To our knowledge, this is the first study conducted in Spain in which the clonal 
structure of extraintestinal pathogenic E. coli was analyzed from clinical E. coli non-
redundant and consecutively isolated. Indeed, the previous Spanish studies focused on 
selected clinical isolates. Thus, Blanco et al. (2011) evaluated the incidence of only three 
high-risk clones among 500 consecutively collected E. coli isolates, causing 
extraintestinal infections in five Spanish hospitals in 2009. They found that ST131 
accounted for 12%, ST393 for 3% and ST69 for 4%, and these three clones accounted for 
30% of the MDR isolates. In the present study, ST131 was one of the most prevalent ST 
in the enrolled Spanish hospital and accounted for 12%. This result strongly suggests that 
the ST131 rate has remained stable between 2009 and 2016 in Spain. The ST69 rate seems 
to have increased as this ST accounted for 8% in 2016, compared to 4% in 2009. 
Inversely, the non-detection of any ST393 isolate in the current study seems to indicate 
that its rate has declined dramatically in Spain between 2009 and 2016. Oteo et al. (2014) 
analyzed the ST distribution among OXA-1-producing E. coli isolates resistant to 
amoxicillin-clavulanate collected from clinical samples (>70% from urine), from seven 
Spanish hospitals in 2010 and found that ST88 (37.3%) and ST131 (32.8%) were the most 
prevalent STs in this E. coli subgroup. Interestingly, we found in the present study that 
ST88 (9%) was one of the most common STs after ST131 in Spain but not in France 
(3.1%). 
In France, Van der Mee-Marquet et al. (2015) studied the genetic diversity of 412 E. 
coli bloodstream isolates recovered during 2014 and found 12 major ST complexes (STCs 
10, 12, 14, 23, 31, 69, 73, 92, 95, 131, 141 and 155), containing 77.9% of the collected 
isolates. Clermont et al. (2017) analyzed 243 bacteremia isolates obtained in 2010 in the 
Paris area and found four most prevalent STCs: STC95 (14.0%), STC73 (13.2%), 
STC131 (8.6%) and STC69 (7.8%). La Combe et al. (2019) analyzed 260 respiratory tract 
isolates obtained from patients who had pneumonia and were hospitalized between 2012 
and 2014 in intensive care units located throughout France. The most commonly 
identified lineages were STC73 (15.4%), STC131 (9.2%), STC69 (7.7%), STC141 
(6.2%), STC127 (6.2%) and STC95 (5.4%). They compared this STC distribution to that 
observed in bacteremia and commensal isolates and noted that STC127 and STC141 were 
overrepresented and STC95 underrepresented in pneumonia isolates compared with 
bacteremia isolates. Brisse et al. (2012) compared the phylogenetic diversity of 152 CTX-
M-producing and 152 non-ESBL-producing clinical E. coli isolates, obtained between 
2008 and 2009 from ten hospitals located in the Paris area. The five most prevalent STs 
were distributed differently between CTX-M-producing and non-ESBL-producing E. coli 
isolates: ST131 (36.2% vs. 9.9%), ST10 (8.6% vs. 5.9%), ST73 (0% vs. 10.5%), ST95 
(0% vs. 5.3%) and ST141 (0% vs. 4.6%). In the present study, the most prevalent STs in 
the enrolled French hospital were ST73 (12.5%), ST131 and ST141 (11.5% for each), 
ST10 (6.3%), ST69 (5.2%), ST12, ST95 and ST127 (4.2% for each). The comparative 
analysis of the present study and the four previously published studies shows that the 
distribution of the most prevalent STs appears to have been stable in France during the 
period-time covered by the five studies (2008-2016). However, our study highlighted that 
ST141, which was already present in 2008 (Gati et al., 2019), has not only persisted in 
any type of source, except for blood, but has increased to become as prevalent as ST131, 
although it does not belong to the MDR-ST group.  
The clonal structure of different collections of E. coli clinical isolates has also been 




conducted in UK, focusing either on UTI isolates (2007-2009) (Gibreel et al., 2012) or 
bacteremia isolates (2001-2012) (Horner et al., 2014; Day et al., 2016; Kallonen et al., 
2017). Independently of the sample source and the location of the enrolled centers, the 
distribution of the predominant STs was the same in UK, with some variations in terms 
of frequency. Thus, ST73 varied from 16.6% to 18.6%, ST131 from 12% to 16.8%, ST69 
from 5.4% to 10.5%, ST95 from 6.3% to 10.6% and ST12 from 4.4% to 4.6%. ST10 
(4.3%) and ST127 (3.6%) were identified as prevalent ST among only the UTI isolates 
and ST12 only among bacteremia isolates. Kallonen et al. (2017) highlighted that after 
the emergence of ST69 (2002) and ST131 (2003) and their spread, a new  equilibrium of 
E. coli populations was observed, resulting in a relative stability of the major STs. The 
notable difference between the UK studies and ours is the absence of ST88 and ST141 
among the predominant STs in UK, whereas the rate of ST88 was high in Spain (9%) and 
that of ST141 in France (11.5%). In contrast, both ST88 and ST141 were identified in 
Germany among the prevalent STs and each accounted for 4.2% of 265 UTI isolates 
collected between 2004 and 2006 (Toval et al., 2014). ST141 was also identified among 
44 E. coli isolated from UTIs in Switzerland during 2016. It accounted for 11.4% of the 
isolates, whereas ST131 and ST69 accounted, each, for 13.6%, and ST73 for 6.8% 
(Nüesch-Inderbinen et al., 2017). These features suggest that the clonal structure of E. 
coli in Germany and Switzerland seems to be closer to that of Spain and France than to 
that of UK. 
Some studies were also conducted in North America. In Canada, Fibke et al. (2019) 
analyzed the genome of E. coli isolates responsible for UTI, in 385 women between 2012 
and 2015. The major STs included ST95 (18.4%), ST73 (10.1%), ST127 (9.1%), ST131 
(8.8%) and ST69 (7.5%). Among the studies performed in the USA on UTI isolates, 
different ST distributions were observed. Thus, Banerjee et al. (2013a) studied 299 
clinical extraintestinal E. coli isolates (90% from UTIs) obtained during 2011 in 
Minnesota, and identified the five most prevalent STs, consisting of ST131 (27%), ST95 
(11%), ST73 (8%), ST127 (6%) and ST69 (5%). On their side, Yamaji et al. (2018), who 
studied 233 E. coli isolated from UTIs in California during 2016 and 2017, and 225 
isolates collected similarly between 1999 and 2000, showed that the ST131 isolates were 
less frequently identified than the ST95, ST127, ST73, and ST69 isolates in these two 
periods. Similar to UTI isolates, bacteremia isolates were differently distributed in ST 
according to the studies. Thus, Adams-Sapper et al. (2013), analyzing 220 bloodstream 
isolates obtained in San Francisco between 2007 and 2010, found only five prevalent STs 
and clonal complexes, accounting for 65% of the isolates. They comprised ST131 (23%), 
ST95 (18%), STC73 (8%), ST69 (9%) and STC12 (6%). On their side, Cole et al. (2019), 
studying 43 bacteremia E. coli isolates from newborns obtained between 2006 and 2016 
in Oklahoma, found that ST95 was the most prevalent ST (11.3%) followed by ST131 
(9.2%) and ST1193 (3.7%). Cole et al. (2019) noted that ST95 and ST131 isolates were 
present throughout the studied years, while ST1193 was only seen in the recent years. 
Overall, neither ST88 nor ST141 belong to the most prevalent clones in North America. 
In North America, ST95 is more prevalent than ST73, while, in Europe, the opposite is 
true. 
Similar to Cole et al. (2019), we recently identified, i.e. in 2016, the global emergent 
MDR ST1193. To our knowledge, it is the first identification of this clone in Spain and 
the second in France. Indeed, Birgy et al. (2019) found that among 218 ESBL-producing 
E. coli causing febrile UTI in children between 2014-2017, ST1193 was one of the most 
prevalent clones during the most recent period of the study.  
ST1193 seems to be more prevalent in Asia than in Europe and the USA. Indeed, 




(China) in 2015 showed that, among the most prevalent clones, ST131 (15.3%) was 
followed by ST1193 (7.1%), then, by ST95 (5.9%) and ST69 (5.9%). This ST distribution 
suggests that strong antibiotic pressure has displaced the frequently antimicrobial 
susceptible STs among blood E. coli isolates, such as ST73 and ST95. However, in China, 
ST95 isolates have not been fully displaced, since some isolates have acquired plasmids 
encoding ESBL enzymes. 
To our knowledge, the analysis of the clonotypes (analysis of the fumC and fimH 
alleles: CH), in addition to the phylogroup and ST types, allowing clone determination, 
was only carried out by Tchesnokova et al. (2013) in the USA and Matsumura et al. 
(2017a) in Japan. Tchesnokova et al. (2013) found 222 CH clonotypes among 1518 E. 
coli isolates (93% from UTIs), recovered between 2010 and 2011. Matsumura et al. 
(2017a) found 103 clonotypes among 329 E. coli (65% from UTIs and 11.9% from 
bacteremia), collected from 10 Japanese hospitals in 2014. In our study, 107 clonotypes 
were identified among 196 isolates, which suggests a higher diversity of clones in our 
study than in the American and Japanese studies. However, the most remarkable 
difference between the three studies is the distribution of the most prevalent STs among 
the MDR isolates: B2-CH40-30-ST131 and D-CH35-27-ST69 clones in the USA, B2-
CH40-30-ST131 clone in Japan, and B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-
39-ST88 and D-CH35-27-ST69 clones in Spain and France. Consequently, it can be noted 
that ST88 is not a predominant ST in Japan, like in UK and the USA. 
Fibke et al. (2019) provided data on the fimH alleles displayed by the 34 Canadian 
ST131, that they identified among UTI isolates: fimH22 (20.6%), fimH27 (5.9%), fimH30 
(23.5%) and fimH41 (44.1%). In our study, the distribution of the fimH alleles among our 
23 ST131 isolates was very different: fimH22 (13.0%), fimH30 (56.5%), fimH41 (26.1%) 
and fimH298 (4.3%). Kallonen et al. (2017), based on single nucleotide polymorphisms 
(SNPs), identified eight clades among English ST73 isolates associated with different 
O:H serotypes. Using the fimH allele type, we identified six fimH alleles among our 23 
ST73 isolates (fimH 10, 12, 13, 27, 30, 32 and 103), that defined six clones, among which 
B2-CH24-10-ST73 and B2-CH24-103-ST73 clones predominated. Gordon et al. (2017b) 
studied the phylogeny of 200 STC95 isolates from humans living in France, Australia and 
the USA. The SNPs analysis revealed five main clusters associated to different fimH 
alleles and serotypes. In the present study, we have also identified five clones among our 
10 ST95 isolates with different fimH alleles (fimH 15, 27, 30, 41 and 54) and serotypes 
(O1:H7, O2:H4, O2:H5, O2:H7, O18:H7, O25:H4 and O45:H7). Here, the most common 
clone was the B2-CH38-15-ST95, displaying serotypes O2:H5 (1 isolate), O2:H7 (1), 
O18:H7 (2). 
Taking into consideration that Gati et al. (2019) identified hybrid shigatoxin-
producing E. coli /UPEC isolates among ST141 isolates, we searched for these hybrid 
isolates among our 14 ST141 isolates, but no hybrid isolates were detected. However, we 
detected a French ExPEC isolate of serotype O153:HNT, that carried three VFs-encoding 
genes (aatA, aaiC and aggR), specific for EAEC. This hybrid belonged to A-CH11-54-
ST10 clone and harbored 14 VFs typically found in ExPEC. Interestingly, Olesen et al. 
(2012) found that the EAEC isolates of serotype O78:H80 and ST10 were responsible for 
an outbreak of UTI in Denmark. On their side, Abe et al. (2008) and Lara et al. (2017) 
found some UPEC isolates with properties of EAEC in Brazil, including hybrid 
UPEC/EAEC ST69, ST73 and ST131 isolates.  
In summary, approximately 10% of the extraintestinal E. coli infections that had 
occurred in 2016 in the two studied hospitals were caused by ST131 isolates, and 
approximately 60% of these infections were caused by isolates belonging to only 10 STs 




isolates were particularly frequent in the Spanish and French hospitals, respectively, 
while, so far, these two STs are absent among the dominant STs in UK, the USA and Asia 
but present in Germany and Switzerland. Our results confirm that in Europe, ST73 is 
much more prevalent than ST95, while in North America it is the opposite. The majority 
of ST12, ST73, ST95 and ST141 isolates were susceptible to most antibiotics, indicating 
that MDR was not the reason for their success. The results of the present study support 
the idea that their success is mainly due to the high number of VF-encoding genes that 
they possess. This study also shows that among the MDR isolates, four clones are 
predominant, especially: B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-39-ST88 
and D-CH35-27-ST69. Clone B2-CH40-30-ST131 was also the most prevalent clone 
among the ESBL-producing isolates. Lastly, this study confirmed the presence of the new 
MDR global emergent ST1193 in both France and Spain. All these results suggest that 
surveillance of the clonal structure and antibiotic susceptibility of ExPEC is required at 
both local and global levels, notably to evaluate the evolutive impact of the antibiotic 
overuse on one of the most important human bacterial pathogens. 
5.1.2 EXTENDED-SPECTRUM Β-LACTAMASE-PRODUCING E. COLI CAUSING 
EXTRAINTESTINAL INFECTIONS IN HUMANS 
The management of urinary tract and bloodstream infections due to E. coli has been 
complicated by the emergence of multidrug-resistance, especially of that related to the 
expansion of high-risk clones such as ST131 (Nicolas-Chanoine et al., 2007b; de Toro et 
al., 2017). Since 2006, the prevalence of ESBLEC among E. coli causing bacteremia has 
raised in Lucus Augusti hospital. This increase has been due to the spread of the 
multidrug-resistant ST131 subclade C2 associated with the production of CTX-M-15. 
Thus, the number of ESBLEC isolates increased from 1.0% during 2000-2005 to 5.5% 
during 2006-2011. While during the first period 0% of the ESBLEC isolates belonged to 
subclade C2, during the second period this subclone represented 39.8% (Mamani et al., 
2019). A similar situation has been reported in France in different hospitals (Brisse et al., 
2012; Sauget et al., 2016) and worldwide (Peirano et al., 2012).  
The main change with respect to previous studies conducted at the Lucus Augusti 
hospital, is the emergence of isolates producing CTX-M-27. Indeed, this enzyme was not 
produced by any of the 105 ESBLEC isolates recovered from extraintestinal infections 
between 2006 and 2007 (Blanco et al., 2009) and by any of the 92 ESBLEC bloodstream 
isolates collected from 2001 to 2011 (Mamani et al., 2019) and only by one of 47 ST131 
ESBLEC isolated from urinary tract infections in 2012 (Dahbi et al., 2013). Furthermore, 
the CTX-M-27 was only detected in one of the 44 Spanish hospitals analyzed in a study 
carried out in 2006 (Diaz et al., 2010), in one of 94 clinical ESBLEC collected during 
2008 in Vall d´Hebron hospital of Barcelona (Coelho et al., 2011), and in none of the 92 
ESBLEC obtained in eight Spanish hospitals during 2010 and 2011 (Merino et al., 2016). 
In the present study, CTX-M-27 was significantly more frequent in Beaujon (15.6%) than 
in Lucus Augusti (6.5%). However, the Beaujon’s CTX-M-27 percentage appeared as 
remarkably higher than those found before 2014 (4.5%-5.4%) in other 19 hospitals 
located as Beaujon in the Paris area (Robin et al., 2017; Surgers et al., 2018). Inversely, 
this percentage was closer to that found between 2014 and 2017 in 24 pediatric centers 
located in six French regions, i.e. 12.4% among  251 ESBLEC isolated from febrile 
urinary tract infections (FUTIs) (Birgy et al., 2019). In addition, it has to be noted that 
CTX-M-27-producing isolates had already been found in 2012 in the feces of children in 
day care centers (DDCs) in France (Blanc et al., 2014) and also in feces of patients 
hospitalized in Madrid during a European survey conducted between 2014 and 2015 




The increased prevalence of the CTX-M-27 in the two hospitals enrolled in the 
present study was mainly due to the expansion of cluster C1-M27 since 17 of the 21 
positive CTX-M-27 isolates belonged to this cluster. The four remaining isolates 
belonged to three different STs, including ST38 (2 isolates), ST90 and ST1193. In the 
FUTI study, Birgy et al. (2019) also showed that their 31 CTX-M-27-producing isolates 
mostly belonged to cluster C1-M27 (10 isolates) and ST38 (8 isolates), and also that two 
belonged to ST1193. 
The two ST1193 isolates identified in the present study belonged to clonotype CH14-
64 and serotype O75:HNM and were positive for CTX-M-14 (the isolate from Spain) and 
CTX-M-27 (the isolate from France). As far as we know, this is the first report of the new 
emerging global clone ST1193 among clinical ESBLEC isolates from Spain. Inversely, 
the ST1193 has already been described in France and shown producing either CTX-M-
15 or CTX-M-27 in the  pediatric FUTIs study (Birgy et al., 2019) and CTX-M-14 among 
the fecal isolates  obtained from children in DCCs in France (Blanc et al., 2014). ST1193 
has also been detected in two of 243 third-generation-cephalosporin-resistant E. coli 
isolates obtained from patients with bloodstream infection in Denmark during 2015 (Roer 
et al., 2018), in three of 51 clinical ESBLEC isolated in Germany during 2015 and 2016 
(Valenza et al., 2019) and in 11 of 225 cefotaxime-resistant E. coli isolated from UTIs in 
South-West England during 2017 and 2018 (Findlay et al., 2020). ST 1193 is currently 
much more expanded in China (Xia et al., 2014; Wu et al., 2017) and the USA (Johnson 
et al., 2019; Tchesnokova et al., 2019). 
Despite the emergence of ST1193 and ST131 cluster C1-M27, it is clear that ST131 
subclade C2 associated to CTX-M-15 remains the most prevalent sublineage among 
ESBLEC in the two hospitals studied here, as it is the case in most of the European 
hospitals (Merino et al., 2016; Sauget et al., 2016; Roer et al., 2018; Birgy et al., 2019; 
Valenza et al., 2019; Findlay et al., 2020). The C2 subclade isolates showed a higher 
virulence score (mean 14.250) compared with the subclade C1-M27 ST131 isolates 
(mean 10.875) (P<0.001) and non-ST131 isolates (mean 7.661) (P<0.001). Interestingly, 
the papAH, papC, papEF, cnf1 and hlyA genes were associated with the C2 subclade 
isolates, which mostly displayed the vitotypes A, A-like, C2, E and F. The virotype A-
like is new and differs from the virotype A in the type of capsular kpsM II gene that is K5 
instead of K2 (Dahbi et al., 2014). In future studies, it would be very interesting to 
determine the whole genome sequence of the C2 subclade isolates belonging to the new 
virotype A-like. 
Of note, four isolates belonging to clones B2-CH38-15-ST95 and B2-CH38-294-
ST95 were those with the highest number of VF-encoding genes (mean 21.000). These 
four UTI isolates were classified as APEC and could be of avian origin and foodborne 
pathogens (Vincent et al., 2010; Singer, 2015; Liu et al., 2018a). ST95 is one of the most 
frequently ST identified among E. coli causing human extraintestinal infections, but it is 
rarely producer of ESBL enzymes (Kallonen et al., 2017). Nevertheless, recently Birgy 
et al. (2019) detected nine ST95 isolates among 251 ESBLEC from pediatric FUTIs. The 
combination of so many virulence genes and resistance-encoding genes in this successful 
ST is very worrying. 
Despite the enormous genetic diversity observed in our ESBLEC collection (71 
clones amongst 188 ESBLEC), it can be concluded that the majority of the isolates belong 
to only three clonal complexes (CC10, CC23, and CC131) and that ST131 subclade C2 
associated with the production of CTX-M-15 remains the most prevalent E. coli lineage 




5.1.3 BIOFILM PRODUCTION IN E. COLI CAUSING EXTRAINTESTINAL INFECTIONS IN 
HUMANS 
Here, we assessed the early biofilm production, i.e., adhesion stage of 394 E. coli 
clinical isolates obtained from different sources, at the same time periods, in two distant 
hospitals (Spanish and French hospitals). This study is in accordance with previous 
researches with regard to the wide spectrum of biofilm formation within ExPEC 
(Ponnusamy et al., 2012; Agarwal et al., 2013; Shokouhi Mostafavi et al., 2018). Using 
the BioFilm Ring Test® like us, Olivares et al. (2016) found that P. aeruginosa causing 
infection in cystic fibrosis patients segregated into three groups (strong, moderate, and 
weak producers) at the early stage of biofilm formation. Accordingly, difference in ability 
to quickly adhere seems to exist within isolates of different bacterial species. The biofilm 
production displayed by our ESBLEC collection is also in accordance with that displayed 
by the ESBLEC collection recently published by Surgers et al., (2019), i.e., predominance 
of weak biofilm producers among ESBLEC. 
The novelty provided by our study consisted of the molecular characterization of the 
394 isolates with regard to phylogroups, clonal lineages, VF-encoding genes, and FimB, 
a co-factor of the regulation of the synthesis of type 1 fimbriae that are critical adhesins 
for E. coli biofilm formation (Beloin et al., 2008). Thus, we showed that among the 
characteristics significantly associated with EBF, clonal lineage was the most suitable 
characteristics to explain the variability of EBF. Association between clonal lineage and 
EBF phenotype has recently been shown among bone and joint infection Staphylococcus 
aureus isolates analyzed by using the BioFilm Ring Test® (Tasse et al., 2018). 
Among the limited number (<10%) of our E. coli that quickly and persistently 
produced early biofilm at high levels (G1 isolates), five clones (B2-CH14-2-ST127, 
CH52-5, and CH52-14 sub-lineages of B2-ST141, B2-CH40-22-ST131, and E-CH100-
96-ST362) accounted for 41.7% of the 36 G1 isolates. Notable features have previously 
been provided by different studies for these clones. The B2-ST127 clone, which is one of 
the dominant clones among uropathogenic isolates (Yamaji et al., 2018), was shown to 
be shared by humans, dogs, and cats (Johnson et al., 2008b) and to be a dominant gut 
colonizer of humans (Ulleryd et al., 2015) and fruit bats (Nowak et al., 2017). The B2-
ST141 clone was characterized by Clermont et al. (2017) as a commensal clone, i.e., 
digestive tract resident with low level of human invasiveness, through a study assessing 
the pathogenesis of bacteriaemic E. coli by matching large collections of bacteriaemic 
(Lefort et al., 2011) and commensal isolates (Massot et al., 2016). Other studies showed 
that this clone accounted for the gut dominant E. coli population of some healthy subjects 
(Leflon-Guibout et al., 2008; Nicolas-Chanoine et al., 2013) and was one of the dominant 
clones in the digestive tract of Antarctic pinnipeds (Mora et al., 2018). The B2-CH40-22 
ST131 clone was shown to have similar features to the B2-CH52-5 ST141 clone with 
regard to healthy subjects (Nicolas-Chanoine et al., 2017) and Antarctic pinnipeds (Mora 
et al., 2018). It was also found in poultry digestive tract and retail chicken meat and was 
shown to be a foodborne uropathogen (Liu et al., 2018a). Concerning the E-CH100-96 
ST362 clone, our study is, to our knowledge, the first one reporting the presence of this 
clone in humans. Indeed, it was identified so far in chicken (Cortés et al., 2010) and as 
an agent causing bovine mastitis (Freitag et al., 2017). Accordingly, most of these clones 
appear to be both ExPEC and intestinal dominant colonizers in some mammals and birds. 
We found that some VF genes, including papC, sfa/focDE, cnf1, hlyA, and ibeA, were 
mostly identified in G1 isolates, i.e., strong biofilm producers. All these VFs had already 
been shown to be associated with E. coli strong biofilm producers (Naves et al., 2008), 
and two of them, sfa/focDE and ibeA, had been shown to be characteristic traits of 




al., 2009b). The implication of AIEC in Crohn’s disease (Darfeuille-Michaud et al., 2004) 
was notably based on their high biofilm production. Indeed, in an inflamed intestinal 
environment, their biofilm-related mucosal attachment could allow them to penetrate the 
inner mucus layer and adhere to the epithelial surface, thus enabling more direct 
stimulation of epithelial and immune cells (Glasser et al., 2001; Sartor, 2018). It is 
interesting to note here that Martinez-Medina et al. (2009a) found two ST131 isolates 
carrying the ibeA gene in the AIEC collection that they compared with ExPEC isolates. 
This finding suggests that it would be of interest to investigate all the AIEC phenotypic 
and genotypic features in our strong biofilm producers (Camprubí-Font et al., 2019). 
The present study in which a wide collection of E. coli isolates was analyzed confirms 
the results that we previously obtained with few isolates about the difference in early 
biofilm production between B2-CH40-22 ST131 and B2-CH40-30-ST131 clones, i.e., 
strong and weak production, respectively (Nicolas-Chanoine et al., 2017). Knowing that 
the B2-CH40-22 ST131 clone is the ancestor of the globally disseminated B2-CH40-30-
ST131 clone (Ben Zakour et al., 2016), the loss of the ability to strongly produce biofilm 
at the early step of biofilm formation by the B2-CH40-30-ST131 clone could appear as 
an evolutionary adaptative trait in ST131 lineage. 
In conclusion, this study highlights that the ability to quickly and persistently produce 
biofilm at high levels is a property displayed by a limited number of clones, some of 
which have been found in previous studies as dominant colonizers in some mammals and 
birds. 
5.1.4 WHOLE GENOME ANALYSIS OF 75 ESBLEC 
Knowledge on the bacterial population structure is necessary to better understand 
outbreaks and the dynamics of bacterial changes and spreading (Turrientes et al., 2014). 
Here, we investigate the insights of ST131 clonal complex ESBLEC (STC131 group) and 
other emerging ESBL lineages (non-STC131 group) through the analysis of a total of 75 
ESBLEC genomes. 
The phylogenetic research includes two core genome analysis (CG-1 and CG-2). CG-
1 includes the 75 ESBLEC genomes and represents a total of 16 different STs. In those 
genomes, the core includes 1,659 common CDS and reaches a distance of 38,854 SNPs 
between them. This analysis foregrounds the genomic diversity of ESBLEC population. 
E. coli is the better known example of host-adaptable bacteria species and the remarkable 
diversity of E. coli has been associated with its aptitude to colonize different 
environments (becoming for example an extraintestinal pathogen) and become a very 
important contributor to most mammal’s microbiome outcompeting other bacteria. 
Therefore, E. coli is the dominant specie amongst the human gut Enterobacteriae 
bacterial population in healthy adults (Martinson and Walk, 2020).  
Besides, CG-1 exhibit six clusters with a clear correlation with the phylogroups 
structure of E. coli genomes. The phylogroups structure of E. coli has been historically 
linked with the lifestyle of the strains. The most ancient lineages include strains belonging 
to B2, D, F and G phylogroups which are associated with extraintestinal infections, 
afterward phylogroup E had emerged and diverged on phylogroups A, B1 and C which 
are associated with severe intestinal pathologies such as haemolytic uremic syndrome and 
dysentery (Escobar-Páramo et al., 2004; Clermont et al., 2019). However, a recent study 
supports the hypothesis of long-lived resident E. coli of the human gut belonging to the 
phylogroups B2, A and F (Martinson and Walk, 2020). What is clear is that E. coli strains 
are not equal in regard to their ability to colonize different environments or become a gut 
resident (Martinson and Walk, 2020). We must take into consideration that resident E.coli 
are subject to the exposure of antibiotics during each medical treatment that the host may 




E. coli clones become pathogens it still open for debate. Thus, more research is needed to 
understand this important aspect of the E. coli ecology.  
In CG-2 we included 81 genomes from the ST131 clonal complex (our 30 STC131 
genomes plus other 51 ST131 genome references). The 81 genomes shared 2,147 CDS 
that constitute their core genome and reach a distance of 5,794 SNPs between them. 
ST131 phylogeny is characterised by the presence of a main O, H and fimH type related 
to each ST131 clade. CG-2 exhibit six clusters, cluster 1 includes 49 genomes with 
fimH30 from clade C and reach a distance of 124 SNPs between them, cluster 3 includes 
17 genomes with fimH22 from clade B and reaches a distance of 888 SNPs between them, 
cluster 4 includes one genome with fimH54 from clade I1 and cluster 6 includes 12 
genomes with fimH41 from clade A and reaches a distance of 652 SNPs between them. 
Cluster 2 and 5 constituted two new clades. Cluster 2 includes one genome with the fimH5 
allele variant and a mean distance of 336 SNPs to the closest branch of genomes in CG-
2 (clade C genomes) and cluster 5 includes one genome with the fimH35 allele variant 
and a mean distance of 1,329 SNPs to the closest branches of genomes in CG-2 (clade C 
and clade B genomes). It is interesting to note how cluster 1, which includes genomes 
from clade C, exhibits very short intern branches in comparison with its sister clades A 
and B. Clade C represents the major part of human clinical isolates from the ST131 clone 
(Nicolas-Chanoine et al., 2014; Pitout and DeVinney, 2017) and it seems that those 
genomes had a more conserved core genome structure than those from other clades of the 
ST131 lineage. This population structure certainly reflects some aspects of its 
ecogenetics, which is highly dependent on recombination and mutational events 
involving adaptative mobile genes (Wirth et al., 2006; Jaureguy et al., 2008; Tenaillon et 
al., 2010).  
We also analysed the virulome, resistome and plasmidome of the sequenced genomes 
and confirmed our previous molecular characterisation. There was a clear association 
between ExPEC status, UPEC status and the STC131 group of genomes (p=<0.0001). 
Nonetheless, some VF-encoding genes, significantly associated with the STC131 group 
and related with the ExPEC-UPEC status attribution, were also found in genomes 
belonging to ST38, ST88, ST95, ST354 and ST1193. Therefore, all ST95 and ST1193 
are designated as ExPEC and UPEC. ST38 and ST88 are only ExPEC. 
Furthermore, some VF-encoding genes were found to be significantly associated with 
each defined group of genomes (STC131 or non-STC131). This refers to the toxin 
encoding gene sat, the adhesion encoding genes afaCD/draP and yfcV, the type II capsule 
encoding gene kpsM, the iron uptake encoding genes iucD, iutA, chuA, fyuA and other 
miscellaneous genes such as malX (pathogenicity-associated island marker), usp 
(uropathogenic-sepcific protein) and ompT (outer membrane protein) that were more 
frequent in the STC131 group (p=<0.010). Besides, a distinct distribution was also 
observed for some infrequent genes such as the toxin-encoding genes cnf1, hlyA, hlyB 
and hlyD that were only present in the STC131 group (p= <0.003) or the fimbrial adhesion 
encoding genes afaA-VIII, afaB-VIII, afaC-VIII, afaD-VIII, afaE-VIII, the 
enteroaggregative E. coli HilA homolog encoding gene eilA and the invasion of the brain 
endothelium encoding gene ibeA that were only present in the non-STC131 group 
(p=<0.037). Going deeper, the afa genes codifying for fimbrial adhesin AfaE-VIII were 
found in the ST1615 genomes, the eilA gene was found in the ST38, ST354 and ST648 
genomes and the ibeA gene in the ST95 and ST354 genomes. Moreover, group II capsule 
of E. coli was present in 53% of the screened genomes and was more frequent in the 
STC131 group (p<0.0001). K1 type was detected in seven genomes, three ST1193 and 




A) and one ST354; and K5 type in 16 genomes, nine ST131 (five from subclade C2 and 
four from cluster C1M27), four ST38 and three ST648.  
In regards to the resistome, we first investigated the chromosome. We outline a high 
percentage of quinolone resistance-associated point mutation in the chromosome of both 
groups of genomes.  
It is a well-supported hypothesis that the selective pressure exerted by the widespread 
introduction of fluoroquinolones and extended-spectrum cephalosporins in clinical 
medicine around the nineties have contributed to the persistence of the chromosomal 
fluoroquinolone resistance mutations and the acquisition of a specific IncF-blaCTX-M 
harbouring plasmid among clade C of ST131. Although the evolutionary dynamics of 
plasmid-host combination remain to be clearly elucidated, it is evident that this 
association has subsequently favoured the global dispersion of this high risk clone 
(Stoesser et al., 2016b). Thus, a similar phenomenon could plausibly be replicated in other 
emergent resistant lineages of E. coli. 
The plasmidome of the 75 ESBLEC genomes harboured a total of 228 plasmids, of 
which 86 (32%) were found within the 30 genomes that constituted the STC131 group 
and 142 (62%) were found within the 45 genomes that constituted the non-STC131 group. 
Regarding the relaxase families, MOBP, MOBF and MOBQ types were the most frequent 
including 92% of the plasmids. We described a wide variety of incompatibility groups 
(Inc.) and this diversity was higher within the non-STC131 than the STC131 group (12 
Inc. including Col-like, F, Q, I, X, Y, P, 13, HI2, N, R and B/O/K/Z versus 6 Inc. including 
Col-like, F, X, 13, N, and B/O/K/Z, respectively). Interestingly, the plasmid diversity was 
much higher within subclade C2 than within cluster C1M27 and A of ST131. Generally, 
the virulence and resistance encoding genes are carried by plasmids belonging to the IncF 
family.  
Antibiotic resistance often disseminates in bacteria through MGEs. Therefore, in this 
study most of the resistance associated genes were found carried by plasmids. 
Nonetheless, plasmid-bacterium association within bacterial lineages have also been 
described (Price et al., 2013; Johnson et al., 2016c; Stoesser et al., 2016c; Pitout and 
DeVinney, 2017; San Millan, 2018; Kondratyeva et al., 2020). Kondratyeva et al. 2020 
had recently described an existing plasmid-clade association within ST131 lineage: I) 
CTX-M-27-encoding IncF [F1:A2:B20] is strictly found in clade C1, II) CTX-M-15-
encoding IncF [F2:A1:B-] exist only in subclade C2 and III) Col-like replicons Col156, 
Col(MG828) and Col8282 are associated with clade C1 (Kondratyeva et al., 2020). In 
our study, we found two blaCTX-M-27 genes carried by IncF [F1:A2:B20] plasmids and five 
blaCTX-M-15 genes carried by IncF [F2:A1:B-] plasmids associated with the same clades 
than Kondratyeva et al. 2020. Thus, a plasmid-clade association can also be retrieved 
from our study. Regarding clade A, we describe the presence of IncF [F29:A-:B10] and 
ICEs as adistintive features from genomes from clade C. 
In addition, we noticed that Col-like and IncF plasmids were equally dominant within 
both groups of genomes. While Kondratyeva et al. 2020 had only reported this dominance 
within the ST131 plasmidome. It is evident that IncF plasmids represent a clinically 
relevant vehicle of virulence and resistance genes within ESBLEC. The role of Col-like 
plasmids is still unknown (Kondratyeva et al., 2020). However, it can be hypothesised 
that those families of plasmids are the most influent regarding the evolutionary success 
of ESBLEC lineages witch is mediated by a stable plasmid-bacterium association that 
favours clonal expansion (Johnson et al., 2016b; Stoesser et al., 2016b; San Millan, 2018). 
Moreover, the quantity and diversity of plasmids found within the ESBLEC genomes 
highlight the important role that MGEs plays in the evolution of E. coli, in particular with 




et al., 2016b; Kondratyeva et al., 2020). In this study, we highlight the diversity of 
plasmids existing within different ESBLEC emerging lineages.  
5.2.STRAINS OF ANIMAL ORIGIN 
5.2.1 COMPANION ANIMAL: DOG RESERVOIR 
To get more insights into the population structure of canine E coli, we investigated 
those harboured in the intestinal tract of 104 healthy Spanish dogs by using different 
approaches, knowing that the gut is the reservoir of the great majority of E. coli causing 
extraintestinal infections. The phylogenetic group, VF-encoding gene and antibiotic 
susceptibility analyses, showed that among the 197 canine faecal isolates obtained from 
the 104 dogs, 84 (42,6%) belonged to B2 phylogroup, 91 (46,2%), mostly B2 group 
isolates, were classified as ExPEC and/or UPEC, and 28 (14.2%), mostly non-B2 group 
isolates, as MDR. This strongly suggests that the intestinal tract of healthy dogs might be 
an important reservoir of ExPEC and/or UPEC isolates, and in a lesser extent, of MDR 
E. coli isolates. However, some studies that focused on antibiotic-resistant canine isolates 
suggested that dogs might also be an important reservoir for antibiotic-resistant strains 
(Hordijk et al., 2013; Belas et al., 2014; Haenni et al., 2014; Rocha-Gracia et al., 2015; 
Schaufler et al., 2015; Damborg et al., 2015; Pires et al., 2016; Seni et al., 2016; Hansen 
et al., 2016; Wedley et al., 2017; Melo et al., 2018; Liakopoulos et al., 2018; Suay-García 
et al., 2019; Umeda et al., 2019; Dupouy et al., 2019; Hong et al., 2019; Karkaba et al., 
2019; Abreu-Salinas et al., 2020; Sevilla et al., 2020), notably for those producing ESBLs 
or CMY-2 (Hordijk et al., 2013; Belas et al., 2014; Haenni et al., 2014; Liakopoulos et 
al., 2018; Dupouy et al., 2019). Although there was a low prevalence of MDR isolates 
among the 197 studied isolates, we found, as previously described that they produced 
ESBLs or CMY-2.  
MLST assigned the 91 Spanish canine faecal isolates with an ExPEC and/or UPEC 
status to 34 STs among which six were displayed by 67% of the 91 isolates: ST372 
(31.9%), ST12 (9.9%), ST127 (8.8%), ST648 (6.6%), ST141 (5.5%) and ST73 (4.4%). 
Few studies have been carried out so far to characterise the ST structure of canine ExPEC 
and/or UPEC isolates. In the USA, LeCuyer et al. (2018) analysed 295 E. coli isolates 
from canine UTI. They found that ST372, which is uncommon among the human E. coli 
pathogens (Adler et al., 2012; Izdebski et al., 2013; Flament-Simon et al., 2019, 2020b; 
Manges et al., 2019), was the predominant ST in canine UTI isolates (21.7%), and this 
was, well ahead of the five other most frequent STs: ST12 (6.4%), ST73 (6.4%), ST127 
(4.1%), ST131 (4.1%) and ST297 (3.7%). A total of 170 (57.4%) of these isolates met 
the criterion to be classified as ExPEC, and, except for ST297, the most prevalent STs 
were associated with ExPEC status. In France, Valat et al. (2020) analysed 618 canine E. 
coli isolates collected from diagnostic laboratories, including 403 (65.2%) from UTIs. B2 
phylogroup was over-represented (79.6%) and positively associated with the presence of 
numerous VFs, including those defining the ExPEC status. MLST of a randomly chosen 
subset of 89 isolates belonging to B2 phylogroup revealed five dominant STs: ST372 
(17.9%), ST73 (17.9%), ST12 (10.1%), ST141 (7.9%) and ST961 (5.6%). In Australia, 
Kidsley et al. (2020b) focused their study on the canine fluroquinolone-susceptible E. coli 
clinical isolates (n=449) that were identified during a nation-wide survey of antibiotic 
resistance in Australian animals between January 2013 and January 2014. They found 
that these isolates mostly (n=317; 71%) belonged to B2 phylogroup. By using the RAPD 
typing system, they found a distribution of the 317 B2 group isolates into 35 main clusters. 
To pursue their molecular investigation, they sequenced and analysed the whole genome 
of 77 representatives of the B2 group fluoroquinolone-susceptible isolates. Thus, they 




dominant: ST372 (31%), ST73 (17%), ST12 (7%) and ST80 (7%). In sum, the present 
study and those previously published show that three STs (ST372, ST12 and ST73) are 
the dominant ST in healthy and infected dogs irrespective of the countries (the USA, 
France, Australia and Spain) and strain sources (clinical samples and faeces). Such a 
finding might argue for the “prevalence” theory with regard to UTI pathogenesis (most 
UTIs are opportunistic infections caused by bacteria that predominate in the faecal 
microbiota) in dogs. Nevertheless, the fact that the canine isolates belonging to the most 
dominant ST, either present in all studied countries (ST372, ST12 and ST73) or present 
in some studied countries (ST127 in the USA and Spain, and ST141 in France and Spain) 
were shown to harbour numerous VF-encoding genes might also argue for the “special 
pathogenicity” theory in dogs. 
Concerning the ST structure of canine MDR isolates, there seems to exist a more 
important difference between the countries than for the non-MDR isolates. MLST 
assigned the 28 Spanish canine MDR isolates to a great diversity of STs comprising 15 
established STs (ST10, ST12, ST38, ST57, ST58, ST88, ST93, ST155, ST457, ST648, 
ST695, ST1011, ST1140, ST3774, and ST8953) and seven new STs. The first 10 STs 
here listed have been identified in canine MDR isolates from different countries (Dierikx 
et al., 2012; Wagner et al., 2014; Ewers et al., 2014; Rocha-Gracia et al., 2015; Schaufler 
et al., 2015; Liu et al., 2016c, 2016b, 2017; Seni et al., 2016; Falgenhauer et al., 2016; 
Hansen et al., 2016; Wedley et al., 2017; Kawamura et al., 2017; Boehmer et al., 2018; 
LeCuyer et al., 2018; Liakopoulos et al., 2018; Maeyama et al., 2018; Marques et al., 
2018; Melo et al., 2018; Zhang et al., 2018; Zogg et al., 2018; Bortolami et al., 2019; 
Chen et al., 2019b; Umeda et al., 2019; Dupouy et al., 2019; Karkaba et al., 2019; 
Loncaric et al., 2020; Pepin-Puget et al., 2020; Valat et al., 2020). In contrast to some 
studies, we did not detect neither canine MDR isolates displaying the five important 
emerging MDR STs in humans: ST69, ST127, ST131, ST410 and ST1193 (Platell et al., 
2011; Harada et al., 2012; Haenni et al., 2014; Schaufler et al., 2015; Bogaerts et al., 
2015; Liu et al., 2016b, 2016c; Seni et al., 2016; Falgenhauer et al., 2016; Kawamura et 
al., 2017; Belas et al., 2018; Boehmer et al., 2018; LeCuyer et al., 2018; Liakopoulos et 
al., 2018; Maeyama et al., 2018; Marques et al., 2018; Zhang et al., 2018; Zogg et al., 
2018; Melo et al., 2019; Umeda et al., 2019; Bortolami et al., 2019; Bourne et al., 2019; 
Chen et al., 2019b; Pepin-Puget et al., 2020; Valat et al., 2020), canine isolates harbouring 
the mcr-1 gene encoding resistance to colistin as described in China (Wang et al., 2018a) 
nor canine isolates producing carbapeneamases, notably OXA-48, as described in 
Germany (Pulss et al., 2018), France (Melo et al., 2016), and United States (Liu et al., 
2016c). Finally, we found that none of the 29 here studied ST372 was MDR while 
previous studies have found ST372 isolates producing different types of ESBLs and 
CMY-2 (Wagner et al., 2014; Hansen et al., 2016; Liu et al., 2016c; Boehmer et al., 2018; 
Zhang et al., 2018; LeCuyer et al., 2018; Maeyama et al., 2018; Melo et al., 2018; Chen 
et al., 2019b; Karkaba et al., 2019; Pepin-Puget et al., 2020; Valat et al., 2020). 
To get more insight into the potential link between the canine ExPEC and/or UPEC 
and the E. coli isolates causing extraintestinal infections in humans, we determined which 
clone (defined by the association of phylogroup, clonotype and ST) and which serotypes 
characterised the 91 canine ExPEC and/or UPEC in order to compare them with human 
E. coli clinical isolates collected in 2015 and 2016 in Spain and France and characterised 
for these two traits (Flament-Simon et al., 2019). This approach allowed us to found that 
among the 50 clones identified in the 91 Spanish canine ExPEC and/or UPEC isolates, 
15 were present in the human collection accounting for 49 (18,8%) of the human isolates. 
However, only 31 of the 49 human ExPEC and/or UPEC isolates presented the same O:H 




lineage shared by dogs and humans, we observed various features about the distribution 
of the human isolates when the lineages included several clones and several clone-related 
serotype in dogs. This feature shows that it is difficult to make hypotheses about the 
relationship between canine and human isolates sharing a given clone-serotype couple in 
a given lineage without knowing the structure of the clone-serotype couples in the given 
lineage in humans. For example, we had found (Flament-Simon et al., 2020b) that the 
human ST73 isolates were distributed into four clones of which two here were identified 
in dogs. In human, three of the four clones comprised, each, isolates with different 
serotypes but one serotype (O6:H1) was exhibited by isolates distributed into the four 
clones. In dogs, the ST73 isolates exhibited only serotype O6:H1. This suggests that 
serotype might be an ecological niche marker meaning, in this case, that isolates of the 
lineage ST73 exhibiting serotype O6:H1 are adapted to both dogs and humans. However, 
the Kidsley et al. (2020b) study in which a phylogenetic tree was built with the genome 
of ST73 strains from dogs, cats and humans, seems to contradict this hypothesis. Indeed, 
the 13 studied Australian canine isolates of the lineage ST73 exhibited four serotypes 
among which serotype O6:H1 was exhibited by only one isolate that formed an animal-
specific cluster (containing cat O6:H1 ST73 isolates) distinct from the four main clusters 
of human O6:H1 ST73 isolates. Nevertheless, the hypothesis that we made for serotype 
O6:H1 with regard to Spanish canine and human ST73 isolates could be made for 
serotype O2:H1 with regard to Australian canine and human ST73 isolates as this serotype 
was shared by clustered canine and human isolates. By extending the comparison of the 
structure of clone-serotype couples to the other human-specific-human ST lineages 
(ST127, ST141 and ST1193) shared by the Spanish studied dogs and humans, we 
observed that the clone-serotype couples shared by dogs and humans comprised mostly 
the serotype the most frequent in the human clones. This feature seems to indicate that 
serotype frequency might be a variable involved in the E. coli exchanges between dogs 
and humans. Concerning the dog-specific lineage ST372, we had found only one clone 
comprising to isolates in Spanish humans while we found here five clones in the 29 
Spanish dogs. Among the six serotypes exhibited by these 29 canine isolates, the serotype 
exhibited by the two human ST372 isolates corresponded to one (O18:H31) of the two 
dominant serotypes in dogs that was, on the other hand, exhibited by canine isolates 
belonging to three different clones. Thus, the suggestions that we made about the fact that 
serotype could be an ecological niche marker and that serotype frequency could shape the 
E coli exchange between dogs and humans seems to be able to be applied to the lineage 
ST 372.  
Interestingly, concerning the 24 clones identified in the 28 canine MDR isolates, 
which were mostly non-B2-group isolates, we observed that if there were some clones 
(n=9) shared by the Spanish human (35 of 394) and canine (10 of 197) isolates there was 
only one isolate that shared the same clone and the same serotype as one canine isolate.  
To better understand the potential relationship between canine and human E. coli 
isolates with regard to the lineage ST372, we turned to the whole genome sequencing and 
analysis of 197 ST372 strains (151 from dogs and 46 from humans). The SNP analysis of 
the core genome of these 197 strains revealed an extensive phylogenetic diversity of the 
ST372 isolates that was segregated into six clusters. Cluster 1 comprised 91.4% of canine 
strains while cluster 2 comprised 60.9% of human strains. Cluster 2 was specific of human 
strains associated with serotypes O18:H31 and O45:H31, the latter serotype being 
exclusively found in human ST372 strains. Three other serotypes were the most prevalent 
serotype among strains belonging to cluster 1, including O4:H31 and O15:H31 associated 
with canine strains, and O83:H31 identified in similar proportion among canine and 




CH103-9-ST372, belonging to cluster 1 and having serotype O83:H31 might cause 
extraintestinal infections in humans and dogs, as already suggested by the clone-serotype 
couple analysis, whereas strains of this clone belonging to cluster 2 and having serotypes 
O18:H31 and O45:H31 might cause only human extraintestinal infections. Molecular 
epidemiological studies on E. coli ST372 in human extraintestinal infections are required 
to confirm these suggestions.  
Furthermore, we localised ICEs in the chromosome of 22 of the ST372 sequenced 
genomes and confirmed that all ICEs belong to a yersiniabactin synthesis-associated ICE 
type (ICEKp1 family) with relaxase type MOBQ. In contrast, we found very few plasmids. 
Moreover, we found that the number of plasmids retrieved from the human ST372 strains 
was higher than that of plasmids found in the canine strains (four plasmids in the two 
human strains versus seven plasmids in the 21 canine strains). Interestingly, the genome 
of canine LREC_356 strain from cluster 4 carried two plasmids, and was the canine strain 
genome the most similar to human strain genomes. Those plasmids were not rich with 
genes encoding of antibiotic resistance and virulence-factors. Nonetheless, a high number 
of virulence factor encoding-genes were found in the chromosome of the ST372 genomes 
and we hypothesised that the origin of the UPEC status of ST372 strains is due to the 
acquisition of ICEs harbouring the genes associated with this status. Although there is 
still limited knowledge about the origin of genomic islands, like ICEs or pathogenicity 
islands (PAIs), it has been speculated that they derive from the integration of plasmids or 
phages into the chromosome. Further, genomic research has shown that genomic islands 
have played a major role in the transformation of avirulent into virulent bacteria. Besides, 
most VFs of ExPEC are encoded by ICEs and PAIs (Schubert et al., 1998; Dobrindt et 
al., 2004; Robinson et al., 2018; Denamur et al., 2020; Desvaux et al., 2020). 
In summary, the intestinal tract of healthy dogs appears as an important reservoir of 
ExPEC and/or UPEC and, to a lesser extent, of MDR E. coli isolates. However, the canine 
MDR isolates could be a good reservoir of ESBLs and CMY-2 because most of them 
produce these enzymes. Among the canine isolates displaying an ExPEC and/or UPEC 
status, clone B2-CH103-9-ST372 was dominant. This canine clone and 14 others, also 
displaying an ExPEC and/or UPEC status, had been identified in isolates previously 
published as causing extraintestinal infections in human suggesting a zoonotic potential 
of these clones. WGS analysis suggests that canine strains of clone B2-CH103-9-ST372, 
belonging to cluster 1 and having serotype O83:H31 might cause extraintestinal 
infections in both humans and dogs, whereas those strains of this clone belonging to 
cluster 2 and serotypes O18:H31 and O45:H31 might cause only human infections. 
Taking into consideration that Kidsley et al. (2020b) have recently characterised the 
phylogenetic relationship between canine, cat, and human isolates of the lineage ST73, 
such studies are still required for the other ST lineages and clones that we showed in this 
study to be shared by canine and human isolates in order to clarify their potential role in 
infection occurrence in both dogs and humans. 
5.2.2. PRODUCTION ANIMAL: SWINE RESERVOIR 
As far as we know, there are only six reports on ST131 from swine: (I) Trobos et al. 
(2009) studied 68 sulphonamide-resistant E. coli from different hosts and identified the 
first swine ST131 isolate obtained from pork meat in Denmark in 2003; (II) Schink et al. 
(2013) detected a CTX-M-1 ST131 isolate recovered from a porcine gastrointestinal tract 
infection among 495 ESBL-producing E. coli analysed in Germany during the years 
2006–2007; (III) Herrera Estévez (2015) detected 18 ST131 isolates from 200 pork meat 
samples obtained in Spain during the years 2011 and 2012; (IV) Liu et al. (2018c) 
collected an isolate from a diarrheal pig among 44 ESBL-producing E. coli from 




isolates recovered from the 1823 piglets with diarrhoea sampled in Spain between the 
years 2009 and 2017; and (VI) Reid et al. (2019) reported two highly related ST131 E. 
coli isolates, the first from a healthy pig and the second from a human urinary tract 
infection, obtained in New South Wales (Australia) in 2007 and 2009, repectively.  
In the present study, we performed WGS analysis of a collection of 11 representative 
ST131 isolates obtained from piglets with diarrhoea and pork meat in Spain. All of the 
11 ST131 isolates belonged to serotype O25b:H4 and clade B, and presented a high 
number of virulence genes typical of E.coli that cause extraintestinal infections. In 
addition, the 11 porcine isolates harboured traits that genetically satisfied the criteria for 
designation as ExPEC, UPEC and APEC status being designated as APEC, UPEC and 
ExPEC like isolates due to their site of isolation. Although seven of the 11 ST131 isolates 
were isolated from piglets with diarrhoea, none of them were positive for virulence genes 
of intestinal pathogenic E. coli (Mora et al., 2011). 
In annex 2, Figure S21, based on the results published by Matsumura et al. (2017) 
and Ben Zakour et al. (2016) we had represented the already known ST131 lineages plus 
the new lineages found in this study. These sublineages were designated according to 
their fimH allele (type 1 fimbriae adhesin gene), phylogenetic clade (A, B, B0, I1, C0, C, 
C1, C2, and C3) and resistance profile. Briefly, B-H22 clade, a fluoroquinolone (FQ) and 
cephalosporin susceptible ancestor, evolved in C-H30R (where “R” indicates resistance 
to FQ) clade that was the predecessor of two sister subclades C1-H30R and C2-H30Rx 
(often carrier of the blaCTX–M–15 enzyme). Later, two additional ST131 sublineages 
referred to C1-M27 (positive for the blaCTX–M–27 enzyme) and C1-nM27 (non ESBL or 
positive for the blaCTX–M–14 enzyme) have been described. The ST131 clonal group 
accounted for 490 (16%) of 2995 isolates obtained from extraintestinal clinical samples 
collected in five Spanish hospitals during the period 2005 to 2012 (Dahbi et al., 2014). 
The most common lineages in this clinical collection were the C2-H30Rx (61.6%), B 
(17%) and C1-nM27 (16%). Recently, Mamani et al. (2019) also described the subclade 
C2-H30Rx as the most prevalent (85%) among 41 ST131 ESBL-producing E. coli 
causing bacteraemia in a Spanish hospital over a 12-year period (2000 to 2011). In 
contrast, almost all Spanish ST131 isolates obtained from animal origin belonged to clade 
B. In our laboratory we have tested a collection of 98 ST131 isolates from animals (57 
from avian, 36 porcine and five from Antarctic pinnipeds) and all but one from pinnipeds 
belonged to clade B. Although clade B isolates share numerous virulence genes, virotypes 
vary depending on the origin of the isolates. Thus all avian isolates have virotype D4 
(ibeA, neuC-K1) while swine isolates have virotypes D2 (ibeA, papG III, cdtB, kpsM-II-
K5) and D5 (ibeA, papG III, cnf1, hlyA, kpsM-II-K5). Among the 45 clade B isolates 
causing bacteraemia in humans in Spain, the most frequent virotype was D2 (n=19), 
followed by virotypes D3 (n=12), D1 (n=8), D4 (n=6) and D5 (n=6) (Blanco et al. 
unpublished data).  
The core genome SNP-based phylogenetic tree of 84 human and animal ST131 
isolates analysed in this study showed (Figure 18) that they are mostly clustered into three 
well-defined clades (A, B and C), and similarly to Petty et al. (2014) study, we have 
observed that clade A is the most divergent from clades B and C. Our results also agree 
with those published by other authors (Ben Zakour et al., 2016; Matsumura et al., 2017b; 
Liu et al., 2018a; Decano and Downing, 2019) regarding that clade B isolates are 
displayed into multiple subclades. We identified the six subclades (B0, B1, B2, B3, B4, 
B5, B6) described by Ben Zakour et al. (2016) and five new ones (B6-like, B7, B8, B9). 
Notably, the 11 ST131 porcine isolates from this study were grouped in the new subclades 
B6 (four isolates from pork meat and virotype D2) and B7 (seven isolates from piglets 




porcine origin, while the new subclades B8 and B9 included only ST131 isolates from 
Antarctic pinnipeds. In contrast, avian isolates of virotype D4 were distributed in the 
subclades B2, B3 and B5. 
The newly described B6 and B7 subclades were primarily associated with porcine 
isolates, but also include some isolates causing bacteraemia and other extraintestinal 
infections in humans. Therefore, it is remarkable how those human isolates were closely 
related (46-60 SNPs average distance) with porcine isolates. Those results suggest the 
ecological overlap of human and animal isolates. Recently, Reid et al., (2019) compared 
the genomes of two ST131 clade B fimH22 isolates obtained in Australia, the first one 
isolated in 2007 from a healthy piglet and the second one obtained in 2009 from a human 
urinary tract infection. This study showed that the two isolates were highly related, 
separated by only 20 core SNPs (Reid et al., 2019). Thus, the analysis of the phylogeny 
confirmed E. coli ST131 as pathogen capable of frequent inter-species movements.  
The plasmidome of E. coli ST131 clade B from porcine origin had shown variability 
and some interesting differences concerning the actual published data. IncF plasmids are 
a common feature in all ST131 isolates (Lanza et al., 2014), having at least one per isolate 
in this study. Specifically, F1:A2:B20 and F2:A1:B- plasmids are more commonly 
associated with the C1-H30R clade and C2-H30Rx, respectively (Johnson et al., 2016b) ⁠. 
In contrast, F2:A-:B1 plasmids were dominant in the porcine clade B isolates used in this 
study. This type of plasmid was absent in 35 non-ST131 E. coli porcine isolates from 
colibacillosis (García-Meniño et al., 2019), suggesting that IncF plasmids vary greatly 
within the different lineages. Reid et al., (2019) reported 23 F-types among 282 isolates 
from a mixture of origins belonging to the clade B of ST131 and the F2:A-:B1 IncF-
subtype was one of the commonest (32%).  
In accordance with previous studies, plasmids carrying virulence genes belong to the 
IncF family (Lanza et al., 2014; Nicolas-Chanoine et al., 2017). All the IncF plasmids 
found in this study conserved the ColV region, frequently detected among avian 
pathogenic E.coli (APEC) (Liu et al., 2018a). This region comprises the iss (increased 
serum survival) gene, the iroBCDEN gene cluster (encoding the salmochelin siderophore 
system present in Salmonella enterica spp. and some ExPEC isolates), the iucABCD 
operon (encoding the enzymes of the biosynthetic pathway for aerobactin), iutA (outer 
membrane receptor of ferri-aerobactin complexes) gene, cvaB and cvaC (production of 
colicin) genes, sitC (Salmonella iron transporter C) and an ompT-hlyF-mig14 cassette 
(outer membrane related genes). Some APEC cause human infection (Liu et al., 2018a), 
nevertheless ColV plamids were absent in specific human clades, so they may not be a 
necessary feature to cause human infection (Reid et al., 2019). It is currently unknown 
which advantages could the IncF plasmids confer to the bacterial cell apart from virulence 
and resistance to antibiotics. However, Johnson et al. (2016) has hypothesised that they 
must play multiple roles in the host success because ST131clone has adapted to harbour 
these plasmids at lower fitness cost, and has stabilized them through mutational events. 
We assume that the presence of both, resistance and virulence genes, on the same MGE 
is worrying for public health, as shown in our study in IncF plasmids like pLREC161_1 
and pLREC 159_2. For instance, the evolutionary analysis performed by Ben Zakour et 
al. (2016) proved that ST131 emergence was adapted by isolates that had acquired first a 
subset of virulence genes followed by the gain of antibiotic resistances. 
ColE1-like plasmids were the second more prevalent in our collection and the 
replication protein could not be determined, these results are in accordance with the 
findings of Lanza et al. (2014). Furthermore, ColE plasmids have been reported as mcr-
4 and mcr-5 carriers (Borowiak et al., 2017; Carattoli et al., 2017; García-Meniño et al., 




they might be an important adaptive weapon. Moreover, we described one MOBP131 and 
two MOBV2 plasmids, which are not frequently documented and therefore absent among 
the description given by Lanza et al., (2014) over ST131 plasmidome. Although, another 
MOBP131 plasmid has been recently found from a blaOXA-48  E. coli ST131 isolate collected 
from a patient with urinary infection (Stoesser et al., 2016c), and MOBv2 plasmids have 
been described in other STs, such as ST69 from a human urine sample and ST93 from 
chicken meat samples (de Been et al., 2014). Besides, MOBV2 plasmids pLREC153_4 
and pLREC157_4 showed structural homology (around coordinates 3.7 kb to 7 kb in 
annex 2, Figure S12) with the pEC0674 plasmid (6 kb), an mcr-5 carrier plasmid 
belonging from an ST29 E. coli isolate recovered from porcine faeces in Germany 
(Hammerl et al., 2018). Finally, and also barely documented, were the cryptic plasmids 
found in our study. Similar small no-MOB plasmids than pLREC158_3, pLREC159_5, 
pLREC159_6, pLREC160_7 and pLREC161_4, have been reported among ST131 
isolates. The role of these  plasmids is still unknown but researchers have suggested that 
they could be providing useful mobilization tools for ST131 adaptation (Lanza et al., 
2014).  
ARGs conferring resistance to penicillin/ampicillin, tetracycline, quinolones and 
colistin were the most common determinants. García-Meniño et al., (2019) described 
chromosomal mutation (PmrB V161G or PmrA S39I) in addition to the plasmid 
mechanism (mcr) in 16 (46%) of non-ST131 colistin-resistant porcine E.coli isolates. 
Here, any complementary chromosomal mechanism related with system PmrAB was 
found. Nonetheless, some drug efflux genes were found in plasmids. Members of the lnu 
(previously lin) gene family (mediate lincosamide resistance) (Achard et al., 2005; 
Roberts, 2008) and the mef(B) gene, which coexists with the aadA and sul3 resistance 
genes (pLREC161_2). This combination has previously been described in plasmids from 
porcine E. coli isolates and mediates macrolide resistance (Liu et al., 2009). 
The recent analysis of 35 colistin-resistant non-ST131 E. coli isolates from porcine 
colibacillosis showed that 18 isolates (51%) were carriers of the mcr-1.1 gene variant. 
Those isolates were all MDR and the 50% belonged to Clonal Complex 10 (6 ST10, 1 
ST5786, 2 ST7323). However, the remaining isolates belonged to different linages with 
single representants (ST1, ST29, ST42, ST93, ST100, ST118, ST156, ST398, ST4247). 
The mcr-1.1 gene was located in plasmids IncHI2 (33%) and IncX4 (22%), but it was 
also found chromosomally encoded in four isolates (García-Meniño et al., 2019).  
Currently, the mcr-1 cassette was found in a large diversity of plasmids and clonal 
lineages of E. coli. The broad adaptation of colistin resistance all over the world could be 
due with the ease with which the mcr-1 gene integrates into various regions (Hadjadj et 
al., 2017). There is an association with successful plasmid families (Matamoros et al., 
2017; Zhong et al., 2018). On the other hand, any association with clonal lineages of E. 
coli is described (Li et al., 2018). However, the description of mcr-1 positive E. coli 
ST131 isolates is exceptionally worrying. Because ST131 has once been responsible for 
the worldwide appearance ESBL resistances due to the acquisition of specific IncF 
epidemic plasmids harbouring blaCTX-M-15 gene (Nicolas-Chanoine et al., 2007b, 2014; 
Mathers et al., 2015) and therefore, major therapeutic failure could come due to the 
association of mcr-1 gene with other broad-spectrum resistance mechanisms, such as 
ESBLs and/or carbapenemases (Du et al., 2016; Haenni et al., 2016; Li et al., 2016; 
Olaitan et al., 2016; Skov and Monnet, 2016). Further, clade B of ST131 has been 
signalled out as a potential foodborne uropathogen and as a stronger early biofilm 
producer than clade C of ST131 (Nicolas-Chanoine et al., 2017; Liu et al., 2018a; 




In this study the genetic context of mcr-1 gene was diverse. Recent studies propose 
that the transposon Tn6330, flanked at both ends by ISApl1, has lead mobilization of mcr-
1 gene. Therefore, four structures of mobile elements carrying mcr-1 have been described: 
(I) The composite transposon Tn6330 (ISApl1–mcr-1–orf–ISApl1 structure); (II) a single 
ISApl1 upstream (ISApl1–mcr-1–orf structure); (III) a single ISApl1 downstream (mcr-
1–orf–ISApl1 structure); and (IV) and sequences lacking ISApl1 altogether (mcr-1–orf 
structure). Although a few other truncated or interrupted versions have been reported 
(Pham Thanh et al., 2016; Snesrud et al., 2016). In the study carried by  Snesrud et al. 
(2018) a prevalence of 11 % for structure I, 22% for structure II, 1% for structure III and 
66% for structure IV (with no associated IS) have been described. Besides, the upstream 
ISApl1 element was observed in 78% of IncHI2 plasmids (Matamoros et al., 2017) while 
the mcr-1–orf structure has been described as dominant in small mcr-1-IncX4 
plasmids(Li et al., 2017b; Sun et al., 2017). These results are in line with our findings. 
The five ST131 colistin-resistant isolates from this study presented the mcr-1.1 allele 
(KP347127.1) and showed the mcr-1–orf structure. However, pLREC159_1(IncHI2) 
presumptively harbored the ISApl1 upstream while any copy of ISApl1 was present 
around the mcr-1 gene in pLREC160_2 (IncX4). Nevertheless, pap2 gene and insertion 
sequences IS26 and IS1924 were present in pLREC160_2. Zhong et al. (2018) suggested 
that for IncX4 plasmids IS26/26 structures could be involved in mcr-1 gene mobilization. 
The BRIG comparison showed that the mcr-1 harbouring IncX4 plasmids were 
genetically homologous between each other as previously described (Sun et al., 2017), 
suggesting that mobilization of the mcr-1 cassette was quite stable within this type of 
plasmids. Furthermore, pLREC159_1 and pLREC176_1 had almost identical in structure 
around the mcr-1 gene and were related to the presence of tellurium resistance genes, as 
well as, for pLREC161_1. This heavy metal resistance lend HI2 plasmids to success in 
wastewater environments (Reid et al., 2019). 
Moreover, a highly relevant finding of the present study was the appearance of 
chromosomally encoded colistin resistance. We found a presumptive ISApl1–mcr-1–orf–
ISApl1-like structure. This genetic arrangement was described as the most prevalent by 
Li et al. (2018) ⁠ in bacterial chromosomes. It has been proposed that the lack of one or 
both of the ISApl1-elements, implies stabilization of the mcr-1 gene (non-transposable) 
(Snesrud et al., 2016, 2018). Thus, chromosomally encoded colistin resistance might 
mean a more stable inheritance in ST131 porcine lineage. Nevertheless, it also implies 
less mobilization among isolates.  
Some studies have proved that stopping using colistin in positive mcr-1 carriers 
porcine farms has resulted in the disappearance of the resistance (Randall et al., 2018). 
However, due to the MDR profile of our ST131 isolates, this might not be that easy, due 
to co-selection by other antimicrobials and host fitness adaptation. The fitness effects of 
carrying the mcr-1 gene were evaluated by Wu et al. (2018). They proved that IncI2 and 
IncX4 mcr-1 positive plasmids conferred fitness advantage for its host. In contrast, 
IncHI2 plasmids imposed a slight fitness cost and competitive disadvantage. 
To sum up, it seems that epidemic plasmids type IncX4 and IncHI2, which have been 
reported as the more prevalent carriers of mcr-1 gene, are responsible for the acquisition 
of the colistin resistance in the high-risk clone ST131 of E.coli in our isolates from 
porcine origin. Worryingly, the mcr-1 gene has also integrated an IncF plasmid form 
ST131. The clinical significance of this category of plasmids is therefore highlighted 
because they are responsible of the epidemic dissemination of ESBL resistance 
worldwide (Johnson et al., 2016b). We hypothesise that IncF plasmids like pLREC161_1 
had acquired the mcr gene via cointegrating an IncHI2 mcr-1 harbouring plasmid. The 




also shared 89 kb with pHNSHP45-2 (mcr-1-carrying IncHI2 plasmid) and possibly the 
same phenomenon had occurred.  
The impact that humans have on the environment and other species is evident. A 
multidisciplinary point of view, taking into account the environment, animals, and human 
for the surveillance of health, is given by the concept of “One Health” (Destoumieux-
Garzón et al., 2018). This philosophy fits perfectly the actual global situation. Measures 
to reinforce prevention and proper management for overall antimicrobials might be the 
right strategy to fight against antibiotic resistance. 
Further studies to understand why some plasmids evolve to become genetically stable 
are necessary to be able to anticipate the evolutionary dynamic of high risk clones. 
As a limitation, mentioning that short reads obtained by WGS do not always allow a 
perfect genome reconstruction due to the high amount of repeated sequences in the 
bacterial genomes. Long read sequencing technologies will probably bring new 
perspectives in future researches. 
In summary, the clade B of ST131 showed a huge genetic diversity, and five new 
subclades were defined (B6, B6-like, B7, B8, and B9). The majority of ST131 porcine 
isolates belong to new subclades B6 and B7. An association between the phylogeny, the 
virotype, and the origin of porcine isolates was established. Some porcine and human 
clinical isolates were highly related. Most porcine ST131 isolates are MDR (91%) and 
carry many ARGs. Colistin resistance was introduced through MGEs and had been able 
to stabilize chromosomally. IncX4 and IncHI2 epidemic mcr-1–harboring plasmids are 
responsible for acquired colistin resistance encoded by mcr-1.1 gene. The surrounding 
environment of the mcr-1 cassette is variable but within the same family of plasmids, 
insertion, and stabilization had common structures. The plasmidome of ST131 clade B is 
distinct from other clades within ST131 clone and contains an impressive variety of 
different plasmids. Characteristically ST131 porcine isolates have APEC [F2:A-:B1]–
IncF plasmids. ColE1-like plasmids and IncX plasmids are also frequently observed. This 
behaviour could be related to the clonal success due to its ability to easily rearrange DNA 









1. Approximately 10% of the extraintestinal E. coli infections that had occurred in 
2016 in the two studied hospitals were caused by ST131 strains, and 
approximately 60% of these infections were caused by strains belonging to only 
10 STs (ST10, ST12, ST58, ST69, ST73, ST88, ST95, ST127, ST131 and 
ST141). 
2. The majority of ST12, ST73, ST95 and ST141 human extraintestinal strains were 
susceptible to most antibiotics, indicating that MDR was not the reason for their 
success. The results of the present study support the idea that their success is 
mainly due to the high number of VF-encoding genes that they possess. 
3. Among the MDR human extraintestinal strains, four clones are predominant, 
especially: B2-CH40-30-ST131, B2-CH40-41-ST131, C-CH4-39-ST88 and D-
CH35-27-ST69. 
4. Despite the enormous genetic diversity observed in our ESBLEC collection (71 
clones amongst 188 ESBLEC), it can be concluded that the majority of the strains 
belong to only three clonal complexes (CC10, CC23, and CC131) and that ST131 
subclade C2 associated with the production of CTX-M-15 remains the most 
prevalent E. coli lineage among the ESBLEC strains identified in the studied 
Spanish and French hospitals. 
5. Among our 394 extraintestinal E. coli strains, <10% are able to quickly and 
persistently produce high biofilm levels over 5 h. These strains belong to a few 
clones previously described in various studies as dominant gut colonizers in 
mammalians and birds, and comprised the B2-CH40-22-ST131 clone, i.e., the 
ancestor of the globally disseminated B2-CH40-30-ST131 clone that is the 
dominant clone among the weak biofilm producers. 
6. The core genome analysis of ESBLEC highlights genomic diversity among ESBL 
E. coli population. That includes representatives from phylogroups A, B1, B2, C, 
E and F. We described two new clades in ST131 clonal complex represented by 
genomes harbouring the fimH5 and fimH35 alleles. Clade C is characterised by 
showing less SNPs distance in the core genome than its sister clades A and B. 
7. There is a correlation between VF-encoding gene profiles and STs.  
8. There is an impressive diversity of plasmids among ESBLEC. However, MOBF, 
MOBP and MOBQ families of relaxases represent 92% of the plasmidome and 
Col-like and IncF are the most frequent incompatibility groups. Besides, most of 
the virulence and resistance associated encoding genes are carried by plasmids 
belonging to the IncF family. 
9. In ST131 lineage, the plasmid incompatibility group diversity is higher among 
subclade C2 than among clade A and cluster C1-M27 subclade C1. Clade A is 
related with the presence of ICEs and [F29:A-:B10]-IncF plasmids. 
10. The intestinal tract of healthy dogs appears as an important reservoir of ExPEC 
and/or UPEC, and, in a lesser extent, of MDR E. coli strains. 
11. Among the canine strains displaying an ExPEC and/or UPEC status, clone B2-
CH103-9-ST372 was dominant. 
12. WGS analysis suggests that canine strains of clone B2-CH103-9-ST372, 
belonging to cluster 1 (serotypes O4:H31, O21:H31 and O83:H31) and cluster 6 
(serotype O6:H31) might cause extraintestinal infections in both humans and 
dogs, whereas those strains of this clone belonging to cluster 2 and serotypes 
O18:H31 and O45:H31 might cause only human infections. 
13. Clade B of ST131 showed a huge genetic diversity, and five new subclades were 
defined (B6, B6-like, B7, B8, and B9). The majority of ST131 porcine strains 




14. Most porcine ST131 strains are MDR (91%) and carry many antibiotic resistance 
genes. Colistin resistance was introduced through MGEs and had been able to 
stabilize chromosomally. IncX4 and IncHI2 epidemic mcr-1–harboring plasmids 
are responsible for acquired colistin resistance encoded by mcr-1.1 gene. The 
surrounding environment of the mcr-1 cassette is variable but within the same 
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8.1 ANNEX 1: MATERIAL AND METHODS SUPPLEMENTARY MATERIAL 
Table S1. Assembly information of genomes. 
Genome kmer No. of contigs 
No. of contigs > 
1kb N50 
Longest contig 
(bp) Total bp 
Human origin genomes 
LREC_263 93 113 72 203374 350007 5140392 
LREC_264 115 103 61 243728 693027 5105112 
LREC_265 117 102 50 222698 624019 5088133 
LREC_266 113 102 58 196351 623442 5203023 
LREC_268 115 151 77 290559 512299 5399129 
LREC_269 117 159 68 221057 515993 5140621 
LREC_270 117 102 63 217209 957382 5087242 
LREC_271 89 114 66 194949 928860 5128192 
LREC_272 117 147 71 323644 757085 5269464 
LREC_273 117 152 71 214599 696746 5267138 
LREC_274 117 103 60 338527 562364 5173361 
LREC_275 117 94 46 297751 512897 5194217 
LREC_276 113 101 49 204926 673059 5341151 
LREC_277 117 172 74 191857 414832 5306873 
LREC_278 113 123 62 193172 659355 5296741 
LREC_279 113 165 67 192014 431183 5406813 
LREC_280 115 130 64 204363 658862 5403286 
LREC_281 115 81 46 288560 774020 5346311 
LREC_282 113 86 48 265392 619346 5265015 
LREC_283 113 113 49 342281 658956 5163448 
LREC_284 113 92 47 282391 720386 4895377 
LREC_285 117 86 56 234793 849655 4967927 
LREC_286 117 149 58 342415 626222 5211994 
LREC_287 117 125 65 258141 660190 5181373 
LREC_288 117 113 55 379986 776221 5170343 
LREC_289 113 81 38 472249 926038 5077629 
LREC_290 115 107 54 261454 484687 5094876 
LREC_291 113 120 53 319777 884132 5138992 
LREC_292 117 122 51 251466 884253 5114696 
LREC_293 113 168 81 184646 829973 5402287 
LREC_294 113 178 91 125770 358142 4992032 
LREC_295 113 142 64 184135 361914 4987057 
LREC_296 117 194 104 112670 263666 5184662 
LREC_298 89 115 55 269939 896901 5176306 
LREC_299 117 104 38 388083 844183 5167647 
LREC_300 117 106 37 384528 809990 5089070 
LREC_301 117 173 85 182793 467306 5314537 
LREC_302 115 133 67 157126 357708 4870632 
LREC_303 117 129 64 235849 488907 5068117 
LREC_304 117 133 63 175873 360474 4936865 
LREC_305 109 199 58 366005 758657 5377588 
LREC_306 115 223 73 359018 759064 5323487 
LREC_307 113 141 53 296449 540602 5238001 
LREC_308 117 97 43 247620 1147271 5092158 
LREC_309 117 86 39 447425 738469 5066850 
LREC_310 117 112 46 410939 526915 5296446 
LREC_311 113 118 61 332451 638235 5133186 
LREC_312 115 110 57 332455 589442 5048514 
LREC_313 113 155 73 198707 638574 5313931 
LREC_314 113 189 77 110784 295290 4871776 
LREC_315 117 215 100 144552 448963 5197349 
LREC_316 113 140 67 173221 408695 4800578 




Table S1. Cont. 
Genome kmer No. of contigs No. of contigs > 1kb N50 Longest contig (bp) Total bp 
Human origin genomes 
LREC_318 117 154 77 180225 375767 4896108 
LREC_319 113 129 71 131563 263942 4877624 
LREC_320 111 155 84 117598 232285 5023956 
LREC_321 89 131 69 150213 392450 4758372 
LREC_322 87 220 113 119222 292155 5307554 
LREC_323 89 187 83 130886 434550 4944756 
LREC_324 85 169 79 135677 605768 5247965 
LREC_325 89 162 81 113152 344562 5053174 
LREC_326 93 123 53 324350 765552 5380491 
LREC_327 91 131 54 398957 765417 5387169 
LREC_328 89 207 97 172902 432860 5754113 
LREC_329 89 173 78 204185 599010 5774177 
LREC_331 89 95 52 159131 431279 5054900 
LREC_332 89 123 74 160816 435673 5141499 
LREC_333 89 227 81 169280 411679 5164249 
LREC_334 93 211 90 201968 619956 5256962 
LREC_335 89 151 77 212378 564133 5220032 
LREC_336 89 156 80 212147 372413 5266493 
LREC_337 89 277 127 116032 457865 5585838 
LREC_338 89 128 50 260986 680138 5246463 
LREC_339 89 195 78 303701 686628 5330377 
LREC_340 89 124 50 305907 680041 5244820 
Canine origin genomes 
LREC_341 89 72 44 326460 672653 4840787 
LREC_342 93 58 32 673054 720458 4789379 
LREC_343 89 170 52 402644 823930 5173983 
LREC_344 89 107 32 628916 1207514 5110297 
LREC_345 91 180 52 391453 824252 5272043 
LREC_346 93 116 35 598033 823983 5217811 
LREC_347 98 118 32 592244 1702793 5104975 
LREC_348 89 181 52 409123 824017 5158712 
LREC_349 93 129 37 520829 824077 5150651 
LREC_350 91 133 38 463354 824208 5150646 
LREC_351 93 136 39 583831 824105 5159107 
LREC_352 89 118 38 399516 657523 5082876 
LREC_353 89 121 38 399704 657637 5083364 
LREC_354 91 127 40 399799 657586 5080519 
LREC_355 91 179 52 402920 824131 5159806 
LREC_356 93 98 37 397327 2540863 5355508 
LREC_357 91 85 25 864233 1677509 5045168 
LREC_358 93 99 28 659764 777701 5099113 
LREC_359 89 11 29 628732 1317107 5093206 
LREC_360 93 109 34 506708 825202 5088464 
LREC_361 93 112 29 628853 1317062 5093489 
LREC_362 93 105 31 592465 743574 5056878 
Porcine origin genomes 
LREC_153 101 101 34 400,612 1,112,169 5,358,477 
LREC_154 101 140 59 202,640 547,553 5,133,266 
LREC_155 89 129 69 274,127 719,927 5,482,745 
LREC_157 101 93 40 325,448 633,164 5,094,477 
LREC_158 89 64 32 392,821 674,978 5,001,845 
LREC_159 89 119 69 165,826 712,711 5,375,593 
LREC_160 101 136 64 220,432 696,874 5,252,736 
LREC_161 89 116 54 370,583 601,486 5,456,371 
LREC_162 93 75 34 468,418 1,208,336 4,940,669 
LREC_168 93 124 50 412,870 801,182 5,265,150 




Table S2. Database sources and input parameters. 
DATA BASE Minimum Threshold for %ID 





version Reference DOI 
Clermont Typing Web DEFAULT DEFAULT   20.03 DOI: 10.1099/mgen.0.000192; DOI: 10.11111/1462-2920.14713 
SerotypeFinder 2.0 85 60 2.0.1 (2019-01-28) 
1.0.0 (2019-02-
27) DOI: 10.1128/JCM.00008-15 
PlasmidFinder 2.1 95 60 2.0.1 (2020-02-07) 
2.0.1 (2020-02-
07) DOI: 10.1007/978-1-4939-9877-7_20 
pMLST 2.0 DEFAULT DEFAULT 0.1.0 (2018-12-20) (2019-07-29) DOI: 10.1007/978-1-4939-9877-7_20 
ResFinder 3.2 90 60 3.2 (2020-03-31) (2020-02-11) doi: 10.1093/jac/dks261 
PointFinder 90 60 3.1.0 (2019-02-27) (2019-07-02) doi: 10.1093/jac/dks261 
VirulenceFinder 2.0 90 60 2.0 (2020-02-06) (2019-09-30) doi:10.1128/JCM.03617-13 
CARD db 90 80 March 2020 release  3.0.8 DOI: 10.1093/nar/gkz935 
MLST 2.0 (Multi-Locus Sequence 




13) doi: 10.12.0/JCM.06094-11 
MyDbFinder 2.0 (Upload your own 
database) 80 60 2.0     
CSI Phylogeny 1.4 DEFAULT DEFAULT 1.4 (2019-05-26) https://doi.org/10.1371/journal.pone.0104984 






Table S3. Plasmid references. 













pMR0516mcr MRSN388634 Escherichia coli KX276657.1 
22506











McGann, P. et al. (2016) 
(10.1128/AAC.01103-16) 








Xavier, B.B. et al. (2016) 
(https://doi.org/10.1093/jac/dkw
191) 
pECJS-59-244 EC59 Escherichia coli KX084394.1 
24357
2 Pig feaces Yes China IncHI2 Tn6330 
Ruichao, Li. et al. (2017) 
(https://doi.org/10.1093/jac/dkw
411) 
pHNSHP45-2 SHP45 Escherichia coli KU341381.1 
25149
3 Pig feaces Yes China IncHI2 
ISApl1-
mcr-1-orf 












hospital Yes China IncHI2 
ISApl1-
mcr-1-orf Zhao,F. et al. Unpublished 




blood Yes China IncHI2 
ISApl1-
mcr-1-orf 
Zheng, B. et al. (2016) 
(https://doi.org/10.1093/cid/ciw5
53) 







Yes Brazil IncX4 mcr-1-orf 






a coli KY463454.1 33309 
Wastewater 
hospital Yes China IncX4 mcr-1-orf 
Zhao, F. et al. (2017) 
(10.3389/fmicb.2017.02094) 
pESTMCR ENV-187 Escherichia coli KU743383.1 33311 Pig feaces Yes Estonia IncX4 mcr-1-orf 
Brauer, A. et al. (2017) 
(10.1128/AAC.00443-16) 
pMCR1_IncX4 SZ04 Klebsiella KU761327.1 33287 human no (ST25) China IncX4 mcr-1-orf 
Du,H. et al. (2016) 
(10.1016/S1473-
3099(16)00056-6) 
pECGD-8-33 GD-8 Escherichia coli KX254343.1 33307 Pig feaces Yes China IncX4 mcr-1-orf 
Ruichao, Li. et al. (2017) 
(https://doi.org/10.1093/jac/dkw
411) 






(ST131) - IncF Negative Toh,H. et al. (2010) 
plasmid F K-12 Escherichia coli AP001918.1 99159 
human 




Table S3. Cont. 
Plasmid 
genome Isolate Species 
Assembly 








environment Reference (DOI) 




enterica JX258655.1 32447 - no - IncX4 Negative Gokulan,K. et al. (2013) 
pJIE143 JIE143 Escherichia coli JN194214.1 34345 
human-
ESBL Yes (ST131) - IncX4 Negative Partridge,S.R. et al. (2011) 
pHS30-1 HS30-1 Escherichia coli CP029493.1 179444 - Yes - 
Composite transposon-
Tn6330 Li,R. et al. Unpublished 
pJIE186_2 JIE186 Escherichia coli NC_020271 137728 Human urine yes (ST131) 
Sydney, 
Australia IncF Negative 
Zong Z. (2013) (DOI: 
10.1128/AAC.01081-12) 
ColE1 A745 Escherichia coli J01566.1 6646 - yes - ColE1 Negative 
Tomizawa,J.I. et al. (1977) (DOI: 
10.1073/pnas.74.5.1865) 
p2ESCUM UMN026 Escherichia coli 
NC_011739.
1 33809 Human urine yes (ST69) Minnesota, UK. IncX1 Negative 





enterica JX258654.1 33765 - no - IncX4 Negative 
Gokulan,K. et al. (2013) (DOI: 
10.1371/journal.pone.0077866) 
pEK204 C Escherichia coli EU935740 93732 Human yes (ST131) Belfast, UK. IncI Negative 





a coli CP015071.1 69471 Human urine yes (ST131) 
Dubai, United 
Arab Emirates IncL/M Negative 
Stoesser,N. et al. (2016) 
(doi:10.1128/AAC.01130-16.) 




meningitis no North America - Negative 







a coli MF684783.1 6268 Pig feaces no Germany - Negative 







8.2. ANNEX 2: STUDIES SUPPLEMENTARY MATERIAL 
8.2.1 STUDY 1  
Supplementary material in Flament-Simon SC et al. 2020 Antibiotics 9 (4) 161 doi: 
10.3390/antibiotics9040161. 
Table S4. Phylogenetic groups of the 196 studied E. coli isolates and dominant sequence types 
with further characterization for ST131 (clades, subclades and virotypes). 
Characteristic No. (%) of isolates P-Value 
 Lugo, Spain  (n= 100) Clichy, France (n= 96)  
Phylogenetic group 
A 14 15  
B1 10 8  
B2 48 56  
C 11 4  
D 9 5  
E 5 5  
F 3 3  
ST131 
Total 12 11  
Clade A 5 1  
Clade B 2 2  
Cluster C1-M27 0 1  
Non-C1-M27 subclade C1  3 3  
Subclade C2 (H30-Rx) 2 3  
Clade-NTa 0 1  
Clonotype CH40-22 1 2  
Clonotype CH40-30 5 8  
Clonotype CH40-41 5 1  
Clonotype CH40-298 1 0  
Virotype A 3 0  
Virotype A-like 1 0  
Virotype C2 1 2  
Virotype C3 3 0  
Virotype D2 1 1  
Virotype D3 0 1  
Virotype D5-like 1 0  
Virotype E 0 2  
Virotype F 0 1  
Virotype NT 2 4  
Non-ST131 STb 
ST10 3 6  
ST12 4 4  
ST58 4 1  
ST69 8 5  
ST73 9 12  
ST88 9 3  
ST95 6 4  
ST127 3 4  
ST141 3 11 0.0265 






Table S5. Characteristics of the 13 ESBL-producing E. coli isolates. 








and cluster  
A24 Spain CTX-M-1 A-CH11-54-ST34 O9:H1 - -  
C6 France CTX-M-1 A-CH11-43-ST3596 O8:HNM - -  
A46 Spain CTX-M-1 A-CH27-23-ST new 2-437like O98:HNM - -  
A7  Spain CTX-M-14 B1-CH4-27-ST58 O9:H25 - -  
A10  Spain CTX-M-14 B1-CH6-35-ST448 O11:H10 - -  
C22  France CTX-M-15 
B2-CH40-30-
ST131 O25:H4 + + C2 
C27  France CTX-M-15 
B2-CH40-30-
ST131 O25:H4 - + NT
a 
C44  France CTX-M-15 
B2-CH40-30-
ST131 O25:H4 + + C2 
C3  France CTX-M-27 
B2-CH40-30-
ST131 O25:H4 + + C1-M27 
A82 Spain CTX-M-1 B2-CH40-41-ST131 ONT:H5 + - A 
C80  France CTX-M-55 
B2-CH14-64-
ST1193 O75:HNM + +  
A62  Spain CTX-M-14 E-CH37-27-ST405 O18:H6 - -  
C93  France CTX-M-32  F-CH4-58-ST648 ONT:H42 + -  




Table S6. Antimicrobial resistance and Virulence factor(VF)-encoding genes. 
 Number (%) isolates P-Value 
VF gene MDR (n=73) 
non-MDR 
(n= 123) 
MDR vs.  
non-MDR 
Adhesins    
fimH 71 (97.3) 122 (99.2)  
fimAvMT78 10 (13.7) 17 (13.8)  
papAH 24 (32.9) 60 (48.8)a 0.03661 
papC 26 (35.6) 61 (49.6) 0.07414 
papEF 29 (39.7) 63 (51.2)  
sfa/focDE 7 (29.6) 51 (41.5) 0.000001 
afa/draBC 7 (9.6) 4 (3.3)  
yfcV 28 (38.4) 78 (63.4) 0.00104 
Toxins    
sat 20 (27.4) 27 (22.0)  
cnf1 8 (11.0) 41 (33.3) 0.00054 
hlyA 7 (9.6) 48 (39.0) 0.000014 
hlyF 20 (27.4) 24 (19.5)  
cdtB 3 (4.1) 9 (7.3)  
tsh 2 (2.7) 5 (4.1)  
vat 12 (16.4) 68 (55.3) 8.5x10-8 
Iron uptake    
iucD 42 (57.5) 57 (46.3)  
iutA 42 (57.5) 57 (46.3)  
iroN 24 (32.9) 69 (56.1) 0.00190 
fyuA 59 (80.8) 103 (83.7)  
chuA 43 (58.9) 92 (74.8) 0.02546 
Capsule    
kpsM II 34 (46.6) 85 (69.1) 0.00241 
neuC-K1 5 (6.8) 30 (24.4) 0.00180 
kpsM II-K2 6 (8.2) 11 (8.9)  
kpsM II-K5 23 (31.5) 44 (35.8)  
kpsM III 2 (2.7) 4 (3.3)  
Miscellaneous    
cvaC 13 (17.8) 22 (17.9)  
iss 21 (28.8) 25 (20.3)  
traT 51 (69.9) 60 (48.8) 0.00463 
ibeA 4 (5.5) 19 (15.4) 0.03993 
malX  30 (41.1) 79 (64.2) 0.00185 
usp 29 (39.7) 78 (63.4) 0.00176 
ompT 50 (68.5) 101 (82.1) 0.03517 
ExPEC status 38 (52.1) 83 (67.5) 0.03459 
UPEC status 27 (37.0) 79 (64.2) 0.00034 
Mean of VF 9.90 12.67  





8.2.2. STUDY 2  
 
Supplementary material in Flament-Simon SC et al. 2020 Front Cell Infect Microbiol 





8.2.3. STUDY 3 
Supplementary material in Flament-Simon SC et al. 2020 Front Microbiol 10:1183 
doi: 10.3389/fmicb.2019.01183. 
 
Figure S1A. Pearson´s correlation between the BFI values obtained for each of the 394 E. coli 
isolates. A: 0.96 at 2h, B: 0.96 at 3h and C: 0.95 at 5h. 
 
   
Figure S1B. Assessment of repeatability between the BFI values obtained for each of the 394 E. 
coli isolates using the Bland and Altman statistical method (Bland and Altman, 1986). The mean 
of individual BFI measures (continuous line) and standard deviation (dashed line) of all 
representing ±2SD from mean line were calculated at 2, 3 and 5h. Only 3.4% of values at 2h, 5.5% 




Figure S2. Phylogenetic tree of FimB. In parenthesis are indicated the access numbers of the 





Table S7. Distribution of phylogroups A, B1, B2, C, D, E and F among G1, G2 and G3 isolates. 
Phylogroup Number (%) of isolates P-Valuea 
Total (n=394) G1 (n=36) G2 (n=28) G3 (n=330) G1 vs. G3 
A 59 (15.0) 0 (0) 6 (21.4) 53 (16.1) 0.0098 
B1 38 (9.6) 3 (8.3) 1 (3.6) 34 (10.3)  
B2 202 (51.3) 28 (77.8) 17 (60.7) 157 (47.6) 0.0006 
C 38 (9.6) 0 (0) 0 (0) 38 (11.5) 0.0419 
D 17 (4.3) 0 (0) 4 (11.1) 13 (3.9)  
E 20 (5.1) 2 (5.6) 0 (0) 18 (5.4)  
F 20 (5.1) 3 (8.3) 0 (0) 17 (5.2)  
a Two-tailed P-Values by Fisher´s exact test are shown where P<0.05. 
Table S8. Distribution of the most frequent sequence types (STs) among G1, G2 and G3 isolates.  
Sequence Type 
 
Number (%) of isolates P-Valuea 
Total (n=394) G1 (n=36) G2 (n=28) G3 (n=330) G1 vs. G3 
ST10  17 (4.3) 0 (0) 2 (7.1) 15 (4.5)  
ST69 15 (3.8) 0 (0) 3 (10.7) 12 (3.6)  
ST73  22 (5.6) 4 (11.1) 5 (17.9) 13 (3.9)  
ST88  17 (4.3) 0 (0) 0 (0) 17 (5.2)  
ST95  14 (3.6) 0 (0) 0 (0) 14 (4.2)  
ST131  104 (26.4) 4 (11.1) 3 (10.7) 97 (29.4) 0.0289 
ST141  16 (4.1) 9 (25) 2 (7.1) 5 (1.5) <0.0001 
Remaining-ST  189 (48.0) 19 (57.8) 13 (46.4) 157 (47.6)  
a Two-tailed P-Values by Fisher´s exact test are shown where P<0.05 
Table S11 fimB gene status in G1, G2 and G3 isolates. 
fimB gene status Number (%) of isolates  P-Valuea 
Total (n=127) G1 (n=14) G2 (n=12) G3 (n=101) G1 vs. G3 
 Intact 89 (70.1) 13 (92.9) 10 (83.3) 66 (65.3) 0.0301 
Disrupted 28 (22.0) 1 (7.1) 1 (8.3) 26 (25.7)  
Absent 10 (7.9) 0 1 (8.3) 9 (8.9)  
aOne-tailed P-Values by Fisher´s exact test are shown P<0.05. 
Table S13. Distribution of FimB variants in G1, G2 and G3 isolates. 
FimB variant Number (%) of isolates  P-Valuea 
Total (n=89) G1 (n=13) G2 (n=10) G3 (n=66) G1 vs. G3 
P1 52 (58.4) 3 (23.1) 3 (30) 46 (69.7) 0.0023 
P2 17 (19.1) 7 (53.8) 3 (30) 7 (10.6) 0.0011 
P3 4 (4.5) 2 (15.4) 2 (20) 0 0.0235 
P2 or P3 21 (23.6) 9 (69.2) 5 (50) 7 (10.6) <0.0001 
Others 16 (18.0) 1 (7.7) 2 (20) 13 (19.7)  






Table S9. Distribution (%) of the 31 clones including at least three isolates into G1, G2 and G3. 
Clone Number (%) of isolates P-Value
a 
G1 (n=36) G2 (n=28) G3 (n=330) G1 vs. G3 
A-CH11-54-ST10 0 1 (3.6) 9 (2.7)  
A-CH11-0-ST93 0 0 4 (1.2)  
A-CH11-0-ST167 0 1 (3.6) 2 (0.6)  
A-CH99-54-ST361 0 0 5 (1.5)  
A-CH11-54-ST744 0 0 5 (1.5)  
B1-CH4-27-ST58 0 0 4 (1.2)  
B1-CH6-31-ST453 0 0 3 (0.9)  
B2-CH13-106-ST12 1 (2.8) 1 (3.6) 2 (0.6)  
B2-CH24-10-ST73 1 (2.8) 2 (7.1) 3 (0.9)  
B2-CH24-103-ST73 0 1 (3.6) 5 (1.5)  
B2-CH24-12-ST73 0 1 (3.6) 2 (0.6)  
B2-CH24-30-ST73 1 (2.8) 1 (3.6) 2 (0.6)  
B2-CH38-15-ST95 0 0 6 (1.8)  
B2-CH14-2-ST127 2 (5.6) 1 (3.6) 1 (0.3) 0.0265 
B2-CH40-22-ST131 3 (8.3) 0 1 (0.3) 0.0033 
B2-CH40-30-ST131 0 3 (10.7) 84 (25.5) <0.0001 
B2-CH40-41-ST131 0 0 10 (3)  
B2-CH52-5-ST141 6 (16.7) 2 (7.1) 5 (1.5) 0.0002 
B2-CH14-27-ST404 0 0 3 (0.9)  
B2-CH14-64-ST1193 0 0 4 (1.2)  
C-CH4-35-ST23 0 0 3 (0.9)  
C-CH4-39-ST88 0 0 11 (3.3)  
C-CH4-24-ST410 0 0 7 (2.1)  
C-CH263-32-ST1615 0 0 6 (1.8)  
D-CH35-27-ST69 0 3 (10.7) 11 (3.3)  
E-CH26-0-ST38 0 0 3 (0.9)  
E-CH100-96-ST362 2 (5.6) 0 1 (0.3) 0.0265 
E-CH37-27-ST405 0 0 4 (1.2)  
F-CH32-41-ST59 0 0 4 (1.2)  
F-CH45-97-ST117 0 0 3 (0.9)  
F-CH88-58-ST354 0 0 5 (1.5)  





Table S10. Distribution of the 26 G1-detected clones among G1, G2 and G3 isolates  
Clone Number (%) of isolates P-Valuea 
 G1 (n=36) G2 (n=28) G3 (n=330) G1 vs. G2 G1 vs. G3 
B1-CH23-54-ST205 1 (2.8) 0 0   
B1-CH6-31-ST1196 1 (2.8) 0 0   
B1-CH4-31-ST2766 1 (2.8) 0 0   
B2-CH13-106-ST12 1 (2.8) 1 (3.6) 2 (0.6)   
B2-CH13-223-ST12 1 (2.8) 0 0   
B2-CH24-10-ST73 1 (2.8) 2 (7.1) 3   
B2-CH24-13-ST73 1 (2.8) 0 0   
B2-CH24-30-ST73 1 (2.8) 1 (3.6) 2 (0.6)   
B2-CH24-32-ST73 1 (2.8) 0 0   
B2-CH24-2-ST104 1 (2.8) 0 0   
B2-CH14-2-ST127 2 (5.6) 1 (3.6) 1 (0.3)  0.0265 
B2-CH40-22-ST131 3 (8.3) 0 1 (0.3)  0.0033 
B2-CH40-298-ST131 1 (2.8) 0 0   
B2-CH40-22-ST2556 1 (2.8) 0 0   
B2-CH52-5-ST141 6 (16.7) 2 (7.1) 5 (1.5)  0.0002 
B2-CH52-14-ST141 2 (5.6) 0 0  0.0094 
B2-CH52-76-ST141 1 (2.8) 0 0   
B2-CH38-5-ST569 1 (2.8) 0 0   
B2-CH108-75-ST636 1 (2.8) 0 0   
B2-CH24-12-ST1154 1 (2.8) 0 0   
B2-CH319-197-ST2015 1 (2.8) 0 0   
B2-CH43-0-ST2558 1 (2.8) 0 0   
E-CH100-96-ST362 2 (5.6) 0 1 (0.3)  0.0265 
F-CH4-171-ST648 1 (2.8) 0 1 (0.3)   
F-CH4-58-ST648 1 (2.8) 0 1 (0.3)   
F-CH231-58-ST1485 1 (2.8) 0 0   
 36 (100) 7 (25) 17 (5.2) <0.0001 <0.0001 










39 57 72 80 93 103 114 117 156 198 237 246 249 256 285 294 297 315 319 324 330 339 345 384 396 402 485 495 498 519 537 540 556 570 573 579 580 # 27 35 86 107 162 180 186 195
A1 P1 (MK301552) G A A C A T T G T A C G T G C G C G G T A G G C C G A T G T C T G A C A C C T Y V V Q N G Q
A22 P9 (MK301573) . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . I . . . .
A7 P1 (MK301558) . . . . . . . . . . . . C . . . . A . . G A . . . . . . . . . . . . . . . . . . . . . . . .
A16 P5 (MK301567) . . . . . . . . . . . . C . . . . A . . G A . . . . . . . . . A . . . . . . . . . . . K . .
A4 P1 (MK301555) . . . . . . . . . . . . C . . . . A . . G . . . . . . . . . . . . . . . . . . . . . . . . .
A8 P1 (MK301559) . . . . . . . . . . . . C . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A9 P1 (MK301560) . . . . . . . . . . . . C . . . . . . . G . . . . . . G . . . . . . . . . . . . . . . . . .
A23 P10 (MK301574) . . . A . . . . . . . . C . . . . . . . G . . . . . . . . . . . . . . . . . N . . . . . . .
A5 P1 (MK301556) . . . . . . . . . . . . C . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . .
A15 P5 (MK301566) . . . . . . . . . . T . C . . . . . . . T A . . . . . . . . . A . . . . . . . . . . . K . .
A17 P6 (MK301568) . . . . . C . . . . T . C . . . . . . . T A . . . . . . . . . . . . . . . . . H . . . . . .
A11 P1 (MK301562) . . . . . . . . . . . . C . . . . . . . T A . . . . . . . . . . . . . . . . . . . . . . . .
A10 P1 (MK301561) . . . . . . . . . . T . C . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . .
A2 P1 (MK301553) . . . . . . . . . . T . C . . . . . . . T A . . . . . . . . . . . . . . . . . . . . . . . .
A19 P7 (MK301570) . . . . . . . . . C . . C . . . . A . . G . . . . . . . . . . . A G . . . . . . . . . . S .
A3 P1 (MK301554) . . . . . . . . . C . . C . . . . A . . G . . . . . . . . . . . . G . . . . . . . . . . . .
A18 P6 (MK301569) . . . . . C . . . . . . C . . T T . . . G . . . . . . . . . . . . . . . . . . H . . . . . .
A6 P1 (MK301557) . . . . . . . . . . . . C . . T T . . . . . . T . . . . . . . . . . . G A . . . . . . . . .
A12 P1 (MK301563) . . . . . . . . . . . . C . . T T . . . . . . T . . . . . . . . . . . . . . . . . . . . . .
A20 P7 (MK301571) . . . . . . . . . . . . C . . T T . . . . . . T . . . . . . . . A . . . . . . . . . . . S .
A21 P8 (MK301572) . . . . . . . . . . . A C . . T T . . . . . . T . . G . . . . . . . . . . . . . . . R . . .
A31 P2 (MK301582) T . . . T . . . C . . . C A . T T . . . . . A . . . . . . . . . . . . . . . . . I . . . . .
A24 P2 (MK301575) . . T . T . A A C . . . C A . T T . . . . . A . . . . . A . . . . . . . . . . . I . . . . .
A33 P4 (MK301584) . . T . T C A A C . . . C A . T T . . . . . A . . . . . A . . . . . . . . . . H I . . . . .
A34 P4 (MK301585) . . . . T C A A C . . . C A . T T . . . . . A . . . . . A . . . . . . . . . . H I . . . . .
A32 P3 (MK301583) . . . . T . A A C . . . C A . T T . . . . . A . . . . . A . . . . . . . . G . . I . . . . E
A28 P2 (MK301579) . . . . T . A A C . . . C A . T T . . C . . A . . . . . A . . . . . . . . . . . I . . . . .
A30 P2 (MK301581) . . . . T . A A C . . . C A . T T . . C . . A . . . . . . . . . . . . . . . . . I . . . . .
A27 P2 (MK301578) . . . . T . A A C . . . C A . T T . . . . . . . . . . . A . . . . . . . . . . . I . . . . .
A29 P2 (MK301580) . . . . T . A A C . . . C A . T T . . . . . . . . . . . . . . . . . . . . . . . I . . . . .
A26 P2 (MK301577) . . . . T . A A C . . . C A . T T . . . . . A . . . . . A . . . . . . . . . . . I . . . . .
A25 P2 (MK301576) . . . . T . A A C . . . C A . T T . . . . . A . . . . . . . . . . . . . . . . . I . . . . .
A14 P1 (MK301565) T G . . . . . . . . . . C . A T T . . . . . . T T A . . . . T . . . . G A . . . . . . . . .
A13 P1 (MK301564) . G . . . . . . . . . . C . . . T . . . . . . T T A . . . A . . . . T G A . . . . . . . . .




8.2.4. STUDY 4  
PLACNETw is a graph-based tool for reconstruction of plasmids. However, manual 
pruning of the graphs is a necessary requirement, and not all plasmids could always be 
successfully separate without assuming some risk of error. For this reason, some plasmids 
remain together and the plamidome remains presumptive. 
The presumptive plamsidome has been described following structure: plasmid name 
(size), plasmid typing by relaxase (MOB) and/or Incompatibility group (Inc.), number of 
copies based on coverage (plasmid coverage/chromosome coverage) and the carried 
virulence and resistance genes. Transferability was presumptively deduced based on 
identification of relaxases (mobilizable plasmids) and mating pair formation (Mpf) 
system proteins (conjugative plasmids). 
 
Plasmidome analysis of STC131 genomes (n=30)  
 
Genome LREC263 (B2-CH40-30-ST131) includes five plasmids:  
pLREC263_1+2 (126 kb). MOBF12/IncF [F1:A6:B66] and a MOBP/ColRNAI plasmid that could not be 
separated. Conjugative (Mpf presence).  
pLREC263_3 (6 kb). ColRNAI (>10 copies/genome). 
pLREC263_4 (4kb). MOBQ/ColRNAI (7-10 copies/genome). 
pLREC263_5 (4 kb). MOBQ12/ColRNAI (2-6 copies/genome). 
 
Genome LREC264 (B2-CH40-30-ST131) includes six plasmids:  
pLREC264_1 (99 kb). MOBF12/IncF [F1:A2:B20]. Harbouring resistance genes that confer resistance to 
beta-lactams (blaCTX-M-27), aminoglycosides (aadA5, aph(3'')-Ib, aph(6)-Id), sulfonamides (sul1, sul2), 
trimethoprim (dfrA17) and tetracycline (tet(A)). 
pLREC264_2 (37 kb). MOBP3/IncX4 with a ColRNAI presumably cointegrated (2-6 copies/genome). 
Conjugative (Mpf presence). 
pLREC264_3 (16 Kb). MOBQ12 (2-6 copies/genome). Harbouring the virulence gen senB. 
pLREC264_4 (5 kb). ColRNAI (2-6 copies/genome). 
pLREC264_5 (2 kb). Col(BS512) and Inc13 (2-6 copies/genome). 
pLREC264_6 (2 kb). ColRNAI (2-6 copies/genome). 
 
Genome LREC265 (B2-CH40-30-ST131) includes three plasmids: 
pLREC265_1 (150 kb). MOBF/IncF [F4:A2:B20] with a ColRNAI presumably cointegrated. Harbouring 
the virulence genes senB and iha. Conjugative (Mpf presence). 
pLREC265_2 (5 kb). MOBQ12/ColRNAI (2-6 copies/genome). 
pLREC265_3 (3 Kb). ColRNAI (2-6 copies/genome). 
 
Genome LREC266 (B2-CH40-30-ST131) includes six plasmids: 
pLREC266_1 (132 kb). MOBF12/IncF [F1:A2:B20] with a ColRNAI presumably cointegrated. Harbouring 
the virulence gene senB and resistance genes to beta-lactams (blaCTX-M-27), aminoglycosides (aph(3'')-Ib, 
aph(6)-Id) sulfonamides (sul2) and tetracycline (tet(A)). Conjugative (Mpf presence). 
pLREC266_2 (32 kb). MOBP3/IncX4. Conjugative (Mpf presence). 
pLREC266_3 (7 kb). MOBP51/ColRNAI (2-6 copies/genome). 
pLREC266_4 (6 kb). MOBP51/ColRNAI (2-6 copies/genome). 
pLREC266_5 (5 kb). MOBQ12/ColRNAI (7-10 copies/genome). 
pLREC266_6 (2 kb). ColRNAI (7-10 copies/genome). 
 
Genome LREC268 (B2-CH40-30-ST131) includes six plasmids: 
pLREC268_1 (125 kb). MOBF/IncF [F2:A1:B-]. Harbouring resistance genes to quinolones and 
aminoglycosides (acc(6’)-Ib-cr), macrolides (mph(A)), sulfonamides (sul1), trimethoprim (dfrA14) and 
phenicols (catB3). Conjugative (Mpf presence). 
pLREC268_2 (65 kb). MOBP/IncK (IncB/O/K/Z). Conjugative (Mpf presence). 
pLREC268_3 (36 kb). MOBP3/IncX. 
pLREC268_4 (19 kb). MOBF11/IncN. Conjugative (Mpf presence). 
pLREC268_5 (7 kb). MOBP51/ColRNAI. 





Genome LREC269 (B2-CH40-30-ST131) includes five plasmids: 
pLREC269_1 (87 kb). MOBP12/ Inck (IncB/O/K/Z). Conjugative (Mpf presence). 
pLREC269_2 (46 kb). IncF [F2:A1:B-] with a ColRNAI and an IncN presumably cointegrated. Conjugative 
(Mpf presence). 
pLREC269_3 (5 kb). MOBQ12/ColRNAI (2-6 copies/genome). 
pLREC269_4 (2 kb). MOBV2 (2-6 copies/genome). 
pLREC269_5 (2 kb). ColRNAI.  
 
Genome LREC270 (B2-CH40-30-ST131) includes four plasmids: 
pLREC270_1 (99 kb). IncF [F2:A1:B-]. Harbouring resistance genes to beta-lactams (blaCTX-M-15, blaOXA-
1) macrolides (mph(A)), aminoglycosides (aac(6')-Ib-cr, aadA5), quinolones (aac(6')-Ib-cr), sulfonamides 
(sul1), trimethoprim (dfrA17), phenicols (catB3) and tetracycline (tet(A)). Conjugative (Mpf presence). 
pLREC270_2 (4 kb). MOBQ/ColRNAI (2-6 copies/genome). Conjugative (Mpf presence). 
pLREC270_3 (2 kb). MOBV2 (2-6 copies/genome). 
pLREC270_4 (2 kb). ColRNAI (>10 copies/genome). 
 
Genome LREC271 (B2-CH40-30-ST131) includes four plasmids: 
pLREC271_1 (95 kb). IncF [F2:A1:B-]. Harbouring resistance genes to beta-lactams (blaCTX-M-15, blaOXA-
1), macrolides (mph(A)), aminoglycosides (aac(6')-Ib-cr, aadA5), quinolones (aac(6')-Ib-cr), sulfonamides 
(sul1), trimethoprim (dfrA17), phenicols (catB3) and tetracycline (tet(A)).  
pLREC271_2 (5 kb). MOBQ12/ColRNAI (2-6 copies/genome). 
pLREC271_3 (2 kb). MOBV2 (2-6 copies/genome). 
pLREC271_4 (2 kb). ColRNAI (7-10 copies/genome). 
 
Genome LREC272 (B2-CH40-30-ST131) includes four plasmids: 
pLREC272_1 (211 kb). MOBF12/IncF [F2-F10:A1:B-]. Harbouring resistance genes to beta-lactams 
(blaCTX-M-15, blaOXA-1), macrolides (mph(A)), aminoglycosides (aac(6')-Ib-cr, aadA5), quinolones (aac(6')-
Ib-cr, qnrS1), sulfonamides (sul1), trimethoprim (dfrA14, dfrA17) and phenicols (catB3). 
pLREC272_2 (20 kb). MOBF11/IncN. 
pLREC272_3 (7 kb). MOBP51/ColRNAI. 
pLREC272_4 (4 kb). MOBQu/ColRNAI  
 
Genome LREC273 (B2-CH40-30-ST131) includes four plasmids: 
pLREC273_1 (109 kb). MOBF/IncF [F2:A1:B-]. Harbouring resistance genes to beta-lactams (blaCTX-M-15, 
blaOXA-1), quinolones-aminoglycosides (aac(6')-Ib-cr), phenicols (catB3) and tetracycline (tet(A)). 
Conjugative (Mpf presence). 
pLREC273_2 (36 kb). MOBP3/IncX4. Conjugative (Mpf presence). 
pLREC273_3 (4 kb). MOBQu/ColRNAI (2-6 copies/genome). 
pLREC273_4 (2 kb). Col(MG828) (2-6 copies/genome). 
 
Genome LREC274 (B2-CH40-30-ST131) includes four plasmids: 
pLREC274_1 (74 kb). IncF [F-:A1:B-]. Harbouring resistance genes to beta-lactams (blaCTX-M-15, blaOXA-
1), aminoglycosides-quinolones (aac(6')-Ib-cr), phenicols (catB3) and tetracycline (tet(A)). Conjugative 
(Mpf presence). 
pLREC274_2 (36 kb). MOBP3/IncX4. Conjugative (Mpf presence). 
pLREC274_3 (4 kb). MOBQu/ColRNAI (2-6 copies/genome).  
pLREC274_4 (2 kb). Col(MG828) (2-6 copies/genome).  
 
Genome LREC275 (B2-CH40-30-ST131) includes two plasmids: 
pLREC275_1 (152 kb). MOBF12/IncF [F22:A1:B1]. Harbouring resistance genes to beta-lactams (blaCTX-
M-15, blaTEM-1B), sulfonamides (sul1), trimethoprim (dfrA7) and tetracycline (tet(B)). Conjugative (Mpf 
presence). 
pLREC275_2 (2kb). ColRNAI (7-10 copies/genome). 
 
Genome LREC276 (B2-CH40-30-ST131) includes one plasmid: 
pLREC276_1 (220 kb). MOBF/IncF [F36:A4:B1] with a ColRNAI presumably cointegrated. Harbouring 
resistance genes to beta-lactams (blaCTX-M-15), macrolides (mph(A)), aminoglycosides (aadA5), 





Genome LREC277 (B2-CH40-30-ST131) includes one plasmid: 
pLREC277_1 (92 kb). MOBF12/IncF [F2:A2:B-]. Harbouring resistance genes to beta-lactams (blaTEM-1B), 
aminoglycosides (aph(3'')-Ib, aph(6)-Id), sulfonamides (sul2) and trimethoprim (dfrA17, dfrA8). 
Conjugative (Mpf presence). 
 
Genome LREC278 (B2-CH40-30-ST131) includes one plasmid: 
pLREC278_1 (616 kb). MOBF/IncF [F36:A4:B-]. Harbouring resistance genes to beta-lactams (blaCTX-M-
15, blaOXA-1), aminoglycosides and quinolones (aac(6')-Ib-cr) and phenicols (catB3). Conjugative (Mpf 
presence). 
 
Genome LREC279 (B2-CH40-30-ST131) includes two plasmids: 
pLREC279_1 (87 kb). MOBF/IncF [F10:A-:B-]. Conjugative (Mpf presence). 
pLREC279_2 (49 kb). MOBF/IncN-ST9. Conjugative (Mpf presence). 
 
Genome LREC280 (B2-CH40-30-ST131) includes two plasmids: 
pLREC280_1 (145 kb). MOBF/IncF [F31:A4:B1] with a ColRNAI presumably cointegrated. Harbouring 
resistance genes to beta-lactams (blaCTX-M-15), aminoglycosides (aadA5), sulfonamides (sul1), macrolides 
(mph(A)), and trimethoprim (dfrA17). Conjugative (Mpf presence). 
pLREC280_2 (2 kb). ColRNAI and Inc13 (2-6 copies/genome). 
 
Genome LREC281 (B2-CH40-30-ST131) includes three plasmids: 
pLREC281_1 (374 kb). MOBF12/IncF [F36:A4:B1]. Harbouring the virulence genes sat and iha and 
resistance genes to beta-lactams (blaCTX-M-15, blaOXA-1), aminoglycosides and quinolones (aac(6')-Ib-cr), 
phenicols (catB3) and tetracycline (tet (A)). Conjugative (Mpf presence). 
pLREC281_2 (4 kb). MOBQ. 
pLREC281_3 (2 kb). Col(BS512) and Inc13 (2-6 copies/genome). 
 
Genome LREC282 (B2-CH40-30-ST131) includes four plasmids: 
pLREC282_1+2 (246 kb). MOBF12/IncF [F31-F36:A4:B1] and a MOBP51/ColRNAI that could not be 
separated. Harbouring the virulence gene iss and resistance genes to beta-lactams (blaCTX-M-15, blaOXA-1), 
aminoglycosides and quinolones (aac(6')-Ib-cr), phenicols (catB3) and tetracycline (tet(A)). Conjugative 
(Mpf presence). 
pLREC282_3 (4 kb). MOBQu 
pLREC282_4 (2 kb). Col(BS512) and Inc13 (2-6 copies/genome). 
 
Genome LREC283 (B2-CH40-30-ST131) did not present any plasmids.  
 
Genome LREC284 (B2-CH40-30-ST131) includes three plasmids:  
pLREC284_1 (68 kb). IncF [F2:A1:B-]. Harboring resistance genes to beta-lactams (blaCTX-M-15), 
macrolides (mph(A)), aminoglycosides (aadA5), sulfonamides (sul1) and trimethoprim (dfrA17).  
pLREC284_2 (34 kb). MOBP3/IncX1. 
pLREC284_3 (2kb) ColRNAI (>10 copies/genome).  
 
Genome LREC285 (B2-CH40-30-ST131) includes two plasmids: 
pLREC285_1 (137 kb). MOBF/IncF [F1-F35:A-:B41]. Harbouring resistance genes to aminoglycosides 
(aadA5), sulfonamides (sul2, sul1) and trimethoprim (dfrA17). Conjugative (Mpf presence). 
pLREC285_2 (4 kb). MOBQu (2-6 copies/genome). 
 
Genome LREC286 (B2-CH40-30-ST131) includes two plasmids: 
pLREC286_1+2 (113 kb). MOBF/IncF [F10:A6:B20] and a MOBP/ColRNAI that could not be separated. 
Harbouring resistance genes to beta-lactams (blaTEM-1B), aminoglycosides (aadA5, aac(3)-IId, aph(6)-Id), 
trimethoprim (dfrA17) and sulfoamidas (sul2). Conjugative (Mpf presence). 
 
Genome LREC287 (B2-CH40-35-ST131) includes three plasmids: 
pLREC287_1 (118 kb). MOBF/IncF [F2:A1:B-]. Harbouring resistance genes to beta-lactams (blaCTX-M-15, 
blaOXA-1), aminoglycosides (aac(6')-Ib-cr, aadA5), quinolones (aac(6')-Ib-cr), sulfonamides (sul1), 
trimethoprim (dfrA17) and phenicols (catB3). Conjugative (Mpf presence). 
pLREC287_2 (5 kb). MOBQ12/ColRNAI (2-6 copies/genome). 





Genome LREC288 (B2-CH40-41-ST131) includes a MOBH in the chromosome (ICE) and two plasmids: 
pLREC288_1 (294 kb). MOBF/IncF [F-:A-:B10] with a ColRNAI presumably cointegrated. Harbouring 
the virulence gen senB and resistance genes to beta-lactams (blaTEM-1B), aminoglycosides (aadA5, aph(3’’)-
Ib , aph(6)-Id), sulfonamides (sul1, sul2) and trimethoprim (dfrA17). Conjugative (Mpf presence). 
pLREC288_2 (4 kb). MOBQ/ColRNAI. 
 
Genome LREC289 (B2-CH40-41-ST131) includes a MOBH in the chromosome (ICE) and two plasmids: 
pLREC289_1 (550 kb). MOBF12/IncF [F29:A-:B10]. Harbouring the virulence gen iha and resistance genes 
to beta-lactams (blaCTX-M-1) and macrolides (mph(A)). Conjugative (Mpf presence). 
pLREC289_2 (109 kb). IncFIB (H89-PhagePlasmid).  
 
Genome LREC290 (B2-CH40-41-ST131) includes a MOBQ in the chromosome (ICE) and two plasmids: 
pLREC290_1 (143 kb). MOBF. 
pLREC290_2 (121 kb). MOBF12/IncF [F29:A-:B10] with a ColRNAI presumably cointegrated. Harbouring 
resistance genes to beta-lactams (blaTEM-1B) macrolides (mph(A)), aminoglycosides (aac(3)-IId, aadA5, 
aph(3'')-Ib, aph(6)-Id), sulfonamides (sul1, sul2), trimethoprim (dfrA17) and tertaciclinas (tet(A)). 
Conjugative (Mpf presence). 
 
Genome LREC291 (B2-CH40-41-ST131) includes a MOBH in the chromosome (ICE) and one plasmid: 
pLREC291_1 (150 kb). MOBF12/IncF [F29:A-:B10] with a ColRNAI presumably cointegrated. Harbouring 
the virulence gen senB and resistance genes to beta-lactams (blaTEM-1B), macrolides (mph(A)), 
aminoglycosides (aadA5, aph(3'')-Ib, aph(6)-Id), sulfonamides (sul1, sul2), trimethoprim (dfrA17)and 
tetracycline (tet(A)). Conjugative (Mpf presence). 
 
Genome LREC292 (B2-CH40-41-ST131) includes a MOBH in the chromosome (ICE) and one plasmid: 
pLREC292_1 (152 kb). MOBF/IncF [F29:A-:B10] with a ColRNAI presumably cointegrated. Harbouring 
the virulence gen senB and resistance genes to beta-lactams (blaTEM-1B), aminoglycosides (aadA5, aph(3'')-
Ib, aph(6)-Id), sulfonamides (sul1), trimethoprim (dfrA17), tetracycline (tet(A)) and macrolides (mph(A)). 
Conjugative (Mpf presence). 
 
Genome LREC293 (B2-CH40-5-ST2279) includes one plasmid: 
pLREC293_1 (172 kb). MOBF12/IncF [F31:A4:B1] with a ColRNAI presumably cointegrated. Harbouring 





























































8.2.5. STUDY 5 
Supplementary materials in Flament-Simon SC et al. 2020 Microorganims 8 (11): 
E1712 doi: 10.3390/microorganisms8111712 (Table S2: SNP matrix and VF-encoding genes 
of 197 ST372 genomes and Table S8: In silico determination of VF-encoding genes, antibiotic-
resistance encoding genes (ARGs) and point mutations in 23 ST372 E. coli genomes). 
Table S14. Prevalence of the phylogenetic groups in the 197 canine E. coli isolates. 
Phylogenetic group Number of isolates 
A 32 (16.2%) 
B1 26 (13.2%) 
B2 84 (42.6%) 
C 10 (5.1%) 
D 6 (3.0%) 
E 14 (7.1%) 
F 18 (9.1%) 
Clade V 1 (0.5%) 
Not typeable 6 (3.0%) 
 
Table S15. Comparison of the distribution of the phylogenetic groups among the 
197 canine isolates according to the strain ExPEC and UPEC status. 
Phylogenetic 
group 
Number of isolates  




A 2 (2.2%) 30 (28.3%) <0.00001 
B1 2 (2.2%) 24 (22.6%) 0.00001 
B2 78 (85.7%) 6 (5.7%) <0.00001 
C 0 10 (9.4%) 0.00199 
D 1 (1.1%) 5 (4.7%)  
E 1 (1.1%) 13 (12.3%) 0.00371 
F 7 (7.7%) 11 (10.4%)  
Clade V 0 1 (0.9%)  
Not typeable 0 6 (5.7%) 0.03155 





Table S16. Comparison of the distribution of the phylogenetic groups among the 
197 canine isolates according to the strain multidrug resistant (MDR) status. 
Phylogenetic 
group 





A 4 (14.3%) 28 (16.6%)  
B1 8 (28.6%) 18 (10.7%) 0.01597 
B2 2 (7.1%) 82 (48.5%) 0.00004 
C 1 (3.6%) 9 (5.3%)  
D 5 (17.9%) 1 (0.6%) 0.00022 
E 5 (17.9%) 9 (5.3%) 0.03238 
F 3 (10.7%) 15 (8.9%)  
Clade V 0 1 (0.6%)  
Not typeable 0 6 (3.6%)  
1Two-tailed P-Values by Fisher´s exact probability test are shown where P < 0.05. 
Table S17. Comparison of the strain ExPEC and UPEC status among canine 
multidrug resistant (MDR) and non-MDR isolates.  
Status 





ExPEC 8 (28.6%) 66 (39.1%)  
UPEC 4 (14.3%) 78 (46.2%) 0.00156 
ExPEC and/or 
UPEC 
8 (28.6%) 83 (49.1%)  
Non ExPEC 
and non-UPEC 
20 (71.4%) 86 (50.9%)  









adk fumC gyrB icd mdh purA recA 
1 10 11 4 666 560 8 2 
2 13 13 9 13 16 2126-like 9 
3 13 13 9 13 439 10 9 
4 88 103 19 18 23 44 26 
5 88 103 119-like 36 23 44 26 
6 6 11 4 8 235 8 2 
7 13 40 9 13 16 126 9 
8 13 363 302 97 23 94 93 
9 13 24 9 912 17 11 25 
10 36 24 10 912 17 10 25 
11 9 23 33 628 11 8 6 
12 13 40 459 912 23 28 109 
13 13 40 13 912 23 25 66 
14 21 35 27 6 286 5 4 
15 6 4 4 16 474 8 14 
16 6 4 5 18 11 319 6 
17 6 29 33 402 11 7 2 
18 63 30 3 628 43 350 6 


















Figure S3. Comparison of contigs harbouring integrative conjugative elements (ICEs) from 22 
ST372 E. coli genomes. 
 
The Figure includes 22 complete contigs with a length ranging from 2,540,863 to 86,362 (pb). The 
shadow parallelograms denote genetic regions that exhibit sequence homology among different 
segments. Light shadow denotes regions with a lower level of sequence identity (99%) by BLAST. The 




8.2.6. STUDY 6 
Supplementary materials in Flament-Simon SC et al. 2020 Front Microbiol 2020 
11:387 doi: 10.3389/fmicb.2020.00387 (Supplementary Table S1. Primers used for PCR 
amplification of virulence genes and virulence genes of 11 ST131 porcine isolates.and 
Supplementary Table S2. Core-genome analysis isolates, SNPs and references). 



















The network contains nodes of different colours (blue for contigs, orange for references, yellow for 
replication proteins, red for relaxases and green for replication proteins and relaxases). Nodes are linked by 
scaffold links (solid grey lines). The size of the contig nodes is proportional to the contig length (Lanza et al., 
2014). *nd, is a 2,014 pb contig (transposases + aminoglycoside resistance protein + LinF) which could not be 



















































































Figure S19. Structural comparison between plasmids from ST131 mcr-1 porcine isolates, other 






Figure S20. Genetic environment of the mcr-1 gene found in the studied genomes. The mcr-1 gene is colored in red, the pap2 gene in blue and the insertion elements 




Figure S21. Graphic representation of the ST131 lineage. 
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